0001104506-24-000016.txt : 20240509 0001104506-24-000016.hdr.sgml : 20240509 20240509070030 ACCESSION NUMBER: 0001104506-24-000016 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 24928460 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 10-Q 1 insm-20240331.htm 10-Q insm-20240331
0001104506false--12-312024Q1http://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMember0.02553840.0307692122168511352xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureinsm:reportingUnitinsm:saleinsm:dayinsm:days00011045062024-01-012024-03-3100011045062024-05-0600011045062024-03-3100011045062023-12-3100011045062023-01-012023-03-310001104506us-gaap:CommonStockMember2022-12-310001104506us-gaap:AdditionalPaidInCapitalMember2022-12-310001104506us-gaap:RetainedEarningsMember2022-12-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100011045062022-12-310001104506us-gaap:RetainedEarningsMember2023-01-012023-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001104506us-gaap:CommonStockMember2023-01-012023-03-310001104506us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001104506us-gaap:CommonStockMember2023-03-310001104506us-gaap:AdditionalPaidInCapitalMember2023-03-310001104506us-gaap:RetainedEarningsMember2023-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100011045062023-03-310001104506us-gaap:CommonStockMember2023-12-310001104506us-gaap:AdditionalPaidInCapitalMember2023-12-310001104506us-gaap:RetainedEarningsMember2023-12-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001104506us-gaap:RetainedEarningsMember2024-01-012024-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001104506us-gaap:CommonStockMember2024-01-012024-03-310001104506us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001104506us-gaap:CommonStockMember2024-03-310001104506us-gaap:AdditionalPaidInCapitalMember2024-03-310001104506us-gaap:RetainedEarningsMember2024-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001104506insm:VertuisBioIncMember2024-01-012024-03-310001104506insm:VertuisBioIncMember2023-01-012023-03-310001104506insm:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-03-310001104506insm:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-03-310001104506insm:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-03-310001104506insm:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-03-310001104506insm:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-03-310001104506insm:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-03-3100011045062023-01-012023-12-310001104506us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001104506us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001104506us-gaap:PerformanceSharesMember2024-01-012024-03-310001104506us-gaap:PerformanceSharesMember2023-01-012023-03-310001104506us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001104506us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001104506us-gaap:PerformanceSharesMember2024-01-012024-03-310001104506us-gaap:PerformanceSharesMember2023-01-012023-03-310001104506us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-03-310001104506us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001104506insm:MotusBiosciencesIncMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-08-012021-08-310001104506insm:MotusBiosciencesIncMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-08-012021-08-310001104506insm:MotusBiosciencesIncMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-08-012021-08-310001104506insm:MotusBiosciencesIncMember2022-08-012022-08-310001104506insm:MotusBiosciencesIncMember2023-08-012023-08-310001104506insm:AccruedLiabilitiesCurrentMember2024-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:MeasurementInputSharePriceMember2024-03-310001104506insm:MotusBiosciencesIncMember2021-08-012021-08-310001104506insm:AlgaeneXIncMember2021-08-042021-08-040001104506insm:MeasurementInputProbabilityOfSuccessMember2024-03-310001104506insm:MotusBiosciencesIncMemberinsm:DevelopmentAndRegulatoryMilestonesMember2021-08-310001104506insm:MotusBiosciencesIncMemberinsm:DevelopmentAndRegulatoryMilestonesMember2021-08-012021-08-310001104506insm:MotusBiosciencesIncMemberus-gaap:FairValueInputsLevel3Member2024-03-310001104506insm:MotusBiosciencesIncMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001104506insm:DevelopmentAndRegulatoryMilestonesMember2024-03-310001104506insm:MeasurementInputProbabilityOfSuccessMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberinsm:DevelopmentAndRegulatoryMilestonesMember2024-03-310001104506insm:MeasurementInputProbabilityOfSuccessMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Memberinsm:DevelopmentAndRegulatoryMilestonesMember2024-03-310001104506insm:PriorityReviewVoucherMilestoneMember2024-03-310001104506insm:MeasurementInputProbabilityOfSuccessMemberinsm:PriorityReviewVoucherMilestoneMemberus-gaap:FairValueInputsLevel3Member2024-03-310001104506insm:PriorityReviewVoucherMilestoneMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Member2024-03-310001104506us-gaap:FairValueInputsLevel2Member2022-12-310001104506us-gaap:FairValueInputsLevel3Member2022-12-310001104506us-gaap:FairValueInputsLevel2Member2023-01-012023-03-310001104506us-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001104506us-gaap:FairValueInputsLevel2Member2023-03-310001104506us-gaap:FairValueInputsLevel3Member2023-03-310001104506us-gaap:FairValueInputsLevel2Member2023-12-310001104506us-gaap:FairValueInputsLevel3Member2023-12-310001104506us-gaap:FairValueInputsLevel2Member2024-01-012024-03-310001104506us-gaap:FairValueInputsLevel3Member2024-01-012024-03-310001104506us-gaap:FairValueInputsLevel2Member2024-03-310001104506us-gaap:FairValueInputsLevel3Member2024-03-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2024-03-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2022-10-012022-10-310001104506insm:ARIKAYCEGlobalNetSalesMemberus-gaap:RoyaltyAgreementsMember2022-10-010001104506srt:ScenarioForecastMemberinsm:ARIKAYCEGlobalNetSalesMemberus-gaap:RoyaltyAgreementsMember2025-09-010001104506insm:BrensocatibGlobalNetSalesMemberus-gaap:RoyaltyAgreementsMember2022-10-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2022-10-310001104506country:US2024-01-012024-03-310001104506country:US2023-01-012023-03-310001104506country:JP2024-01-012024-03-310001104506country:JP2023-01-012023-03-310001104506insm:EuropeAndTheRestOfTheWorldMember2024-01-012024-03-310001104506insm:EuropeAndTheRestOfTheWorldMember2023-01-012023-03-310001104506insm:AcquiredResearchAndDevelopmentMember2023-12-310001104506insm:AcquiredResearchAndDevelopmentMember2024-01-012024-03-310001104506insm:AcquiredResearchAndDevelopmentMember2024-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001104506us-gaap:InProcessResearchAndDevelopmentMember2024-01-012024-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2024-03-310001104506us-gaap:LicensingAgreementsMember2023-12-310001104506us-gaap:LicensingAgreementsMember2024-01-012024-03-310001104506us-gaap:LicensingAgreementsMember2024-03-310001104506insm:AcquiredResearchAndDevelopmentMember2022-12-310001104506insm:AcquiredResearchAndDevelopmentMember2023-01-012023-03-310001104506insm:AcquiredResearchAndDevelopmentMember2023-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2022-12-310001104506us-gaap:InProcessResearchAndDevelopmentMember2023-01-012023-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2023-03-310001104506us-gaap:LicensingAgreementsMember2022-12-310001104506us-gaap:LicensingAgreementsMember2023-01-012023-03-310001104506us-gaap:LicensingAgreementsMember2023-03-310001104506us-gaap:EquipmentMember2024-03-310001104506us-gaap:EquipmentMember2023-12-310001104506us-gaap:FurnitureAndFixturesMember2024-03-310001104506us-gaap:FurnitureAndFixturesMember2023-12-310001104506srt:MinimumMemberinsm:ComputerHardwareAndSoftwareMember2024-03-310001104506srt:MaximumMemberinsm:ComputerHardwareAndSoftwareMember2024-03-310001104506insm:ComputerHardwareAndSoftwareMember2024-03-310001104506insm:ComputerHardwareAndSoftwareMember2023-12-310001104506us-gaap:OfficeEquipmentMember2024-03-310001104506us-gaap:OfficeEquipmentMember2023-12-310001104506insm:ManufacturingEquipmentMember2024-03-310001104506insm:ManufacturingEquipmentMember2023-12-310001104506srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2024-03-310001104506us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2024-03-310001104506us-gaap:LeaseholdImprovementsMember2024-03-310001104506us-gaap:LeaseholdImprovementsMember2023-12-310001104506us-gaap:ConstructionInProgressMember2024-03-310001104506us-gaap:ConstructionInProgressMember2023-12-310001104506srt:MinimumMember2024-01-012024-03-310001104506srt:MaximumMember2024-01-012024-03-310001104506us-gaap:ConvertibleNotesPayableMember2024-03-310001104506us-gaap:ConvertibleNotesPayableMember2023-12-310001104506insm:TermLoanMember2024-03-310001104506insm:TermLoanMember2023-12-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2021-05-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2021-05-012021-05-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member2018-01-012018-01-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:DebtInstrumentConversionTermOneMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMemberinsm:DebtInstrumentConversionTermOneMember2021-05-012021-05-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMemberinsm:DebtInstrumentConversionTermTwoMember2021-05-012021-05-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:DebtInstrumentConversionTermTwoMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMemberinsm:DebtInstrumentConversionTermThreeMember2021-05-012021-05-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:DebtInstrumentConversionTermThreeMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506insm:DebtInstrumentConversionTermFourMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506insm:DebtInstrumentConversionTermFourMemberus-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506us-gaap:ConvertibleNotesPayableMember2018-01-310001104506us-gaap:ConvertibleNotesPayableMember2021-05-310001104506us-gaap:ConvertibleNotesPayableMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2024-01-012024-03-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2024-01-012024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2024-03-310001104506us-gaap:ConvertibleNotesPayableMember2024-03-310001104506us-gaap:ConvertibleNotesPayableMember2023-12-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2022-10-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMemberinsm:SecuredOvernightFinancingRateSOFRMember2022-10-012022-10-310001104506us-gaap:SecuredDebtMemberinsm:VariableRateComponentTwoMemberinsm:TermLoanMemberinsm:SecuredOvernightFinancingRateSOFRMember2022-10-012022-10-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2022-10-012022-10-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2024-03-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2023-12-310001104506us-gaap:ConvertibleDebtMember2024-01-012024-03-310001104506us-gaap:ConvertibleDebtMember2023-01-012023-03-310001104506insm:TermLoanMember2024-01-012024-03-310001104506insm:TermLoanMember2023-01-012023-03-310001104506us-gaap:RoyaltyAgreementsMember2024-01-012024-03-310001104506us-gaap:RoyaltyAgreementsMember2023-01-012023-03-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2021-05-012021-05-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member2021-05-012021-05-310001104506us-gaap:RoyaltyAgreementsMember2022-10-310001104506srt:MaximumMemberus-gaap:RoyaltyAgreementsMember2022-10-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2023-12-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2022-12-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2024-01-012024-03-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2023-01-012023-12-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2024-03-310001104506us-gaap:SecuredDebtMember2024-01-012024-03-310001104506us-gaap:SecuredDebtMember2023-01-012023-12-310001104506us-gaap:RoyaltyAgreementsMember2024-03-310001104506us-gaap:RoyaltyAgreementsMember2023-12-310001104506us-gaap:EmployeeStockOptionMember2024-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2024-03-310001104506us-gaap:PerformanceSharesMember2024-03-310001104506insm:MotusBiosciencesIncMember2024-03-310001104506insm:MotusBiosciencesIncMember2021-09-300001104506insm:MotusBiosciencesIncMember2021-07-012021-09-300001104506insm:MotusBiosciencesIncMember2022-07-012022-09-300001104506insm:MotusBiosciencesIncMember2023-07-012023-09-300001104506insm:AdrestiaTherapeuticsLtdMember2023-04-012023-06-300001104506insm:VertuisBioIncMember2023-01-310001104506insm:VertuisBioIncMember2023-01-012023-01-310001104506insm:VertuisBioIncMember2023-12-310001104506insm:PublicStockOfferingMember2022-10-012022-10-3100011045062022-10-3100011045062022-10-012022-10-310001104506insm:AtTheMarketAgreementMember2021-01-012021-03-310001104506insm:AtTheMarketAgreementMember2023-01-012023-12-310001104506insm:AtTheMarketAgreementMember2023-12-310001104506insm:AtTheMarketAgreementMember2024-01-012024-03-310001104506insm:A2019IncentivePlanMember2020-05-122020-05-120001104506insm:A2019IncentivePlanThirdAmendmentMember2024-03-310001104506insm:EmployeeStockPurchasePlan2018Member2018-05-150001104506insm:EmployeeStockPurchasePlan2018Member2018-05-152018-05-150001104506insm:StockOptionsAndRestrictedStockUnitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMember2024-01-012024-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMember2023-01-012023-03-310001104506insm:AdrestiaTherapeuticsLtdMember2023-06-012023-06-3000011045062023-06-300001104506insm:VertuisBioIncMember2023-01-012023-01-3100011045062023-01-310001104506insm:MilestoneEvent1Memberinsm:VertuisBioIncMember2023-01-012023-01-310001104506insm:MilestoneEvent2Memberinsm:VertuisBioIncMember2023-01-012023-01-310001104506insm:MilestoneEvent3Memberinsm:VertuisBioIncMember2023-01-012023-01-310001104506insm:MotusBiosciencesIncMember2021-08-042021-08-040001104506insm:MotusBiosciencesIncMember2021-08-040001104506insm:AlgaeneXIncMember2021-08-012021-08-310001104506insm:AlgaeneXIncMember2021-08-310001104506insm:MotusBiosciencesIncMember2021-08-3100011045062021-05-242021-05-240001104506insm:MotusBiosciencesIncAndAlgaeneXIncMember2021-08-012021-08-310001104506insm:WilliamLewisMember2024-01-012024-03-310001104506insm:WilliamLewisMember2024-03-310001104506insm:SaraBonsteinMember2024-01-012024-03-310001104506insm:SaraBonsteinMember2024-03-310001104506insm:DraytonWiseMember2024-01-012024-03-310001104506insm:DraytonWiseMember2024-03-310001104506insm:S.NicoleSchaefferMember2024-01-012024-03-310001104506insm:S.NicoleSchaefferMember2024-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to
Commission File Number 000-30739
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
Virginia54-1972729
(State or other jurisdiction of incorporation or organization)(I.R.S. employer identification no.)
700 US Highway 202/206,
 
Bridgewater, New Jersey
08807
(Address of principal executive offices)(Zip Code)
(908) 977-9900
(Registrant’s telephone number including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section12(b) of the Act:
Title of each classTrading symbolsName of each exchange on which registered
Common stock, par value $0.01 per shareINSMNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company ☐
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
As of May 6, 2024, there were 148,604,548 shares of the registrant’s common stock outstanding.



INSMED INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2024
 
INDEX
 
 
 
 
 
Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
 
Unless the context otherwise indicates, references in this Form 10-Q to “Insmed Incorporated” refers to Insmed Incorporated, a Virginia corporation, and the “Company,” “Insmed,” “we,” “us” and “our” refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, ARIKARES and ARIKAYCE are trademarks of Insmed Incorporated. This Form 10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form 10-Q is the property of its owner.

2

PART I.  FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
INSMED INCORPORATED
Consolidated Balance Sheets
(in thousands, except par value and share data)
As ofAs of
March 31, 2024December 31, 2023
 (unaudited) 
Assets  
Current assets:  
Cash and cash equivalents$595,729 $482,374 
Marketable securities— 298,073 
Accounts receivable37,162 41,189 
Inventory82,957 83,248 
Prepaid expenses and other current assets42,874 24,179 
Total current assets758,722 929,063 
Fixed assets, net68,660 65,384 
Finance lease right-of-use assets20,307 20,985 
Operating lease right-of-use assets17,157 18,017 
Intangibles, net62,441 63,704 
Goodwill136,110 136,110 
Other assets95,698 96,574 
Total assets$1,159,095 $1,329,837 
Liabilities and shareholders’ equity  
Current liabilities:  
Accounts payable and accrued liabilities$189,362 $214,987 
Current portion of long-term debt224,194 — 
Finance lease liabilities2,695 2,610 
Operating lease liabilities4,609 8,032 
Total current liabilities420,860 225,629 
Debt, long-term939,081 1,155,313 
Royalty financing agreement156,967 155,034 
Contingent consideration63,700 84,600 
Finance lease liabilities, long-term26,320 27,026 
Operating lease liabilities, long-term13,809 11,013 
Other long-term liabilities3,166 3,145 
Total liabilities1,623,903 1,661,760 
Shareholders’ equity:  
Common stock, $0.01 par value; 500,000,000 authorized shares, 148,560,882 and 147,977,960 issued and outstanding shares at March 31, 2024 and December 31, 2023, respectively
1,486 1,480 
Additional paid-in capital3,138,578 3,113,487 
Accumulated deficit(3,603,236)(3,446,145)
Accumulated other comprehensive loss(1,636)(745)
Total shareholders’ deficit(464,808)(331,923)
Total liabilities and shareholders’ deficit$1,159,095 $1,329,837 
See accompanying notes to the unaudited consolidated financial statements
3

INSMED INCORPORATED
Consolidated Statements of Comprehensive Loss (unaudited)
(in thousands, except per share data)
 Three Months Ended March 31,
 20242023
Product revenues, net$75,500 $65,214 
Operating expenses:
Cost of product revenues (excluding amortization of intangible assets)17,457 13,830 
Research and development121,083 127,865 
Selling, general and administrative93,102 79,914 
Amortization of intangible assets1,263 1,263 
Change in fair value of deferred and contingent consideration liabilities(11,900)(9,500)
Total operating expenses221,005 213,372 
Operating loss(145,505)(148,158)
Investment income8,783 10,524 
Interest expense(21,042)(20,003)
Change in fair value of interest rate swap2,362 (1,533)
Other expense, net(1,100)(111)
Loss before income taxes(156,502)(159,281)
Provision for income taxes589 483 
Net loss$(157,091)$(159,764)
Basic and diluted net loss per share$(1.06)$(1.17)
Weighted average basic and diluted common shares outstanding
148,456 136,355 
Net loss$(157,091)$(159,764)
Other comprehensive income (loss):
Foreign currency translation losses(855)(171)
Unrealized (loss) gain on marketable securities(36)498 
Total comprehensive loss$(157,982)$(159,437)
    
See accompanying notes to the unaudited consolidated financial statements

4

INSMED INCORPORATED
Consolidated Statements of Shareholders' Deficit (unaudited)
(in thousands)
 Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Income (Loss)		Total
SharesAmount
Balance at December 31, 2022135,654 $1,357 $2,782,416 $(2,696,578)$756 $87,951 
Comprehensive loss:
Net loss(159,764)(159,764)
Other comprehensive income327 327 
Exercise of stock options and ESPP shares82 1 1,138 1,139 
Issuance of common stock for vesting of RSUs193 1 1 
Issuance of common stock for asset acquisition50059,245 9,250 
Stock-based compensation expense16,443 16,443 
Balance at March 31, 2023136,429 $1,364 $2,809,242 $(2,856,342)$1,083 $(44,653)
Balance at December 31, 2023147,978 $1,480 $3,113,487 $(3,446,145)$(745)$(331,923)
Comprehensive loss:
Net loss(157,091)(157,091)
Other comprehensive loss(891)(891)
Exercise of stock options and ESPP shares issuance217 2 4,050 4,052 
Net proceeds from issuance of common stock(409)(409)
Issuance of common stock for vesting of RSUs366 4 4 
Stock-based compensation expense21,450 21,450 
Balance at March 31, 2024148,561 $1,486 $3,138,578 $(3,603,236)$(1,636)$(464,808)
See accompanying notes to the unaudited consolidated financial statements
5

INSMED INCORPORATED
Consolidated Statements of Cash Flows (unaudited)
(in thousands)
 Three Months Ended March 31,
 20242023
Operating activities  
Net loss$(157,091)$(159,764)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation1,588 1,248 
Amortization of intangible assets1,263 1,263 
Stock-based compensation expense21,450 16,443 
Amortization of debt issuance costs1,851 1,724 
Paid-in-kind interest capitalized6,242 5,456 
Royalty financing non-cash interest expense4,822 2,615 
Accretion of discount on marketable securities, net(1,963)— 
Finance lease amortization expense678 678 
Non-cash operating lease expense6,516 2,491 
Change in fair value of deferred and contingent consideration liabilities(11,900)(9,500)
Change in fair value of interest rate swap(2,362)1,533 
Vertuis acquisition— 10,250 
Changes in operating assets and liabilities:  
Accounts receivable2,955 (860)
Inventory(598)(1,187)
Prepaid expenses and other current assets(19,330)(3,199)
Other assets333 (5,231)
Accounts payable and accrued liabilities(32,345)(8,841)
Other liabilities(6,144)(1,422)
Net cash used in operating activities(184,035)(146,303)
Investing activities  
Purchase of fixed assets(4,679)(3,398)
Maturities of marketable securities300,000 45,000 
Net cash provided by investing activities295,321 41,602 
Financing activities  
Proceeds from exercise of stock options and ESPP4,052 1,139 
Payments of equity issuance costs(409)— 
Payments of finance lease principal(621)(320)
Payment of debt issuance costs— (1,218)
Net cash provided by (used in) financing activities3,022 (399)
Effect of exchange rates on cash and cash equivalents(953)(29)
Net increase (decrease) in cash and cash equivalents113,355 (105,129)
Cash and cash equivalents at beginning of period482,374 1,074,036 
Cash and cash equivalents at end of period$595,729 $968,907 
Supplemental disclosures of cash flow information:  
Cash paid for interest$8,210 $11,589 
Cash paid for income taxes$1,208 $1,004 
See accompanying notes to the unaudited consolidated financial statements
6
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. The Company and Basis of Presentation
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
The Company's pipeline includes clinical-stage programs, brensocatib and treprostinil palmitil inhalation powder (TPIP), as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, protein manufacturing, RNA-end joining, and synthetic rescue.
The Company was incorporated in the Commonwealth of Virginia on November 29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.
The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US (GAAP) for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Any references in these notes to applicable accounting guidance are meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).
     The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.
     The Company had $595.7 million in cash and cash equivalents as of March 31, 2024 and reported a net loss of $157.1 million for the three months ended March 31, 2024. The Company has funded its operations through public offerings of equity securities, debt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.
The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company’s commercial, regulatory and development activities. Any future financing will also be contingent upon market
7

INSMED INCORPORATED
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
1. The Company and Basis of Presentation (Continued)



conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals, Inc., Insmed Holdings Limited, Insmed Gene Therapy LLC, Insmed Ireland Limited, Insmed France SAS, Insmed Germany GmbH, Insmed Limited, Insmed Netherlands Holdings B.V., Insmed Netherlands B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, Insmed Italy S.R.L., Insmed Innovation UK Limited, and Adrestia Therapeutics Inc. All intercompany transactions and balances have been eliminated in consolidation.
2. Summary of Significant Accounting Policies
The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Selected significant accounting policies are discussed in detail below.
Use of Estimates—The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.
Concentration of Credit Risk—Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.
The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2024 and their respective percentages for the three months ended March 31, 2023.
Three Months Ended March 31,
20242023
Customer A35%36%
Customer B34%36%
Customer C16%17%
The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.
Finite-lived Intangible Assets—Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See Note 6 - Intangibles, Net and Goodwill for further details.
Impairment Assessment—The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by
8
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.
Business Combinations and Asset Acquisitions—The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&D expense in its consolidated statements of comprehensive loss.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of March 31, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Indefinite-lived Intangible Assets—Indefinite-lived intangible assets consist of IPR&D. IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the
9
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.
Goodwill—Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2024 and December 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2024. See Note 6 - Intangibles, Net and Goodwill for further details.
Leases—A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.
Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See Note 9 - Leases for further details.
Debt Issuance Costs—Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Foreign Currency—The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total shareholders' deficit, as a component of accumulated other comprehensive loss.
The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.
Derivatives—In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.
Inventory and Cost of Product Revenues (excluding amortization of intangible assets)—Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during
10
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&D expense when consumed.
Net Loss Per Share—Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.
The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
 20242023
 
Numerator:
Net loss$(157,091)$(159,764)
Denominator:
Weighted average common shares used in calculation of basic net loss per share:148,456 136,355 
Effect of dilutive securities:
Common stock options— — 
RS and RSUs— — 
PSUs— — 
Convertible debt securities— — 
Weighted average common shares outstanding used in calculation of diluted net loss per share148,456 136,355 
Net loss per share:
Basic and diluted$(1.06)$(1.17)
The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):
 
As of March 31,
 20242023
Common stock options24,098 19,156 
Unvested RS and RSUs3,059 2,058 
PSUs666 671 
Convertible debt securities23,438 23,438 
Recent Accounting Pronouncements (Not Yet Adopted)—In December 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate
11
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.
3. Fair Value Measurements
The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:
•Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
•Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
•Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
As of March 31, 2024
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$595.7 $595.7 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$(1.2)$— $(1.2)$— 
Deferred consideration$5.0 $— $5.0 $— 
Contingent consideration$73.4 $— $— $73.4 
12
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Fair Value Measurements (Continued)
As of December 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$482.4 $482.4 $— $— 
Marketable securities$298.1 $298.1 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$1.2 $— $1.2 $— 
Deferred consideration$5.7 $— $5.7 $— 
Contingent consideration$84.6 $— $— $84.6 
During the three months ended March 31, 2024, $300.0 million of marketable securities, consisting of US Treasury Notes, matured.
The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of March 31, 2024 and December 31, 2023. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March 31, 2024.
As of March 31, 2024, the Company held no available-for-sale securities. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.
The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the three months ended March 31, 2024.
Deferred Consideration
The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.
The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2024, the fair value of deferred consideration included in accounts payable and accrued liabilities was $5.0 million.
The following observable input was used in the valuation of the deferred consideration as of March 31, 2024:
13
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Fair Value Measurements (Continued)
Fair Value as of March 31, 2024 (in millions)
Observable InputInput Value
Deferred consideration
$5.0
Insmed share price as of March 31, 2024
$27.13
Contingent Consideration
The contingent consideration liabilities arose from the Business Acquisition in August 2021 (see Note 16 - Acquisitions). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At March 31, 2024, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.
If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash.
The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of March 31, 2024, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.
The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of March 31, 2024, the fair value of the current and non-current contingent consideration was $9.7 million and $63.7 million, respectively.
A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss. The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2024:
Fair Value as of March 31, 2024 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$65.5Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$5.1Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
15.7%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2024 and 2023 (in thousands):
14
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Fair Value Measurements (Continued)
Deferred
 Consideration
(Level 2 Liabilities)		Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value(1,200)(8,300)
Payments— — 
Balance as of March 31, 2023$6,200 $49,800 
Balance as of December 31, 2023$5,700 $84,600 
Additions— — 
Change in Fair Value(700)(11,200)
Payments— — 
Balance as of March 31, 2024$5,000 $73,400 
Convertible Notes
The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility (collectively, the Current Market Factors), and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.
The estimated fair value of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2024 was $620.1 million, determined using Current Market Factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.
The estimated fair value of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2024 was $238.7 million, determined using Current Market Factors, and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. See Note 10 - Debt for further details on the Company's convertible notes.
Synthetic Royalty Financing Agreement
In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty & Credit Opportunities IV, LP (OrbiMed). Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions.
The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. For more information, see Note 11 - Royalty Financing Agreement.
4. Product Revenues, Net
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to
15
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
4. Product Revenues, Net (Continued)
receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.
Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.
The following table presents a geographic summary of the Company's product revenues, net, for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
US$56,349 $49,067 
Japan14,891 13,156 
Europe and rest of world4,260 2,991 
  Total product revenues, net$75,500 $65,214 
Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.
Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the
16
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
4. Product Revenues, Net (Continued)
government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.
Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.
If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.
The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.
5. Inventory
The Company's inventory balance consists of the following (in thousands):
As of
March 31, 2024December 31, 2023
Raw materials$21,943 $24,562 
Work-in-process29,359 33,480 
Finished goods31,655 25,206 
$82,957 $83,248 
Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.
6. Intangibles, Net and Goodwill
 Intangibles, Net
Finite-lived Intangible Assets
As of March 31, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D and the milestones paid to PARI for the license to use the Lamira® Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.
Indefinite-lived Intangible Assets
As of March 31, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition (see Note 16 - Acquisitions). Indefinite-lived intangible assets are not amortized.
A rollforward of the Company's intangible assets for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):
17
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
6. Intangibles, Net and Goodwill (Continued)
Intangible AssetDecember 31, 2023AdditionsAmortization
March 31, 2024
Acquired ARIKAYCE R&D$32,738 $— $(1,212)$31,526 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,366 — (51)1,315 
$63,704 $— $(1,263)$62,441 
Intangible AssetDecember 31, 2022AdditionsAmortizationMarch 31, 2023
Acquired ARIKAYCE R&D$37,588 $— $(1,212)$36,376 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (51)1,517 
$68,756 $— $(1,263)$67,493 
Goodwill
The Company's goodwill balance of $136.1 million as of March 31, 2024 and December 31, 2023, resulted from the August 2021 Business Acquisition. See Note 16 - Acquisitions for further details. 
7. Fixed Assets, Net
Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):
Estimated
Useful Life (years)		As of
Asset DescriptionMarch 31, 2024December 31, 2023
Lab equipment7$23,468 $22,660 
Furniture and fixtures76,428 6,428 
Computer hardware and software
3-5
6,106 6,001 
Office equipment789 89 
Manufacturing equipment71,336 1,336 
Leasehold improvements
2-10
37,968 38,049 
Construction in progress—39,238 35,449 
114,633 110,012 
Less: accumulated depreciation(45,973)(44,628)
$68,660 $65,384 

8. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
18
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
8. Accounts Payable and Accrued Liabilities (Continued)
As of
March 31, 2024December 31, 2023
Accounts payable and other accrued operating expenses$44,018 $65,393 
Accrued clinical trial expenses23,754 23,711 
Accrued professional fees16,728 13,885 
Accrued technical operation expenses10,293 9,187 
Accrued compensation and employee related costs23,803 48,933 
Accrued royalty and milestones payable6,514 5,674 
Accrued interest payable2,269 2,175 
Revenue Interest Payments payable3,020 3,347 
Accrued sales allowances and related costs17,159 10,937 
Accrued France ATU reimbursement payable15,896 14,685 
Deferred and contingent consideration15,700 6,700 
Other accrued liabilities10,208 10,360 
$189,362 $214,987 
9. Leases
The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.
The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.
The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $4.9 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20242023
Finance right-of-use assets obtained in exchange for lease obligations$— $— 
Operating right-of-use assets obtained in exchange for lease obligations$5,656 $1,751 
19
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
9. Leases (Continued)
In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $52.0 million and $49.1 million incurred by the Company under these additional agreements have been classified within other assets in the Company's consolidated balance sheet as of March 31, 2024 and December 31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.
10. Debt
Current portion of long-term debt and debt, long-term consists of the following commitments as of March 31, 2024 and December 31, 2023 (in thousands):
As of
March 31, 2024December 31, 2023
Convertible notes$789,731 $788,909 
Term Loan373,544 366,404 
Less: current portion of convertible notes(224,194)— 
Debt, long-term$939,081 $1,155,313 
Convertible Notes
In May 2021, the Company completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7 million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased.
In January 2018, the Company completed an underwritten public offering of $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased.
A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.
On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.
Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during
20
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Debt (Continued)
the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a) the second business day immediately preceding the related redemption date or (b) if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes.
Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity’s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9 million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6 million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4 million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December 31, 2022, prior to the adoption of ASU 2020-06. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 0.78 years and 4.17 years, respectively.
The $565.5 million carrying value of the 2028 Convertible Notes as of March 31, 2024 excludes $9.5 million of unamortized debt issuance costs. The $224.2 million carrying value of the 2025 Convertible Notes as of March 31, 2024 excludes $0.8 million of unamortized debt issuance costs. The 2028 Convertible Notes and 2025 Convertible Notes are long-term and current liabilities, respectively, as of March 31, 2024. The following table presents the carrying value of the
21
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Debt (Continued)
Company's convertible notes balance (in thousands):
As of
March 31, 2024December 31, 2023
Face value of outstanding convertible notes$800,000 800,000 
Debt issuance costs(10,269)(11,091)
Less: current convertible notes(224,194)— 
Total long-term convertible notes$565,537 $788,909 
Secured Senior Term Loan
In October 2022, the Company entered into a $350 million senior secured term loan agreement with Pharmakon Advisors LP (Pharmakon), manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. During the three months ended March 31, 2024, paid-in-kind interest capitalized was $6.2 million. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8 million.
The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2024 (in thousands):
As of
March 31, 2024December 31, 2023
Original Term Loan balance$350,000 $350,000 
Paid-in-kind interest capitalized33,779 27,537 
Term Loan issuance costs, unamortized(10,235)(11,133)
Term Loan$373,544 $366,404 
As of March 31, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):
 
Year Ending December 31: 
2024$— 
2025225,000 
2026191,890 
2027191,889 
2028575,000 
2029 and thereafter— 
 $1,183,779 
22
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Debt (Continued)
Interest Expense
Interest expense related to debt and finance leases for the three months ended March 31, 2024 and 2023 is as follows (in thousands):
Three Months Ended March 31,
20242023
Convertible debt contractual interest expense$2,063 $2,063 
Term Loan contractual interest expense12,483 10,911 
Royalty Financing Agreement interest expense4,822 4,764 
Amortization of debt issuance costs1,851 1,724 
Swap interest income(754)(73)
   Total debt interest expense20,465 19,389 
Finance lease interest expense577 614 
   Total interest expense$21,042 $20,003 
11. Royalty Financing Agreement
In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $3.8 million were, $146.2 million.
The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be 12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and updates the effective interest rate on a quarterly basis. 
23
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
11. Royalty Financing Agreement (Continued)
The following table shows the activity within the liability account for the three-month period ended March 31, 2024 and year ended December 31, 2023 (in thousands):
Three Months Ended
March 31, 2024		Twelve Months Ended
December 31, 2023
Royalty financing agreement liability - beginning balance$158,162 $151,538 
Revenue Interest Payments paid and payable(3,020)(12,222)
Interest expense recognized4,822 18,846 
Royalty financing agreement liability - ending balance$159,964 $158,162 
Royalty financing issuance costs:
Royalty issuance costs, unamortized - beginning balance$(3,128)$(3,523)
Amortization of issuance costs131 521 
Other— (126)
Deferred issuance costs, unamortized - ending balance$(2,997)$(3,128)
  Royalty Financing Agreement$156,967 $155,034 

The Revenue Interest Payments payable in connection with the royalty financing agreement were $3.0 million and $3.3 million as of March 31, 2024 and December 31, 2023, respectively, which were recorded within accounts payable and accrued expenses on the consolidated balance sheet. Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss.
12. Shareholders' Equity
Common Stock—As of March 31, 2024, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 148,560,882 shares of common stock issued and outstanding. In addition, as of March 31, 2024, the Company had reserved 24,098,410 shares of common stock for issuance upon the exercise of outstanding stock options, 3,058,943 shares of common stock for issuance upon the vesting of RSUs and 666,382 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430 shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved 9,406,112 shares of the Company’s common stock, subject to certain closing-related reductions. The shares of the Company’s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first and second anniversaries of the closing date of the acquisition, and will also be issued upon the third anniversary of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company’s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.
Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (see Note 16 - Acquisitions) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition. In the third quarter of 2023, the Company issued 177,203 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the second anniversary of the Business Acquisition.
In the second quarter of 2023, in connection with the Company's acquisition of Adrestia Therapeutics Ltd. (Adrestia), the Company issued 3,430,867 shares of the Company's common stock as consideration at closing. See Note 16 - Acquisitions for further details.
In connection with the Company’s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved 550,000 shares of the Company’s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. An additional $1 million of shares of common stock will be issued to Vertuis’ former stockholders on July 1, 2024, based on the share price on June 28, 2024. See Note 16 - Acquisitions for further details.
24
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
12. Shareholders' Equity (Continued)
In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.
In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an “at the market” equity offering program (the ATM program), under which Leerink acted as sales agent. In 2023, the Company issued and sold an aggregate of 6,503,041 shares of common stock through the ATM program at a weighted-average public offering price of $24.12 per share and received net proceeds of $152.2 million. In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through a new “at the market” equity offering program (the new ATM program), under which Leerink acts as sales agent. In connection with entering into the new ATM program, the Company terminated the ATM program. The Company has not issued any shares under the new ATM program.
Preferred Stock—As of March 31, 2024, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.
13. Stock-Based Compensation
The Company's current equity compensation plan, the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders on May 11, 2023. The 2019 Incentive Plan replaced the Insmed Incorporated 2019 Incentive Plan. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. The Company has submitted a proposal to its shareholders to approve an amendment to the 2019 Incentive Plan at the 2024 Annual Meeting of Shareholders (Amendment No.1). Amendment No.1, if approved, will provide for the issuance of an additional 3,000,000 shares under the 2019 Incentive Plan. As of March 31, 2024, 4,705,225 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the three months ended March 31, 2024, the Company granted inducement stock options covering 358,140 shares of the Company's common stock to new employees.
On May 15, 2018, the 2018 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the ESPP: (i) 1,000,000 shares of common stock, plus (ii) commencing on January 1, 2019 and ending on December 31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C) an amount determined by the administrator.
Stock Options—As of March 31, 2024, there was $148.0 million of unrecognized compensation expense related to unvested stock options. As of March 31, 2024, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria.
Restricted Stock Units—As of March 31, 2024, there was $55.8 million of unrecognized compensation expense related to unvested RSU awards.
Performance Stock Units—As of March 31, 2024, there were 266,550 unvested PSUs outstanding with an unrecognized compensation expense of $10.4 million, which assumes a payout at 100% of the target.
The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2024 and 2023, respectively (in millions): 
25
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
13. Stock-Based Compensation (Continued)
 Three Months Ended March 31,
 20242023
Research and development$10.4 $7.9 
Selling, general and administrative11.1 8.5 
Total$21.5 $16.4 
There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three months ended March 31, 2024 or March 31, 2023, as the performance conditions associated with the PSU awards were not probable as of either date.
14. Income Taxes
The Company recorded a provision for income taxes of $0.6 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively. The provisions recorded for the three months ended March 31, 2024 and 2023 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.
The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company’s federal tax returns for the years ended 2020 and later, generally open for certain states for the years 2019 and later, and generally open for international jurisdictions for the years 2018 and later. The Company has incurred net operating losses since inception, except for the year ended December 31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of March 31, 2024 and December 31, 2023, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US. However, given the Company’s valuation allowance position, these reserves do not have an impact on the balance sheet as of March 31, 2024 and December 31, 2023 or the consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023. The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.
15. Commitments and Contingencies
Rent expense charged to operations was $3.1 million and $2.2 million for the three months ended March 31, 2024 and 2023, respectively.
Legal Proceedings
From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.
16. Acquisitions
Asset Acquisitions
Adrestia Therapeutics Ltd.
In June 2023, the Company acquired all of the issued and outstanding share capital of Adrestia, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 3,430,867 shares of the Company’s common stock to Adrestia’s former shareholders (collectively, the Adrestia shareholders). The closing share price on the date of the transaction was $21.10, resulting in a purchase price of $72.4 million. The Adrestia shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement.
The shares of the Company’s common stock issued to the Adrestia shareholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (and, with respect to certain Adrestia shareholders, in reliance on Regulation S
26
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
16. Acquisitions (Continued)
promulgated under the Securities Act of 1933). The Company did not receive any net proceeds from the issuance of common stock to the Adrestia shareholders.
The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the IPR&D acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition. The Company recognized $76.5 million as IPR&D expense, after adjusting for working capital assumed in connection with the asset acquisition.
Vertuis Bio, Inc.
In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to Vertuis’ former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 with an aggregate value of $1.0 million, based on the share price on June 28, 2024, and pay to the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions.
The shares of the Company’s common stock issued to the Vertuis equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933.
The following table summarizes the purchase price (in millions).
Shares of Insmed common stock issued on closing$9.25 
Shares of Insmed common stock issuable on July 1, 20241.00 
  Total purchase price$10.25 
The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.
Business Combination
On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company’s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company’s common stock, following certain closing-related reductions, to Motus’s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35 million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions.
At the closing of the Company’s acquisition of AlgaeneX, the Company paid $1.5 million in cash to AlgaeneX’s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company’s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX’s manufacturing technology, in each case, subject to certain reductions.
27
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
16. Acquisitions (Continued)
The shares of the Company’s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.
The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.
Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5 million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.
The fair value of IPR&D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.


28
ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.
                  Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:
•failure to continue to successfully commercialize ARIKAYCE, our only approved product, in the US, Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain US, European or Japanese approval for ARIKAYCE;
•uncertainties or changes in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;
•our inability to obtain full approval of ARIKAYCE from the FDA, including the risk that we will not successfully or in a timely manner validate a patient reported outcome (PRO) tool and complete the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;
•inability of us, PARI Pharma GmbH (PARI) or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or Lamira;
•our inability to obtain and maintain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;
•development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, TPIP or our other product candidates;
•inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;
•the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon and our royalty financing with OrbiMed, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements;
•our inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;
•failure to obtain regulatory approval to expand ARIKAYCE’s indication to a broader patient population;
•risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies, including, for brensocatib, the ASPEN study;
•risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication;
•failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;
•failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates or to permit the use of ARIKAYCE in the broader population of patients with MAC lung disease, among other things;
•risks that our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected;
•risks that interim or partial data sets are not representative of a complete or larger data set or that blinded data will not be predictive of unblinded data;
29
•failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the US, Europe or Japan, or for our product candidates in the US, Europe, Japan or other markets, including separate regulatory approval for Lamira in each market and for each usage;
•failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us;
•our inability to attract and retain key personnel or to effectively manage our growth;
•our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management’s time and attention devoted to integration activities;
•risks that our acquired technologies, products and product candidates are not commercially successful;
•inability to adapt to our highly competitive and changing environment;
•inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology;
•risk that we are unable to maintain our significant customers;
•risk that government healthcare reform materially increases our costs and damages our financial condition;
•business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;
•risk that our current and potential future use of artificial intelligence (AI) and machine learning may not be successful;
•deterioration in general economic conditions in the US, Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners;
•inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;
•restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;
•the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;
•risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;
•our limited experience operating internationally;
•changes in laws and regulations applicable to our business, including any pricing reform and laws that impact our ability to utilize certain third parties in the research, development or manufacture of our product candidates, and failure to comply with such laws and regulations;
•our history of operating losses, and the possibility that we never achieve or maintain profitability;
•goodwill impairment charges affecting our results of operations and financial condition;
•inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and
•delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.
We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Quarterly Report on Form 10-Q and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q and included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
30
The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2023.
OVERVIEW
      We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, is approved in the US as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the EC approved ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
Our pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we are developing for the treatment of patients with bronchiectasis, and other neutrophil-mediated diseases, including CRSsNP. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for PH-ILD and PAH. Our early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA-end joining, and synthetic rescue.
The information below summarizes our updates and anticipated near-term milestones for ARIKAYCE and our product candidates.
ARIKAYCE
•We announced positive topline results from the ARISE trial in the third quarter of 2023. Based on these results, we have proposed to the FDA that the change of the respiratory score derived from the Quality of Life – Bronchiectasis (QOL-B) respiratory domain PRO be the primary endpoint for the ENCORE study, the second trial in our post-marketing confirmatory clinical trial program for ARIKAYCE.
•In December 2023, we received written feedback from the FDA on the PRO data produced in the ARISE study. We are scheduled to meet with the FDA in late June to gain additional insights and guidance, from which we will finalize our statistical plans for the ENCORE study, including an updated enrollment target for the study.
•In January 2024, we announced that we met our original enrollment target of 250 patients in the ENCORE trial. Enrollment in the study remains ongoing as we await feedback from the FDA on the finalization of our statistical plan. We anticipate reporting topline data from ENCORE in 2025.
Brensocatib
•In the first quarter of 2023, we completed enrollment of adult patients in the Phase 3 ASPEN trial of patients with bronchiectasis, and we anticipate sharing topline data in the latter half of the second quarter of 2024.
•We plan to explore the potential of brensocatib in additional neutrophil-mediated diseases. The Phase 2b BiRCh trial of brensocatib in patients with CRSsNP is underway.
•We are advancing commercial readiness activities in preparation for a launch of brensocatib for patients with bronchiectasis, if approved. If successful, we anticipate a launch in the US in mid-2025, followed by launches in Europe and Japan in the first half of 2026.
•We expect to initiate a Phase 2 study of brensocatib in patients with hidradenitis suppurativa (HS) in the second half of 2024, pending positive results from the ASPEN study.
TPIP
•In May 2024, we reported topline safety data and certain exploratory efficacy endpoints from the Phase 2 study of TPIP in patients with PH-ILD. Based on these Phase 2 results in PH-ILD, we are advancing toward discussions with global regulatory authorities on the design of a Phase 3 study in PH-ILD, which we anticipate initiating in 2025.
•Enrollment in the Phase 2 study of TPIP in PAH remains ongoing. We anticipate topline results in 2025.
Early-Stage Research
31
•We continue to progress our early-stage research programs across a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for products, product candidates and technologies, including those that address serious and rare diseases with significant unmet need.
Our Strategy
Our strategy focuses on the needs of patients with serious and rare diseases. Our first product, ARIKAYCE, is approved in the US as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe or Japan. We believe that ARIKAYCE has the potential to prove beneficial in other patients with refractory MAC. Our product candidates are brensocatib, our Phase 3 product candidate that we are developing for patients with bronchiectasis and other neutrophil-mediated diseases, and TPIP, our Phase 2 product candidate that may offer a differentiated product profile for patients with PH-ILD and PAH. We are also advancing our early-stage research programs encompassing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA-end joining, and synthetic rescue.
Our key priorities are as follows:
•Continue to provide ARIKAYCE to appropriate patients and expand our reliable revenue stream;
•Produce topline clinical data readouts in the near and long term;
•Advance commercial readiness activities to serve significantly more patients with serious and rare diseases; and
•Control spending, prudently deploying capital to support the best return-generating opportunities.
ARIKAYCE for Patients with MAC Lung Disease
ARIKAYCE is our first approved product. ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. In October 2020, ARIKAYCE received approval in Europe for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, ARIKAYCE received approval in Japan for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function. Unlike amikacin solution for intravenous administration, our proprietary Pulmovance™ technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. This technology also prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung and sites of MAC infection via the use of our Pulmovance technology distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily using Lamira, an inhalation device developed and manufactured by PARI. Lamira is a portable nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and was designed specifically for ARIKAYCE delivery.
The FDA has designated ARIKAYCE as an orphan drug and a Qualified Infectious Disease Product (QIDP) for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation provides an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years of exclusivity in the indication for which ARIKAYCE was approved.
ARIKAYCE also has been included in the international treatment guidelines for NTM lung disease. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA), strongly recommend the use of ARIKAYCE for MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options who have failed to convert to a negative sputum culture after at least six months of treatment.
In October 2020, the FDA approved a supplemental new drug application for ARIKAYCE, adding important efficacy data regarding the durability and sustainability of culture conversion to the ARIKAYCE label. The data, which are from the Phase 3 CONVERT study of ARIKAYCE, demonstrate that the addition of ARIKAYCE to guideline-based therapy (GBT) was
32
associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.
Accelerated Approval
In March 2018, we submitted a new drug application (NDA) for ARIKAYCE to the FDA to request accelerated approval. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. In September 2018, the FDA granted accelerated approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs. As required for drugs approved under the LPAD pathway, labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.
As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial. In December 2020, we commenced the post-marketing confirmatory clinical trial program for ARIKAYCE in patients with MAC lung disease consisting of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung infection who have not started antibiotics using the PRO tool validated in the ARISE trial. In September 2023, we announced positive topline results from the ARISE trial. The study met its primary objective of demonstrating that the QOL-B respiratory domain works effectively as a PRO tool in patients with MAC lung disease. Based on these results, we have proposed to the FDA that the change of the respiratory score derived from the QOL-B respiratory domain PRO be the primary endpoint for the ENCORE study. In January 2024, we reached our original target enrollment of 250 patients in the ENCORE trial in patients with newly diagnosed or recurrent nontuberculous mycobacterial lung infection caused by MAC who had not started antibiotics. Enrollment in the study remains ongoing. We received written feedback from the FDA on the patient-reported outcome data produced in the Phase 3 ARISE study in December 2023. We are scheduled to meet with the FDA in late June to gain additional insights and guidance, from which we will finalize our statistical plans for the Phase 3 ENCORE study, including an updated enrollment target for the study.
Regulatory Pathway Outside of the US
In October 2020, the EC granted marketing authorization for ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. ARIKAYCE can now be prescribed for patients across the European Union (EU) countries as well as in the UK. ARIKAYCE is reimbursed nationally in France, Belgium, the Netherlands, the UK and Ireland. We have worked with the German National Association of Statutory Health Insurance Funds (GKV-SV) towards an agreement on the price of ARIKAYCE that would allow us to better serve the needs of patients in Germany; however, since we have been unable to reach an agreement, patient supply of ARIKAYCE in Germany was enabled by import from other EU countries in September 2022. We are working to ensure an uninterrupted supply of ARIKAYCE for patients in Germany and to provide physicians and pharmacists the information they need to obtain ARIKAYCE for their patients through the importation pathway. In January 2023, we agreed upon reimbursement terms with the French authorities. To date, we have been unable to reach an acceptable agreement of a nationally reimbursed price with the Italian Medicines Agency (AIFA); however, ARIKAYCE remains commercially available for physicians to prescribe in Italy under Class C, where we set the price and funding is agreed locally.
In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. In July 2021, we launched ARIKAYCE in Japan.
The CONVERT Study and 312 Study
Accelerated approval of ARIKAYCE was supported by preliminary data from the CONVERT study, a global Phase 3 study evaluating the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. Patients who achieved sputum culture conversion by Month 6 continued in the CONVERT study for an additional 12 months of treatment following the first monthly negative sputum culture in order to assess the durability of culture conversion, as defined by patients that have completed treatment and continued in the CONVERT study off all therapy for three months. In May 2019, we presented at the American Thoracic Society meeting that 41/65 (63.1%) of patients on ARIKAYCE plus GBT who had achieved culture conversion by Month 6 had maintained durable culture conversion for three months off all therapy
33
compared to 0/10 (0%) on GBT only (p<0.0002). Safety data for these patients were consistent with safety data previously reported for patients by Month 6 of the CONVERT study.
Patients who did not culture convert by Month 6 may have been eligible to enroll in the 312 study, an open-label extension study for these non-converting patients who completed six months of treatment in the CONVERT study. The primary objective of the 312 study was to evaluate the long-term safety and tolerability of ARIKAYCE in combination with a standard multi-drug regimen. The secondary objectives of the 312 study included evaluating the proportion of subjects achieving culture conversion (defined in the same way as the CONVERT study) by Month 6 and the proportion of subjects achieving culture conversion by Month 12, which was the end of treatment. We previously reported interim data as of December 2017 for patients in the 312 study, with 28.4% of patients who received GBT only in the CONVERT study (19/67) and 12.3% of patients who had received ARIKAYCE plus GBT in the CONVERT study (7/57) achieving culture conversion by Month 6 of the 312 study. The 312 study has concluded and final efficacy data regarding culture conversion were consistent with these interim data. We have analyzed the safety and efficacy data from the 312 study, and we did not observe any new safety signals.
The ARISE Study
The ARISE trial was a global, randomized, double-blind, placebo-controlled Phase 3b study in adult patients with newly diagnosed or recurrent MAC infections that aimed to generate evidence demonstrating the domain specification, reliability, validity, and responsiveness of PRO-based scores, including a respiratory symptom score. The ARISE study met its primary objective of demonstrating that the QOL-B respiratory domain works effectively as a PRO tool in patients with MAC lung disease. Based on these results, we have proposed to the FDA that the change of the respiratory score derived from the QOL-B respiratory domain PRO be the primary endpoint for the ENCORE study.
Patients in ARISE (N=99) were randomized 1:1 to treatment with ARIKAYCE plus macrolide-based background regimen (ARIKAYCE arm) or placebo plus macrolide-based background regimen (comparator arm) once daily for six months, followed by one month off treatment. ARIKAYCE-treated patients performed better than those in the comparator arm as measured by the QOL-B instrument, with 43.8% of patients achieving an improvement in QOL-B respiratory score above the estimated meaningful within-subject score difference of 14.8, compared with 33.3% of patients in the comparator arm. While the study was not powered to show a statistically significant difference between treatment arms, a strong trend toward significance was observed for improvement from baseline at Month 7 (12.24 vs. 7.76, p=0.1073). Patients in the ARIKAYCE arm also achieved nominally statistically significantly higher culture conversion rates at Month 7 versus patients in the comparator arm (78.8% vs. 47.1%, p=0.0010), and culture conversion was faster and more likely to persist through Month 7 for the ARIKAYCE arm.
Based on the results of ARISE, we plan to explore accelerating the filing for approval of ARIKAYCE in newly infected patients with MAC lung disease with the FDA. Consistent with our expectations, the PMDA in Japan recently confirmed that it would not consider a label expansion for ARIKAYCE based on data from the ARISE study alone.
ARISE Culture Conversion
Consistent with prior clinical studies, a higher proportion of patients in the ARIKAYCE arm achieved culture conversion by Month 6 (defined as negative cultures at Months 5 and 6) compared to patients in the comparator arm (80.6% vs. 63.9%, p=0.0712). Among patients who achieved culture conversion by Month 6, more patients in the ARIKAYCE arm achieved the first of their two required monthly negative cultures for clinical conversion at Month 1 versus the comparator arm (74.3% vs. 46.7%). As reported above, at Month 7 (one month following the cessation of treatment), 78.8% of patients in the ARIKAYCE arm vs. 47.1% of patients in the comparator arm were culture-converted, suggesting that ARIKAYCE-treated patients are more likely to remain negative.
Correlation Between ARISE Culture Conversion and QOL-B Performance
Patients in the ARIKAYCE arm who achieved culture conversion at both Month 6 and Month 7 had nominally statistically significantly greater improvements in QOL-B respiratory domain scores at Month 7 compared to patients in the ARIKAYCE arm who did not achieve culture conversion (15.74 vs. 3.53, p=0.0167 at Month 6 and 14.89 vs. 4.50, p=0.0416 at Month 7).
ARISE Safety and Tolerability
The discontinuation rate of ARIKAYCE or the placebo used in the comparator arm was 22.9% in the ARIKAYCE arm and 7.8% in the comparator arm. Study completion rates were 91.7% in the ARIKAYCE arm and 94.1% in the comparator arm. No new safety events were observed in the ARIKAYCE arm, and the safety profile in general was as expected in both treatment arms. Treatment-emergent adverse events (TEAEs) were reported by 91.7% of patients in the ARIKAYCE arm and 80.4% of patients in the comparator arm. The most common TEAEs were dysphonia (41.7% for the ARIKAYCE arm vs. 3.9% for the comparator arm), cough (27.1% vs. 7.8%), diarrhea (27.1% vs. 25.5%), and COVID-19 (12.5% vs. 9.8%). Of the treatment-emergent serious adverse events observed in the trial, none were determined to be related to ARIKAYCE by investigators.
34
Further Research and Lifecycle Management
We are currently exploring and supporting research and lifecycle management programs for ARIKAYCE beyond treatment of refractory MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. As noted above, we will continue to advance the post-marketing confirmatory MAC lung disease clinical trial program for ARIKAYCE, through the ARISE and ENCORE trials, which are intended to fulfill the FDA's post-marketing requirement to allow for the full approval of ARIKAYCE in the US, as well as to support the use of ARIKAYCE as a treatment for patients with MAC lung disease.
The ENCORE trial is a randomized, double-blind, placebo-controlled Phase 3b study to evaluate the efficacy and safety of an ARIKAYCE-based regimen in patients with newly diagnosed or recurrent MAC infection who have not started antibiotics. Patients are randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for 12 months. Patients will then discontinue all study treatments and remain in the trial for three months for the assessment of durability of culture conversion. The primary endpoint is change from baseline to Month 13 in respiratory symptom score. The key secondary endpoint is the proportion of subjects achieving durable culture conversion at Month 15. In January 2024, we completed our original target enrollment of 250 patients in the ENCORE trial. Enrollment is ongoing, and we anticipate reporting topline data from ENCORE in 2025.
Subsequent lifecycle management studies could also potentially enable us to reach more patients. These initiatives may include new clinical studies sponsored by us and may also include investigator-initiated studies, which are independent clinical studies initiated and sponsored by physicians or research institutions, with funding from us.
Product Pipeline
Brensocatib
Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs) in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the NSPs (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.
Based on the positive results of the WILLOW study discussed below, in December 2020 we commenced our Phase 3 trial, ASPEN, which will investigate brensocatib in bronchiectasis. ASPEN is a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in adult patients with bronchiectasis. Patients with bronchiectasis due to CF were not enrolled in the study. Patients will be randomized to receive brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period. Secondary endpoints include time to first pulmonary exacerbation, percentage of subjects who remain pulmonary exacerbation-free, change from baseline in post-bronchodilator FEV1, rate of severe pulmonary exacerbations, change from baseline in the Bronchiectasis QOL-B Respiratory Symptoms Domain Score, and incidence and severity of TEAEs. This study completed enrollment of adult patients in the first quarter of 2023. The study included approximately 460 sites in nearly 40 countries and enrolled 1,682 evaluable adult patients. We anticipate sharing topline data in the latter half of the second quarter of 2024.
In March 2020, AstraZeneca exercised its first option pursuant to our October 2016 license agreement under which AstraZeneca can advance clinical development of brensocatib in the indications of chronic obstructive pulmonary disease (COPD) or asthma. Under the terms of the agreement, upon exercise of this option, AstraZeneca is solely responsible for all aspects of the development of brensocatib up to and including Phase 2b clinical trials in COPD or asthma. In March 2024, AstraZeneca exercised its second and final option, under the agreement, to further develop brensocatib beyond Phase 2b clinical trials and, if approved, commercialize brensocatib in the indications of COPD or asthma, upon reaching agreement after good faith negotiations resulting in terms, including financial terms, satisfactory to us and to AstraZeneca for such further development and commercialization. We and AstraZeneca each retain all discretion to determine, among other things, whether any proposed terms are acceptable to such party. We retain full development and commercialization rights for brensocatib in all other indications and in all geographies.
In June 2020, the FDA granted breakthrough therapy designation for brensocatib for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbations. The FDA's breakthrough therapy designation is designed to expedite the development and review of therapies that are intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. The benefits of breakthrough therapy designation include more frequent communication and meetings with the FDA, eligibility for rolling and priority review, intensive guidance on an efficient drug development program, and organizational commitment from the FDA involving senior managers. In November 2020, brensocatib was granted access to the PRIME
35
scheme from the European Medicines Agency (EMA) for patients with NCFBE.
In October 2021, the EMA’s Paediatric Committee approved the brensocatib Pediatric Investigational Plan for the treatment of patients with NCFBE. As a result, the ASPEN trial includes 41 adolescent patients between ages 12 to 17, which will fulfill the pediatric study requirements to support marketing applications in this patient population in the US, Europe and Japan.
The WILLOW Study
The WILLOW study was a randomized, double-blind, placebo-controlled, parallel-group, multi-center, multi-national, Phase 2 study to assess the efficacy, safety and tolerability, and pharmacokinetics of brensocatib administered once daily for 24 weeks in patients with NCFBE. The WILLOW study was conducted at 116 sites and enrolled 256 adult patients diagnosed with NCFBE who had at least two documented pulmonary exacerbations in the 12 months prior to screening. Patients were randomized 1:1:1 to receive either 10 mg or 25 mg of brensocatib or matching placebo. The primary efficacy endpoint was the time to first pulmonary exacerbation over the 24-week treatment period in the brensocatib arms compared to the placebo arm.
WILLOW Efficacy Data
We announced topline data for the WILLOW study in February 2020 and full data for the WILLOW study in June 2020. In September 2020, final results from the WILLOW study were published online in the New England Journal of Medicine. The data demonstrate that the WILLOW study met its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period for both the 10 mg and 25 mg dosage groups of brensocatib compared to placebo (p=0.027, p=0.044, respectively). The risk of exacerbation at any time during the trial was reduced by 42% for the 10 mg group versus placebo (HR 0.58, p=0.029) and by 38% for the 25 mg group versus placebo (HR 0.62, p=0.046). In addition, treatment with brensocatib 10 mg resulted in a significant reduction in the rate of pulmonary exacerbations, a key secondary endpoint, versus placebo. Specifically, patients treated with brensocatib experienced a 36% reduction in the 10 mg arm (p=0.041) and a 25% reduction in the 25 mg arm (p=0.167) versus placebo. Change in concentration of active neutrophil elastase in sputum versus placebo from baseline to the end of the treatment period was also statistically significant (p=0.034 for 10 mg, p=0.021 for 25 mg).
WILLOW Safety and Tolerability Data
Brensocatib was generally well-tolerated in the study. Rates of AEs leading to discontinuation in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg were 10.6%, 7.4%, and 6.7%, respectively. The most common AEs in patients treated with brensocatib were cough, headache, sputum increase, dyspnea, fatigue, and upper respiratory tract infection. Rates of adverse events of special interest (AESIs) in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg, respectively, were as follows: rates of skin events (including hyperkeratosis) were 11.8%, 14.8%, and 23.6%; rates of dental events were 3.5%, 16.0%, and 10.1%; and rates of infections that were considered AESIs were 17.6%, 13.6%, and 16.9%.
Further Research and Development
In August 2019, we received notice from the FDA that we were awarded a development grant of $1.8 million for specific work to be performed on a PRO tool. The grant funding is for the development of a novel PRO tool for use in clinical trials to measure symptoms in patients with NCFBE with and without NTM lung infection.
In January 2023, we reported topline data from the Phase 2, multiple-dose, pharmacokinetic/pharmacodynamic study of brensocatib in patients with CF. This Phase 2 study included both patients who were on background CFTR modulator drugs and patients who were not on CFTR modulator drugs. The study duration was approximately one month and dosed CF patients to placebo, 10 mg, 25 mg, and 40 mg of brensocatib. A clear dose-dependent and exposure-dependent inhibition of blood NSPs was observed in patients treated with brensocatib across all doses in this study, consistent with the mechanism of action of brensocatib. Safety and tolerability were consistent with what was observed during the Phase 2 WILLOW study, with no significant drug-related findings. We concluded that an additional cohort evaluating a 65 mg dose of brensocatib is not needed in this patient population.
We also plan to explore the potential of brensocatib in additional neutrophil-mediated diseases, including CRSsNP. CRSsNP currently has one approved pharmacological therapy (corticosteriod nasal spray); however, many patients do not respond to corticosteroids or endoscopic sinus surgery. The Phase 2b BiRCh trial of brensocatib in patients with CRSsNP is underway.
Treprostinil Palmitil Inhalation Powder
TPIP is an investigational inhaled formulation of a treprostinil prodrug that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that TPIP prolongs duration of effect and may provide patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day. Reducing dose frequency has the potential to ease treatment burden for patients and improve compliance. Additionally, we believe that TPIP may be associated with fewer side effects, including severity and/or frequency
36
of cough, headache, throat irritation, nausea, flushing and dizziness that are associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe TPIP may offer a differentiated product profile for PH-ILD and PAH.
In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. The objective of this first-in-human single ascending dose and multiple ascending dose study was to assess the pharmacokinetics and tolerability profile of TPIP. Data from the study demonstrated that TPIP was generally well tolerated, with a pharmacokinetic profile that supports continued development with once-daily dosing. The most common AEs across all cohorts in the study were cough, dizziness, headache, and nausea. Most AEs were mild in severity and consistent in nature with those typically seen with other inhaled prostanoid therapies. There were few moderate AEs and no severe or serious AEs. Subjects in the multiple dose panel that incorporated an up-titration approach beginning at 112.5 µg once-daily and progressing to 225 µg once-daily reported fewer AEs compared to the panel dosed with 225 µg once-daily from the first dose.
Overall pharmacokinetic results demonstrated that treprostinil exposure (AUC and Cmax) was dose-proportional, with low to moderate inter-subject variability. Treprostinil was detected in the plasma at 24 hours at all doses and throughout the 48-hour sampling period for the two highest doses. Compared with currently available inhaled treprostinil therapy, TPIP showed substantially lower Cmax and longer half-life. Data from this study were presented in an oral session at the European Society of Cardiology Congress in August 2021.
In May 2024, we reported topline safety data and certain exploratory efficacy endpoints from the Phase 2 study of TPIP in patients with PH-ILD. Based on these Phase 2 results in PH-ILD, we are advancing toward discussions with global regulatory authorities on the design of a Phase 3 study in PH-ILD, which we anticipate initiating in 2025. We also have an ongoing Phase 2 study designed to investigate the effect of TPIP in patients with PAH. Enrollment in the Phase 2 study of TPIP in PAH remains ongoing and we anticipate topline results in 2025.
Early-Stage Research
Our early-stage research efforts are comprised of our preclinical programs, advanced through internal research and development and augmented through business development activities. In March 2021, we acquired a proprietary protein deimmunization platform, called Deimmunized by Design, focused on the reengineering of therapeutic proteins to evade immune recognition and reaction. In August 2021, we acquired Motus and AlgaeneX, preclinical stage companies engaged in the research, development and manufacturing of gene therapies for rare genetic disorders. In January 2023, we acquired Vertuis, a privately held, preclinical stage company engaged in the research and development of gene therapies for rare genetic disorders. In June 2023, we acquired Adrestia, a privately held, preclinical stage company using precision genetic models to search for therapeutic targets, precision diagnostics, novel drug compounds and new applications for existing drugs.
We continue to progress our early-stage research programs across a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Corporate Development
We plan to continue to develop, acquire, in-license or co-promote other products, product candidates and technologies, including those that address serious and rare diseases that currently have significant unmet needs. We are focused broadly on serious and rare disease therapeutics and prioritizing those areas that best align with our core competencies.
KEY COMPONENTS OF OUR RESULTS OF OPERATIONS
Product Revenues, Net
Product revenues, net, consist of net sales of ARIKAYCE. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors. In December 2020, we began commercial sales of ARIKAYCE in Europe. In July 2021, we began recognizing product revenue from commercial sales of ARIKAYCE in Japan. We recognize revenue for product received by our customers net of allowances for customer credits, including prompt pay discounts, service fees, estimated rebates, including government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US, and chargebacks.
Cost of Product Revenues (Excluding Amortization of Intangible Assets)
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. We began capitalizing inventory upon FDA approval of ARIKAYCE in September 2018.
Research and Development Expenses
R&D expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs and program management. R&D expenses also
37
includes other internal operating expenses, the cost of manufacturing product candidates, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib, and may include the cost of asset acquisitions. Our R&D expenses related to manufacturing our product candidates and medical devices for clinical study are primarily related to activities at CMOs that manufacture brensocatib, TPIP and early-stage research activities. Our R&D expenses related to clinical trials are primarily related to activities at contract research organizations (CROs) that conduct and manage clinical trials on our behalf. These contracts with CROs set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts with CROs primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Deposits for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed.
Selling, General and Administrative (SG&A) Expenses
SG&A expenses consist of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, commercial and pre-commercial, corporate development, field sales, information technology and human resource functions. SG&A expenses also include professional fees for legal services, consulting services, including commercial activities, insurance, board of director fees, tax and accounting services and certain milestones related to ARIKAYCE.
Amortization of Intangible Assets
Upon commercialization of ARIKAYCE, our intangible assets began to be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based on estimates and assumptions we believe are reasonable based on available facts and circumstances. Unanticipated events or circumstances may occur that require us to review the assets for impairment.
Change in Fair Value of Deferred and Contingent Consideration Liabilities
In connection with the Business Acquisition, we recorded deferred and contingent consideration liabilities related to potential future milestone payments. Adjustments to the fair value are due to changes in: the probability of achieving milestones; our stock price; or certain other estimated assumptions. The change in fair value of deferred and contingent consideration liabilities is calculated quarterly with gains and losses recorded in the consolidated statements of comprehensive loss.
Investment Income and Interest Expense
Investment income consists of interest and dividend income earned on our cash and cash equivalents and marketable securities. Interest expense consists primarily of contractual interest costs, Royalty Financing Agreement non-cash interest expense and the amortization of debt issuance costs related to our debt. Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Our balance sheet reflects debt, net of the debt discount, debt issuance costs paid to the lender, and other third-party costs. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Change in Fair Value of Interest Rate Swap
We record derivative and hedge transactions in accordance with GAAP. In the fourth quarter of 2022, we entered into an interest rate swap contract (the Swap Contract) with a notional value of $350 million to economically hedge our variable rate-based term debt for three years, effectively changing the variable rate under the term debt to a fixed interest rate. Our interest rate swap has not been designated as a hedging instrument for accounting purposes. Consequently, all changes in the fair value of the Swap Contract are reported as a component of net loss in the consolidated statements of comprehensive loss.
RESULTS OF OPERATIONS
Comparison of the Three Months Ended March 31, 2024 and 2023
Overview - Operating Results
Our operating results for the three months ended March 31, 2024, included the following:
•Product revenues, net, increased $10.3 million, or 15.8%, as compared to the same period in the prior year as a result of the growth in ARIKAYCE sales;
•Cost of product revenues (excluding amortization of intangible assets) increased $3.6 million as compared to the same period in the prior year as a result of the increase in sales volumes of ARIKAYCE;
38
•R&D expenses decreased $6.8 million as compared to the same period in the prior year primarily as a result of a non-cash asset acquisition in the first quarter of 2023;
•SG&A expenses increased $13.2 million as compared to the same period in the prior year primarily as a result of increases in compensation and benefit-related expenses and stock-based compensation cost;
•Amortization of intangible assets of $1.3 million was consistent with the same period in the prior year;
•Change in fair value of deferred and contingent consideration liabilities increased $2.4 million, primarily as a result of the change in our share price; and
•Interest expense increased $1.0 million as compared to the same period in the prior year due to the Term Loan.
Product Revenues, Net
Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes revenue by geography for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,Increase (decrease)
20242023$%
US$56,349 $49,067 $7,282 14.8%
Japan14,891 13,156 1,735 13.2%
Europe and rest of world4,260 2,991 1,269 42.4%
  Total product revenues, net$75,500 $65,214 $10,286 15.8%
Product revenues, net, for the three months ended March 31, 2024 increased to $75.5 million as compared to $65.2 million in the same period in 2023, an increase of 15.8%, as a result of growth in ARIKAYCE sales in the US, Japan and Europe and the rest of the world.
Cost of Product Revenues (excluding amortization of intangible assets)
Cost of product revenues (excluding amortization of intangible assets) for the three months ended March 31, 2024 and 2023 were comprised of the following (in thousands):
Three Months Ended March 31,Increase (decrease)
20242023$%
Cost of product revenues (excluding amortization of intangible assets)$17,457 $13,830 $3,627 26.2 %
Cost of product revenues, as % of revenues23.1 %21.2 %
Cost of product revenues (excluding amortization of intangible assets) increased by $3.6 million, or 26.2%, to $17.5 million for the three months ended March 31, 2024 as compared to $13.8 million in the same period in 2023. The increase in cost of product revenues (excluding amortization of intangibles) for the three months ended March 31, 2024 was primarily attributable to the increase in product revenues discussed above.
R&D Expenses
R&D expenses for the three months ended March 31, 2024 and 2023 were comprised of the following (in thousands):
39
 Three Months Ended March 31,Increase (decrease)
 20242023$%
External Expenses    
Clinical development and research$41,069 $43,138 $(2,069)(4.8)%
Manufacturing14,076 13,612 464 $(2,069)3.4 %
Regulatory, quality assurance, and medical affairs5,356 10,330 (4,974)(48.2)%
Vertuis non-cash asset acquisition— 10,250 (10,250)(100.0)%
Subtotal—external expenses$60,501 $77,330 $(16,829)(21.8)%
Internal Expenses    
Compensation and benefit-related expenses41,460 33,236 $8,224 24.7 %
Stock-based compensation10,335 7,899 2,436 30.8 %
Other internal operating expenses8,787 9,400 (613)(6.5)%
Subtotal—internal expenses$60,582 $50,535 $10,047 19.9 %
   Total R&D expenses$121,083 $127,865 $(6,782)(5.3)%
R&D expenses decreased to $121.1 million during the three months ended March 31, 2024 from $127.9 million in the same period in 2023. The $6.8 million decrease in R&D expenses was primarily due to the $10.3 million non-cash asset acquisition cost of Vertuis in the first quarter of 2023 and a $5.0 million decrease in regulatory, quality assurance and medical affairs, partially offset by an increase of $10.7 million in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount.
External R&D expenses by product for the three months ended March 31, 2024 and 2023 were comprised of the following (in thousands):
Three Months Ended March 31,Increase (decrease)
20242023$%
ARIKAYCE external R&D expenses$13,926 $18,249 $(4,323)(23.7)%
Brensocatib external R&D expenses19,518 26,535 (7,017)(26.4)%
TPIP external R&D expenses13,782 14,308 (526)(3.7)%
Non-cash asset acquisitions— 10,250 (10,250)(100.0)%
Other external R&D expenses13,275 7,988 5,287 66.2 %
   Total external R&D expenses$60,501 $77,330 $(16,829)(21.8)%
SG&A Expenses
SG&A expenses for the three months ended March 31, 2024 and 2023 were comprised of the following (in thousands):
 
 Three Months Ended March 31,Increase (decrease)
20242023$%
Compensation and benefit-related expenses32,585 $28,395 $4,190 14.8 %
Stock-based compensation11,115 8,545 2,570 30.1 %
Professional fees and other external expenses34,670 29,966 4,704 15.7 %
Facility related and other internal expenses14,732 13,008 1,724 13.3 %
Total SG&A expenses$93,102 $79,914 $13,188 16.5 %
SG&A expenses increased to $93.1 million during the three months ended March 31, 2024 from $79.9 million in the same period in 2023. The $13.2 million increase resulted primarily from an $6.8 million increase in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount and a $4.7 million increase in professional fees and other external expenses driven by commercial readiness activities for brensocatib.
Amortization of Intangible Assets
Amortization of intangible assets for both the three months ended March 31, 2024 and 2023 was $1.3 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&D and amortization of the milestones paid to PARI for the FDA and EC approvals of ARIKAYCE.
40
Change in Fair Value of Deferred and Contingent Consideration Liabilities
The change in fair value of deferred and contingent consideration for the three months ended March 31, 2024 was $(11.9) million. The change is related to the fair value of the potential future consideration to be paid to former equityholders of the businesses we acquired. Adjustments to the fair value are due to changes in: the probability of achieving milestones; our stock price; or certain other estimated assumptions.
Investment Income
Investment income decreased to $8.8 million for the three months ended March 31, 2024 as compared to $10.5 million in the same period in 2023 due to a decrease in our average cash and cash equivalents and marketable securities balances in 2024 relative to 2023.
Interest Expense
Interest expense increased to $21.0 million for the three months ended March 31, 2024 as compared to $20.0 million in the same period in 2023 primarily due to interest related to the Term Loan. See Note 10 - Debt and Note 11 - Royalty Financing Agreement in this Quarterly Report on Form 10-Q for further details.
Change in Fair Value of Interest Rate Swap
The change in fair value of interest rate swap for the three months ended March 31, 2024 was $2.4 million. Adjustments to the fair value are due to changes in interest rates as of March 31, 2024 relative to the fair value of interest rate swap as of December 31, 2023.

LIQUIDITY AND CAPITAL RESOURCES
 Overview
     There is considerable time and cost associated with developing potential pharmaceutical products to the point of regulatory approval and commercialization. We commenced commercial shipments of ARIKAYCE in October 2018. We expect to continue to incur consolidated operating losses, including losses at our US and certain international entities, as we plan to fund R&D for ARIKAYCE, brensocatib, TPIP and our other pipeline programs, continue commercialization and regulatory activities for ARIKAYCE, fund pre-commercialization activities for brensocatib, and engage in other general and administrative activities.
In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through the new ATM program, under which Leerink acts as sales agent. No shares were sold through the new ATM program during the three months ended March 31, 2024.
In October 2022, we entered into the $350 million Term Loan with Pharmakon that matures on October 19, 2027. The Term Loan bears interest at a rate based upon the SOFR, subject to a SOFR floor of 2.5% in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at our election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at our option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8 million.
In October 2022, we entered into the Royalty Financing Agreement with OrbiMed, whereby OrbiMed paid us $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments equal to or greater than $150 million on or prior to March 31, 2028, the royalty rate for ARIKAYCE will be increased for all subsequent fiscal quarters to a rate which, if applied retroactively, would have resulted in aggregate Revenue Interest Payments to OrbiMed for all fiscal quarters ended on or prior to March 31, 2028 equal to $150 million. In addition, we must make a one-time payment to OrbiMed in an amount that, when added to the aggregate amount of Revenue Interest Payments received by OrbiMed as of March 31, 2028, would equal $150 million. The total Revenue Interest Payments payable by us to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $3.8 million, were $146.2 million.
41
In October 2022, we also completed an underwritten offering of 13,750,000 shares of our common stock at a public offering price of $20.00 per share. Our net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.
We may need to raise additional capital to fund our operations, the continued commercialization of ARIKAYCE, launch readiness activities for the potential launch of brensocatib for the treatment of patients with bronchiectasis, if approved, clinical trials for brensocatib, TPIP, and our future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be the ASPEN trial, expenses related to our commercialization efforts and our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and to a lesser extent, expenses related to the clinical development of TPIP and our early-research programs.
Cash Flows
As of March 31, 2024, we had cash and cash equivalents of $595.7 million, as compared with $482.4 million as of December 31, 2023. In addition, as of December 31, 2023, we had marketable securities of $298.1 million. The $113.4 million increase in cash and cash equivalents was primarily due to the maturity of marketable securities, partially offset by our cash used in operating activities. Our working capital was $337.9 million as of March 31, 2024, as compared with $703.4 million as of December 31, 2023.
Net cash used in operating activities was $184.0 million and $146.3 million for the three months ended March 31, 2024 and 2023, respectively. The net cash used in operating activities during the three months ended March 31, 2024 and 2023 was primarily for the commercial, clinical and manufacturing activities related to ARIKAYCE, as well as other SG&A expenses and clinical trial expenses related to brensocatib and TPIP. The increase in cash used in operating activities for the three months ended March 31, 2024 compared to the corresponding period in 2023 was primarily due to the increase in net loss, excluding the adjustments to reconcile net loss to net cash used in operating activities.
Net cash provided by investing activities was $295.3 million and $41.6 million for the three months ended March 31, 2024 and 2023, respectively. The increase in 2024 is due to maturity of marketable securities in three months ended March 31, 2024.
Net cash provided by (used in) financing activities was $3.0 million and $(0.4) million for the three months ended March 31, 2024 and 2023, respectively. The increase in 2024 is due to proceeds received from stock option exercises and the ESPP in the three months ended March 31, 2024.
Contractual Obligations
There were no material changes outside of the ordinary course of business in our contractual obligations during the three months ended March 31, 2024 from those disclosed in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2023.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.
CRITICAL ACCOUNTING ESTIMATES
There have been no material changes to our critical accounting policies and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023. For the required interim disclosure updates related to our accounting policies and estimates, see Note 2 - Summary of Significant Accounting Policies in this Quarterly Report on Form 10-Q.
ITEM 3.                                                QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As of March 31, 2024, our cash and cash equivalents were in cash accounts and money market funds. Our investments in money market funds are not insured by the federal government. As of March 31, 2024, our marketable securities were invested in US treasury notes with an original maturity of greater than 90 days.
As of March 31, 2024, we had $225.0 million of convertible notes outstanding. Our 2025 Convertible Notes and our 2028 Convertible Notes bear interest at a coupon rate of 1.75% and 0.75%, respectively. In addition, as of March 31, 2024, we had a $350 million Term Loan and a $150.0 million Royalty Financing Agreement outstanding. The Term Loan accrues interest
42
quarterly at the SOFR subject to a floor of 2.5%, plus a margin of 7.75% per annum. We entered into the Swap Contract as a hedge to the Term Loan variable interest rate. The Royalty Financing Agreement pays interest at 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% thereafter as well as 0.75% of brensocatib global net sales, if approved. If a 10% change in interest rates had occurred on March 31, 2024, it would not have had a material effect on the fair value of our debt as of that date, nor would it have a material effect on our future earnings or cash flows.
The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds, and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations and during the three months ended March 31, 2024 and 2023, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.
ITEM 4.                                                CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.
ITEM 1A.    RISK FACTORS
Our business is subject to substantial risks and uncertainties. You should carefully consider the information contained in this Quarterly Report on Form 10-Q, the risks and uncertainties described below, and the risk factors and other information contained in our other public filings in evaluating our business, including our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 22, 2024. Any of the risks and uncertainties described herein and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Form 10-Q (please read "Cautionary Note Regarding Forward-Looking Statements" in this Quarterly Report on Form 10-Q).
We rely on third parties including collaborators, CROs, clinical and analytical laboratories, CMOs and other providers for many services that are critical to our business. If we are unable to form and sustain these relationships, or if any third-party arrangements that we may enter into are unsuccessful, including due to non-compliance by such third parties with our agreements or applicable law, our ability to develop and commercialize our products may be materially adversely affected.
We currently rely, and expect to continue to rely, on third parties for significant research, analytical services, preclinical development, clinical development and manufacturing of our product candidates and commercial scale manufacturing of ARIKAYCE and Lamira. For example, we do not own facilities for clinical-scale or commercial manufacturing of our product candidates, and we expect that our future supply requirements for brensocatib and TPIP will be manufactured by CMOs. We currently rely on Resilience Biotechnologies Inc. to provide our clinical and commercial supply of ARIKAYCE, and intend to also rely on Patheon in the future. We currently primarily rely on Esteve Pharmaceuticals, S.A. and Thermo Fisher to provide our clinical supply for brensocatib. Additionally, almost all of our clinical trial work is done by
43
CROs, such as PPD Development, L.P., our CRO for the ARISE, ENCORE, ASPEN, BiRCh, and TPIP trials, and clinical laboratories. In addition, we rely on third parties to manufacture clinical materials for our early-stage research programs. Reliance on these third parties poses a number of risks, including the following:

•The diversion of management time and cost of third-party advisers associated with the negotiation, documentation and implementation of agreements with third parties in the pharmaceutical industry;
•The inability to control whether third parties devote sufficient resources to our programs or products, including with respect to meeting contractual deadlines;
•The inability to control the regulatory and contractual compliance of third parties, including their quality systems, processes and procedures, systems utilized to collect and analyze data, and equipment used to test drug product and/or clinical supplies;
•The inability to establish and implement collaborations or other alternative arrangements on favorable terms;
•Disputes with third parties, including CROs, leading to loss of intellectual property rights, delay or termination of research, development, or commercialization of product candidates or litigation or arbitration;
•Contracts with our collaborators fail to provide sufficient protection of our intellectual property; and
•Difficulty enforcing our contractual rights if one of these third parties fails to perform.
We also rely on third parties to select and enter into agreements with clinical investigators to conduct clinical trials to support approval of our product candidates, and the failure of these third parties to appropriately carry out such evaluation and selection can adversely affect the quality of the data from these studies and, potentially, the approval of our products. In particular, as part of future drug approval submissions to the FDA, we must disclose certain financial interests of investigators who participated in any of the clinical studies being submitted in support of approval, or must certify to the absence of such financial interests. The FDA evaluates the information contained in such disclosures to determine whether disclosed interests may have an impact on the reliability of a study. If the FDA determines that financial interests of any clinical investigator raise serious questions of data integrity, the FDA can institute a data audit, request that we submit further data analyses, conduct additional independent studies to confirm the results of the questioned study, or refuse to use the data from the questioned study as a basis for approval. A finding by the FDA that a financial relationship of an investigator raises serious questions of data integrity could delay or otherwise adversely affect approval of our products.
In January 2024, the US House of Representatives introduced the BIOSECURE Act (H.R. 7085) and the Senate advanced a substantially similar bill (S.3558), which legislation, if passed and enacted into law, would potentially restrict our ability to purchase services or products from, or otherwise collaborate with, any "biotechnology company of concern,” which includes certain Chinese biotechnology companies, without losing the ability to contract with, or otherwise receive funding from, the US government. We do business with companies in China and it is possible some of our contractual counterparties could be impacted by this legislation.
These risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock.
ITEM 2.     UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES
None.
ITEM 5.    OTHER INFORMATION
Rule 10b5-1 Trading Plans
Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities adopted, modified or terminated by our executive officers and directors during the first quarter of 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each, a “Trading Plan”).
44
Name and TitleDate of Adoption of Trading PlanScheduled Start Date of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading PlanDate Plan Terminated
William Lewis
Chief Executive Officer
3/13/202310/27/202305/31/2024105,0002/26/2024
Sara Bonstein
Chief Financial Officer
2/27/20245/28/202411/12/2024241,288N/A
Drayton Wise
Chief Commercial Officer
2/27/20246/03/202410/27/202537,000N/A
S. Nicole Schaeffer
Chief People Strategy Officer
2/27/20246/03/20245/21/202563,734N/A
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.

ITEM 6.    EXHIBITS
Exhibit Index
Articles of Incorporation of Insmed Incorporated, as amended through June 14, 2012 (incorporated by reference from Exhibit 3.1 to Insmed Incorporated’s Annual Report on Form 10-K filed on March 18, 2013).
Amended and Restated Bylaws of Insmed Incorporated (effective as of May 11, 2023) (incorporated by reference from Exhibit 3.1 to Insmed Incorporated’s Current Report on Form 8-K filed on May 11, 2023).
Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101The following materials from Insmed Incorporated’s quarterly report on Form 10-Q for the quarter ended March 31, 2024 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, (ii) Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023, (iii) Consolidated Statements of Shareholders' Deficit for the three months ended March 31, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023, (v) Notes to the Unaudited Consolidated Financial Statements, and (vi) Cover Page.
104The cover page from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in iXBRL and contained in Exhibit 101.

45
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
  INSMED INCORPORATED
 
 
Date: May 9, 2024By/s/ Sara Bonstein
  Sara Bonstein
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

46
 EX-31.1 2 insm-20240331ex311.htm EX-31.1 Document

EXHIBIT 31.1
 
Section 302 Certification
 
I, William H. Lewis, Chief Executive Officer of Insmed Incorporated, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 9, 2024

 
 
/s/ William H. Lewis
William H. Lewis
Chair and Chief Executive Officer
(Principal Executive Officer)
 



 EX-31.2 3 insm-20240331ex312.htm EX-31.2 Document

EXHIBIT 31.2
 
Section 302 Certification
 
I, Sara Bonstein, Chief Financial Officer of Insmed Incorporated, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 9, 2024
 
/s/ Sara Bonstein
Sara Bonstein
Chief Financial Officer
(Principal Financial and Accounting Officer)
 


 EX-32.1 4 insm-20240331ex321.htm EX-32.1 Document

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003
 
In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the "Company") for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, William H. Lewis, Chief Executive Officer of the Company, certify, pursuant to 18 USC. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2003, that:
 
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ William H. Lewis
William H. Lewis
Chair and Chief Executive Officer
(Principal Executive Officer)

May 9, 2024
 
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


 EX-32.2 5 insm-20240331ex322.htm EX-32.2 Document

EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003
 
In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the "Company") for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Sara Bonstein, Chief Financial Officer of the Company, certify, pursuant to 18 USC. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2003, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Sara Bonstein
Sara Bonstein
Chief Financial Officer
(Principal Financial and Accounting Officer)

May 9, 2024
 
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
 


 EX-101.SCH 6 insm-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Intangibles, Net and Goodwill link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fixed Assets, Net link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Royalty Financing Agreement link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Intangibles, Net and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Fixed Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Royalty Financing Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - The Company and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Product Revenues, Net - Product Revenues By Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Intangibles, Net and Goodwill - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Intangibles, Net and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Fixed Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Leases - Lease, costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Debt - Components of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Debt - Future Principal Repayments of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Debt - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Royalty Financing Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Acquisitions - Asset Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 insm-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 insm-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 insm-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Non-cash operating lease expense Noncash Operating Lease Expense Noncash Operating Lease Expense Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Accrued royalty and milestones payable Royalty financing liability Accrued Royalties, Current Customer A Customer A [Member] Customer A [Member] Swap interest income Interest Income, Other Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument Conversion Term [Axis] Debt Instrument Conversion Term [Axis] Debt Instrument Conversion Term [Axis] Equity Award [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value IPR&D expense Research and Development Asset Acquired Other than Through Business Combination, Writeoff Europe and rest of world Europe And The Rest Of The World [Member] Europe And The Rest Of The World Options outstanding, nonvested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Debt Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Cash paid in acquisition Payments to Acquire Businesses, Gross William Lewis [Member] William Lewis Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] PSUs Performance options Performance Shares [Member] Accounts payable and other accrued operating expenses Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Insider Trading Policies and Procedures [Line Items] Debt Instrument Conversion Term [Domain] Debt Instrument Conversion Term [Domain] [Domain] for Debt Instrument Conversion Term [Axis] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Earnings Per Share, Basic and Diluted [Table] Schedule of Earnings Per Share, Basic and Diluted [Table] Schedule of Earnings Per Share, Basic and Diluted [Table] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Shareholders' Equity Equity [Text Block] Other assets Increase (Decrease) in Other Noncurrent Assets Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Probabilities of success Measurement Input, Probability Of Success [Member] Measurement Input, Probability Of Success Issuance of common stock for vesting of RSUs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Concentration Risk [Line Items] Concentration Risk [Line Items] Leases Lessee, Leases [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Revenue Interest Payments payable Revenue Interest Payments Payable Revenue Interest Payments Payable Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted net loss per share (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Face value of outstanding convertible notes Secured Debt Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Indefinite-lived Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Share price used to calculate issuable shares (in dollars per share) Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Contingent Consideration (Level 3 Liabilities) Fair Value, Inputs, Level 3 [Member] Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Deferred and contingent consideration Business Combination, Deferred Payments, Current Business Combination, Deferred Payments, Current Exercise of stock options and ESPP shares Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Term Loan Term Loan [Member] Term Loan Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Accrued interest payable Interest Payable, Current Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Royalty Financing Agreement Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block] Inducement stock options granted to new employees (in shares) Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross Gross number of inducement share options (or share units) granted during the period. Shareholders’ equity: Equity, Attributable to Parent [Abstract] Consecutive trading day period Business Acquisition, Consecutive Trading Day Period Business Acquisition, Consecutive Trading Day Period Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercise of stock options and ESPP shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Cost of product revenues (excluding amortization of intangible assets) Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Schedule of Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share Schedule of Weighted Average Number of Shares [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Marketable securities Marketable Securities, Current Name Forgone Recovery, Individual Name Carrying Value Reported Value Measurement [Member] Goodwill Goodwill Schedule of Fixed Assets Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Royalty financing agreement Royalty financing agreement liability - beginning balance Royalty financing agreement liability - ending balance Accrued Royalties Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] 2026 Long-Term Debt, Maturity, Year Two Measurement Basis [Axis] Measurement Basis [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Amortization of intangible assets, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Royalty Financing Agreement [Roll Forward] Royalty Financing Agreement [Roll Forward] Royalty Financing Agreement Accounts receivable Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast Forecast [Member] Royalty maximum Debt Instrument, Royalty Payable, Maximum Debt Instrument, Royalty Payable, Maximum 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent RS and RSUs Unvested RS and RSUs Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt term (in months) Debt Instrument, Term Payments of equity issuance costs Payments of stock issuance costs Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Payment of debt issuance costs Payments of Debt Issuance Costs 2019 Incentive Plan 2019 Incentive Plan [Member] 2019 Incentive Plan [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Debt, Current and Long-Term Portion of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Conversion Term (iv) Debt Instrument, Conversion Term Four [Member] Debt Instrument, Conversion Term Four [Member] Shares sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction 2018 ESPP Employee Stock Purchase Plan 2018 [Member] Employee Stock Purchase Plan 2018 [Member] Payables and Accruals [Abstract] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Schedule of Asset Acquisition Asset Acquisition [Table Text Block] Stock options and RSUs Stock Options And Restricted Stock Units [Member] Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received. Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Convertible debt contractual interest expense Interest expense recognized Interest Expense, Debt Milestone Event 2 Milestone Event 2 [Member] Milestone Event 2 Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Supplemental Noncash Disclosures included in Consolidated Financial Statements Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Unrealized (loss) gain on marketable securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development Research and Development Expense [Member] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] 2029 and thereafter Long-Term Debt, Maturity, after Year Four And Thereafter Long-Term Debt, Maturity, after Year Four And Thereafter Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Insmed share price (in usd per share) Business Combination, Deferred Consideration Liability, Measurement Input Business Combination, Deferred Consideration Liability, Measurement Input Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Interest expense Total interest expense Interest Expense Unrecognized compensation expense related to unvested RSU awards Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Selling, general and administrative General and Administrative Expense [Member] Shares of common stock, maximum authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Fixed assets, gross Property, Plant and Equipment, Gross Additions Finite-Lived Intangible Assets Acquired Operating right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Revenue Interest Payments paid and payable Payments for Royalties Amortization of intangible assets, remainder of 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Weighted average probability of success Values Business Combination, Contingent Consideration, Liability, Measurement Input Schedule of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Leases Lessee, Finance Leases [Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Accrued Liabilities, Current Accrued Liabilities, Current [Member] Accrued Liabilities, Current Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Discount rate Measurement Input, Discount Rate [Member] Operating lease liabilities Operating Lease, Liability, Current 2027 Long-Term Debt, Maturity, Year Three Finance lease interest expense Finance Lease, Interest Expense Amortization of intangible assets Amortization Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangibles, net Intangibles, net Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Lease cost, future right-of-use asset Lessee, Operating Lease, Lease Not Yet Commenced, Amount Lessee, Operating Lease, Lease Not Yet Commenced, Amount Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Remaining discount amortization period (in years) Convertible Debt Instrument, Discount Amortization Period, Remaining Convertible Debt Instrument, Discount Amortization Period, Remaining Manufacturing equipment Manufacturing Equipment [Member] Manufacturing Equipment Schedule of Earnings Per Share, Basic and Diluted [Line Items] Schedule of Earnings Per Share, Basic and Diluted [Line Items] [Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table] Offering price per share (in dollars per share) Sale of Stock, Price Per Share Finite-lived Intangible Assets [Roll Forward] Finite-Lived Intangible Assets [Roll Forward] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease, cost Variable Lease, Cost Rent expense charged to operations Operating Lease, Cost 0.75% convertible senior notes due 2028 Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member] Zero Point Seven Five Percent Convertible Senior Note Due 2028 Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, issued shares (in shares) Common Stock, Shares, Issued Aggregate value Business Combination, Consideration Transferred Residual equity component of debt Debt Instrument, Convertible, Carrying Amount of Equity Component Security Exchange Name Security Exchange Name Total Long-Term Debt Aggregate net proceeds from stock offering Sale of Stock, Consideration Received on Transaction 2028 Long-Term Debt, Maturity, Year Four Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Common stock options Employee Stock Option [Member] Interest rate swap Interest Rate Derivative Liabilities, at Fair Value Total operating expenses Costs and Expenses Maximum Maximum [Member] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Proceeds from loans Proceeds from Loans Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Issuance of common stock for asset acquisition Stock Issued During Period, Value, Acquisitions Customer C Customer C [Member] Customer C [Member] Entity Address, Address Line One Entity Address, Address Line One Accrued technical operation expenses Accrued Technical Operation Expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage Share Price Measurement Input, Share Price [Member] Business Acquisition [Axis] Business Acquisition [Axis] Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Customer Concentration Risk Customer Concentration Risk [Member] Schedule of Rollforward of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Shares issued upon milestone achievements (in shares) Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares Net proceeds from issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Acquisitions Business Combination Disclosure [Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] AlgaeneX AlgaeneX, Inc. [Member] AlgaeneX, Inc. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Inventory, Net Inventory, Net Paid-in-kind interest capitalized Accumulated Capitalized Interest Costs Payments to acquire marketable securities Payments to Acquire Marketable Securities Statistical Measurement [Axis] Statistical Measurement [Axis] Proceeds from royalty financing Proceeds From Royalty Financing Proceeds From Royalty Financing Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Accretion of discount on marketable securities, net Accretion Of Debt Discount, Marketable Securities Accretion Of Debt Discount, Marketable Securities Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Customer B Customer B [Member] Customer B [Member] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Common stock authorized, aggregate gross sales proceeds (up to) Common Stock Authorized, Aggregate Gross Sales Proceeds Common Stock Authorized, Aggregate Gross Sales Proceeds Original Term Loan balance Face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Leases [Abstract] Accounts payable and accrued liabilities Accounts Payable and Other Accrued Liabilities, Current Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Carrying Value of Term Loan Balance Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Derivatives Derivatives, Policy [Policy Text Block] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Amortization of intangible assets, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Proceeds from royalty financing agreement, net Proceeds From Royalty Financing Agreement, Net Proceeds From Royalty Financing Agreement, Net Common stock, outstanding shares (in shares) Common Stock, Shares, Outstanding Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Initial conversion rate Debt Instrument, Convertible, Conversion Ratio PEO PEO [Member] Option to purchase additional debt Debt Instrument, Option To Purchase Additional Debt Debt Instrument, Option To Purchase Additional Debt Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Balance (in shares) Balance (in shares) Shares, Outstanding Threshold percent of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Brensocatib Global Net Sales Brensocatib Global Net Sales [Member] Brensocatib Global Net Sales Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sara Bonstein [Member] Sara Bonstein Sale of Stock [Axis] Sale of Stock [Axis] Foreign currency translation losses Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Conversion Term (iii) Debt Instrument, Conversion Term Three [Member] Debt Instrument, Conversion Term Three [Member] Customer [Domain] Customer [Domain] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Net loss Net Income (Loss) Available to Common Stockholders, Basic Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Triggering Event [Axis] Triggering Event [Axis] Triggering Event Measurement Input Type [Domain] Measurement Input Type [Domain] Motus and AlgaeneX Motus Biosciences, Inc. And AlgaeneX, Inc. [Member] Motus Biosciences, Inc. And AlgaeneX, Inc. Credit Facility [Axis] Credit Facility [Axis] Vertuis acquisition Adrestia acquisition Noncash Acquisition Related Expense Noncash Acquisition Related Expense Schedule of Future Principal Repayments of Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities The Company and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vesting [Domain] Vesting [Domain] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Common stock shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Fixed Assets, Net Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Accrued professional fees Accrued Professional Fees Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Net loss per share: Earnings Per Share [Abstract] Common stock, $0.01 par value; 500,000,000 authorized shares, 148,560,882 and 147,977,960 issued and outstanding shares at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Shares issued in asset acquisition (in shares) Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares Accrued France ATU reimbursement payable Contract with Customer, Refund Liability, Current Payments of finance lease principal Finance Lease, Principal Payments Triggering Event [Domain] Triggering Event [Domain] Triggering Event [Domain] Contingent consideration Consideration, beginning balance Consideration, ending balance Business Combination, Contingent Consideration, Liability Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Other expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Japan JAPAN Contingent consideration Non-current contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Average sales prices of publicly disclosed priority review voucher sales obligated to pay equity holders, percentage Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage PEO Name PEO Name Concentration risk, percentage Concentration Risk, Percentage Debt Issuance Costs Debt, Policy [Policy Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Current contingent consideration Business Combination, Contingent Consideration, Liability, Current Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other accrued liabilities Other Accrued Liabilities, Current Convertible debt securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Lenders fees and deal expenses Debt Instrument, Fee Amount Furniture and fixtures Furniture and Fixtures [Member] Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total shareholders’ deficit Balance Balance Equity, Attributable to Parent Public Stock Offering Public Stock Offering [Member] Public Stock Offering Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Observable Inputs in Valuation of Deferred Consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Drayton Wise [Member] Drayton Wise Convertible notes Convertible Notes Payable [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Adrestia Therapeutics Ltd Adrestia Therapeutics Ltd [Member] Adrestia Therapeutics Ltd Concentration Risk Type [Axis] Concentration Risk Type [Axis] Change in Fair Value Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Year Ending December 31: Long-Term Debt, Fiscal Year Maturity [Abstract] Contingent payment, value Shares of Insmed common stock issuable on July 1, 2024 Asset Acquisition, Consideration Transferred, Contingent Consideration Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Additions Liabilities, Fair Value Adjustment Level 2 Deferred Consideration (Level 2 Liabilities) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Debt issuance costs, net Debt issuance costs Debt Issuance Costs, Net Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Interest payable Debt Instrument, Percent Of Interest Payable Debt Instrument, Percent Of Interest Payable Document Fiscal Period Focus Document Fiscal Period Focus Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Intangible assets estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Royalty Agreements Royalty Agreements [Member] Schedule of Product Revenues By Geographic Location Revenue from External Customers by Geographic Areas [Table Text Block] Repurchased amount Debt Instrument, Repurchase Amount Paid-in-kind interest capitalized Paid-in-Kind Interest Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Minimum Minimum [Member] Fixed assets, net Fixed assets, net Property, Plant and Equipment, Net Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Shares of Insmed common stock issued on closing Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Royalty financing non-cash interest expense Other Noncash Expense Milestone Event 1 Milestone Event 1 [Member] Milestone Event 1 Liabilities Liabilities [Abstract] Inventory and Cost of Product Revenues (excluding amortization of intangible assets) Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block] Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) Cash paid for income taxes Income Taxes Paid, Net Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Current portion of long-term debt Less: current portion of convertible notes Long-Term Debt, Current Maturities Schedule of Allocation of Employee Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and shareholders’ deficit Liabilities and Equity ATM Program At The Market Agreement [Member] At The Market Agreement Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic net loss per share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation expense related to unvested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Business Combinations and Asset Acquisitions Business Combinations And Asset Acquisitions, Policy [Policy Text Block] Business Combinations And Asset Acquisitions, Policy Remaining lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Arrangement Duration Trading Arrangement Duration Acquired IPR&D In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Revenue from Contract with Customer, Product and Service [Extensible List] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Convertible senior notes Convertible Debt, Fair Value Disclosures Termination Date Trading Arrangement Termination Date Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Common stock, authorized shares (in shares) Common Stock, Shares Authorized Development and regulatory milestones Development And Regulatory Milestones [Member] Development And Regulatory Milestones Motus Motus Biosciences, Inc. [Member] Motus Biosciences, Inc. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Interest payments Debt Instrument, Periodic Payment, Interest Property, Plant and Equipment [Abstract] Milestone Event 3 Milestone Event 3 [Member] Milestone Event 3 Term Loan Long-Term Debt, Gross Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Acquired ARIKAYCE R&D Acquired Research And Development [Member] Acquired Research And Development Award Timing Disclosures [Line Items] Percentage of outstanding shares Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Convertible debt securities Convertible Debt Securities [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments Collateral for interest rate swap Derivative Asset Deferred tax benefit Deferred Income Tax Expense (Benefit) Proceeds from exercise of stock options and ESPP Proceeds from Stock Options Exercised Vertuis Bio, Inc. Vertuis Bio, Inc. [Member] Vertuis Bio, Inc. Statement of Comprehensive Income [Abstract] Third anniversary of closing date Share-Based Payment Arrangement, Tranche Three [Member] S. Nicole Schaeffer [Member] S. Nicole Schaeffer Convertible Debt Convertible Debt [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Amortization of intangible assets, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Shares issued in acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Insider Trading Arrangements [Line Items] 2025 Long-Term Debt, Maturity, Year One Share price (in usd per share) Share Price Other assets Other Assets Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Amortization of intangible assets, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Issuance of common stock for asset acquisition (in shares) Issuance of common stock for business acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Adjustment to Compensation, Amount Adjustment to Compensation Amount Second anniversary of closing date Share-Based Payment Arrangement, Tranche Two [Member] Other Debt Issuance Costs, Other Debt Issuance Costs, Other Change in fair value of deferred and contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Issuance of common stock for vesting of RSUs Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule of Carrying Value and Fair Value of Assets and Liabilities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Finance lease liabilities, long-term Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Amortization of debt issuance costs Amortization of Debt Issuance Costs and Discounts Accrued clinical trial expenses Accrued Clinical Trial Expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses. Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Intangibles, gross Finite-Lived Intangible Assets, Gross Weighted average common shares used in calculation of basic net loss per share: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Provision for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Deferred consideration Business Combination, Deferred Liability Business Combination, Deferred Liability Computer hardware and software Computer Hardware And Software [Member] Computer Hardware And Software Finance lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Accrued compensation and employee related costs Employee-related Liabilities, Current Vesting [Axis] Vesting [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Net proceeds from issuance of common stock Stock Issued During Period, Value, New Issues Equity [Abstract] Inventory Inventory Disclosure [Text Block] 2019 Incentive Plan 2019 Incentive Plan, Third Amendment [Member] 2019 Incentive Plan, Third Amendment Product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Total debt interest expense Interest Expense, Excluding Finance Lease Interest Expense Interest Expense, Excluding Finance Lease Interest Expense Intangibles, Net and Goodwill Intangible Assets Disclosure [Text Block] Royalty percentage Debt Instrument, Royalty, Stated Percentage Debt Instrument, Royalty, Stated Percentage Change in fair value of interest rate swap Change in fair value of interest rate swap Unrealized Gain (Loss) on Derivatives Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value PARI milestones Licensing Agreements [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Credit Facility [Domain] Credit Facility [Domain] Finite-lived Intangible Assets and Impairment Assessment Intangible Assets, Finite-Lived, Policy [Policy Text Block] Interest rate Debt Instrument, Basis Spread on Variable Rate Estimated Useful Life (years) Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Conversion Term (ii) Debt Instrument, Conversion Term Two [Member] Debt Instrument, Conversion Term Two [Member] Debt, long-term Total long-term convertible notes Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Weighted average diluted common shares outstanding (in shares) Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Finance right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 1.75% convertible senior notes due 2025 One Point Seven Five Percent Convertible Senior Note Due 2025 [Member] One Point Seven Five Percent Convertible Senior Note Due 2025 [Member] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Sales Revenue, Product Line Revenue, Product and Service Benchmark [Member] Product Revenues, Net Revenue from Contract with Customer [Text Block] Purchase of fixed assets Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Conversion Term (i) Debt Instrument, Conversion Term One [Member] Debt Instrument, Conversion Term One [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Number of publicly disclosed sales used to determine average sales price owed to equity holders Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders Lease, Cost [Abstract] Lease, Cost [Abstract] ARIKAYCE Global Net Sales ARIKAYCE Global Net Sales [Member] ARIKAYCE Global Net Sales Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Lab equipment Equipment [Member] Investment income Investment Income, Nonoperating Threshold trading days following fundamental change Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change Net proceeds Proceeds from Convertible Debt Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of issuance costs Amortization of Debt Issuance Costs US UNITED STATES Recurring basis Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Construction in progress Construction in Progress [Member] Asset acquisition, consideration transferred Total purchase price Asset Acquisition, Consideration Transferred Finance lease amortization expense Finance Lease, Right-of-Use Asset, Amortization Variable Rate Component Two Variable Rate Component Two [Member] Variable Rate Component Two Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Marketable securities Marketable Securities Equity Component [Domain] Equity Component [Domain] Finance lease liabilities Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Potential award payout Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Interest rate swap Interest Rate Derivative Assets, at Fair Value Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Scenario [Axis] Scenario [Axis] Weighted average basic common shares outstanding (in shares) Weighted average common shares used in calculation of basic net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Term Loan issuance costs, unamortized Royalty issuance costs, unamortized - beginning balance Deferred issuance costs, unamortized - ending balance Unamortized Debt Issuance Expense Operating loss Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Number of reporting units Number of Reporting Units Office equipment Office Equipment [Member] Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Concentration Risk [Table] Concentration Risk [Table] Priority review voucher milestone Priority Review Voucher Milestone [Member] Priority Review Voucher Milestone Scenario [Domain] Scenario [Domain] Accrued sales allowances and related costs Accrued Sales Allowances and Related Costs Accrued Sales Allowances and Related Costs Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Components of Debt Balance Schedule of Carrying Value of Royalty Financing Agreement Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] First anniversary of closing date Share-Based Payment Arrangement, Tranche One [Member] Product [Member] EX-101.PRE 10 insm-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
May 06, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 000-30739  
Entity Registrant Name INSMED INC  
Entity Incorporation, State or Country Code VA  
Entity Tax Identification Number 54-1972729  
Entity Address, Address Line One 700 US Highway 202/206  
Entity Address, City or Town Bridgewater  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08807  
City Area Code 908  
Local Phone Number 977-9900  
Title of 12(b) Security Common stock, par value $0.01 per share  
Trading Symbol INSM  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   148,604,548
Entity Central Index Key 0001104506  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 595,729 $ 482,374
Marketable securities 0 298,073
Accounts receivable 37,162 41,189
Inventory 82,957 83,248
Prepaid expenses and other current assets 42,874 24,179
Total current assets 758,722 929,063
Fixed assets, net 68,660 65,384
Finance lease right-of-use assets 20,307 20,985
Operating lease right-of-use assets 17,157 18,017
Intangibles, net 62,441 63,704
Goodwill 136,110 136,110
Other assets 95,698 96,574
Total assets 1,159,095 1,329,837
Current liabilities:    
Accounts payable and accrued liabilities 189,362 214,987
Current portion of long-term debt 224,194 0
Finance lease liabilities 2,695 2,610
Operating lease liabilities 4,609 8,032
Total current liabilities 420,860 225,629
Debt, long-term 939,081 1,155,313
Royalty financing agreement 156,967 155,034
Contingent consideration 63,700 84,600
Finance lease liabilities, long-term 26,320 27,026
Operating lease liabilities, long-term 13,809 11,013
Other long-term liabilities 3,166 3,145
Total liabilities 1,623,903 1,661,760
Shareholders’ equity:    
Common stock, $0.01 par value; 500,000,000 authorized shares, 148,560,882 and 147,977,960 issued and outstanding shares at March 31, 2024 and December 31, 2023, respectively 1,486 1,480
Additional paid-in capital 3,138,578 3,113,487
Accumulated deficit (3,603,236) (3,446,145)
Accumulated other comprehensive loss (1,636) (745)
Total shareholders’ deficit (464,808) (331,923)
Total liabilities and shareholders’ deficit $ 1,159,095 $ 1,329,837
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 500,000,000 500,000,000
Common stock, issued shares (in shares) 148,560,882 147,977,960
Common stock, outstanding shares (in shares) 148,560,882 147,977,960
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Product revenues, net $ 75,500 $ 65,214
Revenue from Contract with Customer, Product and Service [Extensible List] Product [Member] Product [Member]
Operating expenses:    
Cost of product revenues (excluding amortization of intangible assets) $ 17,457 $ 13,830
Cost, Product and Service [Extensible List] Product [Member] Product [Member]
Research and development $ 121,083 $ 127,865
Selling, general and administrative 93,102 79,914
Amortization of intangible assets 1,263 1,263
Change in fair value of deferred and contingent consideration liabilities (11,900) (9,500)
Total operating expenses 221,005 213,372
Operating loss (145,505) (148,158)
Investment income 8,783 10,524
Interest expense (21,042) (20,003)
Change in fair value of interest rate swap 2,362 (1,533)
Other expense, net (1,100) (111)
Loss before income taxes (156,502) (159,281)
Provision for income taxes 589 483
Net loss $ (157,091) $ (159,764)
Basic net loss per share (in dollars per share) $ (1.06) $ (1.17)
Diluted net loss per share (in dollars per share) $ (1.06) $ (1.17)
Weighted average basic common shares outstanding (in shares) 148,456 136,355
Weighted average diluted common shares outstanding (in shares) 148,456 136,355
Net loss $ (157,091) $ (159,764)
Other comprehensive income (loss):    
Foreign currency translation losses (855) (171)
Unrealized (loss) gain on marketable securities (36) 498
Total comprehensive loss $ (157,982) $ (159,437)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Shareholders' Equity (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Balance (in shares) at Dec. 31, 2022   135,654      
Balance at Dec. 31, 2022 $ 87,951 $ 1,357 $ 2,782,416 $ (2,696,578) $ 756
Comprehensive loss:          
Net loss (159,764)     (159,764)  
Other comprehensive income (loss) 327       327
Exercise of stock options and ESPP shares (in shares)   82      
Exercise of stock options and ESPP shares 1,139 $ 1 1,138    
Issuance of common stock for vesting of RSUs (in shares)   193      
Issuance of common stock for vesting of RSUs 1 $ 1      
Issuance of common stock for asset acquisition (in shares)   500      
Issuance of common stock for asset acquisition 9,250 $ 5 9,245    
Stock-based compensation expense 16,443   16,443    
Balance (in shares) at Mar. 31, 2023   136,429      
Balance at Mar. 31, 2023 (44,653) $ 1,364 2,809,242 (2,856,342) 1,083
Balance (in shares) at Dec. 31, 2023   147,978      
Balance at Dec. 31, 2023 (331,923) $ 1,480 3,113,487 (3,446,145) (745)
Comprehensive loss:          
Net loss (157,091)     (157,091)  
Other comprehensive income (loss) (891)       (891)
Exercise of stock options and ESPP shares (in shares)   217      
Exercise of stock options and ESPP shares 4,052 $ 2 4,050    
Net proceeds from issuance of common stock (in shares)        
Net proceeds from issuance of common stock (409) (409)    
Issuance of common stock for vesting of RSUs (in shares)   366      
Issuance of common stock for vesting of RSUs 4 $ 4      
Stock-based compensation expense 21,450   21,450    
Balance (in shares) at Mar. 31, 2024   148,561      
Balance at Mar. 31, 2024 $ (464,808) $ 1,486 $ 3,138,578 $ (3,603,236) $ (1,636)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating activities    
Net loss $ (157,091) $ (159,764)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,588 1,248
Amortization of intangible assets 1,263 1,263
Stock-based compensation expense 21,450 16,443
Amortization of debt issuance costs 1,851 1,724
Paid-in-kind interest capitalized 6,242 5,456
Royalty financing non-cash interest expense 4,822 2,615
Accretion of discount on marketable securities, net (1,963) 0
Finance lease amortization expense 678 678
Non-cash operating lease expense 6,516 2,491
Change in fair value of deferred and contingent consideration liabilities (11,900) (9,500)
Change in fair value of interest rate swap (2,362) 1,533
Changes in operating assets and liabilities:    
Accounts receivable 2,955 (860)
Inventory (598) (1,187)
Prepaid expenses and other current assets (19,330) (3,199)
Other assets 333 (5,231)
Accounts payable and accrued liabilities (32,345) (8,841)
Other liabilities (6,144) (1,422)
Net cash used in operating activities (184,035) (146,303)
Investing activities    
Purchase of fixed assets (4,679) (3,398)
Maturities of marketable securities 300,000 45,000
Net cash provided by investing activities 295,321 41,602
Financing activities    
Proceeds from exercise of stock options and ESPP 4,052 1,139
Payments of equity issuance costs (409) 0
Payments of finance lease principal (621) (320)
Payment of debt issuance costs 0 (1,218)
Net cash provided by (used in) financing activities 3,022 (399)
Effect of exchange rates on cash and cash equivalents (953) (29)
Net increase (decrease) in cash and cash equivalents 113,355 (105,129)
Cash and cash equivalents at beginning of period 482,374 1,074,036
Cash and cash equivalents at end of period 595,729 968,907
Supplemental disclosures of cash flow information:    
Cash paid for interest 8,210 11,589
Cash paid for income taxes 1,208 1,004
Vertuis Bio, Inc.    
Adjustments to reconcile net loss to net cash used in operating activities:    
Vertuis acquisition 0 10,250
Adrestia acquisition $ 0 $ 10,250
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
The Company and Basis of Presentation
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company and Basis of Presentation
1. The Company and Basis of Presentation
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
The Company's pipeline includes clinical-stage programs, brensocatib and treprostinil palmitil inhalation powder (TPIP), as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, protein manufacturing, RNA-end joining, and synthetic rescue.
The Company was incorporated in the Commonwealth of Virginia on November 29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.
The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US (GAAP) for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Any references in these notes to applicable accounting guidance are meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).
     The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.
     The Company had $595.7 million in cash and cash equivalents as of March 31, 2024 and reported a net loss of $157.1 million for the three months ended March 31, 2024. The Company has funded its operations through public offerings of equity securities, debt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.
The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company’s commercial, regulatory and development activities. Any future financing will also be contingent upon market
conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals, Inc., Insmed Holdings Limited, Insmed Gene Therapy LLC, Insmed Ireland Limited, Insmed France SAS, Insmed Germany GmbH, Insmed Limited, Insmed Netherlands Holdings B.V., Insmed Netherlands B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, Insmed Italy S.R.L., Insmed Innovation UK Limited, and Adrestia Therapeutics Inc. All intercompany transactions and balances have been eliminated in consolidation.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Selected significant accounting policies are discussed in detail below.
Use of Estimates—The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.
Concentration of Credit Risk—Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.
The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2024 and their respective percentages for the three months ended March 31, 2023.
Three Months Ended March 31,
20242023
Customer A35%36%
Customer B34%36%
Customer C16%17%
The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.
Finite-lived Intangible Assets—Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See Note 6 - Intangibles, Net and Goodwill for further details.
Impairment Assessment—The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by
determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.
Business Combinations and Asset Acquisitions—The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&D expense in its consolidated statements of comprehensive loss.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of March 31, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Indefinite-lived Intangible Assets—Indefinite-lived intangible assets consist of IPR&D. IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the
intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.
Goodwill—Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2024 and December 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2024. See Note 6 - Intangibles, Net and Goodwill for further details.
Leases—A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.
Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See Note 9 - Leases for further details.
Debt Issuance Costs—Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Foreign Currency—The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total shareholders' deficit, as a component of accumulated other comprehensive loss.
The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.
Derivatives—In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.
Inventory and Cost of Product Revenues (excluding amortization of intangible assets)—Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during
the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&D expense when consumed.
Net Loss Per Share—Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.
The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
 20242023
 
Numerator:
Net loss$(157,091)$(159,764)
Denominator:
Weighted average common shares used in calculation of basic net loss per share:148,456 136,355 
Effect of dilutive securities:
Common stock options— — 
RS and RSUs— — 
PSUs— — 
Convertible debt securities— — 
Weighted average common shares outstanding used in calculation of diluted net loss per share148,456 136,355 
Net loss per share:
Basic and diluted$(1.06)$(1.17)
The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):
 
As of March 31,
 20242023
Common stock options24,098 19,156 
Unvested RS and RSUs3,059 2,058 
PSUs666 671 
Convertible debt securities23,438 23,438 
Recent Accounting Pronouncements (Not Yet Adopted)—In December 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate
reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements
3. Fair Value Measurements
The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:
•Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
•Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
•Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
As of March 31, 2024
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$595.7 $595.7 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$(1.2)$— $(1.2)$— 
Deferred consideration$5.0 $— $5.0 $— 
Contingent consideration$73.4 $— $— $73.4 
As of December 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$482.4 $482.4 $— $— 
Marketable securities$298.1 $298.1 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$1.2 $— $1.2 $— 
Deferred consideration$5.7 $— $5.7 $— 
Contingent consideration$84.6 $— $— $84.6 
During the three months ended March 31, 2024, $300.0 million of marketable securities, consisting of US Treasury Notes, matured.
The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of March 31, 2024 and December 31, 2023. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March 31, 2024.
As of March 31, 2024, the Company held no available-for-sale securities. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.
The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the three months ended March 31, 2024.
Deferred Consideration
The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.
The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2024, the fair value of deferred consideration included in accounts payable and accrued liabilities was $5.0 million.
The following observable input was used in the valuation of the deferred consideration as of March 31, 2024:
Fair Value as of March 31, 2024 (in millions)
Observable InputInput Value
Deferred consideration
$5.0
Insmed share price as of March 31, 2024
$27.13
Contingent Consideration
The contingent consideration liabilities arose from the Business Acquisition in August 2021 (see Note 16 - Acquisitions). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At March 31, 2024, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.
If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash.
The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of March 31, 2024, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.
The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of March 31, 2024, the fair value of the current and non-current contingent consideration was $9.7 million and $63.7 million, respectively.
A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss. The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2024:
Fair Value as of March 31, 2024 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$65.5Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$5.1Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
15.7%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2024 and 2023 (in thousands):
Deferred
 Consideration
(Level 2 Liabilities)		Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value(1,200)(8,300)
Payments— — 
Balance as of March 31, 2023$6,200 $49,800 
Balance as of December 31, 2023$5,700 $84,600 
Additions— — 
Change in Fair Value(700)(11,200)
Payments— — 
Balance as of March 31, 2024$5,000 $73,400 
Convertible Notes
The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility (collectively, the Current Market Factors), and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.
The estimated fair value of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2024 was $620.1 million, determined using Current Market Factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.
The estimated fair value of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2024 was $238.7 million, determined using Current Market Factors, and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. See Note 10 - Debt for further details on the Company's convertible notes.
Synthetic Royalty Financing Agreement
In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty & Credit Opportunities IV, LP (OrbiMed). Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions.
The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. For more information, see Note 11 - Royalty Financing Agreement.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Product Revenues, Net
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Product Revenues, Net
4. Product Revenues, Net
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to
receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.
Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.
The following table presents a geographic summary of the Company's product revenues, net, for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
US$56,349 $49,067 
Japan14,891 13,156 
Europe and rest of world4,260 2,991 
  Total product revenues, net$75,500 $65,214 
Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.
Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the
government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.
Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.
If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.
The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventory
5. Inventory
The Company's inventory balance consists of the following (in thousands):
As of
March 31, 2024December 31, 2023
Raw materials$21,943 $24,562 
Work-in-process29,359 33,480 
Finished goods31,655 25,206 
$82,957 $83,248 
Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangibles, Net and Goodwill
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net and Goodwill
6. Intangibles, Net and Goodwill
 Intangibles, Net
Finite-lived Intangible Assets
As of March 31, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D and the milestones paid to PARI for the license to use the Lamira® Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.
Indefinite-lived Intangible Assets
As of March 31, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition (see Note 16 - Acquisitions). Indefinite-lived intangible assets are not amortized.
A rollforward of the Company's intangible assets for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):
Intangible AssetDecember 31, 2023AdditionsAmortization
March 31, 2024
Acquired ARIKAYCE R&D$32,738 $— $(1,212)$31,526 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,366 — (51)1,315 
$63,704 $— $(1,263)$62,441 
Intangible AssetDecember 31, 2022AdditionsAmortizationMarch 31, 2023
Acquired ARIKAYCE R&D$37,588 $— $(1,212)$36,376 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (51)1,517 
$68,756 $— $(1,263)$67,493 
Goodwill
The Company's goodwill balance of $136.1 million as of March 31, 2024 and December 31, 2023, resulted from the August 2021 Business Acquisition. See Note 16 - Acquisitions for further details.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fixed Assets, Net
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Fixed Assets, Net
7. Fixed Assets, Net
Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):
Estimated
Useful Life (years)		As of
Asset DescriptionMarch 31, 2024December 31, 2023
Lab equipment7$23,468 $22,660 
Furniture and fixtures76,428 6,428 
Computer hardware and software
3-5
6,106 6,001 
Office equipment789 89 
Manufacturing equipment71,336 1,336 
Leasehold improvements
2-10
37,968 38,049 
Construction in progress—39,238 35,449 
114,633 110,012 
Less: accumulated depreciation(45,973)(44,628)
$68,660 $65,384 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities
8. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
As of
March 31, 2024December 31, 2023
Accounts payable and other accrued operating expenses$44,018 $65,393 
Accrued clinical trial expenses23,754 23,711 
Accrued professional fees16,728 13,885 
Accrued technical operation expenses10,293 9,187 
Accrued compensation and employee related costs23,803 48,933 
Accrued royalty and milestones payable6,514 5,674 
Accrued interest payable2,269 2,175 
Revenue Interest Payments payable3,020 3,347 
Accrued sales allowances and related costs17,159 10,937 
Accrued France ATU reimbursement payable15,896 14,685 
Deferred and contingent consideration15,700 6,700 
Other accrued liabilities10,208 10,360 
$189,362 $214,987 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases
9. Leases
The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.
The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.
The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $4.9 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20242023
Finance right-of-use assets obtained in exchange for lease obligations$— $— 
Operating right-of-use assets obtained in exchange for lease obligations$5,656 $1,751 
In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $52.0 million and $49.1 million incurred by the Company under these additional agreements have been classified within other assets in the Company's consolidated balance sheet as of March 31, 2024 and December 31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.
Leases
9. Leases
The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.
The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.
The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $4.9 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20242023
Finance right-of-use assets obtained in exchange for lease obligations$— $— 
Operating right-of-use assets obtained in exchange for lease obligations$5,656 $1,751 
In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $52.0 million and $49.1 million incurred by the Company under these additional agreements have been classified within other assets in the Company's consolidated balance sheet as of March 31, 2024 and December 31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Debt
10. Debt
Current portion of long-term debt and debt, long-term consists of the following commitments as of March 31, 2024 and December 31, 2023 (in thousands):
As of
March 31, 2024December 31, 2023
Convertible notes$789,731 $788,909 
Term Loan373,544 366,404 
Less: current portion of convertible notes(224,194)— 
Debt, long-term$939,081 $1,155,313 
Convertible Notes
In May 2021, the Company completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7 million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased.
In January 2018, the Company completed an underwritten public offering of $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased.
A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.
On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.
Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during
the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a) the second business day immediately preceding the related redemption date or (b) if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes.
Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity’s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9 million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6 million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4 million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December 31, 2022, prior to the adoption of ASU 2020-06. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 0.78 years and 4.17 years, respectively.
The $565.5 million carrying value of the 2028 Convertible Notes as of March 31, 2024 excludes $9.5 million of unamortized debt issuance costs. The $224.2 million carrying value of the 2025 Convertible Notes as of March 31, 2024 excludes $0.8 million of unamortized debt issuance costs. The 2028 Convertible Notes and 2025 Convertible Notes are long-term and current liabilities, respectively, as of March 31, 2024. The following table presents the carrying value of the
Company's convertible notes balance (in thousands):
As of
March 31, 2024December 31, 2023
Face value of outstanding convertible notes$800,000 800,000 
Debt issuance costs(10,269)(11,091)
Less: current convertible notes(224,194)— 
Total long-term convertible notes$565,537 $788,909 
Secured Senior Term Loan
In October 2022, the Company entered into a $350 million senior secured term loan agreement with Pharmakon Advisors LP (Pharmakon), manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. During the three months ended March 31, 2024, paid-in-kind interest capitalized was $6.2 million. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8 million.
The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2024 (in thousands):
As of
March 31, 2024December 31, 2023
Original Term Loan balance$350,000 $350,000 
Paid-in-kind interest capitalized33,779 27,537 
Term Loan issuance costs, unamortized(10,235)(11,133)
Term Loan$373,544 $366,404 
As of March 31, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):
 
Year Ending December 31: 
2024$— 
2025225,000 
2026191,890 
2027191,889 
2028575,000 
2029 and thereafter— 
 $1,183,779 
Interest Expense
Interest expense related to debt and finance leases for the three months ended March 31, 2024 and 2023 is as follows (in thousands):
Three Months Ended March 31,
20242023
Convertible debt contractual interest expense$2,063 $2,063 
Term Loan contractual interest expense12,483 10,911 
Royalty Financing Agreement interest expense4,822 4,764 
Amortization of debt issuance costs1,851 1,724 
Swap interest income(754)(73)
   Total debt interest expense20,465 19,389 
Finance lease interest expense577 614 
   Total interest expense$21,042 $20,003 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Royalty Financing Agreement
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Royalty Financing Agreement
11. Royalty Financing Agreement
In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $3.8 million were, $146.2 million.
The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be 12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and updates the effective interest rate on a quarterly basis. 
The following table shows the activity within the liability account for the three-month period ended March 31, 2024 and year ended December 31, 2023 (in thousands):
Three Months Ended
March 31, 2024		Twelve Months Ended
December 31, 2023
Royalty financing agreement liability - beginning balance$158,162 $151,538 
Revenue Interest Payments paid and payable(3,020)(12,222)
Interest expense recognized4,822 18,846 
Royalty financing agreement liability - ending balance$159,964 $158,162 
Royalty financing issuance costs:
Royalty issuance costs, unamortized - beginning balance$(3,128)$(3,523)
Amortization of issuance costs131 521 
Other— (126)
Deferred issuance costs, unamortized - ending balance$(2,997)$(3,128)
  Royalty Financing Agreement$156,967 $155,034 

The Revenue Interest Payments payable in connection with the royalty financing agreement were $3.0 million and $3.3 million as of March 31, 2024 and December 31, 2023, respectively, which were recorded within accounts payable and accrued expenses on the consolidated balance sheet. Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Shareholders' Equity
12. Shareholders' Equity
Common Stock—As of March 31, 2024, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 148,560,882 shares of common stock issued and outstanding. In addition, as of March 31, 2024, the Company had reserved 24,098,410 shares of common stock for issuance upon the exercise of outstanding stock options, 3,058,943 shares of common stock for issuance upon the vesting of RSUs and 666,382 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430 shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved 9,406,112 shares of the Company’s common stock, subject to certain closing-related reductions. The shares of the Company’s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first and second anniversaries of the closing date of the acquisition, and will also be issued upon the third anniversary of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company’s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.
Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (see Note 16 - Acquisitions) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition. In the third quarter of 2023, the Company issued 177,203 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the second anniversary of the Business Acquisition.
In the second quarter of 2023, in connection with the Company's acquisition of Adrestia Therapeutics Ltd. (Adrestia), the Company issued 3,430,867 shares of the Company's common stock as consideration at closing. See Note 16 - Acquisitions for further details.
In connection with the Company’s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved 550,000 shares of the Company’s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. An additional $1 million of shares of common stock will be issued to Vertuis’ former stockholders on July 1, 2024, based on the share price on June 28, 2024. See Note 16 - Acquisitions for further details.
In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.
In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an “at the market” equity offering program (the ATM program), under which Leerink acted as sales agent. In 2023, the Company issued and sold an aggregate of 6,503,041 shares of common stock through the ATM program at a weighted-average public offering price of $24.12 per share and received net proceeds of $152.2 million. In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through a new “at the market” equity offering program (the new ATM program), under which Leerink acts as sales agent. In connection with entering into the new ATM program, the Company terminated the ATM program. The Company has not issued any shares under the new ATM program.
Preferred Stock—As of March 31, 2024, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
13. Stock-Based Compensation
The Company's current equity compensation plan, the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders on May 11, 2023. The 2019 Incentive Plan replaced the Insmed Incorporated 2019 Incentive Plan. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. The Company has submitted a proposal to its shareholders to approve an amendment to the 2019 Incentive Plan at the 2024 Annual Meeting of Shareholders (Amendment No.1). Amendment No.1, if approved, will provide for the issuance of an additional 3,000,000 shares under the 2019 Incentive Plan. As of March 31, 2024, 4,705,225 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the three months ended March 31, 2024, the Company granted inducement stock options covering 358,140 shares of the Company's common stock to new employees.
On May 15, 2018, the 2018 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the ESPP: (i) 1,000,000 shares of common stock, plus (ii) commencing on January 1, 2019 and ending on December 31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C) an amount determined by the administrator.
Stock Options—As of March 31, 2024, there was $148.0 million of unrecognized compensation expense related to unvested stock options. As of March 31, 2024, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria.
Restricted Stock Units—As of March 31, 2024, there was $55.8 million of unrecognized compensation expense related to unvested RSU awards.
Performance Stock Units—As of March 31, 2024, there were 266,550 unvested PSUs outstanding with an unrecognized compensation expense of $10.4 million, which assumes a payout at 100% of the target.
The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2024 and 2023, respectively (in millions): 
 Three Months Ended March 31,
 20242023
Research and development$10.4 $7.9 
Selling, general and administrative11.1 8.5 
Total$21.5 $16.4 
There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three months ended March 31, 2024 or March 31, 2023, as the performance conditions associated with the PSU awards were not probable as of either date.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
14. Income Taxes
The Company recorded a provision for income taxes of $0.6 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively. The provisions recorded for the three months ended March 31, 2024 and 2023 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.
The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company’s federal tax returns for the years ended 2020 and later, generally open for certain states for the years 2019 and later, and generally open for international jurisdictions for the years 2018 and later. The Company has incurred net operating losses since inception, except for the year ended December 31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of March 31, 2024 and December 31, 2023, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US. However, given the Company’s valuation allowance position, these reserves do not have an impact on the balance sheet as of March 31, 2024 and December 31, 2023 or the consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023. The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
15. Commitments and Contingencies
Rent expense charged to operations was $3.1 million and $2.2 million for the three months ended March 31, 2024 and 2023, respectively.
Legal Proceedings
From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Acquisitions
16. Acquisitions
Asset Acquisitions
Adrestia Therapeutics Ltd.
In June 2023, the Company acquired all of the issued and outstanding share capital of Adrestia, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 3,430,867 shares of the Company’s common stock to Adrestia’s former shareholders (collectively, the Adrestia shareholders). The closing share price on the date of the transaction was $21.10, resulting in a purchase price of $72.4 million. The Adrestia shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement.
The shares of the Company’s common stock issued to the Adrestia shareholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (and, with respect to certain Adrestia shareholders, in reliance on Regulation S
promulgated under the Securities Act of 1933). The Company did not receive any net proceeds from the issuance of common stock to the Adrestia shareholders.
The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the IPR&D acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition. The Company recognized $76.5 million as IPR&D expense, after adjusting for working capital assumed in connection with the asset acquisition.
Vertuis Bio, Inc.
In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to Vertuis’ former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 with an aggregate value of $1.0 million, based on the share price on June 28, 2024, and pay to the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions.
The shares of the Company’s common stock issued to the Vertuis equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933.
The following table summarizes the purchase price (in millions).
Shares of Insmed common stock issued on closing$9.25 
Shares of Insmed common stock issuable on July 1, 20241.00 
  Total purchase price$10.25 
The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.
Business Combination
On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company’s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company’s common stock, following certain closing-related reductions, to Motus’s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35 million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions.
At the closing of the Company’s acquisition of AlgaeneX, the Company paid $1.5 million in cash to AlgaeneX’s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company’s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX’s manufacturing technology, in each case, subject to certain reductions.
The shares of the Company’s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.
The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.
Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5 million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.
The fair value of IPR&D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net loss $ (157,091) $ (159,764)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities adopted, modified or terminated by our executive officers and directors during the first quarter of 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each, a “Trading Plan”).
Name and TitleDate of Adoption of Trading PlanScheduled Start Date of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading PlanDate Plan Terminated
William Lewis
Chief Executive Officer
3/13/202310/27/202305/31/2024105,0002/26/2024
Sara Bonstein
Chief Financial Officer
2/27/20245/28/202411/12/2024241,288N/A
Drayton Wise
Chief Commercial Officer
2/27/20246/03/202410/27/202537,000N/A
S. Nicole Schaeffer
Chief People Strategy Officer
2/27/20246/03/20245/21/202563,734N/A
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
Non-Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Terminated false
William Lewis [Member]  
Trading Arrangements, by Individual  
Name William Lewis
Title Chief Executive Officer
Adoption Date 3/13/2023
Rule 10b5-1 Arrangement Terminated true
Termination Date 2/26/2024
Arrangement Duration 122 days
Aggregate Available 105,000
Sara Bonstein [Member]  
Trading Arrangements, by Individual  
Name Sara Bonstein
Title Chief Financial Office
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/27/2024
Arrangement Duration 168 days
Aggregate Available 241,288
Drayton Wise [Member]  
Trading Arrangements, by Individual  
Name Drayton Wise
Title Chief Commercial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/27/2024
Arrangement Duration 511 days
Aggregate Available 37,000
S. Nicole Schaeffer [Member]  
Trading Arrangements, by Individual  
Name S. Nicole Schaeffer
Title Chief People Strategy Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/27/2024
Arrangement Duration 352 days
Aggregate Available 63,734
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates—The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.
Concentration of Credit Risk
Concentration of Credit Risk—Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.
The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables.
Indefinite-lived Intangible Assets
Indefinite-lived Intangible Assets—Indefinite-lived intangible assets consist of IPR&D. IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the
intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.
Finite-lived Intangible Assets and Impairment Assessment
Finite-lived Intangible Assets—Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See Note 6 - Intangibles, Net and Goodwill for further details.
Impairment Assessment—The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by
determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.
Business Combinations and Asset Acquisitions
Business Combinations and Asset Acquisitions—The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&D expense in its consolidated statements of comprehensive loss.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of March 31, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Goodwill Goodwill—Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2024 and December 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2024.
Leases
Leases—A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.
Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.
Debt Issuance Costs
Debt Issuance Costs—Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Foreign Currency
Foreign Currency—The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total shareholders' deficit, as a component of accumulated other comprehensive loss.
The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.
Derivatives
Derivatives—In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.
Inventory and Cost of Product Revenues (excluding amortization of intangible assets)
Inventory and Cost of Product Revenues (excluding amortization of intangible assets)—Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during
the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&D expense when consumed.
Net Loss Per Share
Net Loss Per Share—Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.
Recently Adopted Accounting Pronouncements
Recent Accounting Pronouncements (Not Yet Adopted)—In December 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate
reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2024 and their respective percentages for the three months ended March 31, 2023.
Three Months Ended March 31,
20242023
Customer A35%36%
Customer B34%36%
Customer C16%17%
Schedule of Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share
The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2024 and 2023:
 Three Months Ended March 31,
 20242023
 
Numerator:
Net loss$(157,091)$(159,764)
Denominator:
Weighted average common shares used in calculation of basic net loss per share:148,456 136,355 
Effect of dilutive securities:
Common stock options— — 
RS and RSUs— — 
PSUs— — 
Convertible debt securities— — 
Weighted average common shares outstanding used in calculation of diluted net loss per share148,456 136,355 
Net loss per share:
Basic and diluted$(1.06)$(1.17)
Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding
The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):
 
As of March 31,
 20242023
Common stock options24,098 19,156 
Unvested RS and RSUs3,059 2,058 
PSUs666 671 
Convertible debt securities23,438 23,438 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Carrying Value and Fair Value of Assets and Liabilities
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
As of March 31, 2024
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$595.7 $595.7 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$(1.2)$— $(1.2)$— 
Deferred consideration$5.0 $— $5.0 $— 
Contingent consideration$73.4 $— $— $73.4 
As of December 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$482.4 $482.4 $— $— 
Marketable securities$298.1 $298.1 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$1.2 $— $1.2 $— 
Deferred consideration$5.7 $— $5.7 $— 
Contingent consideration$84.6 $— $— $84.6 
Schedule of Observable Inputs in Valuation of Deferred Consideration
The following observable input was used in the valuation of the deferred consideration as of March 31, 2024:
Fair Value as of March 31, 2024 (in millions)
Observable InputInput Value
Deferred consideration
$5.0
Insmed share price as of March 31, 2024
$27.13
The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2024:
Fair Value as of March 31, 2024 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$65.5Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$5.1Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
15.7%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2024 and 2023 (in thousands):
Deferred
 Consideration
(Level 2 Liabilities)		Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value(1,200)(8,300)
Payments— — 
Balance as of March 31, 2023$6,200 $49,800 
Balance as of December 31, 2023$5,700 $84,600 
Additions— — 
Change in Fair Value(700)(11,200)
Payments— — 
Balance as of March 31, 2024$5,000 $73,400 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Product Revenues, Net (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenues By Geographic Location
The following table presents a geographic summary of the Company's product revenues, net, for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended March 31,
20242023
US$56,349 $49,067 
Japan14,891 13,156 
Europe and rest of world4,260 2,991 
  Total product revenues, net$75,500 $65,214 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory
The Company's inventory balance consists of the following (in thousands):
As of
March 31, 2024December 31, 2023
Raw materials$21,943 $24,562 
Work-in-process29,359 33,480 
Finished goods31,655 25,206 
$82,957 $83,248 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangibles, Net and Goodwill (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Rollforward of Intangible Assets
A rollforward of the Company's intangible assets for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):
Intangible AssetDecember 31, 2023AdditionsAmortization
March 31, 2024
Acquired ARIKAYCE R&D$32,738 $— $(1,212)$31,526 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,366 — (51)1,315 
$63,704 $— $(1,263)$62,441 
Intangible AssetDecember 31, 2022AdditionsAmortizationMarch 31, 2023
Acquired ARIKAYCE R&D$37,588 $— $(1,212)$36,376 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (51)1,517 
$68,756 $— $(1,263)$67,493 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fixed Assets, Net (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Fixed Assets
Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):
Estimated
Useful Life (years)		As of
Asset DescriptionMarch 31, 2024December 31, 2023
Lab equipment7$23,468 $22,660 
Furniture and fixtures76,428 6,428 
Computer hardware and software
3-5
6,106 6,001 
Office equipment789 89 
Manufacturing equipment71,336 1,336 
Leasehold improvements
2-10
37,968 38,049 
Construction in progress—39,238 35,449 
114,633 110,012 
Less: accumulated depreciation(45,973)(44,628)
$68,660 $65,384 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
As of
March 31, 2024December 31, 2023
Accounts payable and other accrued operating expenses$44,018 $65,393 
Accrued clinical trial expenses23,754 23,711 
Accrued professional fees16,728 13,885 
Accrued technical operation expenses10,293 9,187 
Accrued compensation and employee related costs23,803 48,933 
Accrued royalty and milestones payable6,514 5,674 
Accrued interest payable2,269 2,175 
Revenue Interest Payments payable3,020 3,347 
Accrued sales allowances and related costs17,159 10,937 
Accrued France ATU reimbursement payable15,896 14,685 
Deferred and contingent consideration15,700 6,700 
Other accrued liabilities10,208 10,360 
$189,362 $214,987 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Supplemental Noncash Disclosures included in Consolidated Financial Statements
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20242023
Finance right-of-use assets obtained in exchange for lease obligations$— $— 
Operating right-of-use assets obtained in exchange for lease obligations$5,656 $1,751 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Debt, Current and Long-Term Portion of Debt urrent portion of long-term debt and debt, long-term consists of the following commitments as of March 31, 2024 and December 31, 2023 (in thousands):
As of
March 31, 2024December 31, 2023
Convertible notes$789,731 $788,909 
Term Loan373,544 366,404 
Less: current portion of convertible notes(224,194)— 
Debt, long-term$939,081 $1,155,313 
Schedule of Components of Debt Balance The following table presents the carrying value of the
Company's convertible notes balance (in thousands):
As of
March 31, 2024December 31, 2023
Face value of outstanding convertible notes$800,000 800,000 
Debt issuance costs(10,269)(11,091)
Less: current convertible notes(224,194)— 
Total long-term convertible notes$565,537 $788,909 
The following table shows the activity within the liability account for the three-month period ended March 31, 2024 and year ended December 31, 2023 (in thousands):
Three Months Ended
March 31, 2024		Twelve Months Ended
December 31, 2023
Royalty financing agreement liability - beginning balance$158,162 $151,538 
Revenue Interest Payments paid and payable(3,020)(12,222)
Interest expense recognized4,822 18,846 
Royalty financing agreement liability - ending balance$159,964 $158,162 
Royalty financing issuance costs:
Royalty issuance costs, unamortized - beginning balance$(3,128)$(3,523)
Amortization of issuance costs131 521 
Other— (126)
Deferred issuance costs, unamortized - ending balance$(2,997)$(3,128)
  Royalty Financing Agreement$156,967 $155,034 
Schedule of Carrying Value of Term Loan Balance
The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2024 (in thousands):
As of
March 31, 2024December 31, 2023
Original Term Loan balance$350,000 $350,000 
Paid-in-kind interest capitalized33,779 27,537 
Term Loan issuance costs, unamortized(10,235)(11,133)
Term Loan$373,544 $366,404 
Schedule of Future Principal Repayments of Debt
As of March 31, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):
 
Year Ending December 31: 
2024$— 
2025225,000 
2026191,890 
2027191,889 
2028575,000 
2029 and thereafter— 
 $1,183,779 
Schedule of Interest Expense
Interest expense related to debt and finance leases for the three months ended March 31, 2024 and 2023 is as follows (in thousands):
Three Months Ended March 31,
20242023
Convertible debt contractual interest expense$2,063 $2,063 
Term Loan contractual interest expense12,483 10,911 
Royalty Financing Agreement interest expense4,822 4,764 
Amortization of debt issuance costs1,851 1,724 
Swap interest income(754)(73)
   Total debt interest expense20,465 19,389 
Finance lease interest expense577 614 
   Total interest expense$21,042 $20,003 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Royalty Financing Agreement (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Carrying Value of Royalty Financing Agreement The following table presents the carrying value of the
Company's convertible notes balance (in thousands):
As of
March 31, 2024December 31, 2023
Face value of outstanding convertible notes$800,000 800,000 
Debt issuance costs(10,269)(11,091)
Less: current convertible notes(224,194)— 
Total long-term convertible notes$565,537 $788,909 
The following table shows the activity within the liability account for the three-month period ended March 31, 2024 and year ended December 31, 2023 (in thousands):
Three Months Ended
March 31, 2024		Twelve Months Ended
December 31, 2023
Royalty financing agreement liability - beginning balance$158,162 $151,538 
Revenue Interest Payments paid and payable(3,020)(12,222)
Interest expense recognized4,822 18,846 
Royalty financing agreement liability - ending balance$159,964 $158,162 
Royalty financing issuance costs:
Royalty issuance costs, unamortized - beginning balance$(3,128)$(3,523)
Amortization of issuance costs131 521 
Other— (126)
Deferred issuance costs, unamortized - ending balance$(2,997)$(3,128)
  Royalty Financing Agreement$156,967 $155,034 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocation of Employee Stock-Based Compensation
The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2024 and 2023, respectively (in millions): 
 Three Months Ended March 31,
 20242023
Research and development$10.4 $7.9 
Selling, general and administrative11.1 8.5 
Total$21.5 $16.4 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions (Tables)
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of Asset Acquisition
The following table summarizes the purchase price (in millions).
Shares of Insmed common stock issued on closing$9.25 
Shares of Insmed common stock issuable on July 1, 20241.00 
  Total purchase price$10.25 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
The Company and Basis of Presentation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Cash and cash equivalents $ 595,729   $ 482,374
Net loss $ (157,091) $ (159,764)  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Narrative (Details) - reportingUnit
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Number of reporting units 1 1
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Concentration Risk (Details) - Sales Revenue, Product Line - Customer Concentration Risk
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Customer A    
Concentration Risk [Line Items]    
Concentration risk, percentage 35.00% 36.00%
Customer B    
Concentration Risk [Line Items]    
Concentration risk, percentage 34.00% 36.00%
Customer C    
Concentration Risk [Line Items]    
Concentration risk, percentage 16.00% 17.00%
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator:    
Net loss $ (157,091) $ (159,764)
Denominator:    
Weighted average common shares used in calculation of basic net loss per share (in shares) 148,456 136,355
Weighted average common shares used in calculation of basic net loss per share:    
Convertible debt securities (in shares) 0 0
Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares) 148,456 136,355
Net loss per share:    
Basic (in dollars per share) $ (1.06) $ (1.17)
Diluted (in dollars per share) $ (1.06) $ (1.17)
Common stock options    
Weighted average common shares used in calculation of basic net loss per share:    
Effect of dilutive securities (in shares) 0 0
RS and RSUs    
Weighted average common shares used in calculation of basic net loss per share:    
Effect of dilutive securities (in shares) 0 0
PSUs    
Weighted average common shares used in calculation of basic net loss per share:    
Effect of dilutive securities (in shares) 0 0
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Common stock options    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 24,098 19,156
Unvested RS and RSUs    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 3,059 2,058
PSUs    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 666 671
Convertible debt securities    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 23,438 23,438
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Liabilities        
Deferred consideration $ 5,000,000.0      
Level 2        
Liabilities        
Contingent consideration 5,000,000 $ 5,700,000 $ 6,200,000 $ 7,400,000
Level 3        
Liabilities        
Contingent consideration 73,400,000 84,600,000 $ 49,800,000 $ 58,100,000
Carrying Value | Recurring basis        
Assets        
Cash and cash equivalents 595,700,000 482,400,000    
Marketable securities 0 298,100,000    
Collateral for interest rate swap 6,000,000.0 6,000,000.0    
Liabilities        
Interest rate swap (1,200,000)      
Interest rate swap   1,200,000    
Deferred consideration 5,000,000.0 5,700,000    
Contingent consideration 73,400,000 84,600,000    
Estimate of Fair Value Measurement | Recurring basis | Level 1        
Assets        
Cash and cash equivalents 595,700,000 482,400,000    
Marketable securities   298,100,000    
Collateral for interest rate swap 6,000,000.0 6,000,000.0    
Liabilities        
Interest rate swap 0      
Interest rate swap   0    
Deferred consideration 0 0    
Contingent consideration 0 0    
Estimate of Fair Value Measurement | Recurring basis | Level 2        
Assets        
Cash and cash equivalents 0 0    
Marketable securities   0    
Collateral for interest rate swap 0 0    
Liabilities        
Interest rate swap (1,200,000)      
Interest rate swap   1,200,000    
Deferred consideration 5,000,000.0 5,700,000    
Contingent consideration 0 0    
Estimate of Fair Value Measurement | Recurring basis | Level 3        
Assets        
Cash and cash equivalents 0 0    
Marketable securities   0    
Collateral for interest rate swap 0 0    
Liabilities        
Interest rate swap 0      
Interest rate swap   0    
Deferred consideration 0 0    
Contingent consideration $ 73,400,000 $ 84,600,000    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Aug. 04, 2021
USD ($)
shares
Aug. 31, 2023
shares
Oct. 31, 2022
USD ($)
Aug. 31, 2022
shares
Aug. 31, 2021
sale
shares
Mar. 31, 2024
USD ($)
Sep. 30, 2023
shares
Sep. 30, 2022
shares
Sep. 30, 2021
shares
Sep. 01, 2025
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Oct. 01, 2022
May 31, 2021
USD ($)
Jan. 31, 2018
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Payments to acquire marketable securities           $ 300,000                    
Deferred consideration           5,000                    
Non-current contingent consideration           63,700         $ 84,600          
Development and regulatory milestones                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Contingent consideration           $ 65,500                    
Convertible notes                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Convertible senior notes                               $ 309,100
0.75% convertible senior notes due 2028 | Convertible notes                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Interest rate (as a percent)           0.75%                    
Convertible senior notes                             $ 371,600  
Original Term Loan balance                             575,000  
1.75% convertible senior notes due 2025 | Convertible notes                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Interest rate (as a percent)           1.75%                    
Convertible senior notes           $ 238,700                 $ 203,400  
Original Term Loan balance                               $ 450,000
Royalty Agreements | ARIKAYCE Global Net Sales                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Royalty percentage                           4.00%    
Royalty Agreements | Brensocatib Global Net Sales                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Royalty percentage     75.00%                          
Royalty Agreements | Forecast | ARIKAYCE Global Net Sales                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Royalty percentage                   4.50%            
Royalty Agreements | Secured Debt                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Proceeds from royalty financing     $ 150,000                          
Original Term Loan balance     150,000                          
Interest payments     $ 150,000                          
Probabilities of success                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Weighted average probability of success           0.42                    
Level 3                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Contingent consideration           $ 73,400         84,600 $ 49,800 $ 58,100      
Level 2                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Contingent consideration           5,000         5,700 $ 6,200 $ 7,400      
Recurring basis | Level 3 | Estimate of Fair Value Measurement                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Marketable securities                     0          
Deferred consideration           0         0          
Contingent consideration           73,400         84,600          
Recurring basis | Level 2 | Estimate of Fair Value Measurement                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Marketable securities                     0          
Deferred consideration           5,000         5,700          
Contingent consideration           0         $ 0          
Recurring basis | Level 2 | 0.75% convertible senior notes due 2028 | Estimate of Fair Value Measurement                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Convertible senior notes           620,100                    
Accrued Liabilities, Current                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Deferred consideration           5,000                    
Motus                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Shares issued in acquisition (in shares) | shares 2,889,367 177,203   171,427     177,203 171,427 2,889,367              
Shares issued upon milestone achievements (in shares) | shares         5,348,572                      
Contingent consideration $ 35,000                              
Motus | Development and regulatory milestones                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage         50.00%                      
Average sales prices of publicly disclosed priority review voucher sales obligated to pay equity holders, percentage         50.00%                      
Number of publicly disclosed sales used to determine average sales price owed to equity holders | sale         3                      
Motus | Second anniversary of closing date                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Shares issued in acquisition (in shares) | shares         184,433                      
Motus | First anniversary of closing date                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Shares issued in acquisition (in shares) | shares         184,433                      
Motus | Third anniversary of closing date                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Shares issued in acquisition (in shares) | shares         184,433                      
Motus | Level 3                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Current contingent consideration           9,700                    
Motus | Other Noncurrent Liabilities | Level 3                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Non-current contingent consideration           $ 63,700                    
AlgaeneX                                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                
Shares issued upon milestone achievements (in shares) | shares 368,867                              
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details)
$ in Millions
Mar. 31, 2024
USD ($)
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Deferred consideration | $ $ 5.0
Level 2 | Share Price  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Insmed share price (in usd per share) | $ / shares 27.13
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 73,400 $ 84,600 $ 49,800 $ 58,100
Probabilities of success        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.42      
Development and regulatory milestones        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 65,500      
Priority review voucher milestone        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 5,100      
Priority review voucher milestone | Probabilities of success | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.164      
Priority review voucher milestone | Discount rate | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.157      
Minimum | Development and regulatory milestones | Probabilities of success | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.14      
Maximum | Development and regulatory milestones | Probabilities of success | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.97      
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Deferred Consideration (Level 2 Liabilities)    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Consideration, beginning balance $ 5,700 $ 7,400
Additions 0 0
Change in Fair Value (700) (1,200)
Payments 0 0
Consideration, ending balance 5,000 6,200
Contingent Consideration (Level 3 Liabilities)    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Consideration, beginning balance 84,600 58,100
Additions 0 0
Change in Fair Value (11,200) (8,300)
Payments 0 0
Consideration, ending balance $ 73,400 $ 49,800
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Product Revenues, Net - Product Revenues By Geographic Location (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 75,500 $ 65,214
US    
Disaggregation of Revenue [Line Items]    
Product revenues, net 56,349 49,067
Japan    
Disaggregation of Revenue [Line Items]    
Product revenues, net 14,891 13,156
Europe and rest of world    
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 4,260 $ 2,991
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 21,943 $ 24,562
Work-in-process 29,359 33,480
Finished goods 31,655 25,206
Inventory, Net $ 82,957 $ 83,248
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangibles, Net and Goodwill - Narrative (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible assets estimated useful life (in years) 12 years  
Amortization of intangible assets, remainder of 2024 $ 5,100  
Amortization of intangible assets, 2025 5,100  
Amortization of intangible assets, 2026 5,100  
Amortization of intangible assets, 2027 5,100  
Amortization of intangible assets, 2028 5,100  
Goodwill $ 136,110 $ 136,110
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangibles, Net and Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     $ 63,704 $ 68,756
Additions $ 0 $ 0    
Amortization (1,263) (1,263)    
Intangibles, net 62,441 67,493 63,704  
Acquired ARIKAYCE R&D        
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     32,738 37,588
Additions 0 0    
Amortization (1,212) (1,212)    
Intangibles, net 31,526 36,376    
Acquired IPR&D        
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     29,600 29,600
Additions 0 0    
Amortization 0 0    
Intangibles, net 29,600 29,600    
PARI milestones        
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     $ 1,366 $ 1,568
Additions 0 0    
Amortization (51) (51)    
Intangibles, net $ 1,315 $ 1,517    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fixed Assets, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 114,633 $ 110,012
Less: accumulated depreciation (45,973) (44,628)
Fixed assets, net $ 68,660 65,384
Lab equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 23,468 22,660
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 6,428 6,428
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 6,106 6,001
Computer hardware and software | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 3 years  
Computer hardware and software | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 5 years  
Office equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 89 89
Manufacturing equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 1,336 1,336
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 37,968 38,049
Leasehold improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 2 years  
Leasehold improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 10 years  
Construction in progress    
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 39,238 $ 35,449
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accounts payable and other accrued operating expenses $ 44,018 $ 65,393
Accrued clinical trial expenses 23,754 23,711
Accrued professional fees 16,728 13,885
Accrued technical operation expenses 10,293 9,187
Accrued compensation and employee related costs 23,803 48,933
Accrued royalty and milestones payable 6,514 5,674
Accrued interest payable 2,269 2,175
Revenue Interest Payments payable 3,020 3,347
Accrued sales allowances and related costs 17,159 10,937
Accrued France ATU reimbursement payable 15,896 14,685
Deferred and contingent consideration 15,700 6,700
Other accrued liabilities 10,208 10,360
Total accounts payable and accrued liabilities $ 189,362 $ 214,987
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Lessee, Lease, Description [Line Items]      
Variable lease, cost $ 4.9 $ 0.1  
Lease cost, future right-of-use asset $ 52.0   $ 49.1
Minimum      
Lessee, Lease, Description [Line Items]      
Remaining lease term 1 year    
Maximum      
Lessee, Lease, Description [Line Items]      
Remaining lease term 10 years 10 months    
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases - Lease, costs (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Lease, Cost [Abstract]    
Finance right-of-use assets obtained in exchange for lease obligations $ 0 $ 0
Operating right-of-use assets obtained in exchange for lease obligations $ 5,656 $ 1,751
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Schedule of Long-Term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Less: current portion of convertible notes $ (224,194) $ 0
Total long-term convertible notes 939,081 1,155,313
Convertible notes    
Debt Instrument [Line Items]    
Term Loan 789,731 788,909
Term Loan    
Debt Instrument [Line Items]    
Term Loan $ 373,544 $ 366,404
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Oct. 31, 2022
USD ($)
May 31, 2021
USD ($)
day
$ / shares
Jan. 31, 2018
USD ($)
day
$ / shares
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Debt Instrument [Line Items]            
Paid-in-kind interest capitalized       $ 6,242 $ 5,456  
0.75% convertible senior notes due 2028            
Debt Instrument [Line Items]            
Initial conversion rate   0.0307692 30.7692      
0.75% convertible senior notes due 2028 | Level 2 | Carrying Value | Recurring basis            
Debt Instrument [Line Items]            
Convertible senior notes       565,500    
1.75% convertible senior notes due 2025            
Debt Instrument [Line Items]            
Initial conversion rate   0.0255384 25.5384      
1.75% convertible senior notes due 2025 | Level 2 | Carrying Value | Recurring basis            
Debt Instrument [Line Items]            
Convertible senior notes       224,200    
Term Loan | Secured Debt            
Debt Instrument [Line Items]            
Original Term Loan balance $ 350,000     350,000   $ 350,000
Debt issuance costs, net $ 15,200          
Interest payable 50.00%          
Debt term (in months) 24 months          
Proceeds from loans $ 334,800          
Term Loan | Secured Debt | Secured Overnight Financing Rate (SOFR)            
Debt Instrument [Line Items]            
Interest rate 2.50%          
Term Loan | Secured Debt | Secured Overnight Financing Rate (SOFR) | Variable Rate Component Two            
Debt Instrument [Line Items]            
Interest rate 7.75%          
Convertible notes            
Debt Instrument [Line Items]            
Debt issuance costs, net       10,269   $ 11,091
Convertible senior notes     $ 309,100      
Effective interest rate   7.10% 7.60%      
Residual equity component of debt     $ 140,900      
Convertible notes | 0.75% convertible senior notes due 2028            
Debt Instrument [Line Items]            
Original Term Loan balance   $ 575,000        
Option to purchase additional debt   75,000        
Debt issuance costs, net   15,700   $ 9,500    
Net proceeds   $ 559,300        
Initial conversion price (in dollars per share) | $ / shares   $ 32.50        
Convertible senior notes   $ 371,600        
Remaining discount amortization period (in years)       4 years 2 months 1 day    
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (i)            
Debt Instrument [Line Items]            
Threshold trading days | day   5        
Threshold consecutive trading days | day   5        
Threshold percent of stock price trigger   98.00%        
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (ii)            
Debt Instrument [Line Items]            
Threshold trading days | day   45        
Threshold consecutive trading days | day   10        
Threshold percent of stock price trigger   10.00%        
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (iii)            
Debt Instrument [Line Items]            
Threshold trading days following fundamental change | day   30        
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (iv)            
Debt Instrument [Line Items]            
Threshold trading days | day   20        
Threshold consecutive trading days | day   30        
Threshold percent of stock price trigger   130.00%        
Convertible notes | 1.75% convertible senior notes due 2025            
Debt Instrument [Line Items]            
Original Term Loan balance     450,000      
Option to purchase additional debt     50,000      
Debt issuance costs, net     14,200 $ 800    
Net proceeds     $ 435,800      
Repurchased amount   $ 225,000        
Loss on extinguishment of debt   17,700        
Initial conversion price (in dollars per share) | $ / shares     $ 39.16      
Convertible senior notes   $ 203,400   $ 238,700    
Remaining discount amortization period (in years)       9 months 10 days    
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (i)            
Debt Instrument [Line Items]            
Threshold trading days | day     5      
Threshold consecutive trading days | day     5      
Threshold percent of stock price trigger     98.00%      
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (ii)            
Debt Instrument [Line Items]            
Threshold trading days | day     45      
Threshold consecutive trading days | day     10      
Threshold percent of stock price trigger     10.00%      
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (iii)            
Debt Instrument [Line Items]            
Threshold trading days following fundamental change | day     30      
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (iv)            
Debt Instrument [Line Items]            
Threshold trading days | day     20      
Threshold consecutive trading days | day     30      
Threshold percent of stock price trigger     130.00%      
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Components of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Less: current portion of convertible notes $ (224,194) $ 0
Total long-term convertible notes 939,081 1,155,313
Convertible notes    
Debt Instrument [Line Items]    
Face value of outstanding convertible notes 800,000 800,000
Debt issuance costs (10,269) (11,091)
Total long-term convertible notes $ 565,537 $ 788,909
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Schedule of Carrying Value of Term Loan Balance (Details) - Term Loan - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Oct. 31, 2022
Debt Instrument [Line Items]      
Term Loan $ 373,544 $ 366,404  
Secured Debt      
Debt Instrument [Line Items]      
Original Term Loan balance 350,000 350,000 $ 350,000
Paid-in-kind interest capitalized 33,779 27,537  
Term Loan issuance costs, unamortized (10,235) (11,133)  
Term Loan $ 373,544 $ 366,404  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Future Principal Repayments of Debt (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Year Ending December 31:  
2024 $ 0
2025 225,000
2026 191,890
2027 191,889
2028 575,000
2029 and thereafter 0
Total $ 1,183,779
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Debt Instrument [Line Items]    
Amortization of debt issuance costs $ 1,851 $ 1,724
Swap interest income (754) (73)
Total debt interest expense 20,465 19,389
Finance lease interest expense 577 614
Total interest expense 21,042 20,003
Convertible Debt    
Debt Instrument [Line Items]    
Convertible debt contractual interest expense 2,063 2,063
Term Loan    
Debt Instrument [Line Items]    
Convertible debt contractual interest expense 12,483 10,911
Royalty Agreements    
Debt Instrument [Line Items]    
Convertible debt contractual interest expense $ 4,822 $ 4,764
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Royalty Financing Agreement - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended
Oct. 31, 2022
Sep. 01, 2025
Mar. 31, 2024
Dec. 31, 2023
Oct. 01, 2022
Debt Instrument [Line Items]          
Royalty financing liability     $ 6,514 $ 5,674  
Royalty Agreements          
Debt Instrument [Line Items]          
Royalty maximum 1.8        
Royalty financing liability     $ 3,000 $ 3,300  
Royalty Agreements | Maximum          
Debt Instrument [Line Items]          
Royalty maximum 1.9        
Royalty Agreements | ARIKAYCE Global Net Sales          
Debt Instrument [Line Items]          
Royalty percentage         4.00%
Royalty Agreements | ARIKAYCE Global Net Sales | Forecast          
Debt Instrument [Line Items]          
Royalty percentage   4.50%      
Royalty Agreements | Brensocatib Global Net Sales          
Debt Instrument [Line Items]          
Royalty percentage 75.00%        
Secured Debt | Royalty Agreements          
Debt Instrument [Line Items]          
Proceeds from royalty financing $ 150,000        
Face amount 150,000        
Interest payments 150,000        
Lenders fees and deal expenses 3,800        
Proceeds from royalty financing agreement, net $ 146,200        
Effective interest rate 12.40%        
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Royalty Financing Agreement [Roll Forward]      
Royalty financing agreement liability - beginning balance $ 155,034    
Royalty financing agreement liability - ending balance 156,967   $ 155,034
Amortization of issuance costs 1,851 $ 1,724  
Royalty financing agreement 156,967   155,034
Royalty Agreements      
Royalty Financing Agreement [Roll Forward]      
Interest expense recognized 4,822 4,764  
Secured Debt      
Royalty Financing Agreement [Roll Forward]      
Amortization of issuance costs 131   521
Secured Debt | Royalty Agreements      
Royalty Financing Agreement [Roll Forward]      
Royalty financing agreement liability - beginning balance 158,162 151,538 151,538
Revenue Interest Payments paid and payable (3,020)   (12,222)
Interest expense recognized 4,822   18,846
Royalty financing agreement liability - ending balance 159,964   158,162
Royalty issuance costs, unamortized - beginning balance 3,128 $ 3,523 3,523
Other 0   (126)
Deferred issuance costs, unamortized - ending balance 2,997   3,128
Royalty financing agreement $ 159,964   $ 158,162
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 04, 2021
Aug. 31, 2023
Jan. 31, 2023
Oct. 31, 2022
Aug. 31, 2022
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2021
Mar. 31, 2021
Dec. 31, 2023
Class of Stock [Line Items]                          
Common stock, authorized shares (in shares)           500,000,000             500,000,000
Common stock, par value (in dollars per share)           $ 0.01             $ 0.01
Common stock, outstanding shares (in shares)           148,560,882             147,977,960
Common stock, issued shares (in shares)           148,560,882             147,977,960
Offering price per share (in dollars per share)       $ 20.00                  
Payments of stock issuance costs       $ 16,200   $ 409     $ 0        
Preferred stock, authorized (in shares)           200,000,000              
Preferred stock, par value (in dollars per share)           $ 0.01              
Preferred stock, shares issued (in shares)           0              
Preferred stock, shares outstanding (in shares)           0              
Public Stock Offering                          
Class of Stock [Line Items]                          
Shares sold in offering (in shares)       13,750,000                  
Aggregate net proceeds from stock offering       $ 258,800                  
ATM Program                          
Class of Stock [Line Items]                          
Shares sold in offering (in shares)           0             6,503,041
Offering price per share (in dollars per share)                         $ 24.12
Aggregate net proceeds from stock offering                         $ 152,200
Common stock authorized, aggregate gross sales proceeds (up to)           $ 500,000           $ 250,000  
Motus                          
Class of Stock [Line Items]                          
Common stock shares reserved for issuance (in shares)           9,406,112         9,406,112    
Shares issued in acquisition (in shares) 2,889,367 177,203     171,427   177,203     171,427 2,889,367    
Contingent consideration $ 35,000                        
Adrestia Therapeutics Ltd                          
Class of Stock [Line Items]                          
Issuance of common stock for business acquisition (in shares)               3,430,867          
Vertuis Bio, Inc.                          
Class of Stock [Line Items]                          
Common stock shares reserved for issuance (in shares)     550,000                    
Issuance of common stock for business acquisition (in shares)     500,000                    
Contingent consideration                         $ 1,000
Convertible notes                          
Class of Stock [Line Items]                          
Common stock shares reserved for issuance (in shares)           23,438,430              
Common stock options                          
Class of Stock [Line Items]                          
Common stock shares reserved for issuance (in shares)           24,098,410              
Unvested RS and RSUs                          
Class of Stock [Line Items]                          
Common stock shares reserved for issuance (in shares)           3,058,943              
PSUs                          
Class of Stock [Line Items]                          
Common stock shares reserved for issuance (in shares)           666,382              
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Narrative (Details) - USD ($)
 3 Months Ended
May 12, 2020
May 15, 2018
Mar. 31, 2024
Mar. 31, 2023
Stock-Based Compensation        
Inducement stock options granted to new employees (in shares)     358,140  
Common stock options        
Stock-Based Compensation        
Unrecognized compensation expense related to unvested stock options     $ 148,000,000  
Options outstanding (in shares)     114,780  
Unvested RS and RSUs        
Stock-Based Compensation        
Unrecognized compensation expense related to unvested RSU awards     $ 55,800,000  
Performance options        
Stock-Based Compensation        
Options outstanding, nonvested (in shares)     266,550  
Unrecognized compensation expense     $ 10,400,000  
Potential award payout     100.00%  
Allocated share-based compensation expense     $ 0 $ 0
2019 Incentive Plan        
Stock-Based Compensation        
Shares available for grant (in shares)     4,705,225  
2018 ESPP        
Stock-Based Compensation        
Number of additional shares authorized (in shares)   1,200,000    
Shares of common stock, maximum authorized for issuance (in shares)   1,000,000    
Percentage of outstanding shares   2.00%    
2019 Incentive Plan        
Stock-Based Compensation        
Number of additional shares authorized (in shares) 3,000,000      
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) - Stock options and RSUs - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Stock-Based Compensation    
Allocated share-based compensation expense $ 21.5 $ 16.4
Research and development    
Stock-Based Compensation    
Allocated share-based compensation expense 10.4 7.9
Selling, general and administrative    
Stock-Based Compensation    
Allocated share-based compensation expense $ 11.1 $ 8.5
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Provision for income taxes $ 589,000 $ 483,000
Deferred tax benefit 0  
Unrecognized tax benefits, interest and penalties accrued $ 0  
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Rent expense charged to operations $ 3.1 $ 2.2
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Aug. 04, 2021
USD ($)
shares
May 24, 2021
days
Aug. 31, 2023
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jan. 31, 2023
USD ($)
$ / shares
shares
Aug. 31, 2022
shares
Aug. 31, 2021
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
Sep. 30, 2023
shares
Sep. 30, 2022
shares
Sep. 30, 2021
shares
Business Acquisition [Line Items]                      
Share price (in usd per share) | $ / shares       $ 21.10 $ 18.50            
Consecutive trading day period | days   45                  
Motus and AlgaeneX                      
Business Acquisition [Line Items]                      
Aggregate value             $ 165,500        
Motus                      
Business Acquisition [Line Items]                      
Shares issued in acquisition (in shares) | shares 2,889,367   177,203     171,427     177,203 171,427 2,889,367
Shares issued upon milestone achievements (in shares) | shares             5,348,572        
Contingent consideration $ 35,000                    
Share price used to calculate issuable shares (in dollars per share) | $ / shares             $ 27.11        
Motus | First anniversary of closing date                      
Business Acquisition [Line Items]                      
Shares issued in acquisition (in shares) | shares             184,433        
Motus | Second anniversary of closing date                      
Business Acquisition [Line Items]                      
Shares issued in acquisition (in shares) | shares             184,433        
Motus | Third anniversary of closing date                      
Business Acquisition [Line Items]                      
Shares issued in acquisition (in shares) | shares             184,433        
AlgaeneX                      
Business Acquisition [Line Items]                      
Shares issued upon milestone achievements (in shares) | shares 368,867                    
Cash paid in acquisition             $ 1,500        
Share price used to calculate issuable shares (in dollars per share) | $ / shares             $ 27.11        
Adrestia Therapeutics Ltd                      
Business Acquisition [Line Items]                      
Shares issued in asset acquisition (in shares) | shares       3,430,867              
Asset acquisition, consideration transferred       $ 72,400              
Contingent payment, value       $ 326,500              
Vertuis Bio, Inc.                      
Business Acquisition [Line Items]                      
Shares issued in asset acquisition (in shares) | shares         500,000            
Asset acquisition, consideration transferred         $ 10,250            
Contingent payment, value         1,000            
IPR&D expense               $ 76,500      
Vertuis Bio, Inc. | Milestone Event 1                      
Business Acquisition [Line Items]                      
Contingent payment, value         1,000            
Vertuis Bio, Inc. | Milestone Event 2                      
Business Acquisition [Line Items]                      
Contingent payment, value         23,000            
Vertuis Bio, Inc. | Milestone Event 3                      
Business Acquisition [Line Items]                      
Contingent payment, value         $ 63,800            
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions - Asset Acquisition (Details) - Vertuis Bio, Inc.
$ in Thousands
 1 Months Ended
Jan. 31, 2023
USD ($)
Business Acquisition [Line Items]  
Shares of Insmed common stock issued on closing $ 9,250
Shares of Insmed common stock issuable on July 1, 2024 1,000
Total purchase price $ 10,250
EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( LXJ5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " +.*E8W]B\;^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.NTH:%&7"X@32$A, G&+$F^+:)HH,6KW]J1EZX3@ 3C&_O/Y ML^16!Z%]Q.?H T:RF*Y&U_5)Z+!A!Z(@ )(^H%.IS(D^-W<^.D7Y&?<0E/Y0 M>X2:\QMP2,HH4C !B[ 0F6R-%CJB(A]/>*,7?/B,W0PS&K!#ASTEJ,H*F)PF MAN/8M7 !3##"Z-)W HX.WI\65>M[!] M(M5KS+^2%70,N&'GR:^KN_OM Y,UKZ\+WA1\O:VX:-:BN7V?7'_X782=-W9G M_['Q65"V\.LNY!=02P,$% @ "SBI6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" +.*E8;V7=9-<% #4'@ & 'AL+W=O&%]FSJ1I>R%2'02RFBB1I M%'&UO1*AW%PV:&/_X"%8++5YT!I>K/A"S(3^O)HJN&L5*GX0B3@)9$R4F%\V M1O3=V&4F(/OB2R VR8MK8JP\2?G-W$S\RX9C2B1"X6DCP>%G+<8B#(T2E./? MG6BC^)\F\.7U7OTV,P]FGG@BQC+\,_#U\K+1;Q!?S'D:Z@>Y>2]VACI&SY-A MDOTEF_S;#FL0+TVTC';!4((HB/-?_KRKB!-,*W@;0)P>CN5:*#*%C)$F299< MB>2BI4'8O&YY.Y&K7(15B+CD3L9ZF9";V!?^]_$M*%!1*K8OU15#!>^X.B<:'PK?$Z=JBORN-6]21F\FY:!W]/7I*M()F]X^M@G*%MEW!],5W MR8I[XK(!G2T1:BT:PU]^HEWG5YN['R3VG=EV8;:-J0^OI9="-]7D<;L2-J=X M.'6:GVR6T*B:ECJ%I+J55:JN4,1I5TUZWL-<] MSMY4J$#ZIA,2& NLR<.5BFY7V>_0^)H^>X7/WI$M4W&81K)9H#J/N-:6=LHKC.YG]W=7)/)_=CF$(VMZ9 ZY5SJ'.-Q$GM20;OD MIHF>D9F&SDBD(F.9QEIMX=>W&C^@_F5D/!=?VRTB\[QN_(]T$].=M?D _P'?D8V_.*2_8< MAWR>D?< G!L %QAZ <*[5N^H4%WO)091%#S^YWUL[J!=/\I-;/6-RUVIP%^( M#70.6RL9X]%US9881'&0>6VVZ,53)==![-DSC6O>_VXU>@HVHB4<41QI7AN= MRD3SD/P5K*H'*ES1Z?>=GM7I*3")EIQ$<;S)VNL(%KO5QG"!@=.WVCH%%=$2 MBRC.,A^D!_F:+F6,8<,!D4&OUQP,',?J[Q101$LJHCC2/ 8:@$C."65OGMZ2 MF?!2!9FTFL25QC**8&:"1;7W[8RLN")K'J:"_.R<.Y2L8)&7K8"M=7 *=J(E M/%&<>@!Y_2!>D-DV>I*AU?IA;++Z.@4QL9*8&,XT^V22FV=OR>.%J*3" T+W MH]GUR+KRQ /K.BP!B1T%2.-4*;-VR1%1=GR48 ML:/ :!+#=)[OS9E%*-\;M_K$%:M\G@*"6 E!["@(,HLT('I@@H54UK'H@,X' MKJ"UCSQ/@!#(^+FDU?$I2(B5),2.(J%9Q,.07*4)O$[L[1;7J5QSXW%U_94 MQ(X"H)M(J(7IF+^!@EX"(T0K'MM3BPM6&ST%_["2?QB.+_M$+@4D$K.'RU3; M.P4'L9*#&(XP^Y$VG^1G^20_R[:TR<=4 ]7&V1SZ)HAW.]UOK>Y_$.WLZB17 MZV1JYDQE/:3M?M=I=]K DFN;X1*,V%'[16,87A40X"3VQ3/Y0]AS>G#;B%(H ME'W=B0?736P)/PQGEU$D8C_;^;L-^<+J#A>H;K&GH!^WI!\7AY8]%-P&B4'X MKP*(%-N]/2#7;%+6=*GU1.$4$.26$.3BR%)LW;YT>@L/K?/( ;&JO6D\K*[' M$H!<'%=>>]SMQE>[Q.4^V?/X0^&G]>+_@=02P,$% @ "SBI6'1Z$?.?!@ PQL !@ !X;"]W M;W)K,S)M"Y5$EZ2<9)]^1Y(CV2)%)T OG$CVD/J'',XWI*X>A/RIMIQK M]%CDI;J>;+7>7<[G*MWR@JD+L>,E_+(6LF :;N5FKG:2LU73J,CGQ//"><&R MD\*_FM1*HJ"B:?/O)*+T7^;[;2 MV^M)/$$KOF95KK^)A[_YP:%&8"IRU?Q%#P=;;X+22FE1'!J#@B(KV__L\3 0 M1PVP/]* '!J0ES:@AP:T<;15UKAUPS1;7$GQ@&1M#;W5%\W8-*W!FZRLI_%. M2_@U@W9ZL12E$GFV8IJOT$>6LS+EZ*[N3J$9^G%W@_YX^R=ZB[(2?=^*2K%R MI:[F&IY^O8-Z;5VJ'4OY]006C^)RSR>+=V]PZ+VW M>?>;.COQE7:^4E?OBR536P2SAM+Z@O^JLCW+P7GK++9=A4U7=0+8+X(DB$AR M-=\?^V.:^3&AD=^9G2CU.Z6^4RD$R4^NV7W.D>)I)3.=<:O*MIO@Z/'>0*!I M09+8BZA=8- )#)P"/Z2IJ&#D('VE'(81E-KD!<;#:81#,I!H6OD8QXE=8=@I M#)T*/Y=[F%HAGVRZ0N.),8'9'>BR6%'BQW9=4:.%(6":=R,0I\E/V"+F[%3=%)=.=45@V7,DY !?)FJPSL9Y5<#,^IH<^3V;4H]XP7JUF21R,:#[B(G9J_KKC MDNFLW+Q2-3;DX @;J\QF%GLX&E'=@PT[60()0+-RDT%F&@^%0Q295, X2+PF& BV&%!A)QR*P)Q .7U1; MY1F[S_*&X=8""SM)]MH*ZW?U=NITCS?LYEM7&>S84U/ U'QC:2HKR,Q'(V$= M")-<4 =0HV"PV!'L)_'8C/6,PV[(/<_83LAF9R76*!?E9J:Y+&!'=&]/(B;+ M" W&6+98C>V2'O>X7/ .\;)N>$UF49"G!1]S@&T+DC%9BLLP/ MO6'U;;&*/4I&M/; (V[@G=8ZYY2:_/*)%QL%A<6.D" D(W49.=K!N4%W W$Y M[>/4JM$$6$(3+QZ"SF('23.@>*0N(SWJB!MUW\03R_436C8R1QEDIW6R;Y5N2PS-2[-S'!T?OF@$8_V8^DG%1\ M]9G4;^KM]%"J)R-UDW$IB@)J#:5%^G.*WGH7'H;B2:(]RRO^'@6>-_7:#V*5 MW@J9_0>EE*I'#%8*]N-I$'K3."9-J87]:)I$\ D]E"E55UW-"4.E%>R'5O5Z M:YLBIM$7)M-MZ\KSD61C?<-37MQS>?(3G;:WT';'FR/GW'JX0DTH@\AAP-NM M1@*)]NBF;G1_6*VR.D]#U-?'++.L1"G;9; *K%)-)@/KXB :[F*LAICZ8R4G M[>E-W?2&>KDJJKPY=%[Q=99F5B!2D\PS&D*M0XV!M5GZ?CB:3>C1^:D;XL=: M#T=6HH UL:W?9>PAA0ME/TLU*3W#H:G<8A:-JNY13MTH;W.@LF08UWB;L)[Y M(02H$1D60TIQ0D8X0WNNTY?L<(]R=[,T7^M'8!Q0V[?!-D/K-GA^](:E?KT% M.623E0HHOH:6WD4$'>ER+[0617.YY0STUP;P^UH(_7Q3O\?I MWMLM_@=02P,$% @ "SBI6.!L@HRA @ :@< !@ !X;"]W;W)KGH)/*0^..>XW/LF^O)3JH'70(8\EAQH:=>:4Q] MY?LZ+Z&B>B!K$#BSDJJB!KMJ[>M: 2T3FJYA >9+/5?8\SN6@E4@-)."*%A- MO>OP:I;:>!?PE<%.[[6)=;*4\L%V/A53+[""@$-N+ /%SQ9FP+DE0AD_6TZO M6]("]]M/['?..WI94@TSR;^QPI13;^R1 E9TP\V]W'V$UD]B^7+)M7N371.; MC#R2;[2150M&!143S9<^MONP!PB'1P!1"XA.!<0M('9&&V7.UBTU-)LHN2/* M1B.;;;B]<6ATPX0]Q851.,L09[*9%%IR5E #!;FAG(H$>]G/;/^]*US2'J8>_E@:U!2][]R9,@P]]QO\3V<$VQ-TVQ"^QX_E7%;K% M/,L?+DA-%=E2O@%RQ@0I).=4:5*#:D[]O&\K&OZ1X[7H]%E>D1]VJE/7Z$>;PAMJ"B86)]H(3W9 M0E]DOP5_KQ+:6PB+SIH)33BL$!L,1DBBFLK>=(RL77%<2H.EUC5+O Q!V0"< M7TEIGCJVWG;7:_8'4$L#!!0 ( LXJ5B2M[6&1@8 'H9 8 >&PO M=V]R:W-H965T&ULK5E1;]LV$/XKA%<,*9#&(F5)5I882-P6 M*["L0=.N#\4>:(FVB4JB1]).VE^_(R5;MD4QV9(76Y*/I^\[WO$[TA?W0GY7 M2\8T>BB+2ET.EEJOSH=#E2U92=696+$*?ID+65(-MW(Q5"O):&X'E<60!$$\ M+"FO!I,+^^Q63B[$6A>\8K<2J7594OGCFA7B_G* !]L'G_ABJ1B11?L MCNDOJUL)=\.=EYR7K%)<5$BR^>7@"I]/P\ ,L!9_<7:O]JZ1H3(3XKNY^9!? M#@*#B!4LT\8%A:\-F[*B,)X QS^-T\'NG6;@_O76^WM+'LC,J&)347SEN5Y> M#L8#E+,Y71?ZD[C_G36$(N,O$X6RG^B^L0T&*%LK+55_TXXM.GGU&JDEE4PA7J'/2[%6M,K5*7IU<'\QU #6O'*8-<"N:V"D!UB(;D2E MEPJ]JW*6'XX? LD=4[)E>DV\#F^H/$,A/D4D(",'GNG3AX<>..$N\*'U%_;X MV\6Z&^H/529*AKY=S926D.=_NZ)7>Q^YO9OB/UHFFMD:9/$5;(I#O MZ Z"Q#.8PWVP"L=AX,[J\8[4^%%2 MSTA;O_.GI.US/!PP3G>,TT?J6#$JLZ4EF\,<%F)EUF 7O;0;L\((=6D$D)39&)>P9+/DR&46NX5#RWJQ]0+#B=\8)KSMS,2 ?S&XS3 MCFBY[-)];3LDU_88V*OS7T@_5ABEM^S9NVS0GSJCS M^G'263D<5CB(2%\-MM*,O4H($#4#!=3;V78BC+L!@LD>==8)EUT0!'UEU^HI M?D10>\J.;\%#*C"D[NG*"3_IYF 8=\!WK=[@*.S#WLHF]@O31[UDBI_-05ISCJJH;3,"7C'KBD M53OB5SO0^@VW1P. ^%' I*M>T3@] NLP&HU[YIZT D?\ OD= M-B!IL,S-[+1 4I>0X@IY%8?2>+?8%N- MR0[.A9IE\<3 ?NW<;Q.OZ/[7#?=+>3L,02NSQ"^S[T&[^*)"V1KZ\"K[@6#; M4ZFB:;PA!CWBX!#4<73<(;JL<-*G8ZWL$K_L?JDDHP7_":513Q-:4"@$ %Q2 M^9UI:G9"B@&EWCT#<8ALV"F+KM$H[6ENPU:%0[\*U]N%PZ3KJY'&U7&-I./C MIL%MF(["XV5VN'>*73*YL(?["N"L*UT?\^Z>[OY N++'YD?/K_'YM/X;H'53 M_RMQ0^6"5PH5; XN@[,$ BCK@_[Z1HN5/2N?":U%:2^7C,)VSQC [W,A]/;& MO&#W=\OD7U!+ P04 " +.*E8J>,?A?@& !7,@ & 'AL+W=O4D_3OEY(5RR)IQDJG+_%MY@PYAT-QCI3I RN_\@VE%7HL\BV_ M&6VJ:G<]F?!T0XN$OV4[NA6_K%E9))7X6-Y-^*ZDR:IQ*O()L2QO4B39=C2; M-M_=EK,IVU=YMJ6W)>+[HDC*[^]ISAYN1GCT],7'[&Y3U5],9M-=7M/J\ MNRW%I\D19945=,LSMD4E7=^,WN'KF(2U0V/Q;T8?^,E[5$_E"V-?ZP\?5C+FGOG]"CYO)B\E\23B=L_R_;%5M M;D;!"*WH.MGGU4?V\ =M)^36>"G+>?,7/;2VU@BE>UZQHG46(RBR[>$U>6P3 M<>* [3,.I'4@ESK8K8,M.1#_C(/3.CBRP[DYN*V#*SDXWAD'KW7PFMP?DM5D M>I%4R6Q:L@=4UM8"K7[3T-5XBP1GVWIE+:M2_)H)OVHV9UO.\FR55'2%EI5X M$9L+Y"8_1YN4"O7UTA7IMR ME&W1IPW;\V2[XF_0J][GZ:02PZV#3M)V:.\/0R-GAO:)54FN<9N;W>:L*,22 M758L_:KQ7IB]WZW$Y,223W)TFV2KL9C"/-EE^I%$SV"EZ;[8YTUJ%W2=I5FE M 8DO!_FGVM 2B0F*36135_<]11^V*2LH>OTGX_RJ#S\1:^&X(,AQ09 FGG,F MWOLD3[:I !0S/]!ZA9)*C#]]BVS\!A&+$!V71M1Z?[SFNR2E-R,Q=D[+>SJ: M_?H+]JS?=0P?P-P&K-X;[V?8=CW7F4[N3ZF$C!E!@L5 8#T&[2.#]D4,7L+: M +5+LQ\4+/]8.^8:P:^FX'UDN- M&D]+)1E C:=,S";2KC(WAAU*"R18! D6FU/1H\0_4N(;*8D>:9EFG-9'.5X?AA#; MU2<;CL1Q#$7+V]NG8]O)I5Y'DS',T-W05R8:$.E" ADO@@2+@I67F-'"2)?MR#B-H1D' NME/#QF/#1F_ /G^^8@)3*> M'IJ*0^)%/X_N*:^R[5W]V\?EYV=KR!AI: V%*@VA+5$%&3""!(N!P'J48JMK M=RTP4K4MJZ4F7ZJCUL142.9!#J4'%"V&0NL3=*)'X)<3E' NCGI)^FV?\:9- M?Z[NS,&&%EZ+=DJ^:UDRMY A(U"T& JMSVTG+6"SMC",6RV?JC(0$M>2*Y H M%>C*+.F ',DJ,L]GG$R:PL4$^)[O]E91' '-=8;;JQXX>R M#KD C1J!HL50:'TB.XD!FS6&,U*SGCRU]1_;-@Z)LMI]=;4[@7+,4N%LT8TZ M@2^O=EU<4658OMK'.DO_Q*J?I*YQQP&$Z(PA&^?FZZI)^:F'DR+-L<9?)M9[><)EN]K@H:,0-%B*+0^ MK2>/"IC[^1_2I(G:@3N62^324UMY^7Z!'D@Z+T3FJ0Q._,]HY4G7RA-S*U]? M='8E2RE=<;0N68&R<]+*$,_/P, 8!T @ Q"P"0MXW,H097I]K-VYXG M[Z:@SRZ HL50:'UF.]F"F&6+'[UW1%3!07X*I37QSILLS(,<3!"H' &%UB>H MDR.(68YXB<)-U*:?8$>YI6"./+@%N"AH!!HTAD+KD]/)(,3\ ,,%"K>C)0A4 M%R&:9QB

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Ð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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 250 323 1 false 86 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.insmed.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.insmed.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited Consolidated Statements of Comprehensive Loss (unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited) Sheet http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited Consolidated Statements of Shareholders' Equity (unaudited) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - The Company and Basis of Presentation Sheet http://www.insmed.com/role/TheCompanyandBasisofPresentation The Company and Basis of Presentation Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Fair Value Measurements Sheet http://www.insmed.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 0000010 - Disclosure - Product Revenues, Net Sheet http://www.insmed.com/role/ProductRevenuesNet Product Revenues, Net Notes 10 false false R11.htm 0000011 - Disclosure - Inventory Sheet http://www.insmed.com/role/Inventory Inventory Notes 11 false false R12.htm 0000012 - Disclosure - Intangibles, Net and Goodwill Sheet http://www.insmed.com/role/IntangiblesNetandGoodwill Intangibles, Net and Goodwill Notes 12 false false R13.htm 0000013 - Disclosure - Fixed Assets, Net Sheet http://www.insmed.com/role/FixedAssetsNet Fixed Assets, Net Notes 13 false false R14.htm 0000014 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.insmed.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Leases Sheet http://www.insmed.com/role/Leases Leases Notes 15 false false R16.htm 0000016 - Disclosure - Debt Sheet http://www.insmed.com/role/Debt Debt Notes 16 false false R17.htm 0000017 - Disclosure - Royalty Financing Agreement Sheet http://www.insmed.com/role/RoyaltyFinancingAgreement Royalty Financing Agreement Notes 17 false false R18.htm 0000018 - Disclosure - Shareholders' Equity Sheet http://www.insmed.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 0000019 - Disclosure - Stock-Based Compensation Sheet http://www.insmed.com/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Income Taxes Sheet http://www.insmed.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 0000021 - Disclosure - Commitments and Contingencies Sheet http://www.insmed.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 0000022 - Disclosure - Acquisitions Sheet http://www.insmed.com/role/Acquisitions Acquisitions Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.insmed.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.insmed.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.insmed.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.insmed.com/role/FairValueMeasurements 27 false false R28.htm 9954474 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.insmed.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) Tables http://www.insmed.com/role/ProductRevenuesNet 28 false false R29.htm 9954475 - Disclosure - Inventory (Tables) Sheet http://www.insmed.com/role/InventoryTables Inventory (Tables) Tables http://www.insmed.com/role/Inventory 29 false false R30.htm 9954476 - Disclosure - Intangibles, Net and Goodwill (Tables) Sheet http://www.insmed.com/role/IntangiblesNetandGoodwillTables Intangibles, Net and Goodwill (Tables) Tables http://www.insmed.com/role/IntangiblesNetandGoodwill 30 false false R31.htm 9954477 - Disclosure - Fixed Assets, Net (Tables) Sheet http://www.insmed.com/role/FixedAssetsNetTables Fixed Assets, Net (Tables) Tables http://www.insmed.com/role/FixedAssetsNet 31 false false R32.htm 9954478 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.insmed.com/role/AccountsPayableandAccruedLiabilities 32 false false R33.htm 9954479 - Disclosure - Leases (Tables) Sheet http://www.insmed.com/role/LeasesTables Leases (Tables) Tables http://www.insmed.com/role/Leases 33 false false R34.htm 9954480 - Disclosure - Debt (Tables) Sheet http://www.insmed.com/role/DebtTables Debt (Tables) Tables http://www.insmed.com/role/Debt 34 false false R35.htm 9954481 - Disclosure - Royalty Financing Agreement (Tables) Sheet http://www.insmed.com/role/RoyaltyFinancingAgreementTables Royalty Financing Agreement (Tables) Tables http://www.insmed.com/role/RoyaltyFinancingAgreement 35 false false R36.htm 9954482 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.insmed.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.insmed.com/role/StockBasedCompensation 36 false false R37.htm 9954483 - Disclosure - Acquisitions (Tables) Sheet http://www.insmed.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.insmed.com/role/Acquisitions 37 false false R38.htm 9954484 - Disclosure - The Company and Basis of Presentation (Details) Sheet http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails The Company and Basis of Presentation (Details) Details http://www.insmed.com/role/TheCompanyandBasisofPresentation 38 false false R39.htm 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 39 false false R40.htm 9954486 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails Summary of Significant Accounting Policies - Concentration Risk (Details) Details 40 false false R41.htm 9954487 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Details 41 false false R42.htm 9954488 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 42 false false R43.htm 9954489 - Disclosure - Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) Details 43 false false R44.htm 9954490 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 44 false false R45.htm 9954491 - Disclosure - Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details) Details 45 false false R46.htm 9954492 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details) Details 46 false false R47.htm 9954493 - Disclosure - Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) Details 47 false false R48.htm 9954494 - Disclosure - Product Revenues, Net - Product Revenues By Geographic Location (Details) Sheet http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails Product Revenues, Net - Product Revenues By Geographic Location (Details) Details 48 false false R49.htm 9954495 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://www.insmed.com/role/InventoryScheduleofInventoryDetails Inventory - Schedule of Inventory (Details) Details 49 false false R50.htm 9954496 - Disclosure - Intangibles, Net and Goodwill - Narrative (Details) Sheet http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails Intangibles, Net and Goodwill - Narrative (Details) Details 50 false false R51.htm 9954497 - Disclosure - Intangibles, Net and Goodwill (Details) Sheet http://www.insmed.com/role/IntangiblesNetandGoodwillDetails Intangibles, Net and Goodwill (Details) Details http://www.insmed.com/role/IntangiblesNetandGoodwillTables 51 false false R52.htm 9954498 - Disclosure - Fixed Assets, Net (Details) Sheet http://www.insmed.com/role/FixedAssetsNetDetails Fixed Assets, Net (Details) Details http://www.insmed.com/role/FixedAssetsNetTables 52 false false R53.htm 9954499 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables 53 false false R54.htm 9954500 - Disclosure - Leases - Narrative (Details) Sheet http://www.insmed.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 54 false false R55.htm 9954501 - Disclosure - Leases - Lease, costs (Details) Sheet http://www.insmed.com/role/LeasesLeasecostsDetails Leases - Lease, costs (Details) Details 55 false false R56.htm 9954502 - Disclosure - Debt - Schedule of Long-Term Debt (Details) Sheet http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails Debt - Schedule of Long-Term Debt (Details) Details 56 false false R57.htm 9954503 - Disclosure - Debt - Narrative (Details) Sheet http://www.insmed.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 57 false false R58.htm 9954504 - Disclosure - Debt - Components of Debt (Details) Sheet http://www.insmed.com/role/DebtComponentsofDebtDetails Debt - Components of Debt (Details) Details 58 false false R59.htm 9954505 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details) Sheet http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails Debt - Schedule of Carrying Value of Term Loan Balance (Details) Details 59 false false R60.htm 9954506 - Disclosure - Debt - Future Principal Repayments of Debt (Details) Sheet http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails Debt - Future Principal Repayments of Debt (Details) Details 60 false false R61.htm 9954507 - Disclosure - Debt - Interest Expense (Details) Sheet http://www.insmed.com/role/DebtInterestExpenseDetails Debt - Interest Expense (Details) Details 61 false false R62.htm 9954508 - Disclosure - Royalty Financing Agreement - Additional Information (Details) Sheet http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails Royalty Financing Agreement - Additional Information (Details) Details 62 false false R63.htm 9954509 - Disclosure - Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) Sheet http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) Details 63 false false R64.htm 9954510 - Disclosure - Shareholders' Equity (Details) Sheet http://www.insmed.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://www.insmed.com/role/ShareholdersEquity 64 false false R65.htm 9954511 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.insmed.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 65 false false R66.htm 9954512 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) Sheet http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) Details 66 false false R67.htm 9954513 - Disclosure - Income Taxes (Details) Sheet http://www.insmed.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.insmed.com/role/IncomeTaxes 67 false false R68.htm 9954514 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 68 false false R69.htm 9954515 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.insmed.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 69 false false R70.htm 9954516 - Disclosure - Acquisitions - Asset Acquisition (Details) Sheet http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails Acquisitions - Asset Acquisition (Details) Details 70 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration, us-gaap:DebtInstrumentConvertibleConversionRatio1 - insm-20240331.htm 4 insm-20240331.htm insm-20240331.xsd insm-20240331_cal.xml insm-20240331_def.xml insm-20240331_lab.xml insm-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 89 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "insm-20240331.htm": { "nsprefix": "insm", "nsuri": "http://www.insmed.com/20240331", "dts": { "inline": { "local": [ "insm-20240331.htm" ] }, "schema": { "local": [ "insm-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "insm-20240331_cal.xml" ] }, "definitionLink": { "local": [ "insm-20240331_def.xml" ] }, "labelLink": { "local": [ "insm-20240331_lab.xml" ] }, "presentationLink": { "local": [ "insm-20240331_pre.xml" ] } }, "keyStandard": 289, "keyCustom": 34, "axisStandard": 29, "axisCustom": 3, "memberStandard": 40, "memberCustom": 40, "hidden": { "total": 19, "http://fasb.org/us-gaap/2023": 10, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 250, "entityCount": 1, "segmentCount": 86, "elementCount": 615, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 697, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 28 }, "report": { "R1": { "role": "http://www.insmed.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.insmed.com/role/ConsolidatedBalanceSheets", "longName": "0000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R3": { "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)", "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R5": { "role": "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "longName": "0000005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited)", "shortName": "Consolidated Statements of Shareholders' Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows (unaudited)", "shortName": "Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R7": { "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentation", "longName": "0000007 - Disclosure - The Company and Basis of Presentation", "shortName": "The Company and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.insmed.com/role/FairValueMeasurements", "longName": "0000009 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.insmed.com/role/ProductRevenuesNet", "longName": "0000010 - Disclosure - Product Revenues, Net", "shortName": "Product Revenues, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.insmed.com/role/Inventory", "longName": "0000011 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.insmed.com/role/IntangiblesNetandGoodwill", "longName": "0000012 - Disclosure - Intangibles, Net and Goodwill", "shortName": "Intangibles, Net and Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.insmed.com/role/FixedAssetsNet", "longName": "0000013 - Disclosure - Fixed Assets, Net", "shortName": "Fixed Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilities", "longName": "0000014 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.insmed.com/role/Leases", "longName": "0000015 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.insmed.com/role/Debt", "longName": "0000016 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.insmed.com/role/RoyaltyFinancingAgreement", "longName": "0000017 - Disclosure - Royalty Financing Agreement", "shortName": "Royalty Financing Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.insmed.com/role/ShareholdersEquity", "longName": "0000018 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.insmed.com/role/StockBasedCompensation", "longName": "0000019 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.insmed.com/role/IncomeTaxes", "longName": "0000020 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.insmed.com/role/CommitmentsandContingencies", "longName": "0000021 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.insmed.com/role/Acquisitions", "longName": "0000022 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.insmed.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.insmed.com/role/ProductRevenuesNetTables", "longName": "9954474 - Disclosure - Product Revenues, Net (Tables)", "shortName": "Product Revenues, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.insmed.com/role/InventoryTables", "longName": "9954475 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillTables", "longName": "9954476 - Disclosure - Intangibles, Net and Goodwill (Tables)", "shortName": "Intangibles, Net and Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.insmed.com/role/FixedAssetsNetTables", "longName": "9954477 - Disclosure - Fixed Assets, Net (Tables)", "shortName": "Fixed Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables", "longName": "9954478 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.insmed.com/role/LeasesTables", "longName": "9954479 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.insmed.com/role/DebtTables", "longName": "9954480 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementTables", "longName": "9954481 - Disclosure - Royalty Financing Agreement (Tables)", "shortName": "Royalty Financing Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.insmed.com/role/StockBasedCompensationTables", "longName": "9954482 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.insmed.com/role/AcquisitionsTables", "longName": "9954483 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails", "longName": "9954484 - Disclosure - The Company and Basis of Presentation (Details)", "shortName": "The Company and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportingUnits", "unitRef": "reportingunit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportingUnits", "unitRef": "reportingunit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails", "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)", "shortName": "Summary of Significant Accounting Policies - Concentration Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-34", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-34", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)", "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R42": { "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "shortName": "Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "longName": "9954489 - Disclosure - Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details)", "shortName": "Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "insm:BusinessCombinationDeferredLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-55", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R44": { "role": "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "longName": "9954490 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireMarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireMarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "longName": "9954491 - Disclosure - Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details)", "shortName": "Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "insm:BusinessCombinationDeferredLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "insm:BusinessCombinationDeferredConsiderationLiabilityMeasurementInput", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R46": { "role": "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "longName": "9954492 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details)", "shortName": "Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-94", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R47": { "role": "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "longName": "9954493 - Disclosure - Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details)", "shortName": "Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:LiabilitiesFairValueAdjustment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R48": { "role": "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails", "longName": "9954494 - Disclosure - Product Revenues, Net - Product Revenues By Geographic Location (Details)", "shortName": "Product Revenues, Net - Product Revenues By Geographic Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-103", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R49": { "role": "http://www.insmed.com/role/InventoryScheduleofInventoryDetails", "longName": "9954495 - Disclosure - Inventory - Schedule of Inventory (Details)", "shortName": "Inventory - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails", "longName": "9954496 - Disclosure - Intangibles, Net and Goodwill - Narrative (Details)", "shortName": "Intangibles, Net and Goodwill - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails", "longName": "9954497 - Disclosure - Intangibles, Net and Goodwill (Details)", "shortName": "Intangibles, Net and Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.insmed.com/role/FixedAssetsNetDetails", "longName": "9954498 - Disclosure - Fixed Assets, Net (Details)", "shortName": "Fixed Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails", "longName": "9954499 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.insmed.com/role/LeasesNarrativeDetails", "longName": "9954500 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.insmed.com/role/LeasesLeasecostsDetails", "longName": "9954501 - Disclosure - Leases - Lease, costs (Details)", "shortName": "Leases - Lease, costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "longName": "9954502 - Disclosure - Debt - Schedule of Long-Term Debt (Details)", "shortName": "Debt - Schedule of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-147", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R57": { "role": "http://www.insmed.com/role/DebtNarrativeDetails", "longName": "9954503 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaidInKindInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:DebtInstrumentConvertibleConversionRatio1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R58": { "role": "http://www.insmed.com/role/DebtComponentsofDebtDetails", "longName": "9954504 - Disclosure - Debt - Components of Debt (Details)", "shortName": "Debt - Components of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:SecuredDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R59": { "role": "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "longName": "9954505 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details)", "shortName": "Debt - Schedule of Carrying Value of Term Loan Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-149", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "us-gaap:AccumulatedCapitalizedInterestCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R60": { "role": "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails", "longName": "9954506 - Disclosure - Debt - Future Principal Repayments of Debt (Details)", "shortName": "Debt - Future Principal Repayments of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.insmed.com/role/DebtInterestExpenseDetails", "longName": "9954507 - Disclosure - Debt - Interest Expense (Details)", "shortName": "Debt - Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R62": { "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "longName": "9954508 - Disclosure - Royalty Financing Agreement - Additional Information (Details)", "shortName": "Royalty Financing Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedRoyaltiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-189", "name": "insm:DebtInstrumentRoyaltyPayableMaximum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R63": { "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails", "longName": "9954509 - Disclosure - Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details)", "shortName": "Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R64": { "role": "http://www.insmed.com/role/ShareholdersEquityDetails", "longName": "9954510 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R65": { "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "longName": "9954511 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "longName": "9954512 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)", "shortName": "Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-227", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-227", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.insmed.com/role/IncomeTaxesDetails", "longName": "9954513 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "unique": true } }, "R68": { "role": "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954514 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "longName": "9954515 - Disclosure - Acquisitions - Narrative (Details)", "shortName": "Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-230", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-230", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "longName": "9954516 - Disclosure - Acquisitions - Asset Acquisition (Details)", "shortName": "Acquisitions - Asset Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-231", "name": "us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-231", "name": "us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "insm-20240331.htm", "first": true, "unique": true } } }, "tag": { "insm_A2019IncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "A2019IncentivePlanMember", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Incentive Plan", "label": "2019 Incentive Plan [Member]", "documentation": "2019 Incentive Plan [Member]" } } }, "auth_ref": [] }, "insm_A2019IncentivePlanThirdAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "A2019IncentivePlanThirdAmendmentMember", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Incentive Plan", "label": "2019 Incentive Plan, Third Amendment [Member]", "documentation": "2019 Incentive Plan, Third Amendment" } } }, "auth_ref": [] }, "insm_ARIKAYCEGlobalNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ARIKAYCEGlobalNetSalesMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ARIKAYCE Global Net Sales", "label": "ARIKAYCE Global Net Sales [Member]", "documentation": "ARIKAYCE Global Net Sales" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and other accrued operating expenses", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r698" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r284", "r285" ] }, "insm_AccretionOfDebtDiscountMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AccretionOfDebtDiscountMarketableSecurities", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of discount on marketable securities, net", "label": "Accretion Of Debt Discount, Marketable Securities", "documentation": "Accretion Of Debt Discount, Marketable Securities" } } }, "auth_ref": [] }, "insm_AccruedClinicalTrialExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AccruedClinicalTrialExpenses", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical trial expenses", "label": "Accrued Clinical Trial Expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses." } } }, "auth_ref": [] }, "insm_AccruedLiabilitiesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AccruedLiabilitiesCurrentMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities, Current", "label": "Accrued Liabilities, Current [Member]", "documentation": "Accrued Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional fees", "label": "Accrued Professional Fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r103" ] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalty and milestones payable", "verboseLabel": "Royalty financing liability", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31", "r664" ] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty financing agreement", "periodStartLabel": "Royalty financing agreement liability - beginning balance", "periodEndLabel": "Royalty financing agreement liability - ending balance", "label": "Accrued Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": [ "r103" ] }, "insm_AccruedSalesAllowancesandRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AccruedSalesAllowancesandRelatedCosts", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued sales allowances and related costs", "label": "Accrued Sales Allowances and Related Costs", "documentation": "Accrued Sales Allowances and Related Costs" } } }, "auth_ref": [] }, "insm_AccruedTechnicalOperationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AccruedTechnicalOperationExpenses", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued technical operation expenses", "label": "Accrued Technical Operation Expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses." } } }, "auth_ref": [] }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedCapitalizedInterestCosts", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in-kind interest capitalized", "label": "Accumulated Capitalized Interest Costs", "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.insmed.com/role/FixedAssetsNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r67", "r187", "r530" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r40", "r41", "r121", "r196", "r527", "r553", "r554" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r17", "r41", "r464", "r467", "r507", "r549", "r550", "r795", "r796", "r797", "r805", "r806", "r807" ] }, "insm_AcquiredResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AcquiredResearchAndDevelopmentMember", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired ARIKAYCE R&D", "label": "Acquired Research And Development [Member]", "documentation": "Acquired Research And Development" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r748" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r113", "r698", "r874" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r433", "r434", "r435", "r565", "r805", "r806", "r807", "r856", "r876" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r754" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r754" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r754" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r754" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r81", "r82", "r398" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "insm_AdrestiaTherapeuticsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AdrestiaTherapeuticsLtdMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adrestia Therapeutics Ltd", "label": "Adrestia Therapeutics Ltd [Member]", "documentation": "Adrestia Therapeutics Ltd" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r719", "r730", "r740", "r765" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r722", "r733", "r743", "r768" ] }, "insm_AlgaeneXIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AlgaeneXIncMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AlgaeneX", "label": "AlgaeneX, Inc. [Member]", "documentation": "AlgaeneX, Inc." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r754" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r761" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r726", "r734", "r744", "r761", "r769", "r773", "r781" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r779" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocated share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r428", "r436" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "verboseLabel": "Amortization of issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r125", "r350", "r493", "r799" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r350", "r493", "r678", "r679", "r799" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "negatedTerseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r61", "r65" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r253" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r51" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r51" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r852" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, consideration transferred", "totalLabel": "Total purchase price", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r696", "r853", "r854", "r855" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payment, value", "verboseLabel": "Shares of Insmed common stock issuable on July 1, 2024", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r853", "r854", "r855" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of Insmed common stock issued on closing", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r853", "r854", "r855" ] }, "insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in asset acquisition (in shares)", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares", "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r852" ] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTableTextBlock", "presentation": [ "http://www.insmed.com/role/AcquisitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Asset Acquisition", "label": "Asset Acquisition [Table Text Block]", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": [ "r852" ] }, "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in Fair Value", "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r161", "r190", "r221", "r258", "r272", "r278", "r286", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r459", "r461", "r483", "r525", "r597", "r698", "r710", "r815", "r816", "r860" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r183", "r198", "r221", "r286", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r459", "r461", "r483", "r698", "r815", "r816", "r860" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "insm_AtTheMarketAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AtTheMarketAgreementMember", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "At The Market Agreement [Member]", "documentation": "At The Market Agreement" } } }, "auth_ref": [] }, "insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average sales prices of publicly disclosed priority review voucher sales obligated to pay equity holders, percentage", "label": "Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage", "documentation": "Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r776" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r777" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r772" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r772" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r772" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r772" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r772" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r772" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r775" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r774" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r90", "r91" ] }, "insm_BrensocatibGlobalNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BrensocatibGlobalNetSalesMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brensocatib Global Net Sales", "label": "Brensocatib Global Net Sales [Member]", "documentation": "Brensocatib Global Net Sales" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r454", "r691", "r692" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r83", "r84", "r454", "r691", "r692" ] }, "insm_BusinessAcquisitionConsecutiveTradingDayPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BusinessAcquisitionConsecutiveTradingDayPeriod", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consecutive trading day period", "label": "Business Acquisition, Consecutive Trading Day Period", "documentation": "Business Acquisition, Consecutive Trading Day Period" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in acquisition (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r154" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price used to calculate issuable shares (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate value", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r15" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of deferred and contingent consideration liabilities", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r458", "r798" ] }, "insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued upon milestone achievements (in shares)", "label": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares", "documentation": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "periodStartLabel": "Consideration, beginning balance", "periodEndLabel": "Consideration, ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r3", "r86", "r457" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r86" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average probability of success", "terseLabel": "Values", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r478" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "verboseLabel": "Non-current contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r86" ] }, "insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BusinessCombinationDeferredConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insmed share price (in usd per share)", "label": "Business Combination, Deferred Consideration Liability, Measurement Input", "documentation": "Business Combination, Deferred Consideration Liability, Measurement Input" } } }, "auth_ref": [] }, "insm_BusinessCombinationDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BusinessCombinationDeferredLiability", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred consideration", "label": "Business Combination, Deferred Liability", "documentation": "Business Combination, Deferred Liability" } } }, "auth_ref": [] }, "insm_BusinessCombinationDeferredPaymentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BusinessCombinationDeferredPaymentsCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred and contingent consideration", "label": "Business Combination, Deferred Payments, Current", "documentation": "Business Combination, Deferred Payments, Current" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/Acquisitions" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r153", "r455" ] }, "insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations and Asset Acquisitions", "label": "Business Combinations And Asset Acquisitions, Policy [Policy Text Block]", "documentation": "Business Combinations And Asset Acquisitions, Policy" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r95", "r96" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r48", "r185", "r662" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r48", "r133", "r217" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r5", "r133" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r752" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r193", "r194", "r195", "r256", "r360", "r361", "r362", "r364", "r367", "r372", "r374", "r559", "r560", "r561", "r562", "r680", "r787", "r800" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r753" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r753" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r143", "r313", "r314", "r649", "r814" ] }, "insm_CommonStockAuthorizedAggregateGrossSalesProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "CommonStockAuthorizedAggregateGrossSalesProceeds", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock authorized, aggregate gross sales proceeds (up to)", "label": "Common Stock Authorized, Aggregate Gross Sales Proceeds", "documentation": "Common Stock Authorized, Aggregate Gross Sales Proceeds" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r700", "r701", "r702", "r704", "r705", "r706", "r707", "r805", "r806", "r856", "r872", "r876" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r112" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized shares (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r112", "r585" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued shares (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r112" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding shares (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r18", "r112", "r585", "r603", "r876", "r877" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 148,560,882 and 147,977,960 issued and outstanding shares at March\u00a031, 2024 and December\u00a031, 2023,\u00a0respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r112", "r526", "r698" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r758" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r757" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r759" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r756" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r42", "r203", "r205", "r210", "r520", "r534" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss:", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "insm_ComputerHardwareAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ComputerHardwareAndSoftwareMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer hardware and software", "label": "Computer Hardware And Software [Member]", "documentation": "Computer Hardware And Software" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r54", "r56", "r97", "r98", "r283", "r648" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r54", "r56", "r97", "r98", "r283", "r555", "r648" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r54", "r56", "r97", "r98", "r283", "r648", "r791" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r106", "r171" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r648" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r54", "r56", "r97", "r98", "r283" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r53", "r54", "r56", "r57", "r97", "r158", "r648" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r54", "r56", "r97", "r98", "r283", "r648" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued France ATU reimbursement payable", "label": "Contract with Customer, Refund Liability, Current", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current." } } }, "auth_ref": [ "r820" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible senior notes", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining": { "xbrltype": "durationItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining discount amortization period (in years)", "label": "Convertible Debt Instrument, Discount Amortization Period, Remaining", "documentation": "Convertible Debt Instrument, Discount Amortization Period, Remaining" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r145", "r329", "r330", "r340", "r341", "r342", "r346", "r347", "r348", "r349", "r350", "r675", "r676", "r677", "r678", "r679" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt securities", "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r822" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes", "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r109", "r162" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenues (excluding amortization of intangible assets)", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r127", "r516" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r126" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "insm_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "CustomerAMember", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "insm_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "CustomerBMember", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "insm_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "CustomerCMember", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Customer C [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r55", "r283" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r144", "r219", "r328", "r334", "r335", "r336", "r337", "r338", "r339", "r344", "r351", "r352", "r354" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r25", "r109", "r110", "r162", "r163", "r224", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r494", "r675", "r676", "r677", "r678", "r679", "r801" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r25", "r163", "r355" ] }, "insm_DebtInstrumentConversionTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConversionTermAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Conversion Term [Axis]", "label": "Debt Instrument Conversion Term [Axis]", "documentation": "Debt Instrument Conversion Term [Axis]" } } }, "auth_ref": [] }, "insm_DebtInstrumentConversionTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConversionTermDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Conversion Term [Domain]", "label": "Debt Instrument Conversion Term [Domain]", "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]" } } }, "auth_ref": [] }, "insm_DebtInstrumentConversionTermFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConversionTermFourMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Term (iv)", "label": "Debt Instrument, Conversion Term Four [Member]", "documentation": "Debt Instrument, Conversion Term Four [Member]" } } }, "auth_ref": [] }, "insm_DebtInstrumentConversionTermOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConversionTermOneMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Term (i)", "label": "Debt Instrument, Conversion Term One [Member]", "documentation": "Debt Instrument, Conversion Term One [Member]" } } }, "auth_ref": [] }, "insm_DebtInstrumentConversionTermThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConversionTermThreeMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Term (iii)", "label": "Debt Instrument, Conversion Term Three [Member]", "documentation": "Debt Instrument, Conversion Term Three [Member]" } } }, "auth_ref": [] }, "insm_DebtInstrumentConversionTermTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConversionTermTwoMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Term (ii)", "label": "Debt Instrument, Conversion Term Two [Member]", "documentation": "Debt Instrument, Conversion Term Two [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Residual equity component of debt", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion." } } }, "auth_ref": [ "r69" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r146", "r331" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion rate", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r34", "r75", "r149", "r150", "r331" ] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold consecutive trading days", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold percent of stock price trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold trading days", "label": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": { "xbrltype": "integerItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold trading days following fundamental change", "label": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change", "documentation": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original Term Loan balance", "verboseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r100", "r102", "r329", "r494", "r676", "r677" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lenders fees and deal expenses", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r35" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r33", "r100", "r357", "r494" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r33", "r330" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r494", "r675", "r676", "r677", "r678", "r679", "r801" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r36", "r224", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r494", "r675", "r676", "r677", "r678", "r679", "r801" ] }, "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to purchase additional debt", "label": "Debt Instrument, Option To Purchase Additional Debt", "documentation": "Debt Instrument, Option To Purchase Additional Debt" } } }, "auth_ref": [] }, "insm_DebtInstrumentPercentOfInterestPayable": { "xbrltype": "percentItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentPercentOfInterestPayable", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payable", "label": "Debt Instrument, Percent Of Interest Payable", "documentation": "Debt Instrument, Percent Of Interest Payable" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments", "label": "Debt Instrument, Periodic Payment, Interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r36" ] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchased amount", "label": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "insm_DebtInstrumentRoyaltyPayableMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentRoyaltyPayableMaximum", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty maximum", "label": "Debt Instrument, Royalty Payable, Maximum", "documentation": "Debt Instrument, Royalty Payable, Maximum" } } }, "auth_ref": [] }, "insm_DebtInstrumentRoyaltyStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtInstrumentRoyaltyStatedPercentage", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty percentage", "label": "Debt Instrument, Royalty, Stated Percentage", "documentation": "Debt Instrument, Royalty, Stated Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r36", "r75", "r78", "r99", "r100", "r102", "r105", "r148", "r150", "r224", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r494", "r675", "r676", "r677", "r678", "r679", "r801" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt term (in months)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "insm_DebtIssuanceCostsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DebtIssuanceCostsOther", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Debt Issuance Costs, Other", "documentation": "Debt Issuance Costs, Other" } } }, "auth_ref": [] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Issuance Costs", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, net", "negatedTerseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r101", "r818" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r11", "r152", "r177", "r449", "r450", "r803" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r66" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateral for interest rate swap", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r199", "r200", "r482", "r567", "r568", "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r577", "r591", "r592", "r636", "r637", "r639", "r640", "r641", "r642", "r668", "r702", "r873" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r19", "r87", "r88", "r89", "r92", "r223" ] }, "insm_DevelopmentAndRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DevelopmentAndRegulatoryMilestonesMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development and regulatory milestones", "label": "Development And Regulatory Milestones [Member]", "documentation": "Development And Regulatory Milestones" } } }, "auth_ref": [] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesAbstract", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares used in calculation of basic net loss per share:", "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r385", "r681", "r682", "r683", "r684", "r685", "r686", "r687" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.insmed.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r396", "r401", "r429", "r430", "r432", "r694" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r714" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r747" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "insm_DraytonWiseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "DraytonWiseMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Drayton Wise [Member]", "documentation": "Drayton Wise" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r230", "r231", "r232", "r233", "r234", "r239", "r242", "r250", "r251", "r252", "r254", "r471", "r472", "r521", "r535", "r670" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r230", "r231", "r232", "r233", "r234", "r242", "r250", "r251", "r252", "r254", "r471", "r472", "r521", "r535", "r670" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r51", "r52" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r485" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee related costs", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r431" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to unvested RSU awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r849" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to unvested stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r849" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "insm_EmployeeStockPurchasePlan2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "EmployeeStockPurchasePlan2018Member", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 ESPP", "label": "Employee Stock Purchase Plan 2018 [Member]", "documentation": "Employee Stock Purchase Plan 2018 [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r712" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r712" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r712" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r786" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r712" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r712" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r712" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r712" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r18", "r180", "r206", "r207", "r208", "r225", "r226", "r227", "r229", "r235", "r237", "r255", "r287", "r288", "r375", "r433", "r434", "r435", "r445", "r446", "r463", "r464", "r465", "r466", "r467", "r468", "r470", "r486", "r487", "r488", "r489", "r490", "r491", "r507", "r549", "r550", "r551", "r565", "r624" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r755" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r719", "r730", "r740", "r765" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r716", "r727", "r737", "r762" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r342", "r482", "r676", "r677" ] }, "insm_EuropeAndTheRestOfTheWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "EuropeAndTheRestOfTheWorldMember", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe and rest of world", "label": "Europe And The Rest Of The World [Member]", "documentation": "Europe And The Rest Of The World" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r761" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r474", "r475", "r479" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r474", "r475", "r479" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Observable Inputs in Valuation of Deferred Consideration", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r20" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r342", "r388", "r389", "r390", "r391", "r392", "r393", "r475", "r508", "r509", "r510", "r676", "r677", "r688", "r689", "r690" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r94", "r157" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r24", "r93", "r342", "r676", "r677" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r474", "r475", "r477", "r478", "r480" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r342", "r676", "r677" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.insmed.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r342", "r388", "r393", "r475", "r508", "r688", "r689", "r690" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "verboseLabel": "Deferred Consideration (Level 2 Liabilities)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r342", "r388", "r393", "r475", "r509", "r676", "r677", "r688", "r689", "r690" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "verboseLabel": "Contingent Consideration (Level 3 Liabilities)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r342", "r388", "r389", "r390", "r391", "r392", "r393", "r475", "r510", "r676", "r677", "r688", "r689", "r690" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r21" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r342", "r388", "r389", "r390", "r391", "r392", "r393", "r508", "r509", "r510", "r676", "r677", "r688", "r689", "r690" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r473", "r480" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease interest expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r498", "r502", "r697" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r497" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities, long-term", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r497" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of finance lease principal", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r499", "r505" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r496" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease amortization expense", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r498", "r502", "r697" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets estimated useful life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets, 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets, remainder of 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets, 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets, 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets, 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r140" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r303", "r305", "r306", "r307", "r517", "r518" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r139", "r518" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r517" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r62", "r64" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, net", "verboseLabel": "Intangibles, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r139", "r517" ] }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRollForward", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived Intangible Assets [Roll Forward]", "label": "Finite-Lived Intangible Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r304" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r484" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r723", "r734", "r744", "r769" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r723", "r734", "r744", "r769" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r723", "r734", "r744", "r769" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r723", "r734", "r744", "r769" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r723", "r734", "r744", "r769" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r11", "r70", "r71" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r128", "r607" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r124" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r188", "r291", "r519", "r674", "r698", "r811", "r812" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r290", "r301", "r674" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r14" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired IPR&D", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r122", "r165", "r258", "r271", "r277", "r279", "r522", "r532", "r672" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r308", "r310", "r608" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r310", "r608" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r222", "r439", "r441", "r443", "r444", "r447", "r451", "r452", "r453", "r564" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r168", "r178", "r236", "r237", "r266", "r440", "r448", "r536" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r49" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r798" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt securities (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r246", "r247", "r252" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r243", "r244", "r245", "r252", "r400" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r726", "r734", "r744", "r761", "r769", "r773", "r781" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r779" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r715", "r785" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r715", "r785" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r715", "r785" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, Net and Goodwill", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r302" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived Intangible Assets and Impairment Assessment", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r64", "r513", "r514", "r515", "r517", "r669" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 }, "http://www.insmed.com/role/DebtInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "totalLabel": "Total interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r101", "r167", "r209", "r262", "r492", "r609", "r708", "r875" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt contractual interest expense", "verboseLabel": "Interest expense recognized", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r130", "r348", "r358", "r678", "r679" ] }, "insm_InterestExpenseExcludingFinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "InterestExpenseExcludingFinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt interest expense", "label": "Interest Expense, Excluding Finance Lease Interest Expense", "documentation": "Interest Expense, Excluding Finance Lease Interest Expense" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Expense", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Swap interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r213", "r215", "r216" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest payable", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateDerivativeAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest rate swap", "label": "Interest Rate Derivative Assets, at Fair Value", "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets." } } }, "auth_ref": [] }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Interest Rate Derivative Liabilities, at Fair Value", "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities." } } }, "auth_ref": [] }, "insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory and Cost of Product Revenues (excluding amortization of intangible assets)", "label": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]", "documentation": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r289" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.insmed.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/InventoryScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r138", "r665" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.insmed.com/role/InventoryScheduleofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/InventoryScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Inventory, Net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r197", "r663", "r698" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.insmed.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/InventoryScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r138", "r667" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.insmed.com/role/InventoryScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/InventoryScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r138", "r666" ] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income", "label": "Investment Income, Nonoperating", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": [ "r129" ] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "JP", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": [] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.insmed.com/role/LeasesLeasecostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost [Abstract]", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.insmed.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Noncash Disclosures included in Consolidated Financial Statements", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r859" ] }, "insm_LeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "LeaseRemainingLeaseTerm", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Lease, Remaining Lease Term", "documentation": "Lease, Remaining Lease Term" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r142" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.insmed.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r495" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r501" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r501" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r500" ] }, "insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease cost, future right-of-use asset", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount", "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.insmed.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r495" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r30", "r221", "r286", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r460", "r461", "r462", "r483", "r584", "r671", "r710", "r815", "r860", "r861" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r117", "r164", "r529", "r698", "r802", "r810", "r858" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r32", "r184", "r221", "r286", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r460", "r461", "r462", "r483", "r698", "r815", "r860", "r861" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PARI milestones", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r85", "r438", "r851" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r25", "r163", "r341", "r356", "r676", "r677", "r869" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ending December\u00a031:", "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedTerseLabel": "Less: current portion of convertible notes", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r191" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r224", "r346" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r224", "r346" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r224", "r346" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r224", "r346" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r804" ] }, "insm_LongTermDebtMaturityAfterYearFourAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "LongTermDebtMaturityAfterYearFourAndThereafter", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Long-Term Debt, Maturity, after Year Four And Thereafter", "documentation": "Long-Term Debt, Maturity, after Year Four And Thereafter" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, long-term", "totalLabel": "Total long-term convertible notes", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r192" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r36" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r36", "r68" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r283", "r683", "r819", "r870", "r871" ] }, "insm_ManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ManufacturingEquipmentMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing equipment", "label": "Manufacturing Equipment [Member]", "documentation": "Manufacturing Equipment" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r104", "r793" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r793" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r394", "r512", "r548", "r576", "r577", "r629", "r631", "r633", "r634", "r643", "r659", "r660", "r673", "r680", "r693", "r699", "r817", "r862", "r863", "r864", "r865", "r866", "r867" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r753" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r753" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r857" ] }, "insm_MeasurementInputProbabilityOfSuccessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "MeasurementInputProbabilityOfSuccessMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probabilities of success", "label": "Measurement Input, Probability Of Success [Member]", "documentation": "Measurement Input, Probability Of Success" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Price", "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r857" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r476" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "insm_MilestoneEvent1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "MilestoneEvent1Member", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Event 1", "label": "Milestone Event 1 [Member]", "documentation": "Milestone Event 1" } } }, "auth_ref": [] }, "insm_MilestoneEvent2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "MilestoneEvent2Member", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Event 2", "label": "Milestone Event 2 [Member]", "documentation": "Milestone Event 2" } } }, "auth_ref": [] }, "insm_MilestoneEvent3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "MilestoneEvent3Member", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Event 3", "label": "Milestone Event 3 [Member]", "documentation": "Milestone Event 3" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r394", "r512", "r548", "r576", "r577", "r629", "r631", "r633", "r634", "r643", "r659", "r660", "r673", "r680", "r693", "r699", "r817", "r862", "r863", "r864", "r865", "r866", "r867" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r772" ] }, "insm_MotusBiosciencesIncAndAlgaeneXIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "MotusBiosciencesIncAndAlgaeneXIncMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Motus and AlgaeneX", "label": "Motus Biosciences, Inc. And AlgaeneX, Inc. [Member]", "documentation": "Motus Biosciences, Inc. And AlgaeneX, Inc." } } }, "auth_ref": [] }, "insm_MotusBiosciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "MotusBiosciencesIncMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Motus", "label": "Motus Biosciences, Inc. [Member]", "documentation": "Motus Biosciences, Inc." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r780" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r283", "r683", "r819", "r870", "r871" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r754" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r214" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r214" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r133", "r134", "r135" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r123", "r135", "r166", "r182", "r201", "r204", "r208", "r221", "r228", "r230", "r231", "r232", "r233", "r236", "r237", "r248", "r258", "r271", "r277", "r279", "r286", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r472", "r483", "r533", "r605", "r622", "r623", "r672", "r708", "r815" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r212", "r230", "r231", "r232", "r233", "r239", "r240", "r249", "r252", "r258", "r271", "r277", "r279", "r672" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r753" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r723", "r734", "r744", "r761", "r769" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r751" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r750" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r761" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r780" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r780" ] }, "insm_NoncashAcquisitionRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "NoncashAcquisitionRelatedExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vertuis acquisition", "verboseLabel": "Adrestia acquisition", "label": "Noncash Acquisition Related Expense", "documentation": "Noncash Acquisition Related Expense" } } }, "auth_ref": [] }, "insm_NoncashOperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "NoncashOperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Noncash Operating Lease Expense", "documentation": "Noncash Operating Lease Expense" } } }, "auth_ref": [] }, "insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders": { "xbrltype": "integerItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of publicly disclosed sales used to determine average sales price owed to equity holders", "label": "Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders", "documentation": "Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportingUnits", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.75% convertible senior notes due 2025", "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]", "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r258", "r271", "r277", "r279", "r672" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense charged to operations", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r503", "r697" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r497" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r497" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r496" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/TheCompanyandBasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "The Company and Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r108", "r155", "r556", "r557" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r160", "r189", "r524", "r710" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (loss) gain on marketable securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r8", "r16", "r156" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation losses", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r8", "r16", "r156" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r8", "r16", "r156", "r202", "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r37" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty financing non-cash interest expense", "label": "Other Noncash Expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r135" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r131" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r753" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r721", "r732", "r742", "r767" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r724", "r735", "r745", "r770" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r724", "r735", "r745", "r770" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in-kind interest capitalized", "label": "Paid-in-Kind Interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r749" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue Interest Payments paid and payable", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r46" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of equity issuance costs", "terseLabel": "Payments of stock issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r45" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid in acquisition", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r43", "r456" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r809" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of fixed assets", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r132" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r752" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r752" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r751" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r761" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r754" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r750" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PSUs", "verboseLabel": "Performance options", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r481" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r111", "r360" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r111", "r585" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r111", "r360" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r111", "r585", "r603", "r876", "r877" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r794" ] }, "insm_PriorityReviewVoucherMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "PriorityReviewVoucherMilestoneMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Priority review voucher milestone", "label": "Priority Review Voucher Milestone [Member]", "documentation": "Priority Review Voucher Milestone" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from loans", "label": "Proceeds from Loans", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": [ "r47" ] }, "insm_ProceedsFromRoyaltyFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ProceedsFromRoyaltyFinancing", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from royalty financing", "label": "Proceeds From Royalty Financing", "documentation": "Proceeds From Royalty Financing" } } }, "auth_ref": [] }, "insm_ProceedsFromRoyaltyFinancingAgreementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ProceedsFromRoyaltyFinancingAgreementNet", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from royalty financing agreement, net", "label": "Proceeds From Royalty Financing Agreement, Net", "documentation": "Proceeds From Royalty Financing Agreement, Net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options and ESPP", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r22" ] }, "insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage", "label": "Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage", "documentation": "Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/FixedAssetsNet" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Assets, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r141", "r172", "r175", "r176" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.insmed.com/role/FixedAssetsNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r142", "r186", "r531" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.insmed.com/role/FixedAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets, net", "totalLabel": "Fixed assets, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r523", "r531", "r698" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fixed Assets", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r142" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life (years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "insm_PublicStockOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "PublicStockOfferingMember", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Stock Offering", "label": "Public Stock Offering [Member]", "documentation": "Public Stock Offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r749" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r749" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r387", "r394", "r424", "r425", "r426", "r511", "r512", "r548", "r576", "r577", "r629", "r631", "r633", "r634", "r643", "r659", "r660", "r673", "r680", "r693", "r699", "r702", "r813", "r817", "r863", "r864", "r865", "r866", "r867" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r387", "r394", "r424", "r425", "r426", "r511", "r512", "r548", "r576", "r577", "r629", "r631", "r633", "r634", "r643", "r659", "r660", "r673", "r680", "r693", "r699", "r702", "r813", "r817", "r863", "r864", "r865", "r866", "r867" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r716", "r727", "r737", "r762" ] }, "us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Financing Agreement", "label": "Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block]", "documentation": "The entire disclosure for repurchase agreements (also known as repos), resale agreements (also known as reverse repurchase agreements or reverse repos), securities borrowed transactions, and securities loaned transactions." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D expense", "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff", "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination." } } }, "auth_ref": [ "r63", "r850" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r107", "r437", "r868" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r717", "r728", "r738", "r763" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r718", "r729", "r739", "r764" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r725", "r736", "r746", "r771" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "RS and RSUs", "terseLabel": "Unvested RS and RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r114", "r151", "r528", "r552", "r554", "r563", "r586", "r698" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r225", "r226", "r227", "r229", "r235", "r237", "r287", "r288", "r433", "r434", "r435", "r445", "r446", "r463", "r465", "r466", "r468", "r470", "r549", "r551", "r565", "r876" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r259", "r260", "r270", "r275", "r276", "r280", "r281", "r283", "r384", "r385", "r516" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r681" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNet" ], "lang": { "en-us": { "role": { "terseLabel": "Product Revenues, Net", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r179", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r386" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Revenues By Geographic Location", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r23" ] }, "insm_RevenueInterestPaymentsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "RevenueInterestPaymentsPayable", "crdr": "credit", "calculation": { "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Payments payable", "label": "Revenue Interest Payments Payable", "documentation": "Revenue Interest Payments Payable" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/LeasesLeasecostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance right-of-use assets obtained in exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r506", "r697" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/LeasesLeasecostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right-of-use assets obtained in exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r506", "r697" ] }, "us-gaap_RoyaltyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyAgreementsMember", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Agreements", "label": "Royalty Agreements [Member]", "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources." } } }, "auth_ref": [ "r85", "r438", "r851" ] }, "insm_RoyaltyFinancingAgreementRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "RoyaltyFinancingAgreementRollForward", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Financing Agreement [Roll Forward]", "label": "Royalty Financing Agreement [Roll Forward]", "documentation": "Royalty Financing Agreement" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r780" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r780" ] }, "insm_S.NicoleSchaefferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "S.NicoleSchaefferMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "S. Nicole Schaeffer [Member]", "documentation": "S. Nicole Schaeffer" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate net proceeds from stock offering", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares sold in offering (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Revenue, Product Line", "label": "Revenue, Product and Service Benchmark [Member]", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r790" ] }, "insm_SaraBonsteinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "SaraBonsteinMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Sara Bonstein [Member]", "documentation": "Sara Bonstein" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r395", "r808" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r238", "r395", "r788", "r808" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r83", "r84", "r454" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value of Term Loan Balance", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt, Current and Long-Term Portion of Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r36", "r75", "r78", "r99", "r100", "r102", "r105", "r148", "r150", "r676", "r678", "r804" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.insmed.com/role/DebtTables", "http://www.insmed.com/role/RoyaltyFinancingAgreementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Debt Balance", "verboseLabel": "Schedule of Carrying Value of Royalty Financing Agreement", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Employee Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r80" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value and Fair Value of Assets and Liabilities", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r474", "r475" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r62", "r64", "r517" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Rollforward of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r62", "r64" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.insmed.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r26", "r118", "r119", "r120" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Principal Repayments of Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r397", "r399", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r148", "r150", "r151", "r193", "r194", "r195", "r256", "r360", "r361", "r362", "r364", "r367", "r372", "r374", "r559", "r560", "r561", "r562", "r680", "r787", "r800" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r50" ] }, "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]", "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]", "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]" } } }, "auth_ref": [] }, "insm_ScheduleofEarningsPerShareBasicandDilutedTable": { "xbrltype": "stringItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ScheduleofEarningsPerShareBasicandDilutedTable", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]", "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]" } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r53", "r54", "r56", "r57", "r97", "r158" ] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "calculation": { "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face value of outstanding convertible notes", "label": "Secured Debt", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r25", "r163", "r869" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "insm_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r711" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r713" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r283", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r311", "r312", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r674", "r792", "r870" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r281", "r282", "r569", "r572", "r574", "r630", "r632", "r635", "r644", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661", "r682", "r702", "r819", "r870" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, nonvested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r413", "r414" ] }, "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inducement stock options granted to new employees (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross", "documentation": "Gross number of inducement share options (or share units) granted during the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r397", "r399", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r695" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r79" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r405", "r406" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First anniversary of closing date", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third anniversary of closing date", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second anniversary of closing date", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in usd per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential award payout", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r136", "r218" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r181", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r283", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r309", "r311", "r312", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r674", "r792", "r870" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r18", "r39", "r180", "r206", "r207", "r208", "r225", "r226", "r227", "r229", "r235", "r237", "r255", "r287", "r288", "r375", "r433", "r434", "r435", "r445", "r446", "r463", "r464", "r465", "r466", "r467", "r468", "r470", "r486", "r487", "r488", "r489", "r490", "r491", "r507", "r549", "r550", "r551", "r565", "r624" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r281", "r282", "r569", "r572", "r574", "r630", "r632", "r635", "r644", "r647", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661", "r682", "r702", "r819", "r870" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r225", "r226", "r227", "r255", "r516", "r558", "r566", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r604", "r606", "r607", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r703" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r238", "r395", "r788", "r789", "r808" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r225", "r226", "r227", "r255", "r516", "r558", "r566", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r604", "r606", "r607", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r703" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r720", "r731", "r741", "r766" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock for asset acquisition (in shares)", "terseLabel": "Issuance of common stock for business acquisition (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r111", "r112", "r151" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r18", "r111", "r112", "r151", "r559", "r624", "r645" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for vesting of RSUs (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r18", "r111", "r112", "r151" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options and ESPP shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r18", "r111", "r112", "r151", "r410" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for asset acquisition", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r18", "r39", "r151" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r18", "r111", "r112", "r151", "r565", "r624", "r645", "r709" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for vesting of RSUs", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r18", "r151" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options and ESPP shares", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r18", "r39", "r151" ] }, "insm_StockOptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "StockOptionsAndRestrictedStockUnitsMember", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and RSUs", "label": "Stock Options And Restricted Stock Units [Member]", "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 deficit", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r112", "r115", "r116", "r137", "r587", "r603", "r625", "r626", "r698", "r710", "r802", "r810", "r858", "r876" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.insmed.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r147", "r220", "r359", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r373", "r375", "r469", "r627", "r628", "r646" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r760" ] }, "insm_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "TermLoanMember", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r752" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r759" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r779" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r781" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r782" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r783" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r781" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r781" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r784" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r782" ] }, "insm_TriggeringEventAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "TriggeringEventAxis", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triggering Event [Axis]", "label": "Triggering Event [Axis]", "documentation": "Triggering Event" } } }, "auth_ref": [] }, "insm_TriggeringEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "TriggeringEventDomain", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triggering Event [Domain]", "label": "Triggering Event [Domain]", "documentation": "Triggering Event [Domain]" } } }, "auth_ref": [] }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfCostGoodOrServiceExtensibleList", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost, Product and Service [Extensible List]", "label": "Cost, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of cost from product sold and service rendered." } } }, "auth_ref": [ "r821" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Term Loan issuance costs, unamortized", "periodStartLabel": "Royalty issuance costs, unamortized - beginning balance", "periodEndLabel": "Deferred issuance costs, unamortized - ending balance", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r778" ] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of interest rate swap", "negatedTerseLabel": "Change in fair value of interest rate swap", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r11", "r618", "r619", "r620", "r621", "r638" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.insmed.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, interest and penalties accrued", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r442" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r58", "r59", "r60", "r169", "r170", "r173", "r174" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease, cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r504", "r697" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "insm_VariableRateComponentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "VariableRateComponentAxis", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Axis]", "label": "Variable Rate Component [Axis]", "documentation": "Variable Rate Component" } } }, "auth_ref": [] }, "insm_VariableRateComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "VariableRateComponentDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Domain]", "label": "Variable Rate Component [Domain]", "documentation": "Variable Rate Component [Domain]" } } }, "auth_ref": [] }, "insm_VariableRateComponentTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "VariableRateComponentTwoMember", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component Two", "label": "Variable Rate Component Two [Member]", "documentation": "Variable Rate Component Two" } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "insm_VertuisBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "VertuisBioIncMember", "presentation": [ "http://www.insmed.com/role/AcquisitionsAssetAcquisitionDetails", "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vertuis Bio, Inc.", "label": "Vertuis Bio, Inc. [Member]", "documentation": "Vertuis Bio, Inc." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average diluted common shares outstanding (in shares)", "totalLabel": "Weighted average common shares outstanding used\u00a0in calculation of diluted net loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r241", "r252" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average basic common shares outstanding (in shares)", "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r239", "r252" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "insm_WilliamLewisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "WilliamLewisMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "William Lewis [Member]", "documentation": "William Lewis" } } }, "auth_ref": [] }, "insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.insmed.com/20240331", "localname": "ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.75% convertible senior notes due 2028", "label": "Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member]", "documentation": "Zero Point Seven Five Percent Convertible Senior Note Due 2028" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//860/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r787": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r788": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r789": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 90 0001104506-24-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104506-24-000016-xbrl.zip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�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end XML 92 insm-20240331_htm.xml IDEA: XBRL DOCUMENT 0001104506 2024-01-01 2024-03-31 0001104506 2024-05-06 0001104506 2024-03-31 0001104506 2023-12-31 0001104506 2023-01-01 2023-03-31 0001104506 us-gaap:CommonStockMember 2022-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001104506 us-gaap:RetainedEarningsMember 2022-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001104506 2022-12-31 0001104506 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001104506 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001104506 us-gaap:CommonStockMember 2023-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001104506 us-gaap:RetainedEarningsMember 2023-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001104506 2023-03-31 0001104506 us-gaap:CommonStockMember 2023-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001104506 us-gaap:RetainedEarningsMember 2023-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001104506 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001104506 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001104506 us-gaap:CommonStockMember 2024-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001104506 us-gaap:RetainedEarningsMember 2024-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001104506 insm:VertuisBioIncMember 2024-01-01 2024-03-31 0001104506 insm:VertuisBioIncMember 2023-01-01 2023-03-31 0001104506 insm:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001104506 insm:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001104506 insm:CustomerBMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001104506 insm:CustomerBMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001104506 insm:CustomerCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001104506 insm:CustomerCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001104506 2023-01-01 2023-12-31 0001104506 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001104506 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001104506 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001104506 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001104506 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001104506 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-03-31 0001104506 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0001104506 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001104506 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001104506 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001104506 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember 2022-08-01 2022-08-31 0001104506 insm:MotusBiosciencesIncMember 2023-08-01 2023-08-31 0001104506 insm:AccruedLiabilitiesCurrentMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel2Member us-gaap:MeasurementInputSharePriceMember 2024-03-31 0001104506 insm:MotusBiosciencesIncMember 2021-08-01 2021-08-31 0001104506 insm:AlgaeneXIncMember 2021-08-04 2021-08-04 0001104506 insm:MeasurementInputProbabilityOfSuccessMember 2024-03-31 0001104506 insm:MotusBiosciencesIncMember insm:DevelopmentAndRegulatoryMilestonesMember 2021-08-31 0001104506 insm:MotusBiosciencesIncMember insm:DevelopmentAndRegulatoryMilestonesMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:FairValueInputsLevel3Member 2024-03-31 0001104506 us-gaap:OtherNoncurrentLiabilitiesMember insm:MotusBiosciencesIncMember us-gaap:FairValueInputsLevel3Member 2024-03-31 0001104506 insm:DevelopmentAndRegulatoryMilestonesMember 2024-03-31 0001104506 srt:MinimumMember us-gaap:FairValueInputsLevel3Member insm:DevelopmentAndRegulatoryMilestonesMember insm:MeasurementInputProbabilityOfSuccessMember 2024-03-31 0001104506 srt:MaximumMember us-gaap:FairValueInputsLevel3Member insm:DevelopmentAndRegulatoryMilestonesMember insm:MeasurementInputProbabilityOfSuccessMember 2024-03-31 0001104506 insm:PriorityReviewVoucherMilestoneMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel3Member insm:PriorityReviewVoucherMilestoneMember insm:MeasurementInputProbabilityOfSuccessMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel3Member insm:PriorityReviewVoucherMilestoneMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001104506 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001104506 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001104506 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001104506 us-gaap:FairValueInputsLevel2Member 2024-01-01 2024-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2024-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2024-03-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2022-10-01 2022-10-31 0001104506 us-gaap:RoyaltyAgreementsMember insm:ARIKAYCEGlobalNetSalesMember 2022-10-01 0001104506 srt:ScenarioForecastMember us-gaap:RoyaltyAgreementsMember insm:ARIKAYCEGlobalNetSalesMember 2025-09-01 0001104506 us-gaap:RoyaltyAgreementsMember insm:BrensocatibGlobalNetSalesMember 2022-10-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2022-10-31 0001104506 country:US 2024-01-01 2024-03-31 0001104506 country:US 2023-01-01 2023-03-31 0001104506 country:JP 2024-01-01 2024-03-31 0001104506 country:JP 2023-01-01 2023-03-31 0001104506 insm:EuropeAndTheRestOfTheWorldMember 2024-01-01 2024-03-31 0001104506 insm:EuropeAndTheRestOfTheWorldMember 2023-01-01 2023-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2023-12-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2024-01-01 2024-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2024-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2024-01-01 2024-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2024-03-31 0001104506 us-gaap:LicensingAgreementsMember 2023-12-31 0001104506 us-gaap:LicensingAgreementsMember 2024-01-01 2024-03-31 0001104506 us-gaap:LicensingAgreementsMember 2024-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2022-12-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2023-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2023-03-31 0001104506 us-gaap:LicensingAgreementsMember 2022-12-31 0001104506 us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0001104506 us-gaap:LicensingAgreementsMember 2023-03-31 0001104506 us-gaap:EquipmentMember 2024-03-31 0001104506 us-gaap:EquipmentMember 2023-12-31 0001104506 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001104506 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001104506 srt:MinimumMember insm:ComputerHardwareAndSoftwareMember 2024-03-31 0001104506 srt:MaximumMember insm:ComputerHardwareAndSoftwareMember 2024-03-31 0001104506 insm:ComputerHardwareAndSoftwareMember 2024-03-31 0001104506 insm:ComputerHardwareAndSoftwareMember 2023-12-31 0001104506 us-gaap:OfficeEquipmentMember 2024-03-31 0001104506 us-gaap:OfficeEquipmentMember 2023-12-31 0001104506 insm:ManufacturingEquipmentMember 2024-03-31 0001104506 insm:ManufacturingEquipmentMember 2023-12-31 0001104506 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2024-03-31 0001104506 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2024-03-31 0001104506 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001104506 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001104506 us-gaap:ConstructionInProgressMember 2024-03-31 0001104506 us-gaap:ConstructionInProgressMember 2023-12-31 0001104506 srt:MinimumMember 2024-01-01 2024-03-31 0001104506 srt:MaximumMember 2024-01-01 2024-03-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2024-03-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2023-12-31 0001104506 insm:TermLoanMember 2024-03-31 0001104506 insm:TermLoanMember 2023-12-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2018-01-01 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member 2018-01-01 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermOneMember 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermOneMember 2021-05-01 2021-05-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermTwoMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermTwoMember 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermThreeMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermThreeMember 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermFourMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermFourMember 2018-01-01 2018-01-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2018-01-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2024-03-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2023-12-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember insm:SecuredOvernightFinancingRateSOFRMember 2022-10-01 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember insm:SecuredOvernightFinancingRateSOFRMember insm:VariableRateComponentTwoMember 2022-10-01 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2022-10-01 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2024-03-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2023-12-31 0001104506 us-gaap:ConvertibleDebtMember 2024-01-01 2024-03-31 0001104506 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0001104506 insm:TermLoanMember 2024-01-01 2024-03-31 0001104506 insm:TermLoanMember 2023-01-01 2023-03-31 0001104506 us-gaap:RoyaltyAgreementsMember 2024-01-01 2024-03-31 0001104506 us-gaap:RoyaltyAgreementsMember 2023-01-01 2023-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member 2021-05-01 2021-05-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member 2021-05-01 2021-05-31 0001104506 us-gaap:RoyaltyAgreementsMember 2022-10-31 0001104506 srt:MaximumMember us-gaap:RoyaltyAgreementsMember 2022-10-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2023-12-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2022-12-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2024-01-01 2024-03-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2023-01-01 2023-12-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2024-03-31 0001104506 us-gaap:SecuredDebtMember 2024-01-01 2024-03-31 0001104506 us-gaap:SecuredDebtMember 2023-01-01 2023-12-31 0001104506 us-gaap:RoyaltyAgreementsMember 2024-03-31 0001104506 us-gaap:RoyaltyAgreementsMember 2023-12-31 0001104506 us-gaap:EmployeeStockOptionMember 2024-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001104506 us-gaap:PerformanceSharesMember 2024-03-31 0001104506 insm:MotusBiosciencesIncMember 2024-03-31 0001104506 insm:MotusBiosciencesIncMember 2021-09-30 0001104506 insm:MotusBiosciencesIncMember 2021-07-01 2021-09-30 0001104506 insm:MotusBiosciencesIncMember 2022-07-01 2022-09-30 0001104506 insm:MotusBiosciencesIncMember 2023-07-01 2023-09-30 0001104506 insm:AdrestiaTherapeuticsLtdMember 2023-04-01 2023-06-30 0001104506 insm:VertuisBioIncMember 2023-01-31 0001104506 insm:VertuisBioIncMember 2023-01-01 2023-01-31 0001104506 insm:VertuisBioIncMember 2023-12-31 0001104506 insm:PublicStockOfferingMember 2022-10-01 2022-10-31 0001104506 2022-10-31 0001104506 2022-10-01 2022-10-31 0001104506 insm:AtTheMarketAgreementMember 2021-01-01 2021-03-31 0001104506 insm:AtTheMarketAgreementMember 2023-01-01 2023-12-31 0001104506 insm:AtTheMarketAgreementMember 2023-12-31 0001104506 insm:AtTheMarketAgreementMember 2024-01-01 2024-03-31 0001104506 insm:A2019IncentivePlanMember 2020-05-12 2020-05-12 0001104506 insm:A2019IncentivePlanThirdAmendmentMember 2024-03-31 0001104506 insm:EmployeeStockPurchasePlan2018Member 2018-05-15 0001104506 insm:EmployeeStockPurchasePlan2018Member 2018-05-15 2018-05-15 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember 2024-01-01 2024-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember 2023-01-01 2023-03-31 0001104506 insm:AdrestiaTherapeuticsLtdMember 2023-06-01 2023-06-30 0001104506 2023-06-30 0001104506 insm:VertuisBioIncMember 2023-01-01 2023-01-31 0001104506 2023-01-31 0001104506 insm:VertuisBioIncMember insm:MilestoneEvent1Member 2023-01-01 2023-01-31 0001104506 insm:VertuisBioIncMember insm:MilestoneEvent2Member 2023-01-01 2023-01-31 0001104506 insm:VertuisBioIncMember insm:MilestoneEvent3Member 2023-01-01 2023-01-31 0001104506 insm:MotusBiosciencesIncMember 2021-08-04 2021-08-04 0001104506 insm:MotusBiosciencesIncMember 2021-08-04 0001104506 insm:AlgaeneXIncMember 2021-08-01 2021-08-31 0001104506 insm:AlgaeneXIncMember 2021-08-31 0001104506 insm:MotusBiosciencesIncMember 2021-08-31 0001104506 2021-05-24 2021-05-24 0001104506 insm:MotusBiosciencesIncAndAlgaeneXIncMember 2021-08-01 2021-08-31 0001104506 insm:WilliamLewisMember 2024-01-01 2024-03-31 0001104506 insm:WilliamLewisMember 2024-03-31 0001104506 insm:SaraBonsteinMember 2024-01-01 2024-03-31 0001104506 insm:SaraBonsteinMember 2024-03-31 0001104506 insm:DraytonWiseMember 2024-01-01 2024-03-31 0001104506 insm:DraytonWiseMember 2024-03-31 0001104506 insm:S.NicoleSchaefferMember 2024-01-01 2024-03-31 0001104506 insm:S.NicoleSchaefferMember 2024-03-31 shares iso4217:USD iso4217:USD shares pure insm:reportingUnit insm:sale insm:day insm:days 0001104506 false --12-31 2024 Q1 http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember 0.0255384 0.0307692 P122D P168D P511D P352D 10-Q true 2024-03-31 false 000-30739 INSMED INC VA 54-1972729 700 US Highway 202/206 Bridgewater NJ 08807 908 977-9900 Common stock, par value $0.01 per share INSM NASDAQ Yes Yes Large Accelerated Filer false false false 148604548 595729000 482374000 0 298073000 37162000 41189000 82957000 83248000 42874000 24179000 758722000 929063000 68660000 65384000 20307000 20985000 17157000 18017000 62441000 63704000 136110000 136110000 95698000 96574000 1159095000 1329837000 189362000 214987000 224194000 0 2695000 2610000 4609000 8032000 420860000 225629000 939081000 1155313000 156967000 155034000 63700000 84600000 26320000 27026000 13809000 11013000 3166000 3145000 1623903000 1661760000 0.01 0.01 500000000 500000000 148560882 148560882 147977960 147977960 1486000 1480000 3138578000 3113487000 -3603236000 -3446145000 -1636000 -745000 -464808000 -331923000 1159095000 1329837000 75500000 65214000 17457000 13830000 121083000 127865000 93102000 79914000 1263000 1263000 -11900000 -9500000 221005000 213372000 -145505000 -148158000 8783000 10524000 21042000 20003000 2362000 -1533000 -1100000 -111000 -156502000 -159281000 589000 483000 -157091000 -159764000 -1.06 -1.06 -1.17 -1.17 148456000 148456000 136355000 136355000 -157091000 -159764000 -855000 -171000 -36000 498000 -157982000 -159437000 135654000 1357000 2782416000 -2696578000 756000 87951000 -159764000 -159764000 327000 327000 82000 1000 1138000 1139000 193000 1000 1000 500000 5000 9245000 9250000 16443000 16443000 136429000 1364000 2809242000 -2856342000 1083000 -44653000 147978000 1480000 3113487000 -3446145000 -745000 -331923000 -157091000 -157091000 -891000 -891000 217000 2000 4050000 4052000 -409000 -409000 366000 4000 4000 21450000 21450000 148561000 1486000 3138578000 -3603236000 -1636000 -464808000 -157091000 -159764000 1588000 1248000 1263000 1263000 21450000 16443000 1851000 1724000 6242000 5456000 4822000 2615000 1963000 0 678000 678000 6516000 2491000 -11900000 -9500000 2362000 -1533000 0 10250000 -2955000 860000 598000 1187000 19330000 3199000 -333000 5231000 -32345000 -8841000 -6144000 -1422000 -184035000 -146303000 4679000 3398000 300000000 45000000 295321000 41602000 4052000 1139000 409000 0 621000 320000 0 1218000 3022000 -399000 -953000 -29000 113355000 -105129000 482374000 1074036000 595729000 968907000 8210000 11589000 1208000 1004000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. The Company and Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's pipeline includes clinical-stage programs, brensocatib and treprostinil palmitil inhalation powder (TPIP), as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, protein manufacturing, RNA-end joining, and synthetic rescue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November 29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US (GAAP) for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 20</a>23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any references in these notes to applicable accounting guidance are meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The Company had $595.7 million in cash and cash equivalents as of March 31, 2024 and reported a net loss of $157.1 million for the three months ended March 31, 2024. The Company has funded its operations through public offerings of equity securities, de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company’s commercial, regulatory and development activities. Any future financing will also be contingent upon market </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.</span></div>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals, Inc., Insmed Holdings Limited, Insmed Gene Therapy LLC, Insmed Ireland Limited, Insmed France SAS, Insmed Germany GmbH, Insmed Limited, Insmed Netherlands Holdings B.V., Insmed Netherlands B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, Insmed Italy S.R.L., Insmed Innovation UK Limited, and Adrestia Therapeutics Inc. All intercompany transactions and balances have been eliminated in consolidation. 595700000 -157100000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. Selected significant accounting policies are discussed in detail below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2024 and their respective percentages for the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"></td><td style="width:33.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;D expense in its consolidated statements of comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of March 31, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2024 and December 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2024. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total shareholders' deficit, as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:62.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,456 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:66.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RS and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In December 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div>The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2024 and their respective percentages for the three months ended March 31, 2023.<div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"></td><td style="width:33.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.35 0.36 0.34 0.36 0.16 0.17 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;D expense in its consolidated statements of comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of March 31, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span>—Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2024 and December 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2024. 1 1 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div>Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total shareholders' deficit, as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:62.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,456 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -157091000 -159764000 148456000 136355000 0 0 0 0 0 0 0 0 148456000 136355000 -1.06 -1.06 -1.17 -1.17 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:66.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RS and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 24098000 19156000 3059000 2058000 666000 671000 23438000 23438000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In December 2023, the FASB issued ASU 2023-09, Income Taxes—Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, $300.0 million of marketable securities, consisting of US Treasury Notes, matured. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of March 31, 2024 and December 31, 2023. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company held no available-for-sale securities. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the three months ended March 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2024, the fair value of deferred consideration included in accounts payable and accrued liabilities was $5.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of March 31, 2024:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:21.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$27.13</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the Business Acquisition in August 2021 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At March 31, 2024, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of March 31, 2024, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of March 31, 2024, the fair value of the current and non-current contingent consideration was $9.7 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$63.7 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss. The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2024:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:25.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$65.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 97%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.1</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:38.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred<br/> Consideration <br/>(Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/> (Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility (collectively, the Current Market Factors), and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2024 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$620.1 million, deter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mined using Current Market Factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2024 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $238.7 million, determined using Current Market Factors, and the ability of the Company to obtain debt on comparable terms to the 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 Convertible Notes. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 - Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the Company's convertible notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Synthetic Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty &amp; Credit Opportunities IV, LP (OrbiMed). Under the Royalty Financing Agreement, OrbiMed paid the Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. For more information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11 - Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 595700000 595700000 0 0 6000000.0 6000000.0 0 0 1200000 0 1200000 0 5000000.0 0 5000000.0 0 73400000 0 0 73400000 482400000 482400000 0 0 298100000 298100000 0 0 6000000.0 6000000.0 0 0 1200000 0 1200000 0 5700000 0 5700000 0 84600000 0 0 84600000 300000000 0 184433 184433 184433 171427 177203 5000000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of March 31, 2024:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:21.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$27.13</span></div></td></tr></table></div>The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2024:<div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:25.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$65.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 97%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.1</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:38.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred<br/> Consideration <br/>(Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/> (Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5000000.0 27.13 5348572 368867 0.42 0.50 0.50 3 9700000 63700000 65500000 0.14 0.97 5100000 0.164 0.157 7400000 58100000 0 0 1200000 8300000 0 0 6200000 49800000 5700000 84600000 0 0 700000 11200000 0 0 5000000 73400000 0.0075 620100000 0.0175 238700000 150000000 0.04 0.045 0.75 150000000 150000000 150000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a geographic summary of the Company's product revenues, net, for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.719%"><tr><td style="width:1.0%"></td><td style="width:42.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.873%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div>The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a geographic summary of the Company's product revenues, net, for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.719%"><tr><td style="width:1.0%"></td><td style="width:42.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.873%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 56349000 49067000 14891000 13156000 4260000 2991000 75500000 65214000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,957 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,248 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,957 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,248 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21943000 24562000 29359000 33480000 31655000 25206000 82957000 83248000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. Intangibles, Net and Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangibles, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D and the milestones paid to PARI for the license to use the Lamira® Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&amp;D from the Business Acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Indefinite-lived intangible assets are not amortized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,704 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,441 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,493 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's goodwill balance of $136.1 million as of March 31, 2024 and December 31, 2023, resulted from the August 2021 Business Acquisition. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions </span>for further details. P12Y 5100000 5100000 5100000 5100000 5100000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,704 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,441 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,493 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 32738000 0 1212000 31526000 29600000 0 0 29600000 1366000 0 51000 1315000 63704000 0 1263000 62441000 37588000 0 1212000 36376000 29600000 0 0 29600000 1568000 0 51000 1517000 68756000 0 1263000 67493000 136100000 136100000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. Fixed Assets, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:33.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.401%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,012 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,660 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:33.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.401%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,468 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,012 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,660 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P7Y 23468000 22660000 P7Y 6428000 6428000 P3Y P5Y 6106000 6001000 P7Y 89000 89000 P7Y 1336000 1336000 P2Y P10Y 37968000 38049000 39238000 35449000 114633000 110012000 45973000 44628000 68660000 65384000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. Accounts Payable and Accrued Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:57.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,362 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,987 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:57.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,362 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,987 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 44018000 65393000 23754000 23711000 16728000 13885000 10293000 9187000 23803000 48933000 6514000 5674000 2269000 2175000 3020000 3347000 17159000 10937000 15896000 14685000 15700000 6700000 10208000 10360000 189362000 214987000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $4.9 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.350%"><tr><td style="width:1.0%"></td><td style="width:51.025%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $52.0 million and $49.1 million incurred by the Company under these additional agreements have been classified within</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other assets in the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheet as of March 31, 2024 and December 31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $4.9 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.350%"><tr><td style="width:1.0%"></td><td style="width:51.025%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $52.0 million and $49.1 million incurred by the Company under these additional agreements have been classified within</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other assets in the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheet as of March 31, 2024 and December 31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</span></div> P1Y P10Y10M 4900000 100000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.350%"><tr><td style="width:1.0%"></td><td style="width:51.025%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 0 5656000 1751000 52000000 49100000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt and debt, long-term consists of the following commitments as of March 31, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:46.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,081 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155,313 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7 million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a) the second business day immediately preceding the related redemption date or (b) if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity’s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9 million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6 million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4 million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December 31, 2022, prior to the adoption of ASU 2020-06. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 0.78 years and 4.17 years, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $565.5 million carrying value of the 2028 Convertible Notes as of March 31, 2024 excludes $9.5 million of unamortized debt issuance costs. The $224.2 million carrying value of the 2025 Convertible Notes as of March 31, 2024 excludes $0.8 million of unamortized debt issuance costs. The 2028 Convertible Notes and 2025 Convertible Notes are long-term and current liabilities, respectively, as of March 31, 2024. The following table presents the carrying value of the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's convertible notes balance (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:55.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secured Senior Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company entered into a $350 million senior secured term loan agreement with Pharmakon Advisors LP (Pharmakon), manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. During the three months ended March 31, 2024, paid-in-kind interest capitalized was $6.2 million. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2024 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:45.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.277%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,544 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"></td><td style="width:64.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,779 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three months ended March 31, 2024 and 2023 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:57.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.290%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,465 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,042 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> urrent portion of long-term debt and debt, long-term consists of the following commitments as of March 31, 2024 and December 31, 2023 (in thousands):<div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:46.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,081 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155,313 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 789731000 788909000 373544000 366404000 224194000 0 939081000 1155313000 575000000 75000000 15700000 559300000 450000000 50000000 14200000 435800000 225000000 -17700000 25.5384 39.16 30.7692 32.50 5 5 5 5 0.98 0.98 45 45 10 10 0.10 0.10 30 30 20 20 30 30 1.30 1.30 309100000 0.076 140900000 371600000 0.071 203400000 P0Y9M10D P4Y2M1D 565500000 9500000 224200000 800000 The following table presents the carrying value of the <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's convertible notes balance (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:55.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,537 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the three-month period ended March 31, 2024 and year ended December 31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:48.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments paid and payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,964 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing issuance costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty issuance costs, unamortized - beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs, unamortized - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,997)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Royalty Financing Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,967 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,034 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 800000000 800000000 10269000 11091000 224194000 0 565537000 788909000 350000000 0.025 0.0775 0.50 P24M 6200000 15200000 334800000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2024 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:45.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.277%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,779 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,537 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,544 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 350000000 350000000 33779000 27537000 10235000 11133000 373544000 366404000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"></td><td style="width:64.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,779 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 225000000 191890000 191889000 575000000 0 1183779000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three months ended March 31, 2024 and 2023 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:57.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.290%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,465 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,042 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2063000 2063000 12483000 10911000 4822000 4764000 1851000 1724000 754000 73000 20465000 19389000 577000 614000 21042000 20003000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $3.8 million were, $146.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be 12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and updates the effective interest rate on a quarterly basis. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the three-month period ended March 31, 2024 and year ended December 31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:48.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments paid and payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,964 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing issuance costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty issuance costs, unamortized - beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs, unamortized - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,997)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Royalty Financing Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,967 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,034 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revenue Interest Payments payable in connection with the royalty financing agreement were $3.0 million and $3.3 million as of March 31, 2024 and December 31, 2023, respectively, which were recorded within accounts payable and accrued expenses on the consolidated balance sheet. Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss.</span></div> 150000000 0.04 0.045 0.75 150000000 150000000 150000000 1.8 1.9 3800000 146200000 0.124 158162000 151538000 3020000 12222000 4822000 18846000 159964000 158162000 3128000 3523000 131000 521000 0 126000 2997000 3128000 156967000 155034000 3000000 3300000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. Shareholders' Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—As of March 31, 2024, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 148,560,882 shares of common stock issued and outstanding. In addition, as of March 31, 2024, the Company had reserved 24,098,410 shares of common stock for issuance upon the exercise of outstanding stock options, 3,058,943 shares of common stock for issuance upon the vesting of RSUs and 666,382 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ved 9,406,112 s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hares of the Company’s common stock, subject to certain closing-related reductions. The shares of the Company’s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first and second anniversaries of the closing date of the acquisition, and will also be issued upon the third anniversary of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company’s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition. In the third quarter of 2023, the Company issued 177,203 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the second anniversary of the Business Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the second quarter of 2023, in connection with the Company's acquisition of Adrestia Therapeutics Ltd. (Adrestia), the Company issued 3,430,867 shares of the Company's common stock as consideration at closing. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company’s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">550,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of the Company’s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. An additional $1 million of shares of common stock will be issued to Vertuis’ former stockholders on July 1, 2024, based on the share price on June 28, 2024. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an “at the market” equity offering program (the ATM program), under which Leerink acted as sales agent. In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 2023, the Company issued and sold an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,503,041</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of common stock through the ATM program at a weighted-average public offering price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$24.12</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> per share and received net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$152.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through a new “at the market” equity offering program (the new ATM program), under which Leerink acts as sales agent. In connection with entering into the new ATM program, the Company terminated the ATM program. The Company has not issued any shares under the new ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—As of March 31, 2024, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.</span></div> 500000000 0.01 148560882 148560882 24098410 3058943 666382 23438430 9406112 9406112 2889367 171427 177203 3430867 550000 500000 1000000 13750000 20.00 16200000 258800000 250000000 6503041 24.12 152200000 500000000 0 200000000 0.01 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. Stock-Based Compensation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's current equity compensation plan, the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders on May 11, 2023. The 2019 Incentive Plan replaced the Insmed Incorporated 2019 Incentive Plan. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. The Company has submitted a proposal to its shareholders to approve an amendment to the 2019 Incentive Plan at the 2024 Annual Meeting of Shareholders (Amendment No.1). Amendment No.1, if approved, will provide for the issuance of an additional 3,000,000 shares under the 2019 Incentive Plan. As of March 31, 2024, 4,705,225 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the three months ended March 31, 2024, the Company granted inducement stock options covering 358,140 shares of the Company's common stock to new employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the 2018 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the ESPP: (i) 1,000,000 shares of common stock, plus (ii) commencing on January 1, 2019 and ending on December 31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C) an amount determined by the administrator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—As of March 31, 2024, there was $148.0 million of unrecognized compensation expense related to unvested stock options. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—As of March 31, 2024, there was $55.8 million of unrecognized compensation expense related to unvested RSU awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—As of March 31, 2024, there were 266,550 unvested PSUs outstanding with an unrecognized compensation expense of $10.4 million, which assumes a payout at 100% of the target.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2024 and 2023, respectively (in millions): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.912%"><tr><td style="width:1.0%"></td><td style="width:47.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.127%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three months ended March 31, 2024 or March 31, 2023, as the performance conditions associated with the PSU awards were not probable as of either date.</span></div> 3000000 4705225 358140 1000000 1200000 0.02 148000000 114780 55800000 266550 10400000 1 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2024 and 2023, respectively (in millions): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.912%"><tr><td style="width:1.0%"></td><td style="width:47.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.127%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 10400000 7900000 11100000 8500000 21500000 16400000 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14. Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a provision for income taxes of $0.6 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively. The provisions recorded for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company’s federal tax returns for the years ended 2020 and later, generally open for certain states for the years 2019 and later, and generally open for international jurisdictions for the years 2018 and later. The Company has incurred net operating losses since inception, except for the year ended December 31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of March 31, 2024 and December 31, 2023, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US. However, given the Company’s valuation allowance position, these reserves do not have an impact on the balance sheet as of March 31, 2024 and December 31, 2023 or the consolidated statements of comprehensive loss for the three months ended March 31, 2024 and 2023. The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.</span></div> 600000 500000 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15. Commitments and Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense charged to operations was $3.1 million and $2.2 million for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</span></div> 3100000 2200000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16. Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adrestia Therapeutics Ltd.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company acquired all of the issued and outstanding share capital of Adrestia, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 3,430,867 shares of the Company’s common stock to Adrestia’s former shareholders (collectively, the Adrestia shareholders). The closing share price on the date of the transaction was $21.10, resulting in a purchase price of $72.4 million. The Adrestia shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company’s common stock issued to the Adrestia shareholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (and, with respect to certain Adrestia shareholders, in reliance on Regulation S </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promulgated under the Securities Act of 1933). The Company did not receive any net proceeds from the issuance of common stock to the Adrestia shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the IPR&amp;D acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition. The Company recognized $76.5 million as IPR&amp;D expense, after adjusting for working capital assumed in connection with the asset acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vertuis Bio, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to Vertuis’ former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 with an aggregate value of $1.0 million, based on the share price on June 28, 2024, and pay to the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company’s common stock issued to the Vertuis equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"></td><td style="width:72.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issuable on July 1, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combination</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company’s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company’s common stock, following certain closing-related reductions, to Motus’s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35 million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's common stock, respectively, after certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Company’s acquisition of AlgaeneX, the Company paid $1.5 million in cash to AlgaeneX’s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company’s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX’s manufacturing technology, in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company’s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5 million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.</span></div> 3430867 21.10 72400000 326500000 76500000 500000 18.50 1000000 23000000 63800000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"></td><td style="width:72.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issuable on July 1, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9250000 1000000.00 10250000 2889367 184433 184433 184433 5348572 35000000 171427 177203 1500000 368867 27.11 27.11 45 165500000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities adopted, modified or terminated by our executive officers and directors during the first quarter of 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each, a “Trading Plan”).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Adoption of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Start Date of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Trading Plan (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Shares Subject to Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Plan Terminated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Lewis</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/28/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,288</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drayton Wise</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Commercial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/03/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/27/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S. Nicole Schaeffer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief People Strategy Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/03/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/21/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,734</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.</span></div> false false William Lewis Chief Executive Officer 3/13/2023 105000 true 2/26/2024 Sara Bonstein Chief Financial Office 2/27/2024 true 241288 Drayton Wise Chief Commercial Officer true 2/27/2024 37000 S. Nicole Schaeffer Chief People Strategy Officer 2/27/2024 true 63734

"_8)=* M<9)X !JYH^D#I74\C$13=^YR)$[6?<$,I\L,:P]9VXT9&K@O)M>:13WUL?6< MX0ZI%)"WQ032[>V>D_=BTT/@A$3#^C.4@:2>D**VE0Y-EG*N+*:<;Q=]WAQ- M1]H+*3BMX+3M3CK=E=-86Q-%R6I?<;^<%BGI>!816.%#I6Q35S9X?[.%;COZ M@6?'X/J)M7&%?TWKI?T3_(B_,B3>L^64.1HNZD#DT14Q$2^L +YFO,]K&@NI48J'Q;I#F,T84Q\<%_.J U<*!A0XCX2F%5"$K<.B ME03_B&IKB WSAPO#F>R]>>!$GZMJE48-)CER?8N%YCQJD\!ZH9]?+3,8Q*R? M>#$"IS)]A?1@#F&P^I4#POE=J-9GH9'\B;-%T6+UE:;65VE-,4VCVNPI+:U5 M57M5O4FK#6+TC7]IH..CEP83CAZ19UKN>93\*),^+/""V*]D[".-)@D2:"^: M4*M:0;#/0VPE7/K]O<&%LP&(6M?CT5E@2^KA4S G(LQW=YV[R]O.5ZG[!!>^7=\]=:5E M_+N!G&G_U/,^+4'_9@ROJQ.&YZ;&73B$E1J+SL6LD7/O/1/'^@^CX\N)G(8_ M.H[YX%$?]TOPS_O^32RXNQ.Y?3791GF"3WRQ7>/'Q/9I*MS/!E-)N946"#TF8 &@%H6/[-JQ4,))R8&_)6GQ[Q*&[082:M7TF" M^&\^6 ^>'^"WAMAI$#X[\EPS- )9ZCS>_M;YY^6US.8YPL)>?O(E?O:[PPP1 M1KF^].%[]Z-$_,DK,8(RA6V=JG\Z(S^T^X#IY#.F M%S['Q/*Q,AW&HP:UD%+ D*4VGGZ(OS/R@9G%Y-/%W[IT!'*O!_/3%+7)XGMX M,P"#*HC;=>P9)2D-]&]C [C5 !UCA4.)O.!/Y%.;OAV7=KYU+C]*=@@N0\3H MB-H1\1@,"T>C19YB.PS! S- .YJ2);0T9N\-MQY6( M#>\ZC+>2N(J:"ULHKL!F0\?<]<8@B0+LQEZ1;AWI'BYQ=&N*S'#-R1@@!A(I MEG$?KF$M$X$S(:REY %Z.0AA2".T4=P-I_B!M7VX>_H60<5RL%B 3= @K"U! M;RP!T-AT<<5S*UUYJ*,^7-Y\9(O\1CQC M@$M49&'N/'/RBP%PCI#]]^_?K'QFN? MQ1&L=98 9M?)IF^9;/Y^V.];!KYKCP%5_LB%.8!F&8'.\!+?8.."[@'P6$DZ MJ:S[V(?7@04P"!+*'"@"!!!^!0@3GTF^_I&K0J:H",L=!>M=,@:>ZP"()[B# M 0FVF7#XYR3+\^@+BC6T^OEX9 @N6927ZD@]*H'8(G8E]Q;#K-(>62.FMW [ MQ Y-^(P!?S+%Y@<( *"?9X\,?5D"[Q1L4 -(ISQ"H?#8]>\>0# @.!E ' YL MRO:S@+4XU&&:T;P3V 'EBERW'&4<%$.",@58"R!M6O@+K)3//=+-^&_? C@C M;$:A/70= H)H,,9#_KA%@2=SN@9_B\&(99/ !P.4HC-\_N'AU_+MUZN/#&[3 MT4#1<)$[,^R'A\ZO'^<-SG?I1Z(.,WM]I)Q7R\3. MA? ,%#C8$#W/:,![/A MUX>N"5H;>T4DL?-,@2T0GV0TEG%>%HHZ9GD$0,<6W#=HV?1 >3GXV8""!J . ML#R%%3C/\N0B\&S8!UT2\LN/=YTRYK7_V[4<=@'GX(\=^!;J 5B*$=*3$C32 M*_'9AJLWY_@2;I>(:>0!7[ MDDV?<3PGX(?V34Q,6;KQL(V4+/U"P;%R@!YNT2EP3/@%M,*8FR!W%,D%+P,A M=8'^_\/_DI..SF^ .>J;:5^-;('3.1)2G063&Y-9P?3"9VSL] MRAB&@E&)PB7TL$=7$,>F/9#M/L_@.L#\/&1>Q(@!XH-83C)OE($[F6#J4790*3,W<'&APX:.: LFPJ0 Z!F; MW4/K)Y<=L]H!L :D3C:=(Y9H2$ V("4Z.VT#5!W5AFVBC M@+)B\X-W_ATZW-1A3BJ..\HI%3RHEL2AB"@,.3G^Z#N BF]NJ M7AS_9?%>8DS'Z8&KQCALJI9 M+U3J!)?$\]!X^IW8(=TL9:4^W;9163%A9;%J20+@V3CE]_KP,,>[SX-*28&O M57ELG^D-C+ "R09@/OOL\5104>>ALKIY'\_@^0I?20T&K=16:XW*8O_V"1@F MSCNH7M $,,>!'ZF\)A01=IV$)\;"-1AX +#A$!-OG]GS M/&C#I.F'Q_\FP]%GC"I,^C\R:IAN027"6#*/I<0>)0_>3")BT\A7M%@6LIEL M;T4;LU+"2<$@]8KO\BB'1\O3 >29U]!+M/J3@*V\[$NS0\\L!(>/HQW \#CNF20$"C=X]%NE!/3\#<#/AMC2+%'&GYHHM(=?I0BJO^ G?L1L#$=@*"D M:I%\DF>^@]$XC^"9BYBR%K:XOQ0;'-%*X)O]T)F75C+_VWEV5Y-M'.H% MPP"G.24+><(3T3?B"* !UQF+1X_ MR/V@[\-!DQD]3+(1R!.*C''N QO#\%R MCQF,C^7CS67C3B5%,'!]&AE:I@E,C^^,!D!D& A8W(OVW=##($V )LPSI_P7 M8MFD9]DHG2,+-%K3M),T!HS9U!(&$KC-8#Z9=$09XT:Q)L![.'*=:?8$EQ(X MLUG'F/6@;WSVI=7\/B.X$BS)O)^%.;+I@%YE1,H__XPOLND,V6'T\]DM,\DF M9Y^[UUB=NY=]&MZ6"45%%.48V7NBY+%MGYQWX%SDS;+QOM]UOE_=8BK>VKP\ M 1W+?6:=21\N8_WQ,0,,K\I.%&N@20)DI#LY)"89B>@[+LE)U';*0CRZ$0HK MXM8;J/7;_OQV<^@P.05&E-MCWD_"GDR8?=RT?!U09[)?L6@L]MBVK$$CF\PF M8Q9 8AU3T,"9Q'58/(M%HMA&"@]8H:F7-$9+$]?YE&-6\>HR%*4%_JK:YO,S__*LY$F-W[!S>TGOKDM??UZ M.;D1[6LNO, W0*5NIYL8@^V%\L_^,NS].KDS_W)B8W0ZI2^5WRO+GN#CS=S] MQ35=Z3=PAP9D M! X&3E]",.XC@CK/)-+66>75[;+*NR"MV>:&$TSW)AY@BB!W_"6YXOH2N:R? M2*ZX%FGM;C@<$IY3EP!/ U#1/$H(_3Y665@4(%19X-2L-W7.5LIE<3^[M/[_C4PYA #9%/) M7-U%!A\P2RPER+_[S'6?+/B8J0C149(H,WG"TDR.Y49R#1["_2V,/[),'):% M$-GQ?F*GF,6.R0\JT7CA/(#I^^%P%&] 8224GYG$;,@A-R$G6W>1&-TLP6>Q M/'AVMP=+6GC(?'9&_P[-Y^@T:T<:@,)P/19$QB [&*@L_P)381WIA?#2(1Y< M3:R$?RB>/H9E@6>B:=D6#]=:='%A4_T0V5V2/Z#QB\'LD-&N%K^'AS#=_V>IXPS(/"]L)3[B)&)\@>6LPYBRU,/,73>8YO^[3J628,N&I ,EF-3+?FYW$@ T>L,?H.X_)2BR, MR],?B/.,J=%^(JINL6Q53$IX9Q_M]F&ZDP;WGEW7Q BTS-,77G#[FG5GG :B MD>@L,]I^D"<4-K/D%5]C1^=B]EZ :B1.>S!84AM/19;ZGCN,]@,F^%CB?R;C MW:ED[*7K8 2#S_[1\G]<@I=M!?C;5.#6EIC"M=U,87'%\ Q$6"R5041"D @@ MDF\263P^P#V1E#-R Y:ZCKLUX#G_.Q:7L6#CV]?3Q?$^HWQU'JR.D[*/41 @ M-):1%#"O$^7RO5-L1D'EMNLRGT_'3I M9WIE0?+-NXI+10K",%V_CJC[41F;HC$I.;GB\7922[=TELE6CIY)3@!KN<0D MRLBG%_$OG\$9!FTXOK <)BG92Y]G9[FDDIY]CM^.MM5KM8JJUE&\1FTJHP]' MF^X5D+R?%J_K>J6EZDMO*15UZ?550VFM2DNOIAIJU76MTE ;V4VJOFZH);VS M8K0 Q='C/+6\FYE:7=;.S'-?^>\;G*KW;O.PUDYGYD2\<)!^>NLWVA4>R$7I M\HU+E^NI=)% L&S0%#Y?9)"B[]OL"0PY0RHJF*TZ^F\,APPZZ^4=PGJ>V&/? MYWX<"!DK6C)'5IC4R>A$CYR09LH&J4Z(>R4+-2@S)S5J:T-:#Q,359V4592U MJ:7>*+7UQ<-Z_Z\@!XR<%69KV6*V"9A=/-!P$\SF4 QN=P"B&&+PRRZZ_[19 MHIXM2[2 )19[/V\G[#+J77S:^&MDBK^6(M).RR =>-(*XTG%9L1_D7%:DC&0/6,RW*ON%[P*[C#ZS1M*O0 MZ@G*K,P NV)BASXZ.YKE2;W0Q[UE5F"=IS:\?49W'S/3@X8[_F#N\8F MUEDO[-!-,Y3S\ W03M/=]NFNXO*))':E M)YO&J_/ZGED+P:A4&;>3B1'EM!F69X1#+$@W<(\<3_40JXTQR_JN2^4$Q?C8 M8R]@T_\E2AL[:D=C%,+]T&,YB#PE=X]M#X['O[= D9;'$B:097T??Q6 ;69'/.'7-S#YHW!^55^G!_K&>5Z3/%9$V UUR_ M<'WHS;(3S]5@C1:BI!CLJ#J%(IE <5*XY=!GG@4UUSDA4DLR-JE-9(F#<>BQ M7J>1 HW*]$>@I2:=K=@2N*:)+EBMI*0KYFNPM D+38"?&^\IN= T8-@AB6:A^Q!4#03 M*(X"*HX"6GD44/H:_,5U"Z/\HQ[)J0S?6FYOL[*]5>\PSPG04HF MWQ728"-2;\A:F-^ M&I#'^RLM6]IT0K&W,UOSD9CPN@8 &SGF6%!X\26*!5Q.CQ?Q.X[)G,_.M+3% MYRXZ_[F8;-HZT9*X&#I2$CR\>)W9>DD("6;R4Z0;[O4F)CE7\\4+Q'P+ID2\ MV2)[=LP'&J78 (,]QHZ.":)##J;]NJ9-L*.RHZC(B^ ! '&H:>;X&G83P9>L MG>J-HX.LL,4P8PPP6\",IPYOK,%E T7)D&@5A^W!L:U&?P6_\'3E>,5&U'3< M\A.%*+S*#9T YQG/LD J!,E-)MX/SA>#["->G7+"P## M(R06(.4L@F3)> A_-F;"KV9P(?'(D\;JA*%P">Z212=3B#BC,**)J$8M]M-8 M"CP3/9$[P@M1,(#CA@&^%9?CO?)@(K;AXU[,;$QT2@QL81.,FE$#P.7$,N$3.'*S,RHY&]*5[PR@DU@JH;9J0C,*^/8[W2_XP%6C;*BRM)RIO_P MY(Y EC:5VL<+Z1)(P.J/8UE^19G['-5KD3R3$UP+ILCCGU+644 MUD3;<,&2^ ]=0N"$'>HR0]KR3!DGBW7%[380?J 4RJ@-/->V>4EBU'DTFS6TK5\+P M7T%IDKE2%<1P7WRG5*4KVS-*;,EERIY;BR2:'2?/OMJ\P[IY+Z_?;I#1,I M6PP8<&7U#9D96CH]?$+4N4- ML5]4=9K))2,EI KH+'#@5T%+R5]+U@=@P8;%L+M.WQD MC(A87CG('5>RC:>VBC8O3W22I$;F$UYYQ)U4&@U_T[&.R^9%5-1.ZC4H?;2 M.E]"+=E)A0%JR$!2%0NQ\O* M! B0)'4S%G.+;F>*HPPD9\J$0YAEI74$"/4!H",NEC:;XZ"E5T;;.GW2297K M*:I-8:DN..9UK[FY3$UY;U2B;BIV(B( :^:E?99XK<4G)XJ2W1 .C;$=H=RZ M/_(M?$ZJQ>>S#*?^7J/X1>&JAO)@19&9M+XPLF=+(X"FL)CC&$[RD"JM.5!$ M:,R);8%W!7!D6P )0\$1 Z/6[P=AI@(JX*"6]1.XV5WD)7P\+BV$0:$B"NI-L_RR+/12)Q]S@SCPP#BU@4 M_M"0+@0T)1I^Z$ZJ^Z&KS4)JJ=T),3_)!.8:H9XBR0X+X'R*79/I!0X MCOF!511TIX;=OH!J15HBDKS?\R(HP?6MB&E,M0Y$KNP\PO= 9@J'EX95LZ%A MNA#-#BI6$IVXR\F)U)ZUYV8H+C+U5+T%$QWXI*=>G.Z8=UDLN+\$*#Y*J@Q M2=.Z(Y1<&_@"-GBA&^6NO1"'S!3T"^I]DX:>\!/]E9!(#6*#$\UA8>]@\$[; M=Q62@/"-C^#@J%$#QS=]0@TR(-9L+YUV@LUECR1I*#^61,D$X^#9/+52#1]0 M]UMNAEHC.6[$3K%E-#/B7LGT;V[=8$;RTUMS&L] BO\=3T-*:3LS.MNV,_>F M0)'_FF\-^):PC_2U@5"YD8&8X9="#RF1!< M,'.\7MK6OVC%4%TVT"O/5E 4- MH^#Y'*H,_ 1]3$2V"**GBI.'15]FE[]+]?N:3?B(7GTB\TN!K#T:$>Z"$2][ M_(2.SB\9-:U0),HWF$/Q*J%KB4P1 2Z$PPLA#AX*WHOJO7P(FP)Q,]V)Y,/1 M%&5N%>CYM(/>44,V)96>^C$%L#\7D]%GDKW":#@V P=% Z*Y1,"BY\!9X]=APTU@UE/^SWE"7 M5ZD5C[ Y'?1M+/ @=(4BG,&#*+SCE-2.>2I1/*ZAX:]P+?ZST-Y<\DPZP4R[ MAO)9\!;\BAR8:&P%J<@^4Q*;\U^$ \7#]D]X8T'FE2H,+]9DYVS= )$@OF+> -H32 %V1*VJ1DKU*_X M]'F*P[(T*Q@_R4^LRDRN?X^I5:,ZM:H2>ZE3J^K4JCJU:J?4JG9J:E5G36I5 M[T12JQ*"DRM0:8+W/I9Y%60TD;"/K8,N1YRQ1RGDOBA58QG=*6YJXWV M3=*2DL&?P(0F_X(3M%6VXK8/\6J7=BPC[5A6*S,H,&D*PA.^9K2ZT>^ MOB_]Y87Q\!S/,\!$A%"=CLR56I.X^A+:.=\934)_S\9QNGD9NYY\2_AV[?3P M]'D>T;"59$H$5%[32Q& S+)[?X_XR=I9X_-OECT%^O6+\IL!+QVLZ0JP=GO=YD'V-[RXL4R6:!J0'(T>O>^H/"6" M$4*5+I\F$PLJ3:%O9">QO"]?>(KP34K/X;IX=2_%JX6TB2^84!.'105B2KV$L6:N*+(U<%L M4EY]PD?I@&& -BD&F;CG6?X52J%$/S>SW96*$PQ$CA\(J:7P2:/6PA/39C02 M,J384-H,O9(;9W[Y*=]>HFA>"CWY)Y]]&3N%/Q S(\7>MU/&8+C,=#=:2B/3 M9/SE>) M#!/_MU%6&$ISI8>OK=DU/G'Y_?''5223ERXKDF'#U^=?T-!,,%P( M?)0!%1'HT9 *;(<'95301WXQN;B?@^#'+5 ]\#=OVW@?^(N& KO+"'E020$@ M#1T&D4^J76EK\O=BM"6RB+]UO'?1M4#EUZ@[07 KR"=:^L-N7WU@+S47 XU! M.H*X.3$*@5NN/%6/$@10;9797=R]R-41?F=?DN"?3&P<80=+K'1F<%65YVE, MO8G?$X*'B/R$C0BD>4+&2@YE)?N=F5/+;BA_UVR>:Q2[FGB*9]H[N#+[HK]2 M!Q,,Z3?G.#W M8\NV^1P$'DZ]=;+7ZFN MO\0V3T>7'8$N>WR%IFRE]2,;NQG*:J?9/$^U%,^LW#N.1][4.TS*KH".2KO2 MY:YXJGA454"'D"QADKFE =]DU#^$_";R1T35T@N5II.@G[JA_#"#=TQ3=D'. M-9]\*1&6YUSJ]I07L# IK&>&[&&"N8@R<44\R]=.D;K1@8/Y&TH9YH2> CY8 MBQX()U3)5XIAA%+)]9\A+:_$;,3/H*?I+^8=K_-9/8KUE$MZ9 MVH,",HH$306H+FR?8+6L:(>'+EZ!-C^>5#&@7953V54YR5WE ]&Y4A :LZZ& M)ZCS;W_\C6>5_56#=W'I+((92/+H7J"JHUP M5?.TYQ!UBUJS3SQ6ICLIZX56B"XMOI+@UCE\/K<,##S^1NG4H"_Q_#32_RU39,6!#>0M/+Y3GCUZCM5=47M= MXRFA,T&W/N*%,VE?R,' FX?QP7&<;DS4=3'3T+.Y5\ /I 1)FB"4(C/*L2\ M:-S4T2^"I#+M,?&RR*4F+XU?E) $*H: RN3T'_UD^VQ6WCY/5AXZ>@6X^'T. MRD6MMNA\R$!WXMWM(LJ3*#^-^K$P7$;90OAC*UQR$1J7&LY4C:[IO&E+T8$2 M_J'R49XFS=ZS%=!@7N(:'$ZP;"@?4U^S0:5O&O^-BSVT=N4L=KZ%4"<%2C#V M*[E(>UM7UQO P\FI [],GJ.\/!HZ;D)L^Z@CC>Z8!+0VWEY1 EPYA-^:G<9 MW(1Z]-R;Z,BR[!6HB&B1/,Z^\=[%W\6H[4^_!#;=B00= 5%%@E2Y9!*HTLKR!S(G,EJN*L'FY+$P3< -*TV C-@" M9L:SD:C[!7.%!"=Y2C2">?;A)4#MX5X="M7#5:KB7SC9]?+S_>?'*^[A2>0( M 64*UYCL.ZK[*]/X]U]+78#?PC1GP#(YO9Y\>'X@7Z6Z %1#K3?918,ZB5": MFASBC(V&*1\PT'9%GQRIOM8IW84PJM6L<[HKL9?=)U+. MPD9D^EP4W@[-07MSJ4U^:B_X 0#D59]@OM7,IA.+[G"\T8*)% H.W[+ J?4&B/-KYQNPG="EF&F)GVD85,_N^H.T, % ( A4PF/X VV5" MEA"9]4MLX3(G9P+5FB\]BCZM@%Q?=2(R_Z?C%9$G?PF:6<)WSJ=5";?!@EJC M4ITI&$Q$!+A(TJ'.9>)'W: 7'F(_0>?7*;X5/1L.F\#&R)&_?K<@DE&YY'EA M:8]3:HOC EHKUE+4L:#;!&6>,PI#'9_Q<'I'5 M1NW"V"]F3W3N9 P#,P(47GT3?Y2?QQ%<.!KX"9\5[%OA%@LQW$@^"?KE' ^8 M(W\K9[ME^K>?L,N29[#'V3\$WMURM)/YU43G#EDE*9RN=R*<+C<@,K- B?S2KC "+!C[LVE8J,E\PY8H$@*1_A"9,4\K0TF$?Y#]^EQ/N=), 3@_] M'MT NA%B\POI=?QKX6$8#AKM(3D9Q,1/\6+A?VC 5W])?MYO-SK#;NI7S48K M]?.LI5K]QK#=+K14]N?=0?I+MMI4[OFJ.^HP>WIK549>YCD FH$AG#EA XRC ;/8V3G-[O#C@\-XRL"(T]Y4S3^2^L+)"L2A% M;N^T4 9%4%DGSIN6>U90ZYS.?-J:.(NB:ID8G;-&I4>IP\F.-).:S"!L!_:A M"G.\]_Q\Y?E$\H S^K\3PB=AI\6QJ<@!F\IQ^>1F)_W33D<,'XTJ 2MUMLO, MHG3/F:ZME,=(%,X9A7\E*M*9>V]B2V#TD48*T;$(_7IJ47@8U_$KT3N!)Z5_ M<=/J#=3FJ)4H/K_:Y290H!2ZD0+<*?:Z,'>JZ>%LZ:%W$'H8(#V,U$&_6U5Z M.$%I>VK:VT>&5>KFSOI;2,'NP/U/+0]=F$7MSGUI=Z7L[@2Q<3O=[ZB,\A]Q MCW^*GQ^3ES4#!S[)6,$X(T:9C=/M8F!+E:#5$S.94H:#+U?QBLJ7M0&KQR!B M1Q'BPO)G"/*G.U2[O7Y"_J2[$$Y *:O1:ZT>K-'J=H%0Y M-1WG$Q4F\8RR1!Y&[;6J)(ZMH;E!E7'M3F@KX1266@=9)R2Z.4H(6+A\4*YF M<.!R^7#KNK8^]BCKX=FBS_[ O)YOO"G*;=!\*F894S>AZ_\PVTJ1&JVFG_96 M::E1*R7;XUN[2OC6.@U\.T$)DJZE5%^"?'^B1#/,[=Q*<*2<^TP)N5,E0FZ7 M1LAK$')F&]'UG5_"]CC#MJ5//NR+ M$'7_--3 VNS85Q#M@+@V. U<.T$!J>I6SSM'S>U20DI#S=*30HZ FBW%,*9 ZB@&^^G M2+E8S1QJYA#5SDNARO9V[&'+C61RJ0XRA];@?)A#1?2MOY"#L>0^:;>FJ\M, M[!<@[_'C-%@7#[S MP>^B-PG YX2=<(EN:]D^/6WML'4^6AV>6?)I:CC=B?<3U&TQ)T2T'0RV&>T^ M>$DM&G4XYK=.ZC5ZO MV%+9G_=ZH_(VU5N[U(8M>%(MX8T:D:W5D(XZWR"]D\]M0.21QF2U)THK;$IZ'=]C'*0[6!\(V5$'OJ6AT47#(^T> M('=7;8Z&)07X*Q&X*RG3Y+TC[+"*"(L]G49J:_=(\R$0]CVDA?PP7YF#)N2N M94SO)TEX5$7"&ES<=-1F;U3I5.$Z-7W[/(QF%;%N"/H'8-W.ZD=)6/<>]/JM MJX;>3P)N3CI=2:22I(;1Q4V_7Y9FDD1M?"9_B"_<7\,Z%:(DK3JS:?'?F=8:@D M,A0X D3E\L%RE7\R^,G46KJA <&'/M@F0R?O3>4C'(B&O?%L DQ<^'S[](>B M.PYM5_,D2LLEK;U*L[N6J&?*!]U9V)8CFPV:>83+'X=-L:5T7UIT&ZS;" M^U-L]F]/QQ2*%YMI+LV3=+07^.,E-!0W;9GXI-O0KVSX/#:(+DY_R6FL(1(0 M4.^V&P-,*UA:#HVM_4!O!,Z6F#\?1/*(:)K!(]K8L3"#)/.1PP>TTY&KU4H; MBLW_.[>#J/4+NQ[#3?V\UF:PV0^:\::M'&1Z818"W$(L/NHV$(3QTV>><3;; MVQDYXP)4M6RZ\@] RM,KL19G;* ;^2Y\UA^U9B_6:T^FD.QPW1^U1 MMS4&*<>Z VTRF_R_P<4-C<9$&L'9YDC.__,7[>;T9]O?/SQ]_?11N7^X>_S^ M[?$[3K8__4,]/#Y_>E*>'Y6[QX>GQR_W'_%8RN?[A]N'N_O;+\K3,WSP]=/# M\U/VJ/H"YZ[,Y&:N@[4;"OW?D[> ?=(0\R>X$GT&&E1,-J,R@WEZF5#@_XUQ M\$#G ?TFZ]OVL'/=+:;O'$&]6=Z:A(*RNFV0Y\"RQH3R')QX["HT\-EUCI;!7 MS4 @BR'/.OR$MQ36ICP9@L;.A_:#M^'2,&(*(I(0G^DFJ!QXV#?:B0)2P2> (Z]6#8\[1 N!NBG.31]&0T'.0/5(*'@4 9'3-OVEF+>ML%> MF8'$\B]O^H*/X68L6(D2D'4Q#5HWP7X.ICJ+C8D$XF W#>7_=&9C?B*:J'QM M4.G?X,\YG_H-6O<$Z3>F1VMD@^,V'&_\+V(8NKO:9"O^''$.A@ PL%8>@%7: MD^:(-&YGT[3F3A3=\$]AO5^CLY/P+8* UZV]RL9< Z[=_SW-N#S,%J*P:9%N M?G'SA?"NY9N7=*EX'9ZI3?_E8#_%./*@?EA MWOTDN&3X+$Q$0"Z(&8N JRC(_1OU71_XKMO1N[ZTX%IPWCOL,7[/HD "+ER@ MR16A!M/I$9^)X.V;P5]CV/(KV29RD'P2(U8X7-[R7N8@*6UN6@,C).;"D0J1 M0\M"&F(@ LZ8')"O^%LZZ.!WAVHH)OJ2&)BASVJD.SC2=:)(!U:N M@<4N\$:-M^SS[VK,'!<4)5=?X$7#G;[--5\ E >'Q."7NB]*+W99&[J M__8X5F8^(.2E6'-A39FQ*1I65ZWZI$V08/\%L!9:U6H3@1_2J")*5*JBA/:& MK[%-$WJ3]88(XZM/3LBN))!+B/L7YG!S)O3:N5"6 $T,QPJ\D@!/E&G(K$#7 MTG[I"]@!+89(!R\+L3IQO7A0T((2O_3,Y&_?YH!C'!)XVK#Z]MD'8,#-G! ? M5EZ8"7O&(C?!I94?3XIK\\68V(?G>K#"#,Q5!Z!/Z8<)V1VQ[7Y#4#MS>IK^ M@9" +=';EZC?(=GHI#=.V6+I&Z%1G<\1K)@H$_,>^?91=,1N+T^Q0%>UCB)H MO*+?SRV#RNQF$?CHKL+>'NK3G]$F"N,(JFC^9WB:987.N0 M+R[%%.REF(*]_<9@CE-W*6KYYJ"^9Q&]BXPOU^*86(K4:GF?Z2 M+3;5K.*F*@FI7G]]]>HUD&[B33=RO">%L":&_1T(8U(10$\*I M$,*@-$+(&743(I#A:$12&14-1+)L9".WS&WJK]Z#VTN[C"X MZ6(J 4_B0]<0YE-0%97SIBUW*7P_-VZ9=L0SXI8Y)N9'V,(KE MK*C%+9'C.^!&7"[=NKZ?,DT4=7&P5WN',5ZU+E83P+%M\(WQ?W,5K5HV-7T3MK,=9-P@R)+]+ULTJCY.'%36_W\$R=J%2C M_[$,H0+HO[F JUR"4DT:-6D4MH!VD0R]9BT9:O0_#?3/,(#V(1EZK:I)AO<0 M >)]CE^P4]AVQD_MY#AU&L\) Z60>8 TD=9U:X5>^^)FT&ET*^+5J-U^-45L M'1C:BB(VEX.5R^.IB:4FEJUC1'LFEFY-+#6QG ZQY 242M*U>I72M>H*P%TJ M -?/\HO__=XGB05]O^I)8O4DL7J26#U)[# 3BK8=&$9SF5*F-;4SQXCQ!MYU MD^D3;9U<-YG>?%-UD^E]-)F6\_4B?:8[,:95]YFNZ[C-=]YFN N#J M/M-; J[N,UWWF:YW5O>9CDCKNL_T>\\W&^VOO6ZO?W'3';9W#XO4B9R; M$/K-/1+"H":$FA!.A1!:AV^BVZO[3-+T MG6?5;# *H]\M911&[:RKL?W8]LPFV-ZKL;W&]M/ ]AQ+9H=Q%_U^U3S0-274 ME+"U%;,+)937,[:ZL9@*IG/N.OBEI"S"^OF2GW\/]O<.@U]J473BHBC/X$[O M:A[B=NM;^_>'Z:W]:Z6L,MA24\)FQG@Q2MA<8:M<\DQ-)365;&W$[R@O!LU: M7M24#.K.R$= C!V'PM1Y!R=.[%EFTBZM_P=M;/T_J$BB09UV M4Z-_8=MH'ZW_!Y7+P:E)HR:-P@;13I*A6TN&&OU/ _TSK*"]2(;*34Q^#]&A MG8?"U)Z.$Z?QO!A1.8W*!_V+FV&WT:^(5Z/V_=44L76L:+]S+@:5R_&IB:4F MEJU#1GLFEKI_1TTL)T0L.5&EDG2M4:5TK7HH3+E#8<*3 M9,6.A')RST)8N( MS@HX,,70@(6/GHV=FMTY@_]O,Z8LX)&YHS#8V53YJMF3>:1C>5=5_E2$RG(D MTC=M18,6C0 !9=-H;EA\^*FTVQFUNH & W=/=N6X2PLRP'_HK#>68Z\ + M 5=6JJ+/%%A+5327?@2(A#!DVF2N_-O3;)?9#05?.LFK1:6FI+A$VE\:'MP0-&D!J@PC+.DDTP8\# W?.C M(0)@7UAXX509:X9F3N#-<\9<> F>)X4RZ!7I;?XW/;'N4!=6 )XB.H3S,_'G MTQ^0/VW[QUKA'G57\1RX2&L,B/%*(-#-I0<0X;!RYX!K__8L/""G F5IZQ-X M D 7VD$$O$5O1] _H;_,:T0=B#L;<7R7 2*V+/J[PB^$GVGE6E11M,X>=*Z MS<(4E< @J6[.C*FR_>C@^X?/I=3F-P/^V;JX,:T$\U2T5TTW<-5K6.K:T2), MLZ&DMLGBG!)O'C'%9,J*:3;BA0&J%9'QQ 4UV$HU]'53Q_#HLS[56=O#J&6XP)T')_O"K"M) ,V5HIK 0K! M/Q>PIO(V9YQ_"D9ZC;"\=MEB:0%77RDZO$&W45 KE/QO9%0AP8)"XN1E@EF4[R'4GAD>*K7+9NN)' ,45[FY"G!=^ MBY\!TB,,?E08)%,%S 5V".YD1? N]>"IWE=\+.R^Y5^*2_P0DE M$S;Y"O!N6-H&%!;");0IE .:XG@S.*F.'RP!$2R2F"X@"I<3XOF)]2IEI\\Z MM #J#(4E%[HA3IUSG\XF?%G9G24?8:!8AKXKT\ON4B,LI\P(IJF9<\ )+0<0 MR;86=,D:ZME\P"073Q9RBC]TRT$$G*!&=&].&LHE?7%%6'QKO&C,9/^?_$K^ M?:5B\>4 ^@3BN*MSKJ)6":$J4";X:]QQYFBTID#UW<2=GXG1UK*[8=V_XDV(/-*G7O1K,D4[2O;AI#;MJM]-) M:#_Y'RC\K%*J"%PGC^C@=]!LK 6P5F ,UN0GZ"E<,HO?SG3;<5448Q::*63W MZ#;^RP0EW'8T6P\6QK:QR++1.(%GO/&_P'Q!XIDPFV0,\ "/M@1*F;#O TIL M4E1!U*"X9[]O=(B_G9S-JF,5T3A^'=11.E7$U%Z M@"B#EMIM)U.')!H@A(J>=E#-T_;QM .UW4R213K2_Q9%][B13>-_4]'UEOP) M7'#Y2E^J6 ,1 KH2'@2^"O1:=$\H+[ LOP# 0H=,6M0OX8?">S$!?>@%%;&P M#P/>Y[^+YJ%DI&.$W0>I_@+4OL5\4E@3 +&TV9S!"F!/XX;@F$[.T< \<;D& M*@"L"KU.1T-&F>H.N3>X)T!;+@V=_SCFEH&;G'@&K7HFKJH,D*$B/$8O5=3F M"WPC-EH(Q IC7A(GA'&>"U_\AVB7.TLX;[PW'40RN@CN)%'!^M"!?9/[9:K# MXB[@7MS5(EU@BV!B+>>'B%VHV1,.>'8$W4/(]1O\T-71Z'#):?6*5G9Z?83" M?B%]<6UJS'S\D=ZZ-V:\^JJ]M+[1VQ0#ES20 R")%3;UIQ%NK_-Z9!!#G%7#$Z]A'VY<#\7)\MF9I9A6&_D_X\3-:*9YP3L=E.!E>DW_A ; M ANY]IPPD]AXM]T8X(#HI<65@@\V,Z@(3LR%%M'1T(/B%IK!(]H8))CG9C]R M^'FZZ??3BD_-#?UW;LO=++47=CVVF?;SFM2-#YKQIJTM,GM1YC8RH__29\UA>]9BO>9T M.ND.Q\U1>]1MC;N=(>L.M,EL\O^ [Q$C00K (#H?+Z?=;#V@/MFCZ/#=B @9 M[Q^>OG[ZJ-P_W#U^__;X_?;YT\?3/]3#X_.G)^7Y4;E[?'AZ_'+_$8^E?+Y_ MN'VXN[_]HCP]PP=?/ST\/RF7=U(*7&U][B,X!]//W6DH]'_!H&?E:Z"[.=F' M]>5UF%%+6=GI7K>3TA(^%7Z3M&>X+$V1L.TO3KDC['4$GH=_UJPSN&@,>SWD'N*/!/QXO63Y]NM1J\] M+&6(/2S5'_5*6:K3; R[_;)VU>ND/R*7*F>0^+85#T>5]'D#U]=$W2\Q ,CU M9R=.EODCQT^CY]UCH(3>HQ):8*;Z:1R03I4R+W[;C@?Y,WZK!I==NB'L'3+5 M91Q9.:X%W "=\LM*AZ-T0W]C]O2^KR_I<,OF_S5(=Z>(;\RF^$#"018I1VMO M2AGIR=$A39JX?4J@880CT@:-5EKT+7'+96?D5B9%(50&>GY)"AL%56(I"VGY M!;'T N728OPOIT][W'MCJYD'NH&=R!2H+F3_I49UA(I M5S/(_6ZS%PPK6?8*56_FN):)(2H-F;5%B5@\&TUYM;P))FGYOZ+'309L%FC? M"3W=4'XL1819F\QU>"7%2S" )N*$H6UD;D*!WX"E'HUI%\HV\9;X3<' [:"9 M$;C-8I49E2318"Z/UMZ:T_1@;M$P[J@%2HG:Z0[5WB#9]T\&P/(S6+>%C()2&H,DQRR)0#Z_GR4J.\9/Q):AZ@LK3L<* M0F69 M;\Q)D$*\65H8D=!Y;B_6,D@483JE&!?)9AXZHVK_2(A MO!2[D3L<0&-608EPNN4,"X'D?*.Z%("5!W"9&"LQ.IU- M4X%'CT0A6 1^O1SX"48J_N1:C"B#I_PHL\ 3@'M\P^\C((A(0^ !$Y2(;V &.\Q,$X;]BQO*#4^*PJ78$K%! MVE,F?A"H5)YY(@F1BS,*KF1)SWR-$MA( <$I^37ZU#1GKLRP3""0IL_S@"OA MM:4("WSL3+*I-K($$*W3-';.]NFR .Z4[8D%)$M: $D"/UE84V;PK+ROB/+* MG68;EN+H"S\OK5#"$'P"IF'V=J:,H>M(7R ZV,C2A43!X@D-[C*)85E .'TQ MO?$5SX&MKW6/*"!L(!RLZ1S%@4/0HL"/8J29XC6A9#7WJE#F7M$M1BKOHAM-V6"X M_L[?9''J#RH$T9$06C,3T0OG!0YZI7>&N..;+)HP.!IW/0[>9"/YK6?OKQ(R;[?+ E^'[GX>TR_ M7Y-UDY*I Y]VXEFA(8D 2)VLL0_D4':6Z$9>(=$"80._ZIKTTD18))YFG &, M3BHPNM5/0>HWAMUVX12D7J/?'Y22[-,:-'K#ILICJ;*1T0?IF!XM<9G%U"TX^P4"!W]B;32D_KC(3+3IVO%$2AHLH?A M58^;;U$$MJTW_N_V]IK+0I].#78TJLTQI]>1[\F?OI#L'>ZC 7M<]G:;-*&M M54CTGOP]I,G4U/CD"5L.N2^M@XWF*!W2%E MY(?B,DY**F,B3=(/;@0Y4,4[*[<\@ <4^ 84APV,#WH-#JC5M' M=&?8:'4[Y82 AXW.L%UHJ>Q7]$;%5EJ[J?7GVW7\9TZ4.?-Y@1'BCD_$4YT> MK9/5N?\SMO\BTI@B>K-"7US*AHFA[G%76UDT]0VLF>\:+>P-;N12YMMF@G_; M".LI#<+]0PQ!(VRQ[M M!%Z%WL7-0(6CE#0\>^. 8!4GSM?4]ZZHKWM\ZNM?W/2&:NL$R.\]3+6_A:U& M.E\DM,AVL0.GLHH3IYK>>JH):8-!GV>_=C)WM%>(-LYQH'6-2 $B]0^%2)4; M]OP>#*,[OU8F<*QMQ593SGXBU'!9)E^E7OFWKD\*'+[.O>E_\ITYGH'JR6?; M6OA?WP8EIX6UD]'%34MMIR@G"3=+0$4*SH'[H[#Q?3\%J:[SAZ; *:#)F*WR-33'S#,5!L M\J??AFBF537-IE:1#Z$B5P@#VU7#P/>@6T>##I&4HTX=<:A]GFLXRN#H/L]6 MY^*FGVI55,WE64<<:NHKE_J&QZ>^[L5-=Z0.3X#\TG/T^X52],O-[,!#=N D M4\O#5*S(*;==^I!;>W^Z43PAH[!Z] [8\+DRV]'QF2UV:%4'I?':$U!H:GJI MTMF*T,NH>7QZZ5_<#+MJOS($\QX\P772PP:TT3I0K+I5)SV<-R*U#X5(==)# MG?10^3AT'E\M)0Z=I(W1Q4V:4EYG-9PX-N4PUR-D-;2Q*U-%@S);IS5L MS7.K$U1NUVD-YXV!&7RZ0AA8IS4D*Z/7][9[E[<##KE5U8 ]'1IA MB$/0 \/QI'OFI0T.],]IXCE5Y6VN@W[%)\0Y_@1[>'"BV?8*&^[1"BIVW-/- M&?P3=#.:NJJ+0=;40C(ZP/PW1Z$)Q'S.*+6_"__]:F&'.NJE>@D ,>0\*K&& M&(_VE4;G*9_YR+TKE9:!700SZG 7L4FFB1.*F7QB^!M?TK4UI -Q=ASC)WO( M\&%(IS\7ZSEK0F"B$V+!II>C7L;<5\E//[*Q>V\ZKNWQ-I8<1[[#/IYPRM5T M[3#;;KMW<=-L#)(3#?X"+=ZU;ZB+ M&;_>QK/K@U[:[?[%3;_=3.FF+2<+J9SJTZ![*"!RCL.GQJ:S*'_V6:A1='BX MIFL!,Z(IPE, G +W@*/>-)L:NB%/\X=^IB-QS9:RV=)@OVQI<''3VHXM]7RV MU#L:6ZHD4RHXXG24,U%G'VQI>''3[@Q3>BW'V%(^:U!+Y0W'9(,I6-Q0GAA+ ME7S'T^AQ8TJKJ5PKB W'!!@G7\]V<5P'H(NF&P[>;Y3?)?36[9E]9:RJIY4) MAP13$I9?:08@_6>PL$V:LG[[8C-B82ZU]A9?G+_]86R]^5.WB9 M[BJ/RZ5EN\A.L4_Y_=]5YRB=[6:5[-SRXN=J]5LIHZ)V/%@+3A8RN"_G*/A,&=;H9[XR=.IJ$.^,;4VY"5\T NU,3P& 8 PZF&.!;JV/$U!0%7VF:,NE;:%7B+-;P9>E M7:#(!!+@E?=<5.,O@"SFFNNS16#<**LEH8#^_@*\\P7.E;T@;@Z6,$"'=\^ MC;::[70^FFYW@3;,;HE/%&6CG4Z%V2@G*Y]O1$+6PZA"L/#@WA?:3Y#X\!B[ M!EN8@7PEY,!G)6[Y4TG(,8L^5V7,W#?&.#:>/N9D">!TQ $^H5M3?2+(2))5 M82SJ5AB+? M1>4,H7#6]P M8'@49/?$!EZ$OG0&RK6)&F 4?Z7=26MPC_F;Y1E3_G:;4B6Y=WT3]I>2U#'D M.@.^^7S1NG2]LM.K+BHW%'3TN188BFM0 ;@>>3?&J[@G1#)!C,Q,0%+C/UVE MU1C^DFX3WV[B 27 ;&^ID(FUT'[I"V^!/VPU1ED/T" ;90(6-[IV2:Y:_ MD!1!$,@4KPRL^ 5SY]8F9T$F.9E8]I02W,B.OWVZ4[J#IDI^*I(!^,FP ^JX M)!E.3I(^B'-[&#[]#^.H;5O.4FQ)[ 0I8<+G^R'7=[RQ SR6IIE%9Z2%G/'\ MXI:^@*'K6FA3%J%(V!_?P'**C#X#("0KTLS&AO(9]@-0Q1]SAD?"RJFH [&E M7&_BO#H*D\T;'H?,"X5%_HBN+IC)P1PCD"8/H'0!GXPK^W$=3?!VJI* 7Z(( MPAS=.]!Q+5C@&1[]P[ F/P.AU;\0H_4\-KUUQ6>X, ,!MX2E0=]C.[_B^SK22V:B(X38=ERV=#\IEZPK@#\OJ MLY64NF%E()#NORN7[=AOQ?JD7UACH$8Q=UEL3BX%3W:N0H>,FZ%DM\./NE>* M!GN<2.LC\1OIK]KXO6C37/:N MTEJKH@8#EP\%!@!SBPD#-#VU;+>$E#N77] M%Z"+C2T#GYR$N^8X#/]?]MUSG4A<)-/ C/77=,/X$)BX66X5V0)FV.IB'YB1F@+H(E9"BIP6Z'AF\7%5+\22(ZT$=#L=WBUN<^@Y& MYINQZ>>(WT?&KV!M>453;F_"JT(H2QN8X6<4E<^G$(SS")36R0V2]>H/?#&- M2V;?UPHOT>&]DD:<*#AE% D [='\<0MSKY?$92DIS%QQ+RW2M88'<@_5OH&B0G^/&$ M\#6\*5P=(*!.QOYRKL'U3HC*,7O=_P)IPM;''F9UDG"A( 6,$H@MD"@2-Z0)L(B.>3 MI)? =WEH1GGQ0:$XW@*.$$]3_,U)H 01H>HK,2X8,4Q9P$[F#@A,4%Y2 M+-N8OK-NZL5H.&>XXR%HN T:G]KN5V6 2]UAO5P,RQE@> @,ZUSEZSU1<3E 'A MEMI*52['5Z&2U18*TQN@[X'["?;YKM*A_AU_IB M[-D.3Y7GO?F"90'ZV@O\[X0G.XJ%+R?A5T_F<.\,J4P\?CF-?$TYN@"NB74M MFWMH#J:I8L8P9:0Z+ JJ2(DUSZ$&T&NVR3.">3GNQ- 3?R?45D:FXID3MP& MU3D;^"I*5:;4;-2$*0L<6\],!&1Y(0+=Y&4 X1#H<;70*:\P&911]386UIF8 MN'Z9>CKX)4_1QJH W@LQJ*R^%/"\:BC_F#/8+/7A <2##RFEU6$A?'.Q3PHE M:4>Q35.HT(%*!RUX,95">>[$0A(*9 ;4UPY P\5%%%#_&=CI&WUB$3J.9^+$J24N2."7B M4UF#@1U PBC(>T[*E99+ ^ @Z)Y.S=.J@U=D, ;!1:8RV3I9#[#05H3:%C9[ MT:BZ7S3ZCC\;:=&%B?>FL9+% \!W_?Y,_%C\]@U1<* I#@@DH(J)9G*[T(:E MY,K1FH6)M_!XO6<\1?D_3)2_8\*^-0%,H/I4OWB>NM0TE%N!%(**$Q> P^7P MIHQ5T#MJ0=2'S7[\)NRA"_;OMJ'<(Q73^KSWBI_'+C;QBFF[M(3_4*SPA&8A M.7%J4R/-730JZB>0QU/)B5L"8P+D]=_-3\[IB##!Q!J6,4.25'Z:UIMY^N4' M=S'!]4&Y$_U#$DG208T!\B&+6CA-"3"61U)MD<0*5>"[R-X7')G8@L^5.='Y M[:*(1*G! U$%D$+! H:8@(V^+"J6PMR.&O[SEI6B_"16OY.YC6CU1+@,!LA2 MG^A+SO(U"6 MG61R>Z0W"B%W1B7$Z6/W=RZ8/T0N)5Y+)/ ]I'B!IF3ZMQO1G"S[10/8\ HT MT@DFL5$/NCT%_<%&+-%6U"39L?C=)]I4,3 G2,P3PLI>/N,5K8MK8$T+]=DU MC*AZ1Y,P3NJ",0GOJZ:R+Q3ILY.)[<'W1C 06RHHR#S1/B4(C\7,.+ T MF+O1K4I-88.KY3S06\*++_6K9./F,(GPJT_#[4M=/+M)WY;WW(^B7_>CJ,1> MZGX4=3^*NA]%?C^*=FH_BLY)]*,(:7*P%I>E(=4Z,/M!,@:_O9YY5"D&8O/% MUA9T9_$%0#6Z- ,V=$]0P(=3EDC25D _*\;U9!H#* TUNHLP9 &X>M($P MX49<+^@C,6-HL1IA(X \2*B:":@5QI@I_E: M_%0'+10WL/8B0Y9CPV]&%CZ* I8(^>5H.E*6TUY$ MW<=<_)0^IU!#C*P^S;+E1<8+8'T=31?D6C'!WX@]2?,UJQ, Y6UOZ+LTO_D'Y!HR+ M]^:96[Q[:D9 MW ^V>:RF@*7- S2[6]PQ9YEPX:*/+.4,H?T'#CS?:3QEBR4'-/IB$*G"\:]( M%U__MXY_%'0RDK=1]E$2=KWP?9\\[:)[W>1^)8J_)'R[ HY!1(C\NDQP1;R1 M#+\[4JO). CY!8J1 0)SY$6JPOF.>!$,# J[V='/0@L@LF[4!_;$+F&-MMWA M74Q\2C <*ZWK: A=I=N=:=B&&*#,N-SBG.WRT^TWYRK<9@<_(#+'=L:F$)@T MLD'R-6!>&G! 4F^1<#$M9"HY$V]T#%H NJ/QUE:B^[1D];@)__F4CM#8%@OI M](6"4+PI>?Q2E22=;=CJM[-=J]][$^>?6/8JF*>7;)+3[>_2)*9OYJ8$)C1:*A[-HV& I:IRZ/[?EK1M,M718*F1*4V!#K&T7W2 M/&PWHL&H,6QW"W60N:R/R:NGE/ DZG'5\!!93Z*C'J@;F/L^_"N5$X.QT'9+?44;=S MHHT]ZL8Z-;%M26PY;77V0&PC(+:NVNNW*T]L[Z'H]!^6_1.LS>LESO1S$I*Y M;BI26"PA1._-;QR>.Y%*KPFD,E([O9T;OM5=:BJ(4)NRWA(1JG5QT^FHW6%9 MY;4'Y[ G:/E\UDU>.4;#,>J.+SLS6 G0_T5X[D8/;:"'EMKO)<>O5ZG]1MW@ M9;\,MD2$PG8N/;7=W+GI5TD(M:L*6UI#@N:ZLNQS-R[+!]#Y$.FF7!_HLC U M=B]NAFUUU-NY86OI%WB*/45J$JY)>"#)!VS,\4 M+H_S1QH"-#WLQ^#9F 82J1Y5+N^^/CI7E.))*5B,\NS\S:2DP,4Q8\/LJ/ZV MV5&N9E*!*O;Z<9UU25*]E!GHO8P9Z">7.M7W4ZF@E8;KEUCNB1 MR#3*,(]2AA8#9P4AF(DHZ3!%TQ'XAT&]+X+C*9Q^3CZ+F!)LTB;?J;%LXED8 M#GH !XW@('D[XSF_$\K]GP;E\=__6ULL?__HI\K#29CC6B:6XF#%"##,;_!C MO[H*[@9;]^#GGBB/^0+'MS78Y*#[.YQ^[.'445MY6L%;%\HE__K*7V'*<*M\ M,&!XP*F?ED^-?WABNTSN^_&D?,;ALKC+C[;WHMQ.%RB$7-$.Y?+SQ]LK^O;3 M'6\(](KY[+'AE$]LZA''("^H)X$Y,^/QPV\XPO^HQ%E$9 YOF&8'PFAP<=-JQR6F@K\! ML7[+(:;)F@1>#R0./N6"FH8(BXLV8;]\SB7['[SI^T- MWM[F ''"Y_C$NU<]P+K/;\QX97SVW6;Z=3\ W' 7:WW'S?\3H/O\9A7>\^C8 M>\9A@T5WW6\>>=>?+<\NO.G6$3?]G2TT%('VX^RSCEO[)Y%\P1.T,1$^V5Z[ MC ^0L1K4 0Q8);**[XG)O9Q>:D^)1O-[TL"6?(#0:32XXBM1\MH>-WJ"<0LU6 MH]LLME+6IEJ#1FO0K=JF.HUAJUVU3;4;[6;E(-5O=)KI7VU89WO$(5BG54$9 M]RML4'VZ88WI:<%A?27I.P+$+6PVXFQX=P (N4 / H.UZ5A'M6 +E:MSU6F# MNNO=2\CRH WTB>VR5&H+Z^O8%R]*<(4%6__BIJ6V6\FV"%M>$YO16?O M=MJ0>I?T2YOD7H'JR1J?0OB44[=;MBDR*LT4J?'I%/&IB+*]%I,&S1J3SAN3 MF>4Z-3 MN>C4/ZC...B4[;ZN\:EB'MHR1 M%&M5I:G@+I-!UO\LFB%\WB[[]^:9W]Z*VD[UZU_<]#OJH-DM2#4'CG759/"^ MR&"C\%1Y*NM@6Y6U)H.:#/:J:Q\R%V(PI%R(?G(>2Z8F7N-_C?][% ,;1;M* M,R!&H NUU6XW:8D>20@4&:NWNUF19OH&1XOU[-QT\ES]H@U>5%>8G6%=4;S" MK/U> 5%7F!VZPJR",(@4D14:VUF7C]7IOW7Z;\F>^>%AW8S#YL5-9Z#VAG7Y M6$UL[X[8-JK5+,V9.6S5Y6,UL9T1L15,3LBAMG)=IL-V73Y64]DY4%DA(FMO M5!%=EF-VV 'ML:]V!G7Y6'4LUKI\[!!TMGV9YG9V6K=B:?4U/I6+3QN5(Y9G MBI37R:+&IU/$I]+*QX;]&I/.&Y,.&NH?#BHFY^KRL3KMOC12.G .\9#2QGK] MLGS[%7!WU.@40J>-JA'+TQG+:SE0XU,E/;1Y"%6X?&S4K,O'3@-1BN')1G6K M9:F$HQ9),1S74PFNLZLG,2\]L<^LG>[^3F,#98+FC(AZ^\#!5KKIJ'UQ MTQ^J@][.H8,2[_-([H::BFLJ+H>*#VL1C,IK*%$3<4W$YTS$A0RQ'FGK?%?464J2W'P"RC7'< S5ZH((H/G$)3%;U7VAF8GA^<7B(8T6& M@:X=91F?[EG"2=(&4F:/Q&RGCL3L'&G&\G-D'O:+ (XRU@S-G- 8WS]M7W7< MBY.6!/YF1-0/B*B_2RN8\K8Q $G2#M/$!QBP,W";FH- 3 X*YP/$9:5C M=(:XJMC,\0R73969;2UH(/FM]^(Y+G[=4O[P'+A(QPE/O&\H3XP=;6QL.G(] M6"Y36GWE.KQ1Q]]DDNB.00%K2!6($N?!SSP;;L &E'(UW7 :R8W'.+D_%QF7 MRA^:W1U=A";I!@/@DPTMHFC\S;:6P*U7WX!6W5MS^@E@O%P $_JH.Q/# P\,+A0%F+V$AU_;81468=B9JI;/Q@9C@_!G-7UXMS4H: ?PT$..+,,PWISE$O=A,G#F3.#AXUN MMU.Q3;6;CC8J!-+ZZC6; M8 !*EXMX]4W=]Z6NV]UG2EU.1_9,Q-XF^:;7Q"$]';5;6F;X\6-[-:G5I+8A MJ>6T6"J9U-I :FVUW]^YH.E<2N2/BBF?/1MPP[,9>1]G<(?P[^V*GDI.ZST+ MA6RT'X6L4Y9"5M=\;L8BS>;BYD.3M M7]QTXI+W.F&=Y>58.X9^9GWD^$M]6_N&D7]#-WF_O9"E9A-DMT M--?&SD9LNYO34;]DMCVDN6>CW3/@:M.YDMB4T_^\9&P: 38-U6:WMJT/&74V M'=?V.#+HI@*:P(O-G/UUL#X[X]KOW55;MGOC0P<-G[9QFN=(;7?JCM_GB4T' MC9^V6X!-/;6[NU2KB&U;9N?=RCR_@;*W0X'#:1/,89DO3IQL==5^I^1>7-7L MF%;=2#8 MNYFRE^?/4T\KU, U1^[>[LNOZ 9 F!=YYNVPN.@(CB9V!Z;?M&UL6[HKLZ<-0U_>]A-(]9P M'#[#]YQ!&^"A: ,L@:0(*%%]JX"3$@+4#MV!GR9S-O4,]CA+PO\9WYD"^E$* MZ$>[@;XJO8-]B"]#$-<$Q(T - @ 1W=<[(*.G8-Y*V!,ME[;#+@ M8IM==N- M 7;R75J\S_@'FX$YI;\RT 1;0P\R'.S'ZE #AA!OS6,@2OT MW[G?)G2IO;#KLM)6###*,<8!<8O%1MX$@C)\^\XRSV=[. MR/$<1)5ED\7[ 80+L_%7L">M,GM1YC;RB__*Y_\@6HE-("'<(:NAC$@M19ZD MNGC\K]P]WC]V^/WV^?/WT\_4,]/#Y_>E*>'Y6[ MQX>GQR_W'_%8RN?[A]N'N_O;+\K3,WSP]=/#\Y-R>2=Y_-6&YSY#B7H,+GBT M<1?IH,O$ U_;2)DSP16"[&^']&UA!2%&08?ME3_J-9KM4=%>^;U!H]?JE=/A M?M1H-PT/?5['PK*)Q?5^JZG_=1^GF7%> &*![)QY1J MH5DTR4C::>@Y G&#E:^_ELQTDHT6\Z#Q/AV5[[4U:W[8/.RJNO-L>XN09*=) M(.QT<5TB2))_ 5;DAQ;1W^FR6. MZPJR/%FDF\[B@X#JG0#J,\+TDP!I86II4RO^0:^LF%@%@M,U&N5QW/+1J,/1 MJ+5SL[O3JD \/FM=VM:,.0Y &ACKC&W)5$\W3;%]BB#6N]%I73:9FUKI1GN MBK@NO(8Y+@@?/R9*VB[N0I%G -405!55!'8;+H7MQT MU&:[K,+^6DVM$AZM\Q*7C$<]Q*-.]T1CJCIP$8ZB8>VM9D[PG^:T=KZ6 M%Y%[0OC>^N %Z K?V1W"MC"98%1NH+9ZM29[COBT052N9'RBD1GJJ+,SWZW5 MVF)\%^ ,]Z?7C$L=PJ5.::V)]\S_U[4*6-=3M;FNK6KSO+H& ME >'\R&J8ATZ4IO);DMA6, W' &)%1UN4]H]EL?3:_*KR6___3M*);_>Q4V[ MU55'AXM6/LC=7YLO[*2_OGTEC[Y%H0\H/OW5;U:ITRWZ>,^7.6L";5[\Y MBH&'4I:6[?Z>@\=4*-XOA/5(7]FC"@=V!2Z6O VKJ+W;_M)6Z=*7.F3?_M M:;;+;)Y]H 5;%?M?X93H)[B=CSI[L53E#38[3]G-C%.E>%5#0>C"L@LGXT2* M]F(SQK/*W+GF*G/ME6%1&GPTP1H)S7QARLRV%O![AWYC*NMIMMN+^*T(3;^S MA::;DF*?84,1)@ZX,_DP]>PWX*<.,P,Z'E[<6"935@"+>)]SQ;7R-M(O;R.C MBQN7F;01N&'\YP)>-G?BNVHH]R;=+EP*P(MP3$ >KP'_S32X.<>#_] -J.%K M ? [BFFY<-L3PYN2>QXP?HFLW<$3P_$8]BJT:3GT S)ZGE_FU&/X(_Q &SMX M@_1"@(NU /C HK ?_15P4.>[C.- 0W 5C@N DX8^6W%,MIGF MC=;OPK)CD)M:C(/.84N-R$IL#, %%W3-_\)R2\ H1'<\E0:D3@3$R9(W+U\A M,>-GKB"@! 5/+7H3XAM@$Q*K/@58*:^: 3?P J2L 2:*5"+=#>T-U0>^JY7D M _3!5+[PG/BY8GFN8WDV)E7A2:.]\0(A]]_41H/T#+@? ^:K#7@39A!C4 MF^[.:2'\<>SV&:<'[*V J.L2TDU$P-+QKPJ[GDZ1KL1-(A+ GZ" 8;97ENB( MH(%BC7$I!R_3<>&B 4%!+&F!U/ );LQ,-L,-$P/%KSR'R5]ERZDX0\"_25E$ M0$UUFTV 3UMO7'C! =[PQ$L/Q(G#N4$@-!Q\(\+$MKR7.=P'?0^0UZTI83PR M(%P'/W:\Y=+0F1W@*TF#R.LG<)<.B\2!/,, LH;8*"#O@6,& T;"+17\(M_RNAF9@]MIEEV??5@C[V8VTD,Q&QG-20!?V%=MS;]XY;%S?-1K+1 MFK]CJ;4"QV!,*#D*J!QP2=1NFQO,LNXU.KUEX^@5\T_SKP[J4=;O*?1%JWUH?'ON.SC[(?#;A'3'P6>WYN?!)9_ MMNQP--8OQH@Z!\A)<_T?9ELI,?)^Y^+FO_]KV&ZU?Z_\Y(MZM$Q-?Z727Z\" M]-<]=?H[005HN[3\8Z$U#@"]\5-?SE<%VC3%NTIW4Y#1IAWQ?-AI">I,-,,K M@Z'F9_[U>]3^KW=&UF_U(6BCH&&&V MUBAM'#S_[]P.O,@O['IL,^WGM3:#S7[0C#=MY> 5A.-?NBD7'W4;",+XZ3// M.)OM[8P8:$&:UP>>8P:_@CUIE=F+,K>1"_U7?M;XX.*&(K\8X<2&$!BC M_)^_:#<;QB6'T;CD,",N>6!/+R'C_/#T^/7^X_XK&4S_)RRYY<7!$SF+?NY(.%ZDJ"< ]3Z[&_[].T)YGG>W!W.G-26V@2S4-$#X2=JT>YL.K^?F!7=*!X_/9\W:[+)_CZ MZ6RI.:*K(/-UR7!'E#46%(>(96D/ #K=;"C48TZQTD@Z4_T]%"[/2DF.%+42 MR3HK^L^#Y?Z3N7<2PVX76+17. D1=(A>NY&L-]\^;[+;/-YIAA"P4S!0W!:3?T4F%YVT*KVDBE_*8VD)V1BH5 MF\TRLW _L@GR/COR52(OEPHLN$CB2$^,#M^FHDQ;:KKH>2NFXB32Y8E3$AH* ML/G8"GAI&("LN/280%4'BA44W@)T0?^0PU]X9?&RH(; M"WOB(OT@;>NNR*C?@FDD4X[C7JQ8]GB:34#GW#%!.0U##INQ/.@W^LUAT8SE M;K\Q;*9_533I%]2D4;&5,I-^.XU6IU_*IEJP4FY"]N:;6I\>74Z*Z=J?G6K* M[RT2=\0;?P!@%4D>/0TP^FG2RL&R9L\$%DFFY M:UHDUJEJ=:K:[KD5W<'Z,'%4)[W3;!O;&13Q; 1QX $H<(/A2!UT=HX$UTFA MU<*YFM+R*6UX0$IK(Z4-U5&SK+$V^Z.T,T^SY+5T:&!_L;3L#OAUD]O="6QT M0 +K7-QT!AVUUZW**. :F4I%IE[S@,B$(Q_[?;7;K HRO0=+"Z-X'Y1)TEZ$BLL2NRA_L;8 M4V(/X%SD65M"->B774)5$4V9WCO@6<&5'1GR,1J=*EMOSGMF;:OF=VJYEPF: M\^%!!038@V5.MI1A@XN;46>D-H=EU5"4<8L5+5FJ:;>FW=+UAQUH%V> M3^VT.B=.O1O-$*AV!E*R#KH="[L]1&R^4\U"NC>5K]H*@ZBM:#8XMF\TF$OY MY3QE],W676Q!O@04TB?8#9_)AI+%,H![.0U2HTZ3S]J$;9^-QD+J;V@UTT#76SEIBG*E27AYVT,?7(EA[(EFXC.290*5&L= \G5OI FYU> M(SFE-B%64O!D"[$B&%VK1[?_5\^@?Z^1*^(G*O'&M9L)"17_+218>N]4L-R& M8W!(L>ETG"&C<98#'TUBA>!2%)5SQB5$V>-W_S5;2IH!!J;6:MN)KN\X XF=8?-K0V'-@)8Y-5.V, M XJF<$.\D F@;&N$H5,-..H"V)7.!0N ?<+HFR3/FUO&%.?5+;259'BXN&YG M,5#-I:E7+L"#X[P.>(IEX/QIA^;!H"8A:[8SUM$=)1/C 0L!)$FDCR3-=G-R M0X(WWOD[^XZ^LI:/U8C%8KSEP3LR!0,;$07:S)3QR_I/RI MI0*J%-":E$LL3'^%UYLTB$DSTP (Z_&A;P4TA&_,?L*-YB@][2W ]@VWDP:V M4?/BIC-JM)*=V0@Z!+@XW*X:2AC_>=5&R+C;"]Y'#,BU.)\FY;;!^;1UML'Y MX=YP?M2"RVLV!OU1BJ*Z->J$7'ABAC M)G[)^*P\FGW&)TO3;CV3= II99R^BO!_1>4RD ]BBR45"BGCNP*)LKF;_V2, M%5NF$6IN$2Y,UNV)MT"%>()8&+I-T26'^RLZC9[=9N]LVJS%^D$DGVTM9TB M>%N4E&8I[:JT1UG+7%$\9:J:8%DD5-E4P<\>6@[O;,#9>/R)X3 M\\O!(/#GER>5T,Z:E)NTW?:;Q]QM]^)F!D(YH3$G56C?V$-C3@PX#MMTW&A$ M]>_0QX?/X* >*AY/N'SH.6#W"[,,3QCRB7R &F]QJI*5"7:ES!0:S6PH?[M88QB M#'@FC"M6(ZL3QR%=. 09W#NRML"-@=SP :QFE*^B' MC[,GM-_(QGVV]9<7?*&X<>#7_I4/UB!KQCY+H+3B^QQ>W(R2T:G$!W^.#0:7 M?QJ:@T-^T?6,8W=A^< ;(;NL^5:S;#89]_W@#[PH,JA@VH!M$P[5,VPIZO ) M\ #':Q<1G8PQJ'ME&'TTL9/V\JE=D6LD-(' 2&Y\4UN@S>:8HQS9RWA9""O M"^[:9/PFJ?>FQI<2R,X74I:&QD=(.Q;5 BCAZ?7HQG+0[N:F(9V9'O"[EP)U M:>B<"Z)'H7GOZ8ZE*^QKJKN&B-$O.'%IH1'WN/#"LED.]:0R_U:YLB_)&D=% MI7%[OSOJ-W&D>6\#5@V["T7Y8$^&)H:Z3Z5#DV[8QU:*\ #"(J9.X!/^&_A_ M?O OPW6(3M00,^=^,NH*JX?Y(J$+G!:H/X\\TXE"^F /C2*94C9Y.:W#HTN! MW;71'MA=RC,>+D5T09;IY^"H$>F>[;,O@H_PZ>7X*N:*Y'U!51YAQ9UBK@EW MJ@I&%D[N"?\@XO-4A4X2?B,U-]9">/RJ&1XCU0+[*5LF:"&KL)8A6L:.+&/"+5S#0AT/J!7E[8H68/@&WATO'&5OV"%CFU53EN3S].F M9\S.. @J5Y;)XE>GA6R1T%?T=Z;.YZ--\PV/%L?9K->#?ECYJK/+ M6N[][A$WV\?8[@9"/#6*'HH)$8H ;J+!C6C(Y%[X+0HDBA#TI?Y*;$R$="A! M&6._4R"8?WO 7"BWCOI6T_<^7B1^Y:L0R3)Z7<2(-MZQH M:KC%-O ^S#O%")@X!G<"Q'9XI1:7'638N,1=W(+8W]NWU;#.WD_=47_?.QKR ML%P]_)MSGC*L$UV8TA3]2.-Y ;PK_$\K%6J,"GT&N_R?QHT/Q$9\)YUFZ>AT^F6:(Y3 M-'%"54.* MKX^T]^*!(8>K$-] :(67TH/Y$U&0Z$YD^W+OG'>N.SS-!_.'KQ# <1V75PN" MI0JO$FEZHHM>+)P6/.L_X)?@K(6Z;Z1*"P'C!71T9&\@2R8>9T%@0/(PF>1- MP&AL[DKCM0#2S ZV0E;C5)_2O1*U8U%>$%V('Y&?,+0N;F&,I3L*9U(:MT]! M:9ABP8+V"KR.^#,R&M+[+<]&5S/G1J# X'@Q$##V3P;P& ,D7D4^V])SP^5J MD[F&4A @Y0##X_+"]QNLEAQ\H7M?>QGQ;*Q[\>N(DLZ&%/[Z3,69$Y)Q,DZ7'NI-QB2#_PS]%D."EH L@UQ4/$<_Y)\Z]G?Q (L M%4O,^$L\J3N"@8EP,KJ!_(B<[OK9-B2=%SA=*I:!.>,:,*TJ1H]--.FN6LNA M8&5$7^*T.) /PW,K:LPV^!WNY\T4ZR8H;#W[6)?L;&9S#8 4)81/4:04*Y7J M#]97EX4V@IKR9SC)W_$@P5@HIV"-5+^%;6J;:YD":R!5]>]>W P:R8*//R/K4PF?;%0VC94J=#='GZ() MED#N=?==[A5GI_M'&L@^S@"5/]$V[^0N"U\]E?XV&UD-P",%LT6I)BU[>T]4 MD]>%8Q]4@S[+02L%MPY -<,]4\T J2;)#XY)-7EEM_NX8G+G=1I9#982C($+O" (4_"H#>@?;;1M38AJM0?INXQ,V M3][61QPLQ@\&AV?Y[=;%3:_?:R0SE?Q:?%^;C\C)K$+-S#&)8%<8WI05Y)&C MW,X$9?0+Z;?;..E^#1#@4)X9<#W*:/$Y/PUZY4RGX(7G=*;:QX5WJ"OXFM8H MV1>>RD[+OO!<3;*<"^\BY\SNI[+QA6?1 9C%+W5//1X, M5;/!W,CA\.NGKE)I5&+>:K_=2]21P&?)>:O/D:I$5[AMR"OBB(!R&BJMGX.Z MMK'FNZPZ;-55AY782UUU6%<=UE6'R:K#=FK5HU?IKW+E.EZ]G:YSGZN1Z:?=)#LX\W*0A;_09V5;A!8D(JE3;T]-S'A10^ M__G,!&D-5^7;5%54?D][33$7G/&?P%IH-FLN*=W*"AV@$.PDWU78_ MF2NQ^8#0>HQS-5$HA[66A4(C0*&6VAPE,RL.CD)GK_%')S?G:OEG/C"W6N.6 M^YUF/6[YA+"G*N.6^YW6B8U;EEYDV"C+QK5]_NH]S8-^MK!O1) OL+UOIYX2 M6T^)+=:^JM$/4>8LISO].YN!D,A^JH MF55P<2K4>XXSGBE=07A1E2=F8NX\WKGRQ=+,4\ZPIN'5]Z8_:X$7!T3Z?%)5 M N]3I6A%$W.C:Z%S>=E$$FT7H;AU^<(^Z1]$##PIK'%YOQ#K?4 M2O3;7(.7_X0G;J>ONF/9CO+EFW+I?WRE*@!S[84WU45@_:%;_%OE#E;676I6 MYO#^P#Z>7/%,5_]O,<*/*I_\61]^LM@SE" M=""L%S'Q7I49>:,PADF_OWQZ_/S]*C+@0E/P,V5F6):]39W1H%^@SN@/S=&= MIR76)C^:?]=L'9D#%AT%G5A")4:=WL5-.R6)_,\JE7"*(:+\$)R@MCI D1E< M!0_0QQJI0TUG;A$'=?C3%9Y?>,#*U-W/,#9 MJME-3Q)#+T.]AV:Z'?1_RJJ/&:Z'+])$:N'+ M:9!]O$JJMNHNZ%?A1J_HHY M_6)&L!LC..K]AATW@.U>_P36F^SL0(V-J7;K?L;_P'&9D6=\<,@Y0!-M26+D M/V**CT8%[/ZPP/3:;W]?,;X0'_.;^FK5?[?-Q,0@A7BZZ!,D&@EAUQ1M167Y MV-O0IOIH43'=Z@"ODPV'0NGGZR!XJ3=8@PN(6&^S2/Y-_XJW UV*9H^\$E#L MA&^$%_Z)&P%4P0XW*;<1JOR/3BV>69[?+@EG]UC\3?Y;Q'G]PPX*'S8Q$$B; MS'7VRN2(QZ CS.WW^[_=_O/N$^_#X,IN1&(&,"A*&O(HWDS!+VEO*!\#(L)G MF$1D#HIH0E,6!H8QKWCE9,[D77CCO?DW>)]D(87E\NCBII]2(Q,KDGQ(G=0: MNHCXR&6J,*:>2,YORHR)0I$IPSK3K6ODSE0MN?IASEZ$I MR@C3P@5/71RRU^FFU/I$+S.J#6]94R/+V:E*R[DUIY]D ;A?N^7PRIM AC@9 M13C==KS7"=;9A6?GG'H]Z#=:_5'1U.MNK]'K M%LN+SOJ\W6@UBV5>9VVJW6FT!\52KP^TJ4'>4H>*9&R8T%OGC9<%K/-+DJ[3 MR_>37G[4>.9VB2M'=5T_VCK(.M!S$Y)\$YPLDKA0)[?7R>U),V.4EPZWBT,W M"(=T.^30?4>9[C6YU>26(+=A\T#DUCT#,+-X7<[ M&&"K'1^O60#P-,RTHX.5!/!3T,'1FW?-X_7+N+9(J+X*3\PX8/F.K)H->/78 M3MDKKR9?LS=GB9#^9NZ!#"6YIG/.$*W-E\?-G4^R%M=I+FP3O.5N?V/=PZ;+9>>,-J6QX!?6RB= M(FAYJ]9IS\.T?O*K>UKO9<=Q.XY[Y(#;PSBN@R,'CXYJ[<-7P'$/L!C*O0(V MINT]*X@^8VTU00!?#NP.C3E%0IT2)N\V%@EUY]7RU)Q!AK7F5BVJ52B)8]P1 M642/5Y+B(4:_5Y,$QGRB,YEPJ1VL]YIM]8M3#IJ MUSNMQ9B)JSZJU:HWCQX$O[C] !'_!,)WSKFNN3A X]?'".F\L N]TB%4J*!' M=? VF0"J:GS6V>26FX8K;?'U6'UKM&<;L^):Z\_+P972JCS%!33$Y>!C@ ;? M/VEPR\H@%IWFHX%8;!88T%:P?.^>&M_YD:7M9VG&CV M2N<1JQ4V!'EP*[CDZ">#''PI+D'5\?4N7ILYVF_>-4X;M9/3!S/'3H6LS1S' M.Q7R?,R!/9-KLT='V./DP3@;.]VQ-GN<['3'L[''QSA+UN:.HS?O.L>/8EGM ME,?:W'%*7I^**;N1]U8>\CG=^O&40DYN, M>'[?&.0.W&T'[O82.G=M58I%7K7&R3TJNK<%TBTW>G0W;;0P;;2YFS:Z$6O9 M31O=31O=31LM3QMM;KK!P .J4==1/UX['<-SI4\VLR' MGU['M=;[4<;I-H\.7D48*##>F=-B*%%BSJM_M-3 -M M"LC0MJ('48S=X30M5D39N(0OA>/R4/R<"H]HPV_AH9!#]HY_JE-[.JRA7;?L M>E&9,VO>"MD4:)IA- 3!:H." ;*;L_M4^W\]H;O&26-Q\*YHR]\CAG>$L\AJ MAT?E/LVM 47981#M^.R!?-9\>CYK;#V?;:$5<;]@QN;KYYUVC6VB@X1:A+5RVBB/0]XD$MI"H;^%KN-U M/'/#Z@V.YRD^U+0 MT=-34 =LMS:$$#/G0ARG0!RO#.QUY\RL1W5LP-C_^S6>NJ$X-8^8P7A ?]/F\>HCR''J M"2Q$)LY_R(!EF>7Z"8M:"Y]9UW8]QF*!PUK[J(P/_J!NGR?HYWEF_^BGI<@Y MRN/9*+*!6 >UUL.A#EZ((K=0,VVAO_#1KNS?950>S7%8R,EE9FTB],*:,U]V M7L16$,H2)V)-0FF]>7?4V.5'=B[%/)?BWN74._R$9SF:UR/8UBO!7MM^;8-' MU:@=MA]<3O#"^ F/X&_M>';'L\]BC#R49SL4!3D\?*SBS\WBV0TQ;.Z#Q8(7 MM!P# RNX[M-*?^U/LJ0_ @M6%^>EUWX*U&%^OO'[ EOW/DZ2^,[WNI%G?HEU MW;YG]=R7VNV/3YB8">Z@.Y7?'3QH=L?FP#HT!-9A0;WC QOD7Q1JH-$AJ 'G MLC^->WZ"< #-&F$(G,5C6,K,H192GT87Q_2'196?=\%TY%PFO>"S[]6=;PCW MLNP[-?5Y9^(&7N[5_[&.!#T]R8G0HUQ<[RJ)P;/RTH])/):UZ*6L)DR/#+V? M EETYD$QPO6$!.D1@:$/K!<-?0W+0,(-\1L2O^\'MW[-@0^ZSK\S-X$S#F=. MSTV#M.8DM$)@/GP*D(-+DXP<_]_85P%?GWLLL/@>YKH*)Y,;6-;,'4Q^=)(< MS&8=R#%4<^ MZ #X?HJ#;O H8N?>QI@(?#6!0=PJ)8V-M1YI8PW86+V<+EBR-2R& M2QR"BRKOKH;P&G=^&.)_U]YESIYOWV>7JQ#XH3F!YIMWA_7C.4?02\ "B?N@ MPWJE4Z@YP^8[&/[FR)B+!(S @.MU0T7#26D4T,*EH7M#0#4@J)WGA.\Y@KV/WNP]B M(D;<$Q#[CH#+XG?5>2H)XP6# 9P:!HY[_O3.]_D&UCJMQF&S^KBJQZU]=/O^ M.J/6K--JKW):@KYJ*,1;0")$9"/W%KT>-0F2(9B<^FT\W$6V4(+WAT6FV MOH.7PE>Q/B?!P)\'/X#"CE!CY>_)$6U(S[@;!?"GNS@+/7X[K"H+IZ0U5R)M MU\P(,V\@>8]O?A1BK[X]D!)![ 5]68E:V=I7V5GA*NO.5\0FHFC8_*, ZB9$ MH-XLQPD6L;N)[X!A.<%_3M<6IR-R@7K%2_KL_@C&V;A*8F*I;?VD MM/T?:FB;,L.1ZX$W@>2R"6[)!>:FA^('U]W)Z>$3[ 1K/>OEU.2\G1"BG],' M?\T-J/^3^2RM@VTZA<^P;'4&(%R7&X*L/3W?R^"E\"?\0HCP54GZ=V?@@Y9% M8>#Y0#\21"6V>9!TZRR1;OY]A=O)FW>M"I+("S> M#=J\[:/ZO)B?XO!M=H6:#*T$&L$-$N?6#3-?$?TBE\>=,N0::F;Y^#2!%#>4I4$ZS"\X&[QK!CS\E2W .0@-\'8TK8$R[D._"LYTY=)XV! MS=&>XZ^3Q 6N#CQR!3^!\ Z=%BBW239-4:P'*:S [04ACJ*$'WH^OD"/9Y<7 MDC$(!DH?X65-0F3L3T?Q*GM!9=KOQXE'F?'NS9G3/CZL,>(B2@;\S4D+K&VE M55CC!,!- <@,-XK0@:I8 2OQ_!G1@4MT;%V+O5GIEU1+&+76:UC#N5K:8A<% M!/^[1K->X7[QAI7.A(O(IG G?ZG#!WF<3F3SBG8'4C8 M[+R2#TH7)W3JZ:FEVN@BTAR[GI_3TG AV<0CRIYS\73L52YPO1"5K RH_>Q0 MQJW"\>R@C'=0QCLHXQV4\;/$O.^'<,QY@;E_;79 R96%[898A82.2YJ4$6M' MB)5+-@JJ-9K!'4Q'HBV--61K5XW->T#8O,Z$O.\E"+TX\%L^4AQ[7&/XWE4! M>S<0CQ?5S>GANGB\[9-Z\[#]*""ZC7KG<"GR[4J+:N*0\.--7-3IXPX.7Z4 M_1F_OQVXIV7,WO_32WYYEPOYK00GNSM..DZ:5)O'0*8#52)2G6D>;/9GJ!Q7 M6GN@M;:KM;912P=69+OGANA1WXOZG@*X\E77/ZVW^==3X=0X789]T>\G8$Y> MJ]C7698D0+/=R/L21WW^8=W"IU-LMNFGG9_#3 M*@9\]>-AA/G2Q_;$=EV?JTOB1X#+/.WL %=?,P4]/=3V*1:4G=1.VD<;0D(_ MA:F\8N#,C[R'1LT>WE/XD_GPZVW^-0F;94"?3^'#8Q%HY[1V^G# YVU 3=IQ MW([C7CI.??)H<>HGY[B?P38=7[QBOEB2^GQ4OC@^/$2^Z#0?@B:]BYS?>P3-BM-G=J'/A_M&2V9-+1X[ M4N8;+,]I/7A S2Y,OI&T$TYLB3'^,C.,H*1UDY/RZCZ:X]> M>OFTXH[+=ERVB:':X\.CAX=J=P7XCSP/8!40V>/WGG$.]W0--6.DW>,V5GS[+RAN8?:Z7<\]FY09=N )?J!I4 MJ(88QH(5&,XTCB1>'_8I)0BX(7A'@G!DZ *?ZO+>+*!6!D9"&$ED2D(2E/B6 MDXY\?UIW0,P<]-UT5)J5A4B&Q;>6/U/Q@A2AT#5Z>#\>3Q)_!)]&&,(P3M," M8.F#9G0=LW]GL7C,; &48':WDM(?,D4=>>)BCPN_\TCRSOL(4C&@[+ MV7"$E./M+9ZH\4AW=)E-0<12LF+M2VHO,%X?:7D80[L'^2"8??NDUCDZK)V< ME OR5Z:G@%Y/%Q&;@RH,))BKG,L:Y-0_G(<57G-R9.T'AQ0=X M+6_\&"G)[5V8W6.1-!$G2G+)F)#^#_\I!^DQ)36 MPVZM0[I%P&8X%/CT]CHJ-:JX$-U'DOW?P7[SR-CX_P9V%-\;Y9J'*\AC)[H:$X1!+H& M)BC\7YFEJHR)N4[UR6TI]J"*W^+_"G"''=^U>63LDASF/::Q_:G4S ?A0O&ZU6()24 M-$>5Q_T>\?7]-'6Z?;"34VO4C2)XHO.-)(E[Z;,79[XF^-RGM?;A4:W1J)), M+TGGFLRKQDW8I)^C23W#!=Q.D)L'A)WOH]%!XUAHI@N*T'3EQQOA.B=0]#F> M9L SAF8YO@!&]S2<:>LI_PDUAH*+O]VI6B];62)$ZN-(&IS\$" # MNTE@EJZ^Z-$4 ADW8?,//H &0I&FP*E0O"*M8J:C(+$?/EOQT3(;09[B]D>! M?\OA,91-<@\>#MF()SQC),)[&&9P(S&\!6@&E%LG_#>NN'0]2/_ M?_-7IT9G%0ZIL#TWM['"3I9M9!O\_[F3-IM84LNGO[:\:[^XO&LLEG=,7(IP MUA0L>54E!+3V&766G)%2DI:.Y*B2"G"+NWB9T"&!ZOU"XUTN!P]Q)IM-K'8Z M.3FMM2J2F=5<^?>T9*&LJO6=O=3WG]K*FAOBJB9ZM'^$M=W' MQ[5FQ>3WY[BFDOVU^)Z>3+^_I)=#$N;SG48ZL[-'$WY',3R9"KTQ2F=PB>#+,%N$YRGYP;A$QKN+[[= M.1&9HG]5X-\_P+2 GYWW08S3"OO MO*K_8JX#85(7M!<6EMFS!NQ^WSNRM&; M=YU.=?9O,[EF=?<\YUS)+$834*P[77OD]**QPG-NK[$L6?1T$O]8YVW+\EY. M1C.$'!A%C-8+%?$120+.#=J;=R%0=&+<&;.U&INY&INY&INY&ICY' MU>+]9J5R2>=69CG )[KL3V..@V(1;NA/J2[*(9%PEP138&Q@\8&?2,G& MVD;KLDJ5&["A+@=DNE8%UBZBKPGLF-^VMMUZBC!&M>,Y#L>*H8HIUAMF/2 X MR R@?37ER9 MKUH=Y'1R.!KK6NLM!+DZJL\#]A6#O7:/UH@"U9>W85UPSO.X]OL^V'C>Y?I4 M;^T+,UN=D_J\.5^RL>U/VE[8*8=2KLB6;:1Z*6^.13Y$ZJG=_(+1H9L_WCN? M?*3?[\ZG3V?.7A3?.=_A?ZA/0_WE"MX2H>,%']EW]N37&!R*G=0'!VX5F5*3 M,F8=#0"')4UE69HSX1'9!)^[)NUUJFF/P&>L (\IX^ZJ=?R&RT#:3*]D$6O3 M7@MI[["B7:? 5"QV@!IP@_A?O#!PVX8C5#_H\38/WX+HQ4,$ZOON3^EWC;>2 MS[!%<3Q,W+&S1Q407S^K7^S76%1)AXRZ0%@.1R04$5!LYB+:3%]R;AZ,BFC MG,'3RD>5MB@>V5B60WU*XZ#5?O/NJ-8Y;-4.V^6@S6:2PYS(D>*< @>PZ<)/ M]+T#]Q:TS-"?;\N\).G8*!#X\Q2X.) MD+Q6*S>,K&UV+"V=N+?940'\:6F8DS?OHGA:ODQMT\T4P?-)5YS25GAM:P;I MKA(%OKCKMM5G\2@-MRUL15JMX7:B+^'E>F[SFU^C[;9]^")MMU67-;?S=J%H M:#<>O>FV:G%5Q8J+U]5$D;56IVV1D'*% (6.V\=#>3@^O!_*@\%SN!P@6_L@ MU]FHI)IB"BS2V;W'O+H*/Y:Q']JM,O9#N_5:L!]:*HN"-WI 1^'8I[7!L#ED MJ>;CWP*9I*R?OK419Q*ZTJ%W 18>;/,BZL?)!%.E\$,7;M\3.K[V"<0$^PH; MI_@Q>"3"EUS!$]B JO@#&%%W6 TS 76.WEI/-+XJYQ KS:RU&P$SA,YGWU=- MLW8F"XLZ/KLSUE$-08BI\X]?JU< GB+LL2]V5=4F*[[$-E?5TP)8LP>66I"R M@0\;4AO09XIF,F:2='KA?>PFF"UP/@3@MT[CI&CARQ:^:2L(S4']H8IU%&-D MMOH"^;]ZG?.)XZ78LB;+LYS7IT+QXJ]R2>Q&##X[/Q ')4B3X; M4RR%&Y$)R&430[Z*+H20"=@68VDT08VD7<3(+$A>;+O9R6%T<5[4ZY$5R_NH>9= MNTVP!$N,.^-+5'+V EMWW;-K+JU0?.C9R8G=ND&(U2<$&WT:O=!10CIC# 2*9T- >NYZ?6P^^Y(N;>NZ__UY^/FRL[].#U4HL2D(4@S:>CU.$C7.K8T=,I7*47FS^" M/L@B>L.Z\!1S&(3"2??FC@N]S$M>'S%%>A%Q 3 %HM9F$<2IQLFW[?L63@B9 M: 7U.IL-R$"^)/9U&ATDIL9)3NQBE5H.D>GJ;(K7QF$8W^'W\H@:6I+ALGYU]H+]]37 ,JB>Q]( ]]>9"&&\ M+@)9C87%),Q2_M=>$.SSO_!C/J-I8H6U"_>2*$%>8]&/AID,#H&/S(-US)LM M$6W7JA:?$M(!?,(OP"EX+MFSO@M2&#<;>6[BS$ OH&1D@PX_C*J$'[C7O<>] M+BWCVB"K"*OP:\TU;]C9>[_@6/@ZGO%80'*CO> ._ M^D'3[!T#?J4]_TU):D-5.7BNZJPR_B,#HB*P#*3AO3.A>7("L.P+Z]O)%C&> MG_(&$X3$>(W1:A;DHF@W/E8-]ABJE_627GE8NG(F5BFU&] I0=^O)O(OB+24 M@A5%])Q^C>& [;]C:.U+//VG#Z_MQ\,(69W.5HYVW619YY#0 9>5'E$B,$KT M*_/A'U6XJ" %0'AFLHV\!5A_LW.T<,RVQO00:+'J9AH&,V0 9]W#(N%AZ0% M^%FR_P\X33A'X+%68,-W_ MM3#XI[)5?=>ZGF]=[^Q:US=B+;O6]5WK^NMJ75]6='7/]G6J2IO[5]+L]]#E M-J%4:7?1K4K>TS X.-O0G:3^K^H?;[T@G83N[-<@HO.@+[W-+P#%8F$6'+V. M_RP2\ZA=/^6.-!EB*R\6>5J'\_VE_/OV<;W3/JG\TV&]4?G[>8^B1J+.6H^: M__OCP^J7W&M1Q\L>53$64UT+Z'W_93ZU9"#Q]LT=GCM6^'2530F?OC*.>D;NG#O7?IO8%I$Q2J[L>67Z?&T3H=?>_^L9^]QL MMA9'<"5:9Z=Y; ?@G.-.51'7XSD1US5'.Z][.4\YB;T@'%::Q+YCKI^8N99 M2=V?N4[>O#NNGVXO;VVA92 YT&VR#&[\$,MG:L[0C_S$#7GZMJF."V[]N59< M<[VCJ!1;V\Z^[.CFR:S24@,OC/MH!O29Q M=OQ4XJSQYEVS\7!Y]NBWM]DNY(Y_=_R[%O_.@0][./\V";SXD2,\&\6_&V+- M_$)9Z,48-5M4N;RL'D[JW]>A\O8R&-=5J7QE6**CUGI\V%XV@_;Q5]A>%3CI MV:H*J39Y_N]+%_UP\CLTTDR3N M46F(R\W\ 8_-@2\^)CA4ZW[@4 B+,_:_NC\,2E2Y/O:H\SHPGMI2;L2;=F#7 M?OID/1K/6>!K1O8)([D,'Y,BEU$'/.]XBCM>NPQ_2>>/)B$1(>_]R!\$*P*6 M6.K^" 'NCN96T%-P<:UU+PFO/=:ZCW'=%1 K:MT*P&>>,'*65# SU(&^S]3< M\H(G;V3?387L?CHR0PZ+X< ;, \>?A5/2-S*(NX0#$F#1!,_8[CV&-X+L8-3OQ;/\I\!L_Y%ZPI]0*>*@X/1+4U M+6!K(.(VZEK#O&TEAE]L\IQ4FCRTC1X_C4Y&;7\KP %6UBY!:H__ M_';C#'P$* ]K0I)X@WFVR*D=U=Z!'\YXDD,8C$%[,^61,$-RR#R&@XKADK2( M*TXEE5?3-Q)_FB7J"?!91 91C#9BHC-5P"CZ\3F^*CY%HYO(]_&? M%<_(;SO/4J4'GI@'EF%LX,@R8@WD.7@^IM% 9##W.2DB\1$6.],1 MBAI9&LK0;!J$V&U50\,7C6+=)*@7A\ ^W0BZX._Q'4A.I"*0M5$E758)0]7R0VM/?;-0 M+R8'8>0RZB +>P5]TW-#^G8Z\H$2W'N <1TYO@SN M]YMUIR#%17RG6JQ?^63H.]N?Q< M9GQX#Y[U1+T_WQ>N* P)2Y%" ;_*B^%+2 HN>'_]8,+2%/'J"&XA=/HC[-[4 M%"G0-,4>]=P;',1O$WSU'\#-=WYXJ^ZSPO$L-KRMZ'8>W<_M9+Q4(D.X+#VD MN ^'M\@1/3Y\'8YH1QQ1ZQB(D7('L?6VPS4A$$N,!R@X&3)+B%8CEF7GKNG/'C3?O6A6E$T_FAC["DG$:WH*Q+@_W0+>(%*LY[I,_ M!"DJ0TK@K+>?N3XN1CH-&&(@F<[P[P@*'6C)RON[\.0I"]ASC;(H:68%GIHB7 M.IT2TB/:B$HAUN#7DH!N&=Z90P H$R8U1E^4<3 MVBQ;4D9MNA[H0/@0.\C*LK+!/"W+: ![ \&+IZ --@X$T$XLJ85.@YN.G %8 M>(^H2T_OITO?RQ7 MGH!^R +=6@%C/_QJX'Q/Q+-VNW_.PO$$MHB7J_>51?= MD:W;TMRKFX/KYJ$=';AH&"= A^!+]E/GT_05!%$N(N>_L\BO<&#=/F$^>^@M MJAAC]2 1&?$"'(HGBI]5!U:C:']P"T(L!*?+#\']!J>N#^O 5#1Z?$.?/#T< M.^!T6:ZB?!!<73(-S+BG.<,X"S,XUT57G8>&W]$D*G;.%0(2 M^UP\Z@6=/<3W[84,"+,V#/0Q0UDZ/C%8&@M;]?A(-6EV("5; 6-:!' MCP/ ;G!E7/%Q:^JW/[C/7J*Z*J8 F67)JLR3ZRANZ\R=;A.,.42(8M>0I_H56?!E#DR[J-/<)]8^ MQV-@NN;1HKP9T E96=E$B-WMCP+_ENU%*S5CM20BF0VS$'%Y9R1 ";HZ(:,. M'@M7$H,8QNP'VL N)NE![F+ /IZY(=C*^LBY6H%>[3I@YF'D=1CZ!UXP#*:8 MO!'H8EP(1FIY-J"U*K"D<:0\O(8FJ%A!53/LA5>H"PJ$C_6\R/F*;T/TVEL1,XU4Q*^],99;N/+T?^4 %%'.X"HC5C+ M#B!J!Q#UN@"BJMSY>X)"<8RC(O+17")7GE1V@IDPSL(A!:#,=))JM;9?2!H% M#-:M+$?\76XT.@]#*HP.*SHL[-F7-RV"&3 MK'OS#=/TQP>'#66BX7 \^JX[I5J?*2;JJ 3 @5# *I&,7 3YS G[%P:T+#4@(X*LS"ES[(!J7;[V-R MT"X/LQQ#+-N)Y+G6*10HRXR\T''8BZOK_W3'D[J8&AX$ES<40 M\.LLI;H0LJYP98E'A$BF&9[Y,;C=3@YAY(-MSDOV2&Z--XG?)5NM&I9D<1'Q MG*2WJRU8VZ.>>T!6SG4M+ZRU!,]8'40W\JQC,*X9G+K&?/[*(] KHK]_)CCR M,+H<#-;VRK#O?Z%3!@=E*$%N!SPI-.@&-GD@U*+HINQ[*R*5K84# M[%XV4GGZYEUG^="G5>*4#AGZVX4D_*JBEO! MS<8)'7!9>)(LUJ=4%?Y4C,&3#E\R_-F\?_CS!,?SG-0KT//SV@-K&WO@5*@2 M(2))XM@Q82Z7S%32_88C5IMN7CV49C-/S1@]/<+K-LC%(-3/O M6,_<-.3#"9D3-? !B7WBSI1%7'T3CQ&';2W#['GFD\3:D=;2B5+WB,72D5KA MV(KX:^0]SI$NPU%YYB-MO7EWU%HZ8&;5(]719>F@*Y\C?$A&(Z(M9D6:U2-@ M;QD7([_ND'(UUUHAY9HI0N=W!**/E=,@'@P5D_3,M^X=B7[(W(LBV5+ KES/ M<=+^2<94%%*&N;D.#S6D-PS;&U&Z6^MB>Q\WZ\WCH\>!T:XWVH_T)%S48L#Q MGP%0YT:+M OP(K@/NB3%T%!F6W<5Q.#'A/[X"< [7BO\1MY=/6C?U_A9XK!6 MV3F=-^].Z\W'PM=Y*,+&*P)*7RXM.'>7]_96$!HK0NN]=@2]Q^*9N0Y#F5>. MR&&=YV;-X94G9HE7H5GY *7Y#&'K"G;BHOQA=86/2E\[ M5OYZBS95S=^7D=/-AEDZ==IDFC>6-WUPR%*WDW.W?SS-F'6ZX=#U(_]_:QSH M72N+>E&=;R]D58M15EL0J:4\3;IU&;*>HA!+$>9]U92=U#G[ P438.+S-8PPTV&7&DB*J5F> MG>O8OU+/-RG;](ERMDR:^6QM9>J!:T+&7%^Z@9!4*V9F*_;[4,H_6@9W\4*$ M?[K BIVSD_9&[N3T,95MF'$#;2DP M<8,UR]";K268_5 M/<#WO .)>%*O=^J$01^#1M7AB1@41;3A%FVX+RTHN016&+$EA(_8Q3 +I5 MQ45P&6E66:U99WXOT^G"7J8*_W1A>]/IR>+ZAKGK:"^&E%I[':>HONN-,D9K M!>P4 Y7?R20?)EF\D5NP>(>JE-R<>&G,0XY*,^ZY M>6A.E YL)7.^4!D"I(G&VM?$Q15^<&=7-&&B?( GAX=OWK4K>GS[YBEHIGH< M$IK)J I@%9 S$>TX8$BZ^?B,H&#BZ288A_;W>OKF;6Y^YAJ>NX"[W^ON( M"(F?K3O?[-NGM''/M]]GEHI=UW0#L'Z,9O &*>XM8P[0=97EP'.H<":.PID5 M09[>Q;K/ED"D_9"'""@).XV'O#^2HHE6KEEJQKJ)WD5_%5RJJ6\V\]D" JXJ M\5G[>F101F75!9\V!\6K#AL1"Y2?P2AN)/-DK:]!RO",G5JI!@L)LX>,E2_5 M,K@T=K ,KF $6H&HBCX-IZ3(LOJS\L**(MVJ8!PB6*N1A4HI8!X'[FL8D+A MJ\J6'T%D_E:L;,.!*Y*"(NH7,(I7Y.R3(C55C%O<3MXMD)P!8V&'@K!6")C&4'#Q'"JJ,6GP MD A3_R"D*&:9G9#)0SKZT&>9FSC8\QB;%(55$8F/[<&KXDA%:.6/:FKFW%I) M?P!K(B6'H5[PI% P@Y[-O5JXL_PU%C.@>/ ;N!5]$!:&D2K:9"UE*9V<1##C M6#QE!<.CK+2\_P-H-T6=RGBCZH'N&+,,?\EH4)P?IRF7!\#+)+::!DLXER5S>L1BM'L?(\5UJY!@H(QR: MMU;0_+XBX]W_Z26_K!JSG!OF6O*4GS*B?S(_HK_Z$ ;$PWAX&D =_"X/\&)Y M@ T*("^._7\]_^PT97J:\[G[I?L;1<4E3GKC?+BX.?MVA*-5''F)X\"F."7/N1MN*VV#RK0DB]W4$FNQ_,C>!FP!G MXMK'B@:T6. 4QDQ'C<.#_R$W F<<.C+B\2"4T[$L:3(^@NB6!NI882$G"=+O M;+[K>3VH?NO.FX]SGU9[PQ/3436#.84*ETQ*8]I?<=N"'4?_!/\9L@EQC6[I MV$363SLU'8AO'G>7!N%AO6.>:K6'GWN3_^";?=J.?F#CO.*!YS]XTI[UY';% MD^V/O=FO4="C>*JNC'^'VP)3D3HS,*N?RIA4/G)74@9D5LX[\C]CG,^);GL0 M<5X!%@0$/(,#?X,V#OXW'>'\3OQ77_WC3OV#9RKA_;R9A$"+^ ]CVM*//3_$ M6@KZ-YJ48_4'\%O_I;\,!ED@_\9.EJ^-5&S4^ MG"T@_/N[@B]DW=AMSD_]OT]<&[BFN)LO;XC%M+\69T (.#HW4D/$)-* 5$CD M/9 XJF*^[U%\%PG#\;^)!6MY_K-FI"'_QHF.>>(XC[Z+O83X;JS80<')09": MBD%3CH,=;EVM9+*9P&B20E(E/$SA%*4.!D#_>I@9B'J=/*EZ22W_!G1M^.'@ MH?A.#3U2W"G^45QTW1CU MZXK;_>[VJ5(.7$\ @G MT\O" ,[#^1# QQ+^&'&<>B8PRP#-#NN17I(-S0 :4M6 W MTDO&V8.\153L6,JJ]RT MNE8,:DU&LQ2$)EI0#DC.@&T1:HDZX%F;$W<6)Y88U&\9^6XX'?6YPWX\QH#_ M;$13?#3@,+TB,I!/Z./YGAJMZNQ=75_NPQ+C4(VYPKBX MK^*R@P"3/!B@!F$Y/6#"I@YDU20^I?FH.NV+ FSN-G=TNEET:F@4!\"#!+J" MFW*N1BY\ D.(G%W-+)9-#)/EJ&TT(:-Z\']HJ1)_&#%*5(Q"XSYMG=@3\EW>0/!J K M^EP^!L10*0)J3@]<[A3K-()>S?EZ=7&5ESMB9(.G#"XFZK5T1PN;10L@)_K] M+ %7B:UBO#L= U1!4GRM^K<.^(G)G&?U>U"$6$+P;Q>M):H-HQ1OZU^J[KC2C@Z$MA0ZXD M/]F1[N:1KC*T*^+F=J4)VC6F2I^FMW*CGA_Y@X JBCAR@?7/: ^G?A0 #82Q M*Y!)INB9\D.@*\X>$U/N$QZP6??L]T$"AL:%:WU M,EEC@8$D8ZO^UH?G32U8"1D3F^HJ!+XBNFL#7GJ:+B(P8L68',>IEN:[>M MR(B\&MQ$A9K0B34=7,R5%N](<;-(T8HCB_MAC^=6D0;X*VABJA050M ]8I*5 MX$I:+.].8A=ED%+8DW@B,YIW5[]95V^B7Y8QB Q.YJ#IZ$ NEN8%(Y%0AX$7 M0L)"Q5G),(V&L=)>DA"V4 ]!I_JII5YK]/V<+4K=0S=7YU_HX[L [,82#25S MP0H"-4191$RUB@B)D\G(E02.77Y+9C>5;I9$D MI*[SFZ[NY8Q 7(7.$-P&?'3B3F:*CG9V\):0!I8.(=\7%0AE1)9',I27-S>4 MH3Y@@B0Y:]R/DA@;+L%/]$F>I1F&V=B<4;J.$^_TY%)Z1]8)#T RQ*@$QTTB M'_>(Q9$#>GB9K.?;U6+88P_$5'5/Y"QS,;.U_:7M+BOTPAC8SN?NF1-F7'?B M$U"-5?F!_D(TW/'*AO$*AU",YBT855:?3.C.?&KDPS9B[(C)L-?24]:;^:AJ MZD!$=D8R(HV=D[T4MD"/CCO$IW$?\YE8:FK27RN7YI/0#OZ M>%KZ((3R8.R0:9Z0?"/QPUT[4O.:^%C%"0?.&G;(,Y?1)@JUU'RZ9WM.QTY0L%M4B/D6;D M( 7]DN(/%498,6^>34E[SJF+I$5*BIK4D\9*P-5$G1VUB'U07!S MUK]L(PYT18=&&U1E<1&7"='OLA0$R,Z*VTS*I&R.'9;'N1^,@Z1B'1.?3IJS M3KH6R/9%_HU06-P44PC1SZ%%I WC-%.AI3(C(X3^J=E>3<[*9(]&E=W:I4B4 M(#-Y+K(<[E(;&YT24VR82"H+OJ)10.+JZ(S(EW:K04D)&AP]VE;]:EYW6"YT[( M7,'['\$WN06)$D0,,NAQ8P=!K$2W0<*P,[M+W>1+)=:K.=D$1+#G2TV>"J ; MY',GG:53?YQR61Z:J%DXE6+%;.(QK@Y5+?X(& ['^BXY9SJWAX6&&(="VL"? M(]B\^?".6C:+6G(]-"B^LXCB)':Q')7M!<,HP&)EQ%S,4K@BL!5WE[FIEVGU M%EA]<0G#/UC]SD&$M6L(R!ST,3N89!,V[CWN+^Z[4ZP4C"-HJ!$<*9X91 ,.'N*,,0HCP?>PE9*LB6PR"0.! MJ3!];W BMX06G\2W@9Y)8"A7ZJ)W4F?#B*W@1W++8\@5![Y$C%FX^ SA@E$F M'V\\P2>S=DEXBA0V!85Q*E%V\E+(3[4YS0(&'%5GT1XN9CS8S=?$?%]6,,:.W(;=/(+=]$HRY2)L*Q0!LCVBB! M%F4I]A!9.8HY3=;5.9=B+Q%/&?-+.0_J#Z<">UB:^W]!UO9=I_L>M*CY>9_[ MHW+0+_E$C+T%;@7B'H]=)]"++VI^Q4KLFPA;57'<;4$>P1-\( M;AV?6*RIL&SH;!H0Z)OJBJ2&5 B30-%8!+NCWR<&B"8EKGN92"7 :R+/[^[ M\\VZ<"ZJ 1X']F78"%D^W M!]8%Q?W+V!P"-$:HFTI#E1+#ND6+I]J\Q>?LR&"CR,"4/?/$&!H?*5UAB#1. MK=U9$!)R(4VY]YB?L>RS$I".?%"WSZ2@81[41!E3 9:K7LZFHS@Q<^TL-"LU M;:<4;8-OX/0Q7.3VSX7Z$YF$3S[Q78I-8PX$>_I"MX]I;6(DOFB*^ ;L=&*6&,8R4 ;L+3)W-78_3C(Y\%_:I!ZD7]^7.YCO0#PZBK&'X71-@L M#8C>/FI[Y4S9*_29:V/A7&H+1[V-':=5"-P>D(7N[JX.9% ?QK>_!#_^?R_N_] M6?]LMDEXG_R"LYYMD/I&(=ES5-"T M'&!:COXLDD$A%-I"EO$#5Y@.8E1"U0LYLLUZRK0GXV_9=:&]A,%W4*0C\'.D M>SDO.,GY$=%IR4ML<\7QA",-676/X20_8T-KZW#7T+H9:WGQ$6V;8FY_M8>7 MJ/DJ-*B"AC Q4(%+^AI$T;_ ]2630&=2?.F"XD#16GN%$ MKKQ".K .?;713N(1JQ+0U,:HTB^3[YL5+9D M5\WC\'N4P*'QB!T2 !;GL%' M,.0"_[H!?XA$*$C.QHF6L1IE'(FW"(>%2\:8IP;%Z061J@R7 M^$.X(H:>!O-0T;)/#\S+&+&W51M\,O7S[S!(!JH6 M%E,@CQ.W3I GQC:Q%EY=X M-XH=+^:IF0@!?_:15O>9AL3#VAI2^?OWU/G\^Z<_5UUA_LST>M6%Y!=+:P@\ M&=:CX!#(STTG&&%#+Q9KEZUWT'-!DF$)E7UO]64OV].E533KDE(?:8ED]DE@ ML;"C E-P<,"R'"5Q%/3-L4M(#[B" WI!@D6KP#1HB//SN-B+2E#A8ST7"\FO_M3-PW2*LD.PN+[,(G!V#R0FQC0_WO[7/?""?SX M);4.W60$A@6V#07AP=CW.,FCK *[WF4C#_'L^B;]_ M'UQ\^D T==7]GVY(>0:;(FPD M5[ 0+PZ\!+1GQ+T!&%'$AG+?3RCKH'Z92U;6G.LOW0/PJ)Q_Q0+[1$FI602/ M!5L-5]W/_.W/,6+0P\XE]4"6W8&*',-RX3'9U^A9NZ.9<9B"*1<]%C/_F$!I*$(RO@!6@4M:U_]DKIKK]RD8^)2-;#3> M@BUBVP+.WO]YQCZ 0)O1_UK4C_X2"J81V1; M8X]"_-B[!#%TP8GT?0^MG=S44B%MHAM"767Y:P(CS"I$*Y0>I.Z _L@'AXZI M?NS[4Y/.QT=243(XV_^=150%,.19@[KP)XA2;JRC!LX,I#R-+Z=E:8.9TF@8 ME*928VK+Q&1?RA$D+BZJ)FB[OED4DB>PVV1I3[$8T7 #;VU'K<])K?\-%A2* M)B#6-A&K$=ZJ_'?L2V-*$@R1"BIN$(5TYS W(<2B!A)-=>?V=*'Y6LQG%E8S@"M$FS<_WA#NQ MHVEY/;XH[%)WOFJZ:O:<]\'UV<@05N&9>3KC@ B&(RB->N?NM/,S>U(89_9N M952DE4K#H@9&\C%0F71_"4-*JRDY+G [:/-1\:IS\[PJ94HPT$']NG,QL"!< M:@59H]^1R\B, P\3XYV:U&>HLC3\)*]5Y9U \' **;!%J1)/\(RC'=4]*]5Q M/1]CL@84)80[%@$B-MLRR3$*/$3CP*^GA.)",X!O76?O]YM]JR 8M8YUTV"" M(AXV-:^KT$$Y9&#&QI4)X\5"RM4V&89S'W% RGWVTT51/V\7C65TTF@N)M67 M#-K#VDHTW%!&V6?7TA&:U.9A$EX:2!EG4OAU;TT'45MK%HL,0- M'+>2Z%7W=^++G?1 M22Y&:[?5(SZGE-4-I:RN)66UJ^BV*[H;NXKNS5C+RU=T[Z3T<]C6V!$81(RR M2LD:0F-=FEYW^TG\3+GUEZQ_F)/7W\ +?O/N^DL7+<.#UUYL((@OW*ZK$!J3 MB/NLF$P)"=H>)XG&9)C&')Q A$?_U@TS-BP/&!M/30^W9HLX\03-]"QB&Y9B M%#)(HE91C<#=$[FY$S;R*+9Z<5>8YQ&7S2U7EFIF"[D\BS#I@<.2MND"YQ2X MPY7=3+%X=CC;AO+"5-8*]P\>C_%E:'35/8O0?Z;*\Q<5X-M=>2X15RPX=N]< M1L6B[@BJ;;3(A0OS6*.BJ,JUXJE$P;+2>P*.:1.0-Z@_"T'!H*P N<+$=ST?/)C$ M!XT>'?!T#@9NM)WEK0O-Y_H$KW)DBL;R)S26/S!Y;KUQ8KP3-2@+?5+M3HA1 M^G2-KWF;?R-Z8"MZ72MV;^U8W*,-Z'M=O$YV23>M^;7L?SYM&RNXMH+EI *S&$Q*-G^.5 >P$F3&$58'.":D3)1.6[EUJV7%/9>4\U6 M>DC-51:.8U+^H,[:)\VW]A!-"HDQC.\!.0_R_RG5'IP0J)$%#SZU9%9(-4E )WA48V#OPB7BV:/ H6"VT"3 M?VH,@M,3?U]-G+)&F-'(41Y=Z)GOR^6BWM3L_/?4AKU5AXCS;9T0(QII;J55 M9\JN=3!EJ(S\P=P&+GU.AJE1%$/?LGU0'J/V9L@$*5(GE9SDJ$?68.F+(+5( MF@I-^OZ!YP:([D8!B$_PI<2MZ:Y25PW?QBE:$K!!049CW#0H/#$"3JRIRP-8 M;*#909Y:1*&YOWP!9_-I(BA\PD]B1#,RA?EA\.\,9!D&=OH"$X<' CP<]-B: MP;JO9!"SIAN#0DO<2/CL#MB?ZUA\+Q]HRW4MRHT]I$)U0\R%K]+E,-(;IU,Q M_9DD*^,$>%$BF)1'X9:U00 ?O1"ZRU)E0SE7$OG:^Y^+#U?[='1%#51W+N69 MYJ7X> ZEP/$.2?#C5U/TT0G!B&C=_]$/@=!(0"O5)^N38"@)2'RU?CB2AL0* MT@(<\0!-AH4/MU9HOT"=W!"HATPF8,\IUSDWFM5/%)%CGD+OX)(H?>)(@KH8 M=NOIRQ 2"F6DLI[O1SEL4SX2:^Z(965@FQ@E'-(Y5/25IM' AU *,="P^4Z- MI]!HE2SQ[PB^!=S?!^%\$_=)K^]UO][LJ[@X?.#::K'4GSF_SGU&_1Y+(U0L MXW, >JL7B!Z*JK@CA0?=G'V^^""CMZH^83U:UNSL77RXZ<)7<%)J-"3;C)QU M 74369_S=#;%_B;[DBQ^:%EB M4HX<&:"AEFB[!&R*[(4"U35K^"PU8WPM6G@KI$5 M>@W=GA\R0^(;:A9(=:&2M>6<77[YX_SZJZD7-.OV?+AB3LN:CFHEKW,DCBVF MBM6%]25_X>S]]O[K/DG2706>78'7W%7@;<9:7KP"[X4HL#B.020-_%@E849) MG VYP=RGR(&E6RQ<)Y)><$+5C_!]I30(VL \@7*FB5H)2 S08G&T3GYR8P:' M=*W075<"1*]!*ZI06..$RKS2K#=&4 ./;(8*%;CWY4-W/^^JV0 =,:&68X2[ M*M:)8R$J(J NI73%.2&-M!?LR^P%P@'6'JVNP'!U]B/&>7L#_P#I$!X;!98U M%B<&L9S4[EX #U8I31<\4Q<_/\A"T6N$HREE%V!<8\90Z+/.#J( M[O;4)/5DE34'3G/$3CL"$>J_Z\?R,%GLVTIN SQOC%_9L;]QG/0".*49!4?S M(6AC*6DOK.H*Y_$A+V*)PKRZ@I6"\J.OY$SBGGXPS08@$$-/WX@ M5]I(8]%C&'%56GNB[>VT3?4$51GJF?Q A;:B834$". M8PJ*&:S+AY/ !^%UU]AX555$5H&7PAR4CJW\D +2,S-CI=)U:1Q: DW,<9 ?A&%#ERU\ A M(KE@ ^$<*BB$L2_8(OY#88W*W78EGD98=1'&PD46W%1-R]M;'AA$@.OH_.AH M(U *' 67EE$!_H',L!'A@]'L8(K%6@BE/'(39B^$'TFEZ>[Z$IX24VJHN#PS M=-'&2:GE7J\S(HQB51#E4D2C:JNIIY8;&VVGK'1.( TP[QRXPXBGGV/UC1K^ MI%=I@M1/M5YU9 +S+486L-06'\O+%1E!$%Y5"%YW;K34*PJ7ICK:F,@S?(G)JS[_MX\B^"*093;34@0]5G/./ M?'HV\8-Q+TMP%V:4.W[X8\+,]]X/AT$VYH/\XJ.#!BSFI35Y'.20' M:$>HH>P1?K^!\PB+_**R-EV)[8BA=P,H)RK7LBDQ&%XEGK< M@W#^S;K30FU5LZFE+QXZ(S/ XU)*BN "R91,LLF4'/S20G*49:W*5;4\'&.8 MC&8I-G#(_&49UP%B-Y6DG(']G>+,3U72$O?(&RKR5F"]U([=20Z"L[ LI8HZ M7VPR/&5PTB94W2%$S.(;-I!:B@*YG(:)>G]6D*.:.!\P91J$QVAF#VF#]!!]H&%,- MP_:[D]L]%0))/@MGLO@[7P%4>3D)PAU9VV^:H)^D\GPW9&(B<;8:3?YIZVFQ M,EAL"^$[-U6EU4Q1$VP[&8.5F\PL(-"I=4YBS.H92GD8'?&]E?LKWK>$E3BW M6]!&5?'"!7')FCC7+G;-W6K!6,C*6^F5/<\?4/:&N@0QU8)1$)H&CAZ\2NM3 M_@4(/_^@=)_8#/_F'#FJS[#@,=:M>NU1K%;F+5B3]4R%?Z =GWS>F2*J.6<% MB+.BP, :^F<@X]2>YM4N8$MDXJGA+JDOMIV5::],J]/ $G6J2#-&H;IB61J, M3RL;AD6QBW<;#P9H,.D<.4M'DQZ3VF,43XU3$D^HA7R.JD^7U,^@7ZCC'.W& M+T<=9^^H56_\;3\G0-%R3_BCLL'<&N M., N#FCMB@,V8RT_:W& 3LB#R#S\I7'H[!VB_(A(2E"^9&_RG^'T[6$=UM'< MKSLW%K">&'NIW8?F)SHLKRTS&XQO@D.HN1)?!\YRKI,E=B2*L3:E>M#,4\8,0JWXT0&EV!S8-H,R6#J8KRV* MHP-Y(T%RVBLS*F].#6"ERN-8?65T/K=&LM1P"W9N ],M/+K&LK.F,5I\1G_; MMI:=QA4? //N'@(JDC-PD/<&OFI0TMSJTO+RS.S?O %(\?Q$Q5O2C!Z1BAZE M+-<"BTT%H-TQN)'N3-E?N0/,&VB2/[K/6_5C&DT[^UQ5V$.1CRK&I)!',!88 M33HF*V#=."X%/0IT2'?2/*FW_Y9W T>QB;5K05-I0>TU3G\Y.MZGDV@TZZWR M@] VT0\K6SK53SW^I8,/7>G\CDK4P81DB 7SS_!-H1B*!_ 2$ X')*\D3]SA^A[$J+".09U']?;B1?:?W M<(HYZ_(ZG&"S'TZU4?.">*]8^Q-Y\1@>Y]4<+\Y 4QSTX!GPTR1T^WXO1H&/ MOZ])TLA7)9T NV"Y9%-+-;-H%2BE:7V4P=>,/M\PQ6@0) M_1KGFNE?/"4=XT I(J40MMX LY]2C$QYTQS&BIO/J\[&$[A=_ARSL9V0VV67 M'R>[O/4\=F7I-":0O2__=7JZSW+:\)C3^+6ABZQ,*#*OAJBQ$BA85G:2\3YRF'#KZD]@2Q[O39Y![$8]@M31I8VX/&!_'(FK3IZZ91*H%7'U M+L;DU9EP)Q^RN"2 J-"0 ?E$W>87@X0_!HI6+8>&V+#5-\D$4Q!/KMVJG^1U MO%'26,XSIH"S,C_+%,ND[?9BR4CYZ10(EIL.=6DGO@EH3NPHQ0Z"),6IKT:[ M?E(KE"NW6D7[HW*WH*.IL=74&J"$1E4[B>]\\;6P4HVM595R#V':S[ ,DQE?HX+FJ=UI6V^*ETJA-L:CU*]MEGL,D3G@GKW]8INNR*_:J;6HG#*_^LR5, S( M@!X D9-4&?HRWBQ0>6MRLO'!GL]34]@SAN_JN*5>OR[8SMO0MJ6P;MO"R^FY M==L::)-GPB)GFD6V8:N+AS\7J(ISB+KB$J^5X/E<)9'R3G=1Z.3EWFIA=#MU MHW,8*C.C!5WJ=$@('>T[=G1NF=0[.:P?L=0[:M5/E=0[;F#0KCN.B^&=U99< M*\!,+=R\2=2PS1F =+R+36UX*7VCMSZP;\):B);]#27[*^5]&_4RR?NC^O'? M]J4B76(89 O45:4]71'/$,&KK9!#5: MK?'@](Y1(\SQ_[CT1A(HQI,AF7_: !4U]ZFG;50?*[I0I$O*FQD^"S'YR2$F(J1S8\A*9'W..O.5_7S ?!\,J0_>,B!OEK.WM?S M[GFJXB2^*<3A?2\UI&"I8,BT5W*S\<[',74PC4&=._1J?K,W2R>C. I<9Z]- M+ZYRU418G)J_%F(H& ! ?V^O25J=_>&3O\'OO7;Y MQ\6'@\8IN=(=_OLI?K7N7 [R!7+F*#5\9_Y(BYDO!DQN?!KVQ6S0MAKB_!8']G[(0H[TKQ-B,M;SB0HPU%?;'+*&J]6M["LNG M8.#W9WW8]6+QV/U]J0PMA0CKR6+\,LG 0<'D?!N_^GA:7)]X_=Q3$TCZB]"U\ M.YP;0N1.JIK=?%, 3BX"<%%^S2XA+0Q_V,@Q4^6TW];S\]=2-RBCT=X_,UVL M%-)5#B0?=$NT:VI=)5.F.'3]'NG5VZ.MI(A;F1V4\I1"6K BB5?,^U5]))_6 MT]73=M&V,&1D>40^%>'*81K<$LZGDXMN6Y?E,E[%L5Q6K43HLLKJ?#68SAD' MJ4I.YU-0<%02[FOA@<9\BMZ'E(ME$0JF9@XQ%@%AH*75_Y&@7J>R2_8>M3S<5X ;J?T+O--$G'VFZV^-9):8A)A+CV89I(B M(R&GVM*(0K*-+.9:.$1 @=I>!1.2$-NV_O=FPM;6,Z2U%];GZ1A5RC@.06V& M8+>"+X?U9P9%*HA&H"(QF()UHU=7#6L4.<^(5-5'72RK^K]^Y/==E&"F\[QQ M5*=O*OSXZ*_9V-<58*J1D\#C.3UMQHQ1."7R>6X68\!^N;E*]SD[K3Y%4.?2 M:DNPF5S8(G*Z1YDB-TGBNSJ""=+(OP.WWLW$6\N0^-C*"!.,JJMH/_2J\4Z>QL(D;)K;#CN1(1AQW@R7'-7CIWFQI K3#MCF)L1//X M%*);6L(TU23*Y@BN?/M5=*Z21"/Z6"4E^/L_+SY]NOQ3 2^!/9JE5,'F@Q]8 M*R*@'.9!I.R9A!+U[-YE;W,3#2F&G;N>.G^9A==#RF6-3V(U M&2J/I";N2*VR>:&PP*IJV^*BKQ;\%8Q8LIK//G(D&!T4MCZM;@.N6,][![V< MFV*Y*/8"&SA?LY;[5;-#O[+\E((_TFG"2OSOZ7S+G\J.)#,SP1$)U)OK_X#' M)3V%-WR/O\_7/"-8>8M#VC&7W5%9"ZG8:"/3^H)!,HIGUT* ,U2"GCP$VG M?6@#KT2>(>A&[>BD*7$ 0I+(K87A.XRSE([Y*% M/;0WNIJO4T!GP!E+EB'E_T#<"\IQ(K :%^9,&!$D2]+,Y8@<"EG;X%*FF074 MP3@8,C/!>D.?.KEEBIT>+9A'IBQ(/,(FBV>7 M5Q^H,AI,F='8Q7$\"E>2D4KD(BW8& (U4\+\GS,Z4YSFXVN4"4 MQM,'AF@Z#UP.TPWC:2 /8M."(4OYTNU.#SR'B,8HRI^PEBL=2(A_&BN/';.B MUKE2<3S:C#$D/ADC2/-H*F3+-/3053M2@&NH.=0!!SG$(.8F@EH';V30NE+E^XD# R' MFR[:(O!]7I5]=S*(&_\X]#%W #8[VOE;;[P2, RHA?SP!P5O1DE>*RU"T 7V M9)OB 5;BWE0V4V'+[0SKJH!@P4P@OR&OU/>^G'U\?\X0QXGO9321.F/\,N^FIE280%LYUH:R' T*$]R''Q<&E.59?:20Q-3DH*& M@T0BDB:'7>-S)<=6834* M6+BOT(_X$.S+DD0>&W9Q,G0CX7 JH!V/@ZEI\5#$#9Y2'%+L.X4K@E5Q.#5A MM_T+GJ'!^[.)&\N#;+#O-%4-9U?7%Y_/=Y@>N5*2SJZ49#/6\HI+2192(*+' MCJT)0!K;L@R?=_Y99C<4(-I0 6U_@"H/8MH0$-//71PBW3A^FSI7+H55$U#& M9R0TI[XUQ8$BP)88O-(?OM Q)Y:X5^&*,V'I7!U":&=CEM?$@2F%G"P ^.T& M&!#@E*1]$O@:'T6JWFE.9Z.)DKAQG(N(V349$[UF!7NLRS%RY106GJN9[2'^ M?:!;[BR%)*8-QB4-35-#]NAO+A/#<_8RS,G_"FL M99#Q!.\2V!5\2C*O[8!NN24]7W;B!^3643@7374*XA9/DLS!*?OCW0EP=0@$?#<;+2 MH(F\!.# O)I1'D=V[!W/XCP:AJ3GXBR)N&91655F#F/U0,7]0GU3Q6#5/M&H5*%;;)/N\^ M"=+O/('76BJ&#Z(9;\O+]!1O@UY#00ZN;6DW33<&KYF6J%O_U6I^OW8.ZYT3 M64WS=%_-=6^=F ?P5A<\X*BIMG.T3S2C<$EK142/4EY,"$EEQFWH!MJ.;2,M M27=ASW%U,5NML.RZL!M/F$CX'/4'=]/\\QI M$7P=BNA],:S%'7#AC&K,#]@"G9:RY]<4D\1:\_,4;3E/Y@,46PYM4S/'DT+* MM:H$.TFN8I*=55$#F_IKSG&]_3?^'#:XYR5ON0\.USAW(;FX'H/.9<-1S1G! MIG#Z3TWQ(/BA"0-48S-=Y+N@0>%;PTRRR> X^DFN1G>*[12F;MHZM6)'VX#A MOLC;1=L=UK[7/;^YX.JL1SK!_#'5>+>(\T(]_^FOTI6)B_F.Y472P&@22J,9 M[/ [T@-&Z:6GL=&HG\ -8!>Q7$FS!7?TUCP-29QBVL8Z;]4[^)VC^J%\!^ZU M =^AD+OZ7A%%S4 ">N3>T ')(HZ)+!HM^@\]\*A^^K=7X'=7-CU],('OK1= M8&1TLR'.W=.8WQJ],L)V C\?M!=2$.I%A"?2Y'8N@$+S2$'_ ;3IP)I#E:%2 MH'J$12?-H0:]"TTS#4?'8H0?94VS4*94(>?MPEKA%P;,SIJJ6,P>TP@K O]2 M5?SS7'+!<(V8X^-L6C$L:*,K,IJ26"P.6=&-T.6Z?3LX]=K M4#(>3[Y2(SXCK^*+!"H:57[#+@G"_HNIPM[*EP49?!9\@T=AE;./EEZ(C380 M#2 2'S_?/BR'-^I.%^@2) H][<#4W5-*C?- :JM MI&1ER!35!,2I;V*J L=: ?H*_((U8$$Z5A:SK,/>T,T<+LZ->.C'(XPQ6U#*KG.DW%"_ M1, ,EH>#CY0=5AF!WK1N/N+^K8A(+0W54#=- 06.BWREPZ:REE7?MW'N#F34 MM6?5?AL#Z^SZ)OUR59?_6OV_"*B,0D"G8I3D"^,AJQ9)V>_UL2&J'V,$&!V_ MR$VQAV:2N#-[*A0-XC*Q6AX99\T3LIX2!Q[5,X @B,&VGZ"8!?.>AF4/_43, M;5TJ]3ZX/AM)*&.I(.9M C%3CA)'4K:#(09\##X+A?N>$8KCQT M+J*1JX9YQW>PM:UG@J]7%U?2/ M(J)^:E0M/HAZ&W3KFAY+EZ-4A>^DU4B?XJLF?D5%LMQ0#GO(".M%Q8DX,@FW M4<+WI^TZ0ZD<, BV3ASB**/]&3T?GU<*A>U8*?:UW7 MJCJ,]*B4*?5GU03'?2XZ5-;+P)6("@,QL=J/RZFX CS :B0PGK1L9T>Z@MB0 MF'K4'TP#*94E-/#O<$(DDIATU=@*0->@PXM_@868'>Q*BNR2HJ-=2=%FK.5G M+2G",OUBG!#+)Q%A-TE$4=7 _,I2"A2&63I2]8Y>\-=?0<2)?ZDD+4H)1%R5 MCN>0:QU#C#>P0*))FA)NY,Y [;%Q\R8/T.NOH&MRBE*+K1B1MC&F(I#;TG<] MD>9CA9>&DO+J]X.+3Q]H65?=W[??V+_()UIY1&8Y4UM*FK+]VS 1"#:8(B2/ M<#J:.;<@68'HJ;@4#>;")*! &E(.4!IE.-(8[Q![>K#:R=,JC=4AMFZ5ZCZHHOQ5;8!\[S>4M<@%^S88V#^/1,-/6G<_X M<(V@!\1&SK>MHNVP C9LN02<(5$+O)+I;*)2;5BBQEN1GH)%7/E5)NMBK340 M]CCV>&P([1&7&*NFN3C11>?4LG:CVO9DWYI8B$2 H_R03QV,CCB9Q#([%.?5 M'TP#E95E:#^QU MOYTQ\.+8_;%/3$J!/H,"@P5I/$X^OJ.0M*(QRD#I61#8X2YB@N NS;OHF?Y4 M V1**5(Z=I%6FFUG!$X"0=R:4!\C;U*7 4:S\2OMDP/\( X!FU!+@%6M0;GL MNY@!R.6.4\3#MZ=0F"B)Z7-0W)4['(F1U%ANX< )A"$QC1/P!)P"DM"9B::- MAM(6>8#]''G!J'M#N4A&#RH-J%9H5E$ M+(1/T#F19F.[<^[+<@,\[55PA$IY 7M2(@E<"0YP$([3K*5"O))>;I;UPT,92VIB&G0(")L.3$#Q!4R74HPR7CUH.M(1.!RMDSIKJ M&=>ZD76P5&>:M'^Q.='-AE(XK;[70]XMQ/YH+J2YR"G(_#X^QU-I;.Z& M0Q<\D_^MY8Z=KXNLS@A%,*P,?J%-&'7BM=)Q \EDV#V=J4V@VV/%;:FO$6\= M?X\; UU X]?3(FA>*[_B/T"I90&5/<+YWW+.=^2'WOR%S^8MNT0HZZ]3BH8+ MB^QB=!YTS7JKY% $_CT@0TB]$JU-+H6098NYIXF"H0/3FO5=:2E %[8FY184 M&L%WH=@7UPC8.]>R@T_6V0+.NK]*@THE*VV87.64O61,GL=554E*#4VLW';0 M\!ZU;LB81K\_BBC%*:X#4(T;DB2S@^86>8-QW[TX\'".8Z1%F"5Z--Y7GIEK MSO67+IJ/!_\"5:S!)M-9!(\5]ZN?/<"]?"'%>Z8\_%=5,?:GFC]CF,L/9_*/"N,9Y*,X&Q6)A\,8[N$)(NP]0&+.P2QAT#W6'OVDMCUJ/YG[@ML MH9G:[?3!7V:I+A:N\DIZZ$=3"L?,DJ-QCRA%?A=@3&A"\908\#/3NJ&OAK@2.C29-58B$XGDK$= MX@Y&P62"C**AJ 4!"A@0#@-L(KNOESUP!84A)=L8/^=HG5)3Y@_ I-,DZ&4T M8 27D0/WL]9A@&G*Z\<5<.1([+/0RDWPU\52_DL*(NQ3XEC(LN=SFS+#Y_"C M?/. .+$>*J6Y."DW=TQX]!B_P%IR=&9DB)W\W>DG"+*2$Z,HC2?8,LHXB(AQ MAB!%?G)+1;\^7K 95YOX/13,.<6/E1416;GZKPJ)DIK0W$!_CP=[T2]!V%WA M+(,/<"H8;L6V+W<"'PS&O2Q)S?0N=>T4>!JA08KVW?:A!I_%S!U%J>#LG?]0 M9]D=8UCX+UT6I=N89>!V:7+N]32 MA!L1,=& +0Q@3TB1$!9YT@]8'I?:HX4HW5+T$363I3%Z2K81$23> <%6%;Y% M#\9>MOYWAE\5EL!!U0GMF$D26:VOMX*DC'DL]76K I%ZG^,9223L?XM2G?DE MV0-N(;8C_,511&S3P# E09)AQ7W5/(JG<2B:*UWTBP8X@WP?;>/D =!?+R0. MYK62..="&UMO*%S_ISN>O/V@B=TV$4#](6@S<(C&OR+(*'()%#=K'M*%6=.X M_UU&:)"E'*52XD':$11@'&':DEB5@_&H'N=&9099U)=>5_.2,:FGT'$' S=( M4I-6=<<6TG_=*6V/0NZ["C&[0NQX5R&V&6OY62O$-&R1JO>0B#Z8\3(Y7K$O M0Q[UQ7S)VP+ER$3>AO"UT #I$BBK6]#Q0F#N9%;+3Y.6;A;[E0+Q0K9'>?RW M#,NL^+ =]A5H>I%V^8R# 1$H22[E2X$3H"&8R#(B0$\5K2:(8HGD"& G!S7ORN*"!EKU'J).68L,#C[?"DQ'O-R/[]+2C]2AU=5.-:^ MM67[*R'BKK9&PDYRR3B7E]I0C6"JGUU?IC)U00A-I5XHJU!X:\Q:MN=CA8:: M8*/>H9M,+C$\1]//I)L,VUAX,H7I C7XWAC5 T98RGHKBL% M?82P0T*Y&FAXSAK,\7!;':Y^8L9P@X<<4 ^!)E!::D;PDH,L+.".ZZ2X-:E5 MANLBD^:GW(%X TW@$1T("GG M68SS0S6JUN+L)0O0L)###!\?)PHU@#90&LP')A>VX7[PR?Q@UD DY%2*WIAA MN!]8,/PS/;DLXAYQ_,X@FW)#QKQ4JD6B-#UVX">)S!G2OA%>]0U=C-H[MX"9 MV M^@X>R\#&J*U3,P$OG-Y!DYJ72+:O-$!NI?N3M\RQN?$)UK3F_R1QERL(* M)%E"QJ:S=_,;R97N_NOQ-]26GLWA0*F'P,D^,'T\\WT)4,3*:9CGC_@__'Z& MUU 3='"N*$9FS#"3 E<7^D.Y.-/P8N.;BU?B'YA?X9]5HLEB+'R''WH<<,2] MD:CC@(3*K'#M*%<\ X/"&C'TIYPC8+G2R>9FBV$=,9?8X8P^7_0G;\%$3? R M!"?=_-(6\@),%B171!F6%>AUU M@30%H-OO8%,X*6I3(U?]*E066CNKQS+AP2>R,<_3M;O3:!JG[X)L(#]+?]D4 MS@[(:"':#9)^-L;:V#XN[UMD"M,\C5N3Y#_&W2/]/C8'HEH6<%4]=9"PU*GW$B_L#+XY&N]D6Q!FEJ&F>_9E@US Q?9*ZZN 5 M*, +,@\C-1]6P3:\5^5H7>,\*827F(!;\L:6.:I^[JA" 63?L9WPT,K,'VW&H IG*3+F> M/64_3DY?3?F0F8UT)K;OM62H/O+8&LQ)ZC$X-"0$ MEQ,4WZ/"4\7,GN?W<+H:3G7J^^5<'6X4/X+N9?F#Y/]JY4U%ZH77:UR=Q/,=FM/'/W?FN5HV.E&^CRI=+W'J@<6FU*!SF'3&2/!TA?PG.1$3 L0 MM^_(NLUWMEO#OW##0?7J"F:'YD&$&71N[MS)IJ?L_U26 ) 3E133,%-T"'UO MB-@,\&RWKS' .69$%$H$^5NW>T4!9E+J,2+E%>;5-_@L/#LRW/!7^ZJ)%='HR-'4BOH_6IU#C2^'U>OPF'@L'9^\!Q0TW$,7 M,NZM^/0D#HB)S&CY&0ABK'E1$@4>0B:"$C6YYUB#S,WM7EMO MD:+(,=E.#9F@^GKI5F6>@U]QJRI$)X-G&*46GO3KB@?3RA\,_CC!3&0T/ C] M 9],[J@.&B=TMRX@8< 8)%#5;B81 MNG2?/O=K1L:M;(6)A6B,[U]R5)[(PDMI1FFG<2,K6ZI*#"DXV$-;5O MH>QW[,8S3F;!9]/04>;/-'A3C_6P7YL;1M[7.;YH13[5A?RVT&2GQDI)CXJY4UVC1*0U$6DQ7R)2--[H MIF:\ BK)+\"W]JDJ3!)Y,GP$"D^X"3NTAT#)X7F>?*#2P8RT'W+)EVK^[@AI M/L=E,?T"+N82C=[HD?&[5]5=3 ]=&.:PE,V\7]6'5R+Y%FS9[24@Y-R<-;1J M'FA"S9:B?B(AA/)*AB*K'O-*X"1*PM@982RD,\2U**VRN1(E1^;2H%'Q5?H<_UGX?UJZ5J_7T07DN_#_OORP M\ YI< CGB]>-IM8PJJD_X1#!M.M9K])K6JM>6^M5V=>K9J-^7Z3+ M.;KA)+-[SD[.V66Q]Y#5^/VC@LF5#"><2B_=VQ5 L7NCW&!H-E\$,; M;D_06S A"'K?.O/@>VYWJ^%-12G"[A<(;4N;CV^:VD'D:M>UNFI66]Q<>QT MX$]K 2*;2SU'9'$N5Z+NH:-NM:56ZHT2=4O4+1SJ-E2C:1P@YJ[S?/%TSO2S MU*M:,T=ZIXA5%4GOI':^F1 TUMML*MO+'P?0JVJSI:_) M+/]M4(?>YSJ81^ MH*=CJGJM7IY.3D]';9BUXA_.R[AX'B6AJ1DYDH0%],#PQOFR/:4ONOZ-^AL) MQY3]%X3 JZI1KVRF'N=)"3[,PS'4UMJ*2WDX.Q.-1GU#;UZ>#N=E;#V'HK%J M:-4MFV")M_L MLE%3:Y5U-8TM@F=/)DA)%"519,.D7E,-O5H214D4)5%$BG5%-9H;>@0+3!0' M[*RJO7K8YIQRS0^OIF#EIDBQ0A3?4=XT:EHMJQCE3;T6*_<5I2ASU2E\S#>U MQ!,YK5CD1.ZW%\PVR$O12_94Q74: MP10(#.D8O:5^.*M30%CY\L3$V&+7IC[F@V2?L)4K8U:#=.Y*9UJUUKJE,V9# M:]:>+9A8K?;"U.K-[16$K/>F_X"_R MRN%5XZP)*L/4]E&=DY?MKQ(9/;*2E'412%^;[98(M.5,A-P\?QCI %L?)M*= M*<^-[MA[,U::R(,ZU)XG\F".A-Z()5"L'(/.)5CG\S_V"5ML-=_,-1)F),3L M$VCQ4$BN8,4;FL:GZ/1>Q+=BZ1[[A'=!R1S;JL>Z2/N^:W<#GGTB.@O'3VKA MA'"(<."AK+"ZSB,K?O-A.3M%#/(N_MS$A6$P>\R-.LK95ZUR]E4^UK+CV5<% M2?UK:&:]N6[J7U77S):QG=PQ0VO6S2TEM-6VE8^8TT75\KFHUC92_W+BLEV: M')+N,"I\4EZ9J)B=J,B/_&79B@> VH>7Z%7F5N8RM[)X@'E1>N4V$*EX(-M+ MDB4 ;D_;O?P)!S"Q1HM>A76"+\]%_9]!@_R%_%<7.3OO<5K"LH1E"6. MXSTGC@$BY$Z;-'-G*F8Q# ' ZB<2!#X^HE:0>'EJ"9ML5\XW555RMK M=W+;1@+);IJIE,B6I[U5354WFR6RY>9 #AG93@WD;*O7<^4'SXJ?P[C\8*I: M<[?'4LA,\/PZ!]*W^]6:! .KYP,G$F9SW+ M&_)21\7J_0E7J9[@R/PN?_U+T]"-]Z5IG\_CP6;VM7+ 6DY/YY0?SU[MZ?)D M,DZFHNWX8 HIP)=H+HT\"_).T/5QMIB07TSF5;*,O,KG '"<[=#6VWR^":%> M46N5#3L![;\?V@N2)DK4+3KJ-AJ;.VD.$W6/'7L+AL"G>EUM&NNG"JV3W5QZ MN5XA'*B7B42%]G)E5:R6549E-4<)RQ*6+^=LA0#7P2G8YJJ818W-:2L5BF2#=I4#6/#6>@Y MP+4#YP1&55MW5$5I;19$-^GX3N_'69?Z1/=B>LJ195)0IEVM#-7G\W0::K.U M;I%V>3B[D@YJ=6TUL3R<72GQ%6W=@O,RFZ(@HOO&'S(7.ZAS=[$S9=@K=_)P MK.Z$IMIH[D-/+6V(%0ZGI<+U\G#R>3BG==TLZQAR>"Q:K0SP;FAR%RX+,A3D M:V=!ED-A#R25#+,@F_F:(EK.,RY1=Z4Z8D#=31UHAXFZQXZ]!4-@O:)6JMN> MR)T3'#YP)Y?>TO;A'2ZDLEPT)Q<_U_B?]Z@S*_/ST#9,7A8SEDPX^[X3X,0F MN:6CY>O;!U"^"4HW=+72-%]4P+$%*.4T3::DDY).))TTU&9]716_I).23HZ+ M3D[K:J.Y?ON9PE/(H3OC:]J.8R2YL2_.:2QIRJ34E+&G.UYR^FQD.>6/1MZ_ M 05/T^7<>:5/#9I7')T\<)TQOJ"AM<(7I,^(S_F<]C=UK1F!@$6CP+/LJ'V< MX]P4\WX0#B_/)63?Z!7-#(&:W90*.*/GXPQBV;]*8-# =N'ZGX'E^LS%WVE( M-]:'6,J;FE9)/2]W64/+M'Z6JC*%#]C6""#J# :XMBX\,HD&PL.7<2L-^;V] MHH ]2:2A+BV7H1^]C 16@KHGD2B^7_C$D%G]'J".7Z1)]^D0"X?2+7!!..:I MZ_2#GO_LL'BNU+]X8KSR0FAR\9>;F=HMK:K7UIVI;58UO57=SE#FJE8W:UN: M%&TVF^6B=K^HQC9F:A_41.9R2G7VE&KE90.JCV>$<3GR.7\CGPL&E1?->SXV M%-I+5=Q>_2#MNZM_M/]]<:FP+ 6[S,\[MB0GW51;QH:U3H>9Y%2B;E%0MZD: MU0VS9$K4S[JZO2!QY/UEEK3BSL,_,!/QZAO4,Y0GLZNA$A#K>AK2)'R M8'8FW>O:CB>B%5*&%] ?=G][=;MEX5W@BA,3<_S*ICEW;AS>QD$*\@!9X5A.;EZ>6KE(\?J0I4-L$3;X):@O#LU\$GB*V MY"B)XL")8@MCN8^.*);NKB2-=0&4;P)YX=COLE%-7L_UB.>"9W:J>:[_P.[+ MZJAY0^H)944W;9K7!O+I6DHOS%YY_/Q!]LTH>XFLWTMD^R2T"C0/ MKR5"V84DEUU(B@>8%S4BV08B%0]DOVS.T0XZ6^1BU=:)JZ#[])65TX^.?OJ1T53-5HG#)0X7&(>KJMY:-^!7$!0^9O&J5S<= M8?]ZIYJ'@,#EB MC;)P+:>'8U:T#9,C2QWA8#QCMZXS8)X'6H$U4@9,# ]QDM55>?".%9' JFI] M;?97UI;L2C:UU%9]PZ;%Y>F\OM.B4:F6AY//P]%KVCY*Y@Y8S M,]+1S-+E\/HN!P)/(^<*!*_U7BB,V+:38<5HV 9U6T<4!'\Q=/)-JBU3U2L; M=IK8$H3RG0124L<14T>CI;;T#9TQ)764.53'4#4.1J&^:9.O8E2.'[&[LZ[M MH[=>P:R6C6O,\UNB;8N2L;[B.\J;EJGI"GQWA$4$_<#%BNO5"K@'KC-6WC1: M6BM\GBJUF>)98Z9,8;U.'R]A+9"FW,,/;\!4-F)WB]HUEWG!")VM4]<&* (0 M^,L!6F_J6C-\0!YB'(Z9MO6N !SN G;:6[4B@W[T,C+9X!^>[\%A,#PA*P8H M^,206?T>;->G5UBI,-G5UM]4M<;B:<(BI^O$WY6^:S^RB=*=(13&S.W9\"N\ M"Y@,O$2Q>K[]:/LV=1?()0JX2C>:>:85J*M#>I^*]M@!SOT_CHO.0+F:^-;D MP4;9W<:F\L7O6S&_0SO:(;7-YWTL8!O#I;R0B\^4CA:6!ZQ.,R5M:,KS'[2] M9 \,:^X):N3OPF_AJ&K91I#XP-S=N&KX. ,6 S2D3"V;N/TM/!RVZ/C\J4W/ M7EXHUA0H]M$:>?BL_$ V(@M85K&"'^ ]=?B @7?$Y8"61:\)+GKC#PK$J$2/ M6%W0^P(_^Y&\-.VH5I+@B/\Y#"NGI]8#.P-F8/TXLP:PV'?6Z,F:>:A.Q,D$ M*&(.AO/;S]SD8/!JF^34V6<]QR5$>@<?+=M5_FF- MKJ)S9@KBMBU[AOT.E@J?A7SP8HJ6O1 : X3&HX1&/PZ-7@2-7@(:J_Z[*0<\/ZQJ@\@1#P9T-G!+=Y M\D7=P"--">#YQ$)! 4*G_]_ \\>(]2FKL."+0L7DBT;+X!U?F>MT.7+,N.@9 MVNP1#8-(I+Q7G,#E&BQJ[3T&%URE!R:?!2<@-#W/!W6>DB@\+QA/:0A-\=6C MJ\DCXV %S0AD-BO0CM+))[8CFW:DR&8BW$9LQFRPYPAE7B?B:HWEBE?I%:VV M@KD8&C_A2O 71#GK$0@$*(S/.$*2QK\@70!:$ZKC18#S#R8Z:[$>6+5D/G2M MD37I$:+SU4F%!3]%5FJ!CC(+.4'K@,.4/>8*M*$LW!0;$N;BG/O"T+7*MG#3 MJ,3>M00W(R^%P%);KG&.Y]\S=ZQ\<2R0#1U8T"N;ZO3&=[8/RG)O!@_A1 M](IR!OI"U]^K'P$I-H_ T0$X=\[,&H$<_&Q/@'>@$&P_ '8AL]PGR#A^@IKQ M1V"Y@'V C'=L"D:@ KC[&90%.-JS/X@B!H%+XK@/#-$>'8 SM)[0U9Q!T2H M=)ZL:8&VNKYB&W$=W*X'VUU7BS6T:LQ%L;ZVF%R"APP5UI7&:N."=E$;3MD) M?]4GUF/C+G,3;WN!E!:G^.'_NN[YA\6WV/U?3YZW*EO5D^+TG/UR]<>WJT]7 M]_]6VM>?E(OV[=5]^XMR=]FY^79W<=EY*21W30_)@-4^ 'H#^N>CS9Z*";FL M/X'/N(S[((4-BJHSF&],F,U G&#$.3V;])LGVQ^"/'ED(V>*(C$R9:=#RQU; M/190Z \MR7[0BSC*U %:1\IVV4, +,%Q9Z'S47Q)1@"$-U-3OC-^%33W^.^* M-[2GG%W%G);(E6YZO@-, WB%WJ3'477L^<2[R/Z76AL8!K1AC#S3OIPI6=^P MHY&#]K2*-XV"?G1%L7PR0[YU^'*%P2MJ WP>\4!8H,&A(AL#DWP*9@<9\0$\ M(MVVR*OEJM5X $%5:/HZ14S@2]R6GMI3AH>*$'UPK3&\.]S+ LSHV3B$XQ&4 M^%=I05.7G:6\(OE,8GWX>C9YL+A4X@M\8!. '3]$JS^V)[;GNYSG1Z\JDNZQ M0$:Z0>8(EU^V"Q3Q)]>]$/]0RJGT$W9ELR8SA9S5#*T&LF,G\'T/+%3 (*D_ M2)?P75^XZP0,/=^!2V_=?):JI"OE>E:>A MW8N6:R%56UZX)]B/IEP[HL@UN!NR>CQ+K-<+]*X MX&&+JUT\#AU,'8[AG9O/=ZKB!=W_"M9IT25E,'(## M>)-X1[2QL363#E,XYK,?-C(BSJS9"/9 LN1JP/_!^FKRSG M3P!P?$_/FI*U M^#_A.89M1H;]%-;9LZ?([L84BY]?S1S4XW*$GD_[M!I^VV7D]@4X$N:@=PL^ M]6=HZ0&\N.#S?+B$+Q7>"MT$W)!<*>J@OQ1NI[;&-,ZZY)- ?GAKPF2HOU5! MCO;8U.P]\? MOEOL,MQB8^TM)M 8?^$.;Z+4H74;E//6- M:88MLJ3M=AQ,<8DGAC/%&[=K?T7*?D)MMCN3%W@0)<"8_#Q;11+[*0QL:3Q3 M]AJBB@O6)^@O*K)5*T9^P"EMP%27UF-S2QAQFK,"3JSP>/67A&+Z,'*Z\,,$ M<$7*:1N_Z"@=("HR(Z;RLY(Z9-,.[:>! ;C81,139)2 M+]IC)/6R=QMB1XP08PZBV(%RD/)MI>P)):E/5579'Y,:!'PK2 :_58@RJ=< M$.E:\V<8?@U@%1A8HO E IPKRZC#_+3'P1AOU+56U@-<*99"X7EQL(1];2P@ M\I8-1\S\C3DGGZ3DTJOAX%OQRYX\Z+3,,KTID=ZDE^E-^5C+$:8WK:X46B// MH:#MB/'F')P-/[FV#]L'0 R8*TP W50;M8H*:XRY5!SR^$6.%&[_3H/NR.Y% M3PN),. AX0H9L?0.3;F!%TQ2^3OJ4%)4\ ^FL_5PP7BA#_(?1:E(D)8+D+%N ML@'FF:9DIT:MN3-#8.]"Y3LW+">,JR.N90-X8E:D,-=#+RLW.44NE<>51NDP M3?$RQQ5M51E9P00TE(P4='TO! :T(]6UJYTUPJ"P K4N#( M@.NZS@1-\Y[/+:R8/:*"=6]/**;@NS9F*B]XI=%KKH9NN(_'\1@WF@!' M740AQYVBM0./NA1+!?P%71*TQ>]#&QC'$]LGJH#!-$*/"++87N "5'VP<\G( M\8+!P.[99#4!FI!R/6:,.W4&7)X:X@[DWD>)$*SC\DK ZE3GWIO584"#^P! M.#K\9>)9Y/NC4Z-S?((O<49.J6,NH]/G=H2D[N2Z(Z-R/+70>8AVAJ5, C*X M@;8&<-5Q!9L98[#, XW.!L!9G/BX[_PI'HKJ,KJ[W;F]O.8XK>93GP\-CEAV MDY2C22;*!@ _*>0\ MO5[B]]Y+LMI9J2C$@X96?TD"*6I=M58MJFU3$ZF")*K>5)NQ[)GEZ2I)K\RR M6\/%I>>ODD;::D8%F[*J4C=C:TD4)&9N$A. %A(9B7UA+$ED?J-R?%,728_%?8KM/COL#KTL63[E(IMF(%9)F9A*E'46C M8JYZ%(>+\.AT>A;^HC*M68TENB)VD&O&W#B/5M2]J>@11?%&KE*.FY.5EK5V M'#A9:QX1=/;>8@V.CS=T8H6Q&O)F M<<^8"-BSG\A'):?#-5UV;F]E-/ZULW9RISK#'2Z*#V#S-]V1_<#]2T4.P,L\ MFB^D= MEN=,0.&9*2/[!\A3%)G\;=))JCBAHSGDF6PP0 ^?,YGSD(89 BBD*8^!7)+2 M6%!%.@D/4\4B%R/)>]308*9GX!+/^73#ZZYD2)3U/K__,,41&!&EO&%^?N!. MD;U&&>N>[P9H'J$R0&N/?@P]J,HCV FD"8;OE/>DT,&*536- E757-Q=W5]= MM+\H[8N+FV_7]U?7OX%:='_UM7W_@IJ:O- .5P8(;[J,35(U ND#1C. ;.L> MQ3%Y,<@( P9<890] "A7/"'$2UEXJ+)PGW6Q&JY<)">+ADG$H^RQQ#YDUL&4 M0G;S$8UGD1C88S[KN WE;*_5R/D"22<8C]$\ 4G:B<7AVM'QWHKCS74)=TA_ M?VPL5?5*I4!B]>K^\JL2J=);78*YA2K)8_[SD-G+4J3\XUL;%+S[]OW5/R^I MB!HN?)'__G35N?ART_EV=]E1VA]OOMTK7]MW_[B\5^ZN.O\HO"*X)(@:AOO2 M@XM432S#C[U8BMO8F;"9\"7SA!(>$[3#%D3D0EJ\C4PRM&= >R'KI#OCA6*L M3W6GH!(Q=S*F,L1GUIWNR19KQF5P!?5;AQ*HX&LS_# 324J4Q&/#:<%'X_[Q M1%%#JZ+TK5FQZUU7C*._,8Q:S)D-=X.E2[V?$< <<.@_]"V*//'CIBJ7B]A] MUW2?3,&@.H?%G[%V<:YT$5 +*Q:I=H/R];'0!5]#)2_S_O"40/RRK5E4B!EN M+:J9XZUWL58AMO-E]4D) "0+,H$\W(#%2C++O/1X7KI1YJ7G8RU[STO?$P9& M=7^BZI7*H!.%T8F::%69C@)O>2GT]Y3R1NQ7I,@0 C(G2QF"21]&XB..L>A] M0_;'^3)3H]\KU0D ME\J[;5\4E(7.3\[*4QRTBYV(4/A01JDE.C!8O*I9A;>YXKVV]*EF^GRY1QB$ MU00.0'AH01$:8,I=\56">TH2^Z\C%1_<> M&$AT$J]]1]X7EM EDG6C.FORM/?L9(+U9> Z<.$CZFX V5L,"8O,[K]; !/F M,>7?; +?M#T?5DI)QBJ< /JVK? 3 \>%G4WD1V91,;!$N$>N=,J31BY 9\VX MHI+JL^>U>ANG-*E+WBPBM.D+ HUXS0V^P*]@%LVO4"W]"GG\\VC]"ANV4B:;I^+A>Z\YZJRIC!F><7&Y8Q27AP NTL!J+8;T. M#P0Q\B_QW^P)]EWGQQ;&DWCM3A3+Y#T'1$*<2QY\\>HG[&,THH0"L!?&MA^A M1.?R@C>)[^$4-.Q&A,OR//RK1^&+L/,0?R7U-8&G9>*='?8E]F(-;,2O\/8P M%+\!^%1Y-A*@"DS]2!Q#9)HM%O&J) M\V?#E7-E$5.? 0)$H*+ST0H$26I=2,U*V%Y))*#0D)C I62,$58N%2[;Z"+J M&7LU$?.?A(!0L*-F#)P\!@;'6GA)D4RJC+7-=0)7=HP<29Q0T'\=2Q=R)1B4 MTT6>J@AN.GBKQ!@I_"OBH0EV&+=&8DV^,@R1*!,JQT=G.H7GJ^K?BIUI]7NS$^<2;;:/.2"2%WCX'%(R1]>0% MMH^-7T>6/8ZK-".0A".9S4\N)Z'9V#SM/R-G.^ZXD77H=&O@XQ 0V8/4(SY M[:EP8<%$.&S4F.17^@[C3<%D@;/L$1B,>.Z,&&I(]4&>,WID9;O%\'4,4/3CTA*O/:U'\[@>(-RZ)(A 8G_\>ZK";/K1&CD3,LY]ZP?#_L4/#*]C9W7D 7%= MEAH DRP*-=LY&LI(]$]-Z0=)35D)O)SWP76>_&%$\F$PBB;_QB9S+72OFDMH MX (U"U@]P=@"CSJR![Q>@):'S7!L[#T5WW.L^ IDNDN^"026/>9],;M4;?T$ M)OC9R'&HH!]8K"^J*1:Y8S24YG0Z$F.?K;YRDJ_4T0LKH 8T@(J46'L7.AD^ MB\U^$9OMA)O=)VF=K"9]WA;.8_ =\0,[3-#VW#YWHI+]+(55#P.+7>3/U'OG MXN[&FZOVM[#NCQ3YP@(EEQ\27 29Z3D=YDG0)HR M=;_MT6; \.!6O!P)&?7.6AC9P>C&L%&6Z 4>YZ1S7!0#_YFHF1.]\GN\*99+ M78"I*B!UJ@C_?0%K$:_B/:%D>R$UCJ,2YU!"L+1>16IZ!Z/%QA;"NEOL4C9W M8@JV'V:+#XF*6+.U4KO*,O]Z) M-XM:=:4/YW3$/ MMH139Y2/-HB"WG "^/: 6[R:]#11/_](9=&!F^0[<0#S92;Z"UJBZ[_H7H4] M+>57;RW@$]'X0;[7N15&C3KD4Y>>C]W;;A/#=P""':VM<2 EQL[RF?;0W:7 MM72QUCDHXF@PV9:-<']$'T&B6"8WY M6,NK)33N![&X^D,2'LRLV]M/8 S&!,<7[583L:V[F]!TI Y]JFC/I_)FA"KP MN[L+89 0]^3=^M1DKZ.X0K78>#Y==Z,(0U&L("4PL ?J #BE2(F \Y.6Z.;/^83MQ_M#WR M0<^-H>/M.A\M,EC+6G#C@?2*),L(M:C-T'U=-JB M*$2VLN6V9-2[I<^L/J[?>Y^MNI1'O:VCYID.T:Q"HO_H,&(&K.0($A_FN+E- M8Z3H]=X,%.*Q%V75+.0KR5L4(&X^Y(N6-,+A8)'K .Q9=-T*>P\,#6YO!6+Z MN(^IZ7TW> C-%[COW)G7J.T2DUX5D^ 40#NS13%BR.QC_J%$_V>P7,2P3@PV MQETMV'C->G3$\%.PF,ISV^*Y?;*]:1"64692,M=C1]1[_P&/ESI(BBG11)\! M#W9/&>H%-*T+'NB#S4@-P?'<[$DHZ2-'2\*/XJ3UK\8N^8L>$[@571L/XA[, M?NG:/L>J4A?8&GK(TJ>82S+AX,5*G5'<=1%3 ^"2ST<\2I=$*K*\1P91GMCV M"!H/(,!R,X;QZ)Z,(,?E-Z=/]')3L&V0:J[AT9(*!\>$CO,E/N&B)"-\9TG' MWH(A[+%0UXB[]><,DU"3$*UB'S@M^+'RJ;F>^I3M0/,5HLG:SSA911W<"&WR MC!/"I459N9@7 9(3NWZ+O.%X:BT&/>3(5?S68NA4Y"&.1 49_I,F;LIA.O!Y MSP=QP/4V-1JV@OY':CF!^8]+7PN8=5:E&<5Q8G"N$4/YZGH1-+^I?S]<*]1NJAV&274?B474H;"TL(?"69[30BZ+491XD M9ERXLM ^BW?TDM# H(]H.B<&9LA:2Q>]-D)OPWW1_F<4/Q. CSXA E\9X$9@ MII*&&"2"1(M)\8IEAP%]4C[P9!FQ>5/A^O;CJ7%]_N+JD&YO1W[4Y3&I5F[6W(OSML M0I,Y^X]H*V/!FI1 MM@>739:HY455'$/!O HZQI(1@4'XB)28F&$63LP,@^DQKPSAKIK$B$CA8R3^ M5"+TDVXL_C;CC>TY,\5J"S#EPNHCOAMN2V#*B^#9%T.;*H+3WD/6!WX+19D8 M(,UY:M)3@6R,+RFQ8M$YFWK4X*-\4^)TXSUI>$/.,#V1"W>Y D4LTN(6K(_1 MLRF8/=3[Q'/&8;INTC,2($N4$IJ3V=R0(LH,B9UN_H/M][$DIH4\+'3(;IQW M)5U (O5J(=UJ,;MJ\QSA6M%RA(W\5D?OLTCWV_7=Y6]7G?O+N\M/2J?]Y;*C MW'Q6+O_X=G7_;X4X\M7]U65'!6J_Q%]$;0(OZKWJ=+Y=WBFWW^XN?F]W,A[- M,3W2]*]KT"E>D"S?+!HAU#)SY5>HRY?[UVY'UOSX OOG MNXDSN0[&\)4>21S Q#L,E??.]!-E8HUAS:S7?_?5=T?8E<:[&=R[_;;KWL.- M'T? .D\(/P9GS8IQ$HW=;/OB&KZ&>3UKBFCN!BPE4V/_@@BK":@+[$S(<=(, MYGN4P$VQ'G)B#E;?!K6 )R4ZO#A4])$=3T?.#*=Y3]'(00&UTMU4J!NZ"'QQ M=-,1KW"&VV9A:"M^QNG%@-P2#"/?"F^$)U.IN54HY^GR3\AD 3GA=F[3JR,, M\!)<'RY/!W1I]YTIZ"F?1];#B<+-4& J/_UW _LGZ\.ICCP689)Y\L'B#_S? M>>*+'U1E[/1Y_3.L=./EW+OCB;_J:JHG'Z2C>7%!$@]86#^<.-CPP.-EF6 - M@IDIBS.QEQ39"V1/:/CWT/JF"(&Y0+TW,R>5?I<_QGR.TT2H<=7P7_M^77Q8_:_#3 M^>)UP] J=2/UIXJFKWG=K%77>B)K43H01+V5OT55&O6\+:JJ-6OI/^UU4573 MS.&BJLLA=4Z$PXD'Z!/YPZ\GYLE_-SO/[>]"FY.@*GP4/@D.@N3LBH"S'&]YUCATND-63_ 6LZ.CP$V M":<2-G'87/ZJ( "@HUTE!P/^^7 C3/C+!DZ[5XDA@>S#; MO9W%-=AE3@"C:L;= -QW=37IH\"++/S:R8?OV-G=&BM?V)/M+9BR2QVWA04" M"?L("G7LW97:"VTY/);0:R9JKDC(VT7MO=+^MLY-*B?(-:*S \/5/-?-<^PJ MD7E:Y3EM?$YZY=QH".B6T'PI-"NU;!""28VYR >J5LG M"URE>D*M-VH^6/6J/_:2K?!*,S_H.>=SP32>\ MO/S7DTK$E)I(-S45=B]9DEQCR9-V+#M6#WY0D"X\PM8F(NH^2LM/2"F]KF>J]:(]"S$AU*CJJM%L;D?M/D0:8&,%#;!^\N&3:\U\H)?OMK>@\11> 4R'P9P"V) *X$74NRNWGLYB MD>TZQ[.QVM;@P%%4@\T M0D?@+7.F" [L],(>9J^@#!ZE#;?^&:4J:<;S[L#6-O1*HW0'YD\9/$J0UL 068:L.LEL[ [>J"YU3]LO=>S*?Z6Z6=S/2E\0V8 M#4P]B^$"=CBV>0L91D,@1GP\(I9]\O&J\5I3&D"!I9Z,.CLP'.S.>_3,%^'1 MT%<6Y1WC^U4EF&(/GEAKO.Y,Z;K.#ZPUY-6=0V?4YY6'^*_X6_G(1R_6]4*T M8 OGS<;O3BD C)=$K5+JF]5T><6B3>"85:,JFX:YUUWV#,JE9K1 M-!K_ 19X%K) HV2!Z[% PR'R+^I-&4=5$JU+\O-XRJ]PU MQK,V$I_N\"$CPMRK&#)ZU;'J.TVDI^F&]^:(3\L'0W MO9 ?)NJ:526]P#?! A=_1!X6_=[NT=0%C'67/#(+D]9LR+7N;9LW62SYU^OS M+T/J<\::^MS+V[CEG!OM1SO3F\HWK:-=:$E&H)NURFHLHU6IERRC9!FOR3*, MD&6LI_(R*GBO$Y=$N#Q&(H!PVZ M2TV2^2,/ M*/WSJ174^>YI) MV;GZ[;I]_^WN,K_#---)\#9FZ/(A[G\&MANIE2NY[/F##[:'M7Z^,K1P)"#( MWYX5>%0%8'O2YH#/=)GBP8'QA%2<'MEE0VLTD'/<";W$#5BIQP(^(1#GJP?^ MT'%A=_V7CE*?0YE"3"BKUC6CWMQ*>515T^OKS:5:NJCE$\KRKV6O-,HD.<5Y M!3T[/QM*MQJ*M*'5ILU<77>^7GY2KJXO;NYN;^[:]Y>?UNFS4YA]KGURAV\8 MEX!ZD0!B\D6TC?W<79(NSGWSI6Y3O>%8G$')YNVNZ',"1Z5 M]6>;[0])2P0M-[1O',P(,Y?86&YH#]B8FMR ,8645(:5&T+ER-&<&Y]R/=NG M?-YU^C/XS] ?CS[\?U!+ P04 " +.*E80U00Z-,2 ""S@ $0 &EN M'-D[5U;<]LV%G[OK^#Z9;LS56SYDL2>.!WYEGK6MC2V MDK3[TH%(2,*&(E0 M*W^^CT +R(%D@ EJ^&6[D,J2S@'P/D.<"XX(#_\_#SS MG4?,.*'!Z4[WS=Z.@P.7>B28G.Y\'EYUWN_\_/&''S[\H]/Y]>S^QKF@;CC# M@7#.&48">\X3$5-'3+'SE;)OY!$Y Q^),66S3N>C(CNG\P4CDZEP]O?V#Y-F MR:_L9/_ 0^^/#W!G-,9[G<.CO5'G&.T?=]Z/O..N^_;PZ+@[_FER\G[4/<2H M^ZXS?CM"G4/OW7$'';Q[UW'WWJ'W[P[PL8NZBNDS/^'N%,^0 U,+^,DS/]V9 M"C$_V=U]>GIZ\W3PAK+)[O[>7G?WU]N;!]5T)V[KD^!;KO7SB/E)^X-=^?,( M<9PT)P&?Y9K++[#WQJ6S73G9O8.#;M)67N"=<1BCGFWF A^ MWY6_RX[V.GO=SGZN*T^D9-E^CG:C'[5>S)WL=_8..G(^2 A&1J' 5X#R!1ZC MT(?.PN"/$/ED3+ '*N1CJ22Y!IF?!6(3+.[0#/,Y0 M=R8(S6OUG*6)>H^_J3."C$)WCX^/=Y^EAA:/H%#I5/N._-CI[@.X-;HMTU[[ MON&O3D+W$F-8KLYZ8TCH-AQ#X8(LTP43I?J;;SJ,=,G6'D9,66L8Q?N,)18) M@03AJ$Z''+MO)O1QUZ5A(-C"9@T6D21_U%E].68>)G7Z3IK+#VOWB5VO3I]) M<_FAH$\4!%0H>OE-_-U\3H(QC;Z K^1:.4D6S#T>)Q9',YP%NY+ZWPEB+J.^ M80O;G3,ZQTP0S+-&5S&8,CP^W9%FHI,8B-_G#+^!D21-M [RJU[^##U@#B9* MS?=F.:&$A53\TQT../@X$E&3Y^_A<=WY PD)R-]B]CX:U9T]D&#__W[B+O+K M3AQ(W-!?1^LE^1!^=XAWNG-.(688H D,3W[_^?ZZS(E3O2Z;)SP3KDLU_+BG M_NLZG660T7$4I2-)/^RN$JRP"CGV^L%']7EU=1&Z6_#R)_ +'A5/Q+5D[,RXF8O>(A M^ QF-44"P+CW!"<0WE/,P M0*%'A(Q.ZZ)HR=>(Z&$5HLM.'#IV@8()&?E*/\%8?J+4>R*^9?!;3FX4_[XN_I274G)ENA-^ M+8+DBCQCK\V;3&QB\$':(% ^T#MX!L68N^& MH!'QB;!VCJPX&<$Y7 4G8>O$?-7*B#D[&=8MPNP&7!%;5.*V1KD?K3,G-2;BT"1,_V64:].IT1 CW"+4@!MDGV@KK?SF!']61N!@>\1I*HA-:( M@1;-*D8=Q MVCE5*2P( M52*C_+4,5,JAG3(O.5RHAT$U$R,F6@ZK\IRBC3CE#Q]J&9 B2B,B6FY+.[QH M(PHV9P]UL*G!SXB8E@JS/=%H(Y#1J4,=J'(41C"TG%A$WD91R^.(.H+.M#>) M^;V6")/$;11RZ2E&'\5[U),SFG@PAR9&NP]X=^V@'MI'T;\ MM:Q#+?QS_3JRXU=%*%^<6,@+=P/,Y"$I#529QC8V@:I^C JA)3WJ;0A81+<* MH7O"71_Q0[J,/V V9RDAL03&J.S)JQ@8W::1W!]]TDMZ= M9?>M5(S" RWY1#$O]+&\4,C8 N2GFH"/E3:GXRCY"-]EDE>U5&4[71N5Q_:Z MCU2K>##1W<=H.'%+Z6]F"*%!-"CU0RZ=]ZI4D3S7\S;M6)E /]924^6@M]N3 M+)1W?\0Q>Y1A\'4PAVTSD"W40.GX H\Q8S(#$G#B858_0'S9+HVJH*7%RE5A M.0A'C<(A@9..0Z[Y9"1.;BBOBI/NYDMC_#F@>4@YD8_SR,":%NB)G#1?UKQL M9T!&I=-R?15&)^/ 9,<8J2"7.BB?59K3P^5(5S3QU1(5*$&R:K-%IEO4N;6Z M,VJ4=3%19[E+YU@LY[-D9 M :Q92=7VX*-4\B^#GS5L6N;14 #70JCR=6SUG*1"4B,H6M*OH :NA4#8%*W5 M@J<.0R-H6K+-O@RNA5A&96GK6:T26@-"1WM:9BRNC6N[+8K$H/YU*1?UUE 9 ML1$-+3F5HJ$^_.0H=JT$1!83+IWI&QI,AEB^FV-4S_J8V1A!TI(YJLXQ[Y%+ MQAW).2Z";"E@Z^UEA91&6+2,2 Q+N_8)>S8VP$4TM'%.Q[*\>D\(W:!&5WZ2.] MVXKT52A ;@-& I?,D7^/YV@QVV!56O(SXEKXS"(98"G^3MJ!L^RA]:OV.A 8 M)B$NGV69=OW%64)OQ$I+3<18)?R1[#C941+?S9.V76LMH>4Q1*_!^^# M$5>]D0)^1X&W\LUG&$#-8N(7Z,B(N_TU/-B+TXZB5BI[K7VI^F^E9F2>FU?S MR$ZC,^*FI7NRC]UKI?0KGI^WWM9:AZ$1+RT55/F OM9OLMD[J.NA5\G!")>6 M[,E=BGU%9RD,=0*=^6)MD,H8&;'2$C@K6"G&V2__[IA]V,V_^#?Z._=R8/EJ MX/@=[PI1"'S\@'_?' T8H R?]'C\2_/2%ANX4L_[()Q/Y=JPA M':#%D$9^_"^16S_ 3-Y#5*\512-P#) K3G?&R)>O097O0E:%AB_824!\7QZD MG^X(%LI7K8Z83T[F&)AZ4B!J9@+)!W#S$ 9$1"A%\(G1<'ZZ$[4F L]V'*%: M>X)UY"?>E4QD-]?PJ^2T?,VR)K=5S8J\7>/*# MG(.*CWBIX%ZX%[/DO##B;2FZZ!NNV%L([3SD AP6UKO%LQ%FV6E' XIFK35[ M\7%G(/?H#)' 8O"WQ ?9T@!?RLK#;O442AHW8B)1,A9&K5[7"RKU" M,ZA-F ML^&485P]-6OR1DSV!L,2POVY6C/!1-44J'_NJ/@-RV,^:._":IG)(IW2A5B7 M39VY1[^-HJ.BTQT7UC.QW;NB;V:@: *QAT5Z.[1\5ZK#H[&2N NEFH(Q"L'PN/XB=B<@H@8;Q3]S:8C 9P"M)@'N@9*# M\5$_@?5R_)-$X(*O4+8MX3F&?P!A[H6,B/ANF8"1LQP;P:Q?YA?YSX0'&Q9>F: MM"7?YESMO M;<^^?$&,R''=0TR3%O]4(U=)T@C\>OM[W>-K]> 9\H@'(,?AE#!P>W#@R9;5 M>XLM=2.F>H$?L4_GZL1;)MPG,IRG;)&Z]MSD)]O2-V*Z<47ZN4\"XB(?-A'D MQVNLVA,L)ZH1J/^EGM]*)OM"F5P%J\FKIEY8UB?*RN M7HCN661Y+*D;D;ZYI2+D9X1RE\BXC<.F9 CHRPD:L7PKH_(GND%(OR1NQ$3/ M0@Y1$N=@'T>PQJ*L<90%&\2E>N_5/EXAMFUTV=4=,@KLSNQCPK%%+);TC MW9-'F5S(Q'ON]GUJK7HSR@3Y$T5)G>7=S^BJH7J2V&*(G\693]UO%;9P2_UM M4YHBZ<9"H,OZ\DO$ IB'/)=0R76IVBX*O OYD#7L#5=CSZRRU.7R K/WQ,ET M(:UC.,+7>OY>R-5I,_\W=\2E/H89(#R&';-Z590VWQZ>]HLC.9.Z8G2V6L-H M/,@J)FKJ)A;E'56E3E_" (.M!JZ"H!$;6Y&_(N3^,61(;B\7:,'5&>.07L+X M754&@ 3JCZ_"P$.2"/GG4]AT;+W9#?OX[NG:,_!FN'K,R>B33T'M[K!0*>9J M13"2-4(=5)!UCV7K)#LD/=>*PYR2]EN"*2&JK=G]N3KGI8.0P1;*\;(8/GJ) MMY7JFI@TU<.U-I,WX,Q+?GQC@YOAM*VC2K].M>!/AK.F_$";->ZU*W-J99:A,I]Q"[4U7J$1=CT<"V1J2* MLJG!3*$FIOZY(8=N1=L(;"O.P]/3VG4.TS/$347X*XR+H-D-?B(&AZBH91., M557M1M^DI);$C=#23-6!JC(8,/!,(_WJCQ]"%XR) <(Z'!HQY3OI6D 6_&^>JY6I(V89-69:OH<%PA UCJ4S3-HZ@%M07&9C*O]"<(!_G6= MVK1B\D;@?1DR.L=1+E>&SOTQ?/A*F6\XW##3-6)ZR;E2_@D>/<;D2;!L>K98 M-HG+S7I/B'G7@1>Z>'EBQS\!B0 PHX0F#)*7.UE;[O5[7QPM<#)*7BQCN F; M7,4RW+O=6G_?6Y#)@S"KE]IJJT8LK/]@1@>4!.)!5I-=R2 I"L8RIP,/. "O M^XX*?!'B_;U]@Y'0::B@:(120^11=U4> M54]Y$XZ-$(FU+]A4KZ_4,;^GOG]%F?1%RN9D1_N]*W:J8FE9O;!^))ZE;@28 MB7NT\F02[*H73"\+)",?TNAEV;+Y_E64Y;FNPK<;+E8S#NMDT6PY;^? V<,N MF2%_0_VO*A0PTS6G:J#P@J[Q>I6)JA%K.KYDG5F+<<&1Y>WL"L*F>HI?P/3# MF,\(-9K5PJ:-P*U0N:K66P5! !^)@$ M%0 &ENOP#W^-__\;>_ M_?W? /[KU[>O'CV;I>4)3A>/CCH,"\R//H\7QX\6Q_CHSUGWU_A3>/1F$A9E MUIT _&/USXYF'T^[\8?CQ2/!A-I\;?.WW<]"YN"\1(@%&2C-(O@@/+B8/4]& M:<_+__WPLXM<8> 6BHD!5+8>@K06$K/!68D^!;YZZ&0\_>OG^B.&.3ZBX4WG MJU]_>7R\6'S\^K;W'O_ M9/6WYU^=CZ_Z(CV6/_FOWUZ]2\=X$F \G2_"--47S,<_SU/ORFU<2MA/, M/Z79R9/ZUT^.9M/Y;#+.5;J_ADF%_>X8<3$G\*N'+4X_XB^/Y^.3CQ/S1U8P+8#BEP5.,ZZG8_/* MR2Q]\Z5)%<:LV_S+28@X67TZ6L[A0P@?1T_G?U&F4JRF\ M$L!Z^NX_FJ,P/WXZS?5_S_^UI/4XH8?.GRZ.0M>=TMK_SS!9X@A5E"@PT-A< MI#6'')SS!8PK,B0KM"RQ\2AW O;MZ+?H\[1+CV9=QHY4V>-'G[&JG3.MMD89 MNG2)5]^NJ+-O/)DO3TY6SX3Q D\V_[YTLY-6O%C,^I;)F@TTHGWI\EOH_L)% MB!-\AVG9C1=C/!^RB$P&S1,X[RP!8@Y\- M5O/?C!!/4YHMB9UO,2$QE8#]CHL-(HZV).491*T]C50F\+(@:!6$+2453*W5 MQDUX=J&$_.XHT4P"S3CQ*"@6,A@LPLR&RDSJSU\M\!UBZ,T-\=(UK+HQE1WBUFZ:_CV83F=5ZM MF<7IR$EM=!0!N,N&"$L_@J1]BUF>B*PE9YT;\^(RBKT-Y]G)R6RZ>N[:'G,T MJ3)I08M/:U"ED.=JT$8>2L+6-? '#D,SA/>5^R2;>9[K;63LYC^O8 MP^0-+;:7TZ/P<;P(DQ&F(H3S$81SC%8N,O"<8,6HLV=*RB!U:T/G:BA#,GL; M4Z#%Y#=CPENRPL=3S,]#-R67;$Y6V/*D3C7F9UC&:;P8E>AR5H+L\:+(02N. M;"\7%2!3-FDOI,JA,2EN1S4D&[@Q/QJ+I*6+M,&QVI1)E7WL\)CVZ?$G?#E- MLQ-\-9O/R91[7=Z'+R.KB+A)22A)T!P$ZRI<#XDS[C/+(HG6O+DCQ"$9U:V5 M3(_":L>HE5DWPNQ]+J& \KY&PH4%)TN 7 JBL)X J%YBCVWP;\Q2+Y7)QBK0 M*5F:0F[ "X' L)3("ZW/]GR_JT-PV"#BG21[B<'WGMR&SN'L(W:+TS>3,%V0 M+U+7Y<=Z6%3=51]E2HY%R+0.04E=0Q(H@4?C@\E2.=4Z8GX3GB$93 VDWVSJ MFY'AQ7A:3V1>89CCVSJ)K\L?Y*'6H8Z8%#Q%K0B0IN$:\GU#KD&,Y)SV/BHM M6@>';H S)-NH 15:37PS)KPF9M+8IQ^NA)0RBL*\AH(608DH(6AO00=68H[< M%U$:<^%&0$,RS_'D\F8Q8<):[P* H M4Y-!:BS4%0Z:Q62-]ESZUA&5S;MW$;/Y?L1\KREMI_._AJ%''HU!:PT(T%NOWT6L]OL1ZWTGMIED7XU#'$]6)]!D9U[AAON8 M4E$8 &UUPXUW$$3(P!Q3B6EEDF^=#W ;IH9C'F&(SC >:1&15E2YAAT]UK!C M3H%I9ZUK?8JQ]?HA.:U-F7"1Y_>=\EX/L(3B/FD/O*"I!VD%' T$N/(%N8W?R#./B]]DT;9+&4I &28<*9\AT",%!#.3X)95\"LI%65)KN5^) M9*#J;#_9[S_G+4^ANB7FM[/3,-DB(ZGK+62:2\T<6:#"D^.G'$.(/F>0RF@M M''E^JK5-LPNN(07F6G&CN3R:,>77Y7P\Q?G\:'82Q]/5G!S-IC5T1)!JKOTX MKT))-4E_/1>G6Y"#*L95\XQ_#2=^X6S)Y MXY&EFOA04R T[6RA9,BYE5J7P [NV]S+?5U4>;\)I+?$X3_!>6Y%7C%K1 MYNV*C)!$S8IDUM34V )H0\XJL-*^9.^N& ?J[M^'-]<5Y?0BKGZ-K@VB4@)F M0SN\EG6OKW4#WNH +' 7=5;1A=8AKIOP##0^T((LS<302[#HO)3,1>&S"9"Y MX63["0W.<@O:2Y%*0I.5Z#%2-, :OL8TV'?2^S:X-YA0&L>$I]V\1&)D% Y" M_1-CFHR\+&UH;U/=B&B@+GP+3C04Q05Z_/W)Q=EZ1;_OWRGBW8)^UH3#^:Q\ MDSQ=TZ:7T[#,-($7@E9W;R&QXUO:]I:XS] :-9WXFGG^@BBW#N8LB19G_""0 MOV*9=6<9ZN_#%YP__[+H K&?-I?N]"4!7]GF]"]I7/2:#R^G"^QP3CN,,\4K MKB$KJTC'J%1/516X))3!:&UN7KS4XW":*;^O&$=9:YJ+Z$D+JUIKQAG$D$@5 M*Q1):Z>E;&U+7P%C2.;R4/AXK;Z\I_2:UL#/%U59K)'06&<;;".C8RR>-G2A M2ZW8S@E"+N09*]K6C;?"-$\=N0G/D$SKH1*KF3P;,FP]K+.2[Y'A(7(3ZPE1 MXK4@UH&KO0!2R2'SA#(T+Z.Y .&.MCG\?TJD^XNM&7?^F'88)N/_P?S/,)[6 M27H]?8;=^!/-#/&<".TPNUH9DD/-_775PM2Y'CZ&I'C19)0UYM(MD(9DXP^5 M6BVEVC8XOZTMU[.RH;]PD15N!*"H/2F018C%.8AD]VNC7'#%]!&@OQ;1D([U MADJTAC)MQK/?<;%E\Y58F%1EU/:3C)&]=0\VUULUBNZ/PU"T19A 8OPH#SSX&1BX!D+.9-QE%5K2^,:*'?T@OJU7ELS M:;^);Q]9WAJ<-,S+8#W0BVLV9-$0L# (B<<4BPY.-*\*NBVX1O<5/.%WB M9K5V(2W^'"^.CY;S!;VA>_XE39:UEW*MV*'_U]:[UY$<.@%&9K9NPUX?V)W6DRJ3.OR9@$0)5LP3O2 MVJ%84ZPM-MC6=NW-8K_?F%Z76I6ZJA7"[M,XX?S=;))'"I6WFAE0-I'CX"0) MS/H$)JMD@C4NAO8M]*Y#,R2]MQ M'R/SQN5$D'2U5C,CVTEXM-+$;..V5BD6"2J=4S:(">X4 G)]#'I%1HO5G> MC&A(0>RF[&@HB @,64@E,@^FM1=WH*$-*13>E*Y#I$9#G^%2Q\KS;I7<\(2I-@I) MTM3Z'?)=T3$H0ECKD$7A6W/U!CA-0_Y//X7QI.9:OY]M]8H^:QOP:YB/TZB$ MXGBHG?%9"5 M70@F! !X_9IE):FY)WA#@LGZ,-CRXNOCZEUO;4\HH9>#'K M:.ZGZ_S+=/J>M,,\I)6$IGGUVYF\\G\OU^DBFSE[4W=(^HO%HAO'Y6(]YC=A MG2$JDF<. P@,&90DK194#O7Z%I6B527RUOE !QW@L'RF?F@]7,;TOBC.%W&9 M=?.P?371W085(B?@-@+)@(,2C@:%B09E2V8^Z9A-\S3+?H:TWS*41KGL]347[K9[BW.2?*(WGMU]]^T'6]]\ M@]UXEHEA72V(>(;K_]/OZX.:YU_2RDI_2Z-Z7@JFQ0BYEC8E#VG59$^$ K&: MXU)A2,P5G7SKNJ7#CK"!&5TAO.EFG\B)R;^>_C&O'4'/3U2>TF[U:5TIK(U0 MFMD )N<(RI MYFEM GT!_B;YG8=16^=4+V MM_AR,W=T@S*"OWMZ[BO^ONFYKNF] M@$^7J(L2D"0BT.8?UUT+2[8Y^RR4:-Z(8'=T@S)5OWMZ[BO^9O1<#_%UV1[V MZ^E>$US#^8YQV@$*5F\AJDQ+S!50UIEHF J*M:XTZ6$8@SJ,^7X(_]"$ZEMQ M7VGW..\C-Q)B;=&M$EH@KU2 CT9QQ,"T'(K9NV_BO+4"G= ,#&.DI)(R$#$) M**4F"@LNN.XU1CXD([XGAMP8$+^3 )JMA6?XL<,T7DW**$L59"@/G:[,B M[4M*FB'3S6^:VSN3XE#6ZH%(TE!$[7KC'X<.?R5K(]< ,$[G:PH72X06*!-/:.5TB<;C>?K+FDC ME0VJ0JZZ-X;(JY$,4LM5O=%>RZQ3\;%?_7(]MB$EP3R(IFDDMG:72ZXN?_Z/ M\32?5[0I9KG$XD&4VCR/:UNKZ>G7%&26'K-FS:^4O(1B2 U?#T24/471O,8\ M5;_R+"&5<1=Y-A&X49(4'@W).9O!.^ZTC-*1(=7'8?*W,(;4\O5 I-A7&(>X M>'1;PXUTO?RTM@82I=Y]R&E7#$82;U'&K*74.K9.$]X1VB[L<3\6>_H0VG>7 M4FRDLLG7CH&VD!*5V8%744,2NEYT%6I&_8^;4NQ_+$8/D30':R3DE93!.@[6 MDB^J8B0+,7OR2I,RB47.F6M]K52#1D*<';#._Q <;"FFO;E3TY%&9P;"T_2O MY7@^KC/U%B<3(90[R0I>2RUE5.[UI M)T+\("'G]E/?E W?=KL];RV":R?Z'*SWX8%VE>8"ZY%*-5]H2O]H=8VL3SY+)X"KE>\@:+=# M'H'9Q) 7Q6WNH>'Q]8!V(H_ZX!]/.;H=< M@^,JRJPM@U(JN%3/^FA3!L?0JF",U+Q]J]^=H.U$,?/#4VQ_L1W JOIZ-]'E M:XE&-I2D$C>@:J,Y)3'5F_X$Y)*D#:A+T'"\?W);TV88/*<5R? M4M=+DS8'T[^%[B]<%1%^K3D<\9QYRLK76[975Y>6>ANA!J93\)EC81?;XU\3 M1;C#2W=BC/]!=L->)?(0Y1J>1Q8C9T#;-JG+VB*7&&Z(SYSK0MZ)<4,IU[A/ M%L7IZIQA+:>7\_FR'KNM4CQ&'HWSDDN0/I.CKK(![[T"PR5*;D*4MG5OR1O@ MW#$C^$'6T+[TN9Q8T48Z[9)NNEE"S*MNU*L6':\_KKI0/_^"71K3'(RB0)FB M,,"3R]6X#>"U#2"-#BX5Y9)L[9/<"NH[2"5NSIRF@FJ8M+4A] K4MXQ6J00N MN0.C*R)O$H0D&&BCDBI"7[)TWW9@&^S%,-C!' MGC!%+LF!$1Y!"3(X@^0%6+!!.ZVD8MHQ M\(BBEO9'<-$AI!1#RE[EDELG:MP9Y'=0&[8OTV[B:3G5H/!;3.O;9W9' M-ZB6]H>B6#^RZ[$5T[LZ@=WIK+P;?YB.RSA5G.L *$W+F]EDG&A2:/IJHM.; M57.JVEFP%L8\H_4RGLR_!;E;BZ8&;]V_=5/KH3=JZ?3G:D%@?OH)N_ !?U^> M1.S(>1U/EK7'5'W]_/5R,5^$:2U)'R7.6:E7@J%CM7"DU,O'R <1Y-(*S4H2 MV%H)W!'BOAKQFM==>L^ZQZ5),L8@"G"E$RC&!$3C$A0RFU0L)I?4VGF^$\ A M[;Q]UZ+ ,VV_G6H\2E9J+6JTEVL.2I%N M=ZK>DJS02H&T>8C6!1#[HQY2;.>0E#RPO _+TZ,9&3?=_/S\8,NNE0YC4>2D M%B8B*+)D@GUD(=4HSXXAC:2=(]6YB8=[?1=.L:\G."L MG'^TAQFYRV/WMQ/O#+Z1(7C^$C)!1SYA89Y%D*'6G"?%J[O@0$3MR5^1Q:C6 M5=W;[]]?8YT]ZVWX3$XW=N,PF:\ZUM:KIZQ_>V5MZ$:DK%V;SY<5BI-A=%P6SO#]>>L^ZOF%LX2SB\ $SQD9K,! M*PH!D\E <$Q#]()[JQ3GI7W.^JVPAF1 M:=)(W&TY\F+>GD2Z>35_6L7"%P< M=UD[D-[7_I5$8.=K*;WQ0MHLE<#6_<]W@#4D,Z8]3QJ)HT<[Y,7X"]EMJPQ2 MPK>'Y7'U@_:W-78 V,BZN#8R6>G@C*X-;C@PV@;(^S8.(DL:LD/A0G3!N.9- M0&[ T^ (Y^IG_[.K;>(8)JXBDU!\/9,5NH!+L4"Q*J*7UNKFA;4W(QJ2U=&, M)U<73.RW3GA^NB^%,H(*0ES"0*419H8 M\@*!?#TDETS+8EN71;7"/JASF][8]R"2[G%GNY"T'JY*6M]CO[O+X_??!>\] MF$9[XRX5 .M+B!8CKGTB;RB"Y;578 T%>F$"R&BT\#;[4%J[K7> MW=*.#VU MGI7/GTXFL\\U164>:O?AU<)99S1QY%YGR\$Y4UU%'L [9D 7:5&ALR**V^BU M^^N&M#7V19-+6>!MA=!RMZS0WLY.PV1[K(5'9FK+,LZ$ Q5+[8 1'"0G0LR1 MEY1;EYY< V5(?GG?;&DIE887:$X774B+/\>+XZ/E?#$[P8ZVM.7T?-2G&WQ" M!8/5^W2,*5!8.'@4K%:)HE4NHV&M(SN[HQN2XWXH(O4DNX9AH'6?Q+-Y..>Y M+3Z6R$ [Z6G(9=7-+$)AP5M/OS/5NM3D:B1#:IA[*,XTD$G;3I;7#],*J9PP MBBQU52]*2!)"3A:L2]DGA[KPUDFK-R,:4G?<0_&EH8S:E4$2EO>8CJ=CDL%9 M1=]L>GY9ME7&H]1D6^6JZQ(F"*(($$$)3%FC5/8N]N[UKQI2%]Q#VKJ-)K^U MG?NFFQ6[F*QDX^3V2GBF4M_Q6"]M,D:EJ]2$\^F8J2X,K:6 MC&4CP_IZL-\U'5K/>QLB7-$=>=.8:P/N MW"'+)G.)&4C"Q-(2#81H-6ART%B(+B?C=B+%[N\<5&_8@Q"D)WFTM&NW)V&# MQ5EG!7GEX*1$PJ($>*L]L)"Y\KQH)GHP8:] ,J@^L@SZ8?WV)VLVM/<_W#Q]H?N?Z1X1^"-#A*WW[/E9@1M9:D) MZY&3M 6B4K;>:26E="72'M>8"C?A&=)I8 ^<:":*GO>/>I?>;%JMGUEIL'-< M][@V>\9.8/O=+13/4>><(8BHU^O::5RYE5XF'2(KK8_3^]DM5G5)-=\J+D8Z M!Z]CE("E)BS4C"F?M*HW).0LM4&'K4]?ME[_'>P.=Y'ZI7LK[SG1#7>%M9MS MUM9FE:-2,_84>I92#F -IT%YCA *]T#.L?$E%,%]:\/G&BB#RG+L@0(M)-", M#E=9*]Y9E2,G\Z2XU=7,M826:)J0^VBM+X8-Q$P\5%Y'#RS8=^)[M@1>+!?+ M[FN_J[?X\2PLTL0PV/'I;>R$^PRE![-AY&2Q@FD+P24#"FO3,,\D<,Y2X,@* M+ZWWU>WWM]049\V9QCC_.INOR]84GX0Q35]7K]6=D^C^'X9NY#PS6M&HI=#5 M@-8&'.8Z'<66E(JRS5N1[8MYJ,;(G;ATD^;I79"];%2WH'XY_9W6[_O/./F$ MO\VFB^/Y*#GC(G<1BM!8.T!\9)%%,T%>*C^\*&(MZ<('X9U M=7&\_SP;D=56%"\T,RH2TN0#1"85!!\$RA@SEM9ICO?!.50#ZW ^*)OU;7<6J?*.#:#*A-L5DGTJ1J77@[GY(AY1C^X#TNK/0'HY@+V;+ M;E1L<-YF"47FVC7)6'"V!CQ%4H+F1I>'5UX5Z)!2WJHHZ'Q>ZTJ(-F$P MCNSY>F&75!6+2JVOM*M(X)7 %C"&[^02AQ74W0?472+M]IJZ"_QAK. M6OBO*VB3%1@1):#-"91'0E24A, -#X:+9&)KD^0F/$/PS1^$+KE7Z"(@0X 8EPBR8+VAOI92 M%2O!%I;)-:%):-Z6?D^>'*Y!X_X\:2V!7CL3_6LYGH]7-Z>M.MMM?;!71Z+; M']NB$]$=P;?J0'3A74?T_G$^JX9]WX7I?)W>,?*:1V,$48;,Z=HF38+/#"$B M,Y$ER67S:WYWQ;:WN;[C>VHOKL7IN44PGR\Q/YWFU;UKM1 G,4P"N8*4@Z7U M53C0NHA@R==(4G'N4^M6H(V@#VEWZX61EXS_!Q!Y._=R1_"UKPKMYC5'=_L; M(X;UMEXLD+FH^7D^@3/1@ OT,SDGK6_>26P_R$/:50?%SQ8BWG%+/ON\_HAD M!/SC;_\+4$L#!!0 ( LXJ5B3!PCL''@ -I8!0 5 :6YS;2TR,#(T M,#,S,5]D968N>&UL[+W9DELYDB9\/T^1?\[MCQ+VI:RKQY12JEK3R@R9I*SN MF1L:%H?$S@A213*T]-./XY",E0P>D@ 9B\RJE*&($,\']^\ [@Y?_N5_?3L[ M_>D+3*;#\>AO/[._T)]_@E$"B9]V'G@Y'?_ZU_!'\%'["Y8VFW5__ M]O.GV>SS7Y\]^_KUZU^^A+9\K=_7OSZMUN__U5TO\V<<\^Z MGU[\ZG2XZA?Q8]FS__SMS?OX"/?Z-M+A:/8L#<^>+7[GF3\]1<3=)\R^?X:__3P=GGT^A>7W M/DT@KT6_7'(!I0J<_UD^[=G>F#XAD$D\#T#PNS J%*^(<=6G[X_YXK-(@NS/ M3V<5$=_^[*IXQV=^6%/ MSZZ MKN@\@9G 68U(1Z[7.OX%R"O(FP?"1N"F>0 M_A+'9\\Z<"_&H^GX=)C*MOI^AG^6?78ZSN\_^0E\&I\FW*5__>?Y@-_G7QK(*_[=K@VPQ&">8[ MU1++Z3A>^Z73LD^.+Q1[Z@.<=M\=G$_)1^\_#RZ>C>#A-7XY'5!!I8]*$BL@ M$ E,$Z^")4E"""I*%V6^38OIDF;93T-'C,4CD"!+X2!\X1%D%9"R%YJ5NMJ4-P?3V7G'D^6:YL M\4IN=;+DR?BLJCYGXVIBG&L*0?_\TWB"=$9C"G_4[1-_C:?C*:2__3R;G,/E M-\>C&;+ZU]/N@?CVPL?R134FS%^G%^.SS^-1>=F>?QM.!YF#T5120BVW1 J* MPHF*$B6L#<9&[JEL18Q5@"KRY([3_@[>[*#H=9S96^"K*+0G&VY@>MF=4[U M#6[8'Y78L!)011:LM9_NX,#^BANWDOK!*.$XSAN$_#V?^= '.Y1A2=IHXZS6:2CP@L[,BB;JLI+)*T=HO_9V '@,%ZDF\P9O_ M#F:X/DB_^LEH./HX7:!2*GAO(!(G(IH_D@/Q3*#QS$!;R"9+$ROS8#62QT" M"C*^K7F^]T80X_G9^6GQOT]FGV!25HR>=SD@O\#K$3KJL "*)UK@N'Z2N7%$ M&NV(YRF2Y!Q7,DJ1>:J]*?0%]QCXT483MRDC]J4,8IF G\)+F/_W]?Q@NQ:M M>3<^/7TUGGSUDS2@"3WK6(XZGQF142L2$G<$OXV4S]'YN"*^MA=QMH1X>/I4 MCD^T5$D#ZZ.+[DU/SF?E]J-<*0UXMMERF?#\"PEM:07$(0H"0EK-'1I)LK:A M>0O$X5G05&TWPQ%[R;R!S7%[J0.EK<\RHRE,K<>S, @\%4$0KK,4@CGA:.TC MYC:*1TZ#_:3>P )9<<[]#K.3_,%_>QZFLXF/LX%RGF?N%5$NHWDLF266^TRL M3YP&$46@M>/6/6 ];J;4UDL#2P3QS(&]&4^G Y%U3@[/3I;0?9(<5XS$#@3W M.8^D-AFLJTR2:P .3X?J*AK7DF^#\V*=45RP+5?]=CSI)#Z;38;A?%9B^!_& M;_'@&\T&+F4=N* DN%2..X[P18'/A:=HJLN4:YL8>T)^?(0ZI X;'%7=9OMZ M.CV']/)\@C;46Y@,QVEN6G4_//EDFA*8,=R@=A= MQKV8&2M,-)+5OUC;%N7C/L@::^TVSV0CGOW#GY[#:L R.T SWB+6+!"F\L1I MYHD6T:'S*"2 /PS-UH-\DBRKI+/;)%---[/?X6OWH^F YLQ3I*+(!+=<@WN^ M9UD24, <^%BMH,VD,WMPEDFFY"[P!-SF'L4@/QUYX7D716(HHGPW!VCK\S M\,[1J*@A2CA/I/*)..$$T52G5.Q!X ?=G_J ?I+$:Z33VZ2T+7>U7OBS2)HI M*4C*@.:CP4/=!:.)EC2&+!3D4#L2L2_F)TG)-AJ]S4C7=)M\'E%6TTY;N)]+ MZ:S60)@3G$AM@7CK+%&!.Z:2\=8>=#N\"NY) M660^$< CNBFAE&"ET^.F[KUBQ K*[Q\$OG61GJ4+@D9TFJB5 M1";)B5>QA,4!77".Z+(];/)"E=OXG*T(RDB2/,5E*5Q@",D08Z-5(2O&7>TL MT'6W\?_R[,:[\@;_6K>:[H6??GIU.OXZ;5)$M^+3F]7.;5I)PY(Y%T!R90DX M59*:@>*^ 8E8DREUU,;4P.]I7#)G-*=,,T=HX!DM?^.)-U&5I!D'B7,5V.,M MF=M"GQM*YK81XWTIF7L^G<+LBKG557W(B-9[4H*87$+W7!KBI,"_BJ!S I:M MJGVAMPK'/2F0VTJM-RV%?<7;(,G@)J9%7F\?5(T*XU8C.DYEW/X:VT"!/<1] M.#)8+Z$T(2&@9-D512:66D%L.TD"1& *YTYI[6KXHZ<9]I:8W>FG6XC[A9&P-5X5@E&C>+P M%*Y!_##>5CH&#\NH&.";$R2:S:Y$;$4B3NM,(3&;8FT*M5C'HV?BT97?((GU M)7R>0!QV(=>!8OA\<(QH$4J3O9B(%QR($(+39#V/CE8FXM7G'\'P.;I&QY74 MT6*O.RNYU__=83G)KT_LQ:G Z4Y,SDZPEG M7)=7B(T$;D( HQ, MV8?JN]:=B'[0IZ;*6B3,EVN*7VY>] RRC#9EA,&L1U0Q!H)?(.NY#$Y8S4S] MFX652'X0J(:*&E1V7:?UJ^'(HYQ&'U^,I[/I\U%Z.9S&\3G*< #@4Y*:$Y_* M)95+D7A62N.#IS)P:R-KNR>MQ_:#7&W4V*#@8GX[_>_#$?XY@PE,9P.:A&22 M"0)!H.V8$R_5T8)D9:5.RFM5O2+]-HH?%-I7-0T*)[HBMM]1,"B%7[^5+1,& M 0+WI1N'R#80Z8TD3GG<+GUV/H9 M:UM1Z^ \8,N>RNG8I%$%QA]'N,$YMO? M2PBSY8[WFY_\"5UMXWN(YY-N_0.*=%8R:B(8H*?*&'JJG%.2:#2,N2R,O7&U MN";$O,5#GS!EFNJG0:W$_/B$-R6#ZUUIG'^243#S2/Z5LH3)DI=#32H1?CE?#HU MO!B/"DH47LE)0^E,_%Q;$X_?[83ZXE/Y\O4(28[;ZTE>\T_>#'T8G@YGW]D@ M6)V]4)F8 +ST&5#$Y8#GM\)-6$;PKGH[CP,M[0FS^SZ3J$6IQ1^C"?C3X7]# M^COJJ)-\ MZ0L<&*9]HD,YX'5GL MEZBRZ4E/F"GU-5&S4J$?.JFUX,YSDC2C1+J<2.#4$(M_*"N4D'HK0ZXG3[;? M0V]7KURHM0N\,W]7:;5#ZHWO"[TMC M5:YX>?8."=^&^CS.@]4H2,"SH*0_YQ@T-^B641.*>2$-OD-*$LZ3!95C\KIV MD+@/KOM0859'L1OYLZ=2&ERBW\;X>O0%7\'QI,20G#_#:XMQ/X[(?I)6283"Z.SN>C>2_PQ6T^ M9 W<>$6X*D,C0G8D."V)9GA\.Y,L/0!Y^B!]0JRJKKB#=&R_N"8YGY3&BDN8 M/LHDJ$M_Y[.761 M\.4JY1S2,OI2MEF0U 7E!1[%$0U&+QUNLT(0+Q,X#=ES53NA?C>D3XA?U177 MX(I]S5MQ&0^_ I5ISP$@DQ!*^W)OT-R+QJ);FQ2/U(M[1<:J2@!G?P:Y 6 MUV*Z+EXB=&8A +%*%\&@%8@.J"-":$ZS"\!E[9C4]B@?:U%9+<4TB!/@^;OL MDE,BIQ- [$CXV?>WIQ[-OE$J#5 ^EU\9*%%22S1*0JLR:1(=52M8(-QZJ235 MS%7O0=$?W;TI JJFZUL9B$T4U8)2DW$$2--7*++WOK/M?O.SDK[T_22O3&F* M&4SV@I+(F"XS@"CQ+):\)AT%2!N8JFT\;0WR\1.LJ=H:A*_ZRP=-O\BLS)EH MEAR1E#(2>'0D6\N8BQ$]B=KM4OJC>_3,:J2H-J-\5B&]*!E8(9A4# (3+"D9 M<:6V"8U"@XBCH";Q&&.0M7.NMT?Y6 VK6HIIL#M=VT[7C?]V*E0:14LY" MZ8ZO$)84+!>-## Y! =-9[*B+:9+MU Q MYE%+FM&*SS0AM*C16TR,1&4M3T%GFVKWC;T#SJ/G22U5-+A>ZR^)@4B6J4!5 M:;6&$HB4E\E[C"2!QER**>LC6KV/GD.-%-7@"NW7G"'.3O*OWV*7-?\.O8*3 M40%?_E]"5E_\*7294\OY%^4'ST?I^C>N_.8@,&N=+LW]0AE1GIU"']'J,CB8 M.\842K'VAM5@&0_>)3NV:AL*OWU7%4_/2VOTJV*:BVZ =J)Q3'B2 ME,3M7F5.O R,!):-,H8;"[4370Z[P@?/\7M,B ;G_W[OKD_XZFH)Q+ALB*0. M3=R,;[%*@G'%.1A:.\;ZM#?@PZFK@6&P'WCP(7:]M+Z_WYY\_SMO+^=#E8X?4HCR=G\^K$BZG8)C#F?28ZEYHP(1P) M/B623#8Y1Y6LK-[2JA^T!_^VM5!!@]2097N:TK &W82!84X'H(S0)"F1+%'B M*:7XILCD@../3&U&W(!P!,VW4-6MQ+/=Y=RFW&-\!A_\-Y@N$64+049KB K" M$@F,DS+9C1C041H&6E=OJGD;Q6-5_E[27AL,KCA@Z/WYV9F??!_G]\./HV$> MQI(D,L^Y+8/OOAM,_7\+,#T^GUY'V&SJTYQ/W'D14 M<\65AA/=>MCE422=8E265L"1,2*YR4@_6X(SP4@ID8FA=GQ^/9J]C;F;GSP? MRR*,4%'33)@/^(J9D(D-I1-_R"X:QIVL?@>Q&LFAAA=5TOS#=2\V$3CH3934O.Y\@WAM'@#ICF4&_O5^_[ONE\S7SB0ZF M\FVD6GLPT1+*\\6('8,V<[0!;5^A I%EG;9L82"MXB%&P9+>9#VN^N##.0\5 M93VN)*B* V2N8?EEB25ZS34+!%>2B52:D4"I(89'%S.#2'._QBLW/OC1*&T7 M0;5ZTUXLL?B<@')<%%=ET*%& @DOT6G5TEEP*N>-?MJJ#WXT2MM%4 URLVZ9 M>;]\_P5&\1,ZJ']V!P+3 4^$E$DVI7U-CD@JK2-QB5)NM90B5K_ZVX#I$9C$ M3<1_$'HLT2W>@S[X&DWZW(3M.#,_ZVIT(UTJJ*-!D'ERW;:*$!2TKMUO0=?('1>:D13.>QNP%; M'(R<6NV,P94[5EH.E>[AVB02 [74VZ23J5UJ=R>@PU\0U-7?S5O":L)O,$!R MQ6OQ ?_I8G8NT,P%(PJ-W5+?)8C--A$+3"2E.!.^5R1N/X-D">=QVR([";U% MNMNMU>(_O!A^O1G:H2R02UCWQOC8384;X_K[R?\0)L<5B#Y)H4P21$-I)V:L M($Y83FCB.:$39X6IG8=[<&IL;V@T9\8V8F_!B*6G?1/BR+MWCRED2,C\ &CD<.3*/% M$XTN0T4]\48#<9)'@4C!V>HI>W?@N0>D>-/FQL/.J&0S;/3+GSJ0?*3NF_\CTS5+J@Z?OX"=+Y*8SSKWXR0ACEPCD\/9^5GGQ+IG+/P7,72K8\=E[!=)[/VYN M\$L6!659$*H"OI T:A*HRH2K*"U%Q9^+TN)>_1N\3!)Z.9H!22$F(@# !YX"$95KPA?!^8( M%0]'U_7-RO JBFH0H+BLS^N@_8&:F;Y[_\J(E0D!PT66'[YLM]SXYE^M! M"B+IE'7MG(P[ ?U@4D6%M>C4!9.NK&@4H1/*= $K9AJ=4H8PEY#I$H!XJP+A M'ATE[17ULO8)N ;*#P9545*;WJ67T\^>?_'#T^(:?1@OPCZ%[)_&I_BLZ<)U MNJA;"TH*X7,@)FI30GJ!."M*)RDG$GI/CKO:%[4[@ST<_PX9V3BL#AL<@]> M#WCV2DMPA%J.(A"E$9$4:&LJ?#\XH$>N&K1RN@1PE&Y-AU#<77392NH-SJ[_ M@#+U'5?V!2;^(_Q^7B1VDN=;Y,GY;#K#MP7?H(4 7@ZG):9V/IF_-A?R$)$: MPQ,E+((E,J)19Q6S),60$FZC0M/:@X/K('_<.],1M'M$CG8B' 2JLY=.D,30 M9999*N)\5D3YP))FG-'J0S"W GCX;>X8+-B1B-NKL '?.CD,OUSI<'\A T:S MB+E,9J0:_599+M;+,$\G><(747O+:KN&Z]$\22954DX#4[YK\+7H-W%Y:3M] M/D//-9S/YJ;%;9_GBDLT2,Y9FHTD3(5 ) V*>%HN["VGC"JK@ZD]665_U(>G M82T.K)HA=C@%MNG^LGD%+\8C?'U+''K>>O;*( _J#+6,HJWA2CLM5?)/@#%2 M\I%1JC8)WF2BZ^Z0GQ;Y*JFNP>:WYF18' 2W#H@!=PJBTKD,#^G"+HQXL(Q( M0/\IF1+/J9T=N"7$)WFZME1C@\3UFT[495,GY9,TS)&$;G3)N8TDV 0DEM'' M/@075&TG8!V6Q^UA5M% @_UHY>('/C%/03BB''>EK7"IWXB21 7 O;&156^+ MN!+(X?>6.GK:H/SMA=SB=O@&J 7=!RD*[27W1&M1%BH8'L[ENBAE"=+9B-99 M8]TOH#Q2[>\BZ/O3 >\Y_BW=,NV:)QO?_=@#91MOL?9*#?%6/_'7;Z4E-J0R MDZE<&Z+9.^MLW9M4NSR[F$]:4(.^%B^5#@YIYWP,),H0J8M6,EV[M5PM['MG M;2U.^I.\)Z)Y-J;W,FJ@ >W$,G/$H]\2*.X,$91CU"B& JZ=KU5U!8=J[G<4 M[M[*ZSJ>\N]-PO5^"__E^^H/Z%+NJ([49RF(#C*7,ZSX4%(19#!%+]]!M+4- MQ8;+.585]3%)>C-?_)Z0I8'!NQK9E;29/O@:99)OPG:DK/#[0H9>)-U3D\=@ MG/76!HE^1!!6X\D6BUNA2F^5@.Z&M(:[VK[6<9BV*8_[H1)M&P4>-,-;:A85 MQ^.'>X=G0'%=K="2@%#)"*"9RMJS& 4)47/D MKV \*!:$KVV^WYO,ZZ9LJ"'P-GT4O\!D-D0OX?JUZ *> NHH UU:=XER.96) MDTZ2; /ZX(HFQ6K?:V^ ],AX45,!#>X)][3#GI^5@.D@:X4TQGW.9U<:^3A3 MLG0- >NBI-RH7/T&H0KP^\*U X?(#J_T0W1.>>6'DW_XTW/X#7RY^^_RCBXO M?5_XR>0[+J/[%3]*%[\^SL^G4YA-\7MOACX,3_>]WV@#9.\;CP/(I](=R,6C MYP]^?NW!"_3I9/2N4'=2ACF/TN_CT63YUW+9.KU\4P+EEHF@"==HGJ,U)G'W MYII LE0%HS4SM:LWJBY@WRV^!IAYF#'&))GUDO!4[D03[CD^H-\C!.@C<8!F>=2&&E,[7WT#I&/=11R))^O86D%?+?SI\:33Q>P"Y\47E]F&"Y.^ M#]1&MPI;P#S.!4-5-=]TP1OKJ &M5@ L&__NK]\]-J!ME-.B$>W"VWL'GQ$TI+D0UL-U#K)U:'Y&S[MT M2$6LSA3MTHC242;P6#U.N!W$P_.IF;IOAA ;ZJK%%>5T-CSS,SC)?>1"HX:0 M' &=42X,+&[5*1"O&16:!2>KE\=O@^_QDJJ9EAI<8JP^]%]-X)_G,(K?NX,? MI$;70SO"30F*&H^^1W&731:)1RZ-N=F/MI$_=PW6#Y^NIMY:4FL5P.6TFQX0 M&_ES/>#=)S]N#]6NHTYEO;3TX>Z *GD"IRCZ(<9P(@.^10&M3**B8I1E):%Z MVM?1J+.3!W=8YFRCC@,Q9GJQ%R_.W)"-\6 5R;*D%J$#2ZQWDC (H$2IGK[9 M1[X)96[B.J+;5DNA/0BSES8:N&M77IJ++_]M"!-\R*?O;^ +G,[?&P;.AZ@) MM;2( 8V%0),L(UZ90HN-,U^[YJW,:[/'Q[@#V@4;06 MZ-'-HVH:[[-M5577H4Z^M:"9SS&K8$G(#-U.SQWQ"0V"D"+EV22JJP>=[@&W M^MM/]X-:VVBI):5>CSZ?SZ:=!-CRU(;,O)8"[4@IB=22$LL@$\= 4,BBAZA!9P7.5I]@=0W!$6EP M]*RV/731Y!IU^@G76O[SZS_/AU_\Z;7WX_(B94!+"RFF/<$W094U)^*4+#U< MM0\^T\-[@CI,'OH<5;MZ,M5-#@F/G-3_Z$KEWAE>:$F0EJ.>YG2F= MVXB6_N; <<=D*)!$:32U:;$*QX-FP-Z";7!DO(0)4K$46,P7.C E7"A=),)S MQ .NY)64SLW!43PCA;+579&;&!ZTDO<2:(-HV97S[V)]GEE)A2U7\=+@^A"7 MS:7)5Z3!>1HCV-JM.U? >,K6P;Y::=)Y> 83F,[>^1G<)/&5+(^!S$)GJ131 M.B),R($X$Q"F$TYYPX7PM>][>D([/*'V5N.M%L+U=7 PJEP5QA6LZ/4D&AW* M@P+:,#R5)%>43/*9!AJ% 5J[@&$;?(^5-!6T4='T^1(R3"9PL0]_'_#,HA&<$^43HK1*$BLY(XA4:\NBU&YC86/OISU0^GF-IWD8:JI?_>32;<+UJZ.OO7!;:J=[\9_+ZN7J7$R>6V( M5DPA+Z@G/FI'&*4T>X-$S+7;.CW2ZF66O:(1M^GLRNPD930I ^8(^!B\8�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